

| Result No. | Score | Query Match | Length | DB | ID | Description |
|------------|-------|-------------|--------|----|----------|--------------------|
| 1 | 161 | 100.0 | 31 | 1 | AAR1092 | Insulinotropic pep |
| 2 | 161 | 100.0 | 31 | 1 | AAR17397 | Glucagon-like pep |
| 3 | 161 | 100.0 | 31 | 12 | AAR13420 | Glucagon-like pep |
| 4 | 161 | 100.0 | 31 | 12 | AAR13422 | Glucagon-like pep |
| 5 | 161 | 100.0 | 31 | 12 | AAR13423 | Glucagon-like pep |
| 6 | 161 | 100.0 | 31 | 15 | AAR15658 | Glucagon-like pep |
| 7 | 161 | 100.0 | 31 | 15 | AAR15659 | Glucagon-like pep |
| 8 | 161 | 100.0 | 31 | 15 | AAR63346 | Insulinotropin (GL |
| 9 | 161 | 100.0 | 31 | 16 | AAR15885 | Glucagon like pep |

| CC | XX | Sequence | 31 ÅÅ; | Query Match | 100.0%; Score 151; DB |
|----|----|----------|--------|--|---------------------------------|
| CC | XX | | | Best Local Similarity | 100.0%; Pred. No. 2.2e- |
| CC | XX | | | Matches 31; Conservative 0; Mismatches | |
| QV | | | | 1 | HAGCTGTSVSYSLGGAAKEFTAWLYKRG 31 |
| DB | | | | 1 | HAGCTGTSVSYSLGGAAKEFTAWLYKRG 31 |

| | |
|-----------|--|
| RESULTS | |
| ARR13420 | |
| ID | ARR13420 standard; Protein; 31 AA. |
| XX | |
| ARR13420: | |
| XX | |
| XX | 29-00T-1991 (first entry) |
| XX | |
| XX | |
| XX | Glucagon-like peptide-1 (H17-GLP-1(7-37)). |
| DE | |
| XX | |

| | |
|----|---|
| KW | gucose; insulin; diabetes; degradation; islet cells |
| OS | Synthetic. |
| OS | Key |
| PH | Location/Qualifiers |
| PH | 1 |
| FT | Modified-site |
| FT | /label= D-H, N'-acetyl-H, N-isopropyl-H |
| XX | |
| XX | W0111457-A. |
| XX | |
| PD | 08-AUG-1991. |
| XX | |

| | | |
|----|---|---------------|
| XX | 24-JAN-1991; | 91WO-0500300. |
| XX | | |
| XX | 24-JUN-1990; | 90US-0468736. |
| XX | | |
| XX | (BUCK) BUCKLEY D I. | |
| XX | | |
| XX | Buckley DI, Habener JP, Mallory JB, Mojsov S; | |
| XX | | |
| XX | WPI; 1991-253609/34. | |
| XX | | |
| XX | New glucagon-like peptide-1 (GLP-1) analogues - have increased | |
| XX | insulin-stimulating activity and/or resistance to degradation in | |
| XX | vivo | |
| XX | | |
| XX | Claim 7; Page 37; 50pp; English. | |
| XX | | |
| XX | The peptides represented in ARI3420-27 are more powerful than 5 | |
| XX | in stimulating insulin release from islet cells and some of them | |
| XX | also more resistant to degradation in the plasma. Doses are usual | |
| XX | 1 picog-I/mg/kg, for the treatment of diabetes type II. | |
| XX | The last three amino acids may sequentially be omitted. | |
| XX | | |

```

SQ      Sequence      31 AA;
Query Match      100.0%; Score 161; DB 12; Length 31;
Best Local Similarity 100.0%; Prid. No. 2,2e-16;
Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY      1 HAEGFTSDVSYLGGQAQKEFIAMLVKGRG 31
      |||||
DB      1 HAEGFTSDVSYLGGQAQKEFIAMLVKGRG 31
      |||||

RESULT 4
REF13422
ID      AARL13422 standard; Protein; 31 AA.
XX
XX
AC      AARL13422;

```

```

XX 29-OCT-1991 (first entry)
XX Glucagon-like peptide-1 (A)8-GLP-1(7-37).
XX Glucagon; insulin; diabetes; degradation; islet cells.
XX Synthetic.
XX Key Location/Qualifiers
XX Modified-site 2 /Label- D-Ala
XX W09111457-A.
XX 08-AUG-1991.
XX 24-JAN-1991; 91WO-US00500.
XX 24-JAN-1990; 90US-0468736.
XX (BUCK/) BUCKLEY D I.
XX Buckley DI, Habener JF, Mallory JB, Mojsov S;
XX WPI; 1991-252609/34.
XX New glucagon-like peptide-1 (GLP-1) analogues - have increased
XX insulin-stimulating activity and/or resistance to degradation in
XX vivo
XX Claim 7; Page 37; 50pp; English.
XX The peptides represented in ARI13420-27 are more powerful than glucagon
XX in stimulating insulin release from islet cells and some of them are
XX also more resistant to degradation in the plasma. Doses are usually
XX 1 picog-lmg/kg, for the treatment of diabetes Type II.
XX The last three amino acids may sequentially be omitted.
XX Sequence 31 AA:
XX Query Match 100.0%; Score 161; DB 12; Length 31;
XX Best Local Similarity 100.0%; Pred. No. 2,2e-16;
XX Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX QY 1 HAEQFTSDVSSYLEGQAAKEFIAMLVKRG 31
XX |||||
XX DB 1 HAEQFTSDVSSYLEGQAAKEFIAMLVKRG 31
XX
XX RESULT 6
XX ARI42668
XX ARI42668 standard; peptide; 31 AA.
XX AC AAR42668;
XX DT 25-MAR-2003 (updated)
XX DT 26-APR-1994 (first entry)
XX DE Glucagon-like peptide (GLP-1(7-37)).
XX XX Glucagon-like peptide; GLP; phospholipid;
XX XX Glucagon; insulin; diabetes;
XX KW Glucagon; L-alpha-phosphatidylcholine; insulinotropic agent.
XX OS Synthetic.
XX FH Key Location/Qualifiers
XX FT Misc-difference 31 /note= "Gly31 may be omitted, in which case the
XX FT C-terminal is amidated"
XX PN W09118785-A1.
XX 30-SEP-1993.
XX 18-MAR-1993; 93WO-DX00098.
XX 19-MAR-1992; 92DK-0000364.
XX (NOVO ) NOVO-NORDISK AS.
XX Kirk O, Fridal I;
XX WPI; 1993-320450/40.
XX Medicament for treatment of diabetes - contains glucagon-like
XX peptide and phospholipid for intranasal admin.
XX Claim 1; Page 18; 24pp; English.

```

```

XX 24-JAN-1990; 90US-0468736.
XX (BUCK/) BUCKLEY D I.
XX Buckley DI, Habener JF, Mallory JB, Mojsov S;
XX WPI; 1991-252609/34.
XX New glucagon-like peptide-1 (GLP-1) analogues - have increased
XX insulin-stimulating activity and/or resistance to degradation in
XX vivo
XX Claim 7; Page 37; 50pp; English.
XX The peptides represented in ARI13420-27 are more powerful than glucagon
XX in stimulating insulin release from islet cells and some of them are
XX also more resistant to degradation in the plasma. Doses are usually
XX 1 picog-lmg/kg, for the treatment of diabetes Type II.
XX The last three amino acids may sequentially be omitted.
XX Sequence 31 AA:
XX Query Match 100.0%; Score 161; DB 12; Length 31;
XX Best Local Similarity 100.0%; Pred. No. 2,2e-16;
XX Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX QY 1 HAEQFTSDVSSYLEGQAAKEFIAMLVKRG 31
XX |||||
XX DB 1 HAEQFTSDVSSYLEGQAAKEFIAMLVKRG 31
XX
XX RESULT 6
XX ARI42668
XX ARI42668 standard; peptide; 31 AA.
XX AC AAR42668;
XX DT 25-MAR-2003 (updated)
XX DT 26-APR-1994 (first entry)
XX DE Glucagon-like peptide (GLP-1(7-37)).
XX XX Glucagon-like peptide; GLP; phospholipid;
XX XX Glucagon; insulin; diabetes;
XX KW Glucagon; L-alpha-phosphatidylcholine; insulinotropic agent.
XX OS Synthetic.
XX FH Key Location/Qualifiers
XX FT Misc-difference 31 /note= "Gly31 may be omitted, in which case the
XX FT C-terminal is amidated"
XX PN W09118785-A1.
XX 30-SEP-1993.
XX 18-MAR-1993; 93WO-DX00098.
XX 19-MAR-1992; 92DK-0000364.
XX (NOVO ) NOVO-NORDISK AS.
XX Kirk O, Fridal I;
XX WPI; 1993-320450/40.
XX Medicament for treatment of diabetes - contains glucagon-like
XX peptide and phospholipid for intranasal admin.
XX Claim 1; Page 18; 24pp; English.

```

CC A medicament for intranasal admin. comprises this glucagon-like
 CC peptide (GLP) and a phospholipid, e.g. dioctanoyl-L-alpha-
 CC phosphatidylcholine, diaurayl-L-alpha-phosphatidylcholine, etc.
 CC The medicament is used as an insulinotropic agent in the treatment
 CC of non-insulin dependent diabetes mellitus. Profile: absorption
 CC is slightly protracted and a constant plasma concn of GLP is provided
 CC over an extended period. In addn. the phospholipid exerts a
 CC stabilising effect on the peptide.
 CC (Updated on 25-MAR-2003 to correct PN field.)
 XX
 XX Sequence 31 AA;
 SQ
 Query Watch 100.0%; Score 161; DB 14; Length 31;
 Best Local Similarity 100.0%; Pred. No. 2,2e-16;
 Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 HAEGETFSDVSSYLEGQAQKEFIAMLVKRG 31
 DB 1 HAEGETFSDVSSYLEGQAQKEFIAMLVKRG 31
 RESULT 7
 AAK45434
 ID AAK45434 standard; protein; 31 AA.
 AC AAK45434;
 AC AAK45434;
 DT 25-MAR-2003 (updated)
 DT 27-JUN-1994 (first entry)
 XX Insulinotropic derivative.
 XX Insulinotropic activity; enhancing insulin activity; treatment;
 XX Type II diabetes.
 XX Synthetic.
 XX W09325579-A1.
 XX 23-DEC-1993.
 XX 14-APR-1993; 93MO-US03389.
 XX 15-JUN-1992; 92US-0899073.
 XX (PFIZ) PFIZER INC.
 XX Andrews GC, Daumy GO, Francoeur ML, Larson ER;
 XX WPI; 1994-007457/01.
 XX New derive. of glucagon-like peptide 1 and insulinotropin - used for
 XX enhancing insulin action in a mammal, partic. by iontophoretic admin.
 XX Claim 3; Page 20; 32pp; English.
 XX The sequence is that of a derivative of insulinotropin which
 XX has insulinotropic activity and is useful for enhancing insulin
 XX action in a mammal, partic. for treating Type II diabetes
 XX (claimed). It is partic. suited for delivery to a mammal by
 XX iontophoresis.
 XX (Updated on 25-MAR-2003 to correct PN field.)
 XX
 XX Sequence 31 AA;
 SQ
 Query Watch 100.0%; Score 161; DB 15; Length 31;
 Best Local Similarity 100.0%; Pred. No. 2,2e-16;
 Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 HAEGETFSDVSSYLEGQAQKEFIAMLVKRG 31
 DB 1 HAEGETFSDVSSYLEGQAQKEFIAMLVKRG 31

RESULT 8
 AAK63246
 ID AAK63246 standard; peptide; 31 AA.
 AC AAK63246;
 AC AAK63246;
 DT 25-MAR-2003 (updated)
 DT 02-MAY-1995 (first entry)
 XX Insulinotropin (GLP-1(7-37)) for use in treating NIDDM.
 XX Insulinotropic activity; GLP-1; glucagon-like protein 1; NIDDM;
 XX non-insulin dependent diabetes mellitus; insulinotropin.
 XX Synthetic.
 XX EP619322-A2.
 XX 12-OCT-1994.
 XX 10-FEB-1994; 94EP-0300981.
 XX 07-APR-1993; 93US-0044133.
 XX (PFIZ) PFIZER INC.
 XX (SCIO-) SCIOS INC.
 XX Danley DE, Gelfand RA, Geoghagan KF, Kim Y, Lambert WJ;
 XX Qi H, Oih, Hong Q, Yesook K;
 XX WPI; 1994-311774/39.
 XX Treatment of non-insulin dependent diabetes mellitus - using a
 XX glucagon-like peptide 1 or deriv. with prolonged action for
 XX sustained glycaemic control
 XX Claim 2; Page 46; 70pp; English.
 XX This peptide is GLP-1(7-37) [GLP = glucagon-like peptide]. GLP-1 and its
 XX deriv.s are useful in the treatment of Non-Insulin Dependent Diabetes
 XX Mellitus (NIDDM). During processing in the pancreas and intestine, GLP-1
 XX (AAK63246) is converted to a 31 amino acid peptide having amino acids
 XX 1-37 of GLP-1, alternatively referred to as insulinotropin. GLP-1(7-37)
 XX has insulinotropic activity. It is a potent secretagogue. Other deriv.s to be
 XX shown in AAK63247-51. It has been discovered that prolonged plasma
 XX elevations of GLP-1, and related polypeptides, are necessary during the
 XX meal and beyond to achieve sustained glycaemic control in patients with
 XX NIDDM. The invention provides a compso. that has prolonged action after
 XX each administration.
 XX (Updated on 25-MAR-2003 to correct PN field.)
 XX (Updated on 25-MAR-2003 to correct PA field.)
 XX
 XX Sequence 31 AA;
 SQ
 Query Match 100.0%; Score 161; DB 15; Length 31;
 Best Local Similarity 100.0%; Pred. No. 2,2e-16;
 Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 HAEGETFSDVSSYLEGQAQKEFIAMLVKRG 31
 DB 1 HAEGETFSDVSSYLEGQAQKEFIAMLVKRG 31
 RESULT 9
 AAK75885
 ID AAK75885 standard; peptide; 31 AA.
 AC AAK75885;
 DT 08-FEB-1996 (first entry)
 XX

DE Glucagon like peptide-1(7-36), (7-36)amide and (7-37).
 XX
 XX Glucagon like peptide-1; GLP-1; (7-36); (7-36)amide; (7-37);
 KW type 2 diabetes; treatment.
 XX
 XX Synthetic.
 OS
 XX
 XX Key Location/Qualifiers
 FH Modified-site 36
 FT /note= "may be amidated when Gly 31 is absent"
 FT Miso-difference 37
 FT /note= "may be absent"
 XX
 XX W09S17510-A1.
 PN
 XX
 XX 29-JUN-1995.
 PD
 XX
 XX 22-DEC-1994; 94WO-DK00487.
 PF
 XX
 XX 23-DEC-1993; 93DX-0001440.
 PR
 XX
 XX (NOVO) NOVO-NORDISK AS.
 PA
 XX Bjorn SE, Rasmussen JS, Thim L;
 XX WPI; 1995-240671/31.
 DR
 XX Prodn. of glucagon-like peptide-1 (7-36) - using transformed
 XX bacteria contg. 2 or more consecutive DNA sequences coding for GLP-1
 FT (7-36)
 FT
 XX Claim 1; Page 1; 27pp; English.
 XX
 XX AAR57585 is the glucagon like peptide-1 (GLP-1) amino acids 7-36, the
 CC featured deriva. GLP-1(7-36)amide and GLP-1(7-37) are also given in
 CC the claims. The peptide and its derivs. can be used for the treatment
 CC of type 2 diabetes.
 XX
 XX Sequence 31 AA;
 SQ
 Query Match 100.0%; Score 161; DB 16; Length 31;
 Best Local Similarity 100.0%; Pred. No. 2.2e-15;
 Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKRG 31
 DB 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKRG 31
 RESULT 10
 AAR69065
 XX ID AAR69065 standard; peptide; 31 AA.
 XX
 XX AAR69065;
 AC
 XX 25-MAR-2003 (updated)
 DT 23-AUG-1995 (first entry)
 DT
 XX Glucagon like Peptide 1 (GLP1) (7-36)-Gly.
 DE
 XX Glucagon like Peptide; GLP; transpeptidation; endopeptidase;
 KW trypsin; thrombin; cleavage.
 KW
 XX Synthetic.
 OS
 XX W09S03405-A2.
 PN
 XX 02-FEB-1995.
 PD
 XX 19-JUL-1994; 94WO-US08125.
 PF
 XX
 XX 20-JUL-1993; 93US-0095162.
 PR
 XX

PA (BION-) BIONEERASKA INC.
 XX
 XX Henriksen D, Manning S, Partridge B, Stout J, Wagner PW;
 PI WPI; 1995-075233/10.
 DR
 XX Transpeptidation of recombinant polypeptides - using
 PT endopeptidase such as trypsin or thrombin to modify C-terminal
 PT residue.
 XX
 XX Claim 34; Page 13; 69pp; English.
 PS
 XX The naturally occurring sequence of Glucagon Like Peptide 1 (GLP1)
 CC is AAR69072. It is a 36 AA peptide that has been recombinantly
 CC produced but without a mechanism for providing for the amidation of
 CC the C-terminal Arg residue. Amidated recombinant GLP1 (7-36)NH2
 CC (AAR69063) was prepd. from a multicopy fusion protein contg. four
 CC copies of a modified truncated GLP peptide having AA residues 7-34
 CC of the native polypeptide and the terminal AA residues A-F-A at
 CC residues 35-37 (GLP1 (7-34)-A-F-A) (AAR69064). The recombinant GLP1 (7-
 CC 34)-A-F-A can be transpeptidated to yield the modified recombinant
 CC native GLP1 (7-36)-NH2 (AAR69063) as follows. Trypsin was used to
 CC cleave the peptide at the lysine bond in the presence of either
 CC GLP Arg-2 or GLP Arg-31. The resulting fragments of the peptide of
 CC the Ala-Phe-Arg leaving unit is followed by the addition of
 CC Gly-Arg-NH2 or Gly-Arg-Gly to the core GLP1 (7-34) to yield either
 CC amidated 7-36 GLP1-NH2 or GLP1 7-36 with a terminal Gly (AAR69065).
 CC (Updated on 25-MAR-2003 to correct PN field.)
 XX
 XX Sequence 31 AA;
 SQ
 Query Match 100.0%; Score 161; DB 16; Length 31;
 Best Local Similarity 100.0%; Pred. No. 2.2e-15;
 Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKRG 31
 DB 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKRG 31
 RESULT 11
 AAR690851
 XX ID AAR690851 standard; peptide; 31 AA.
 XX
 XX AAR690851;
 AC
 XX 25-MAR-2003 (updated)
 DT 14-APR-1997 (first entry)
 DT
 XX Glucagon like peptide 1 (7-37) analogue D-His7.
 DE
 XX Human; glucagon like peptide; GLP-1; analogue; stimulation;
 KW pancreas; insulin; islet cell; treatment; type II diabetes;
 KW degradation; resistant.
 XX
 XX Homo sapiens.
 OS
 XX Key Location/Qualifiers
 FH Miso-difference 1
 FT /note= "D-form residue"
 FT
 XX US5454618-A.
 PN
 XX 13-AUG-1996.
 PD
 XX 10-DEC-1993; 93US-0165516.
 PR
 XX 20-SEP-1991; 91US-0762768.
 PD
 XX 24-JAN-1990; 80US-0468736.
 PR
 XX 10-DEC-1993; 93US-0165516.
 PF
 XX (BUCK/) BUCKLEY D I.
 PA (HASE/) HABENER J F.

PA (MALL/) MALLORY J B.
 PA (MOJS/) MOJSOV S.
 XX
 XX Buckley DI, Habener JF, Mallory JB, Mojsov S;
 XX WPI; 1996-383697/38.
 XX
 XX New modified glucagon-like peptide I fragments - have higher
 PT activity than glucagon or have improved plasma stability, useful for
 PT treating type II diabetes
 XX
 XX Claim 14; page -: 16pp; English.
 XX
 CC The present peptide is a human glucagon like peptide 1 (GLP-1)
 CC analogue, which is useful for stimulating insulin release from
 CC β -cells in the treatment of diabetes mellitus. This peptide has better
 CC resistance to degradation in plasma than GLP-1(7-37), and has a
 CC higher activity than glucagon, as exemplified by the results of an
 CC adenylylate cyclase assay where the peptide had an ED50 of 1.1 nM,
 CC compared to 0.15 nM for GLP-1(7-37) and 80 nM for glucagon.
 CC (Updated on 25-MAR-2003 to correct PF field.)
 XX
 XX Sequence 31 AA:
 SQ
 Query Match 100.0%; Score 161; DS 17; Length 31;
 Best Local Similarity 100.0%; Pred. No. 2.2e-16;
 Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 HAEQFTSDVSSYLEGQAKKEFIAMLVKGRG 31
 DQ 1 HAEQFTSDVSSYLEGQAKKEFIAMLVKGRG 31
 RESULT 12
 AA003907
 ID AA003907 standard; peptide; 31 AA.
 XX
 XX AA003907;
 AC
 AC AA003907;
 DT 25-MAR-2003 (updated)
 DT 15-APR-1997 (first entry)
 XX
 XX Glucagon like peptide 1 (7-37) analogue D-Lys34.
 XX
 KW Human; glucagon like peptide; GLP-1; analogue; stimulation;
 KW pancreas; insulin; islet cell; treatment; type II diabetes.
 XX
 OS Homo sapiens.
 XX
 XX Key Location/Qualifiers
 FT Misc-difference 28 /note= "D-form residue"
 FT Misc-difference 29 /note= "optionally absent when Arg30 and Gly31 are
 FT Misc-difference 30 absent"
 FT Misc-difference 31 /note= "optionally absent when Gly31 is absent"
 FT Misc-difference 32 /note= "optionally absent"
 XX
 XX US545618-A.
 XX
 XX 13-AUG-1996.
 XX
 XX 10-DEC-1993; 9305-0165516.
 XX
 XX 20-SEP-1991; 9105-0762768.
 XX
 XX 24-JAN-1990; 9005-0468736.
 XX
 XX 10-DEC-1993; 9305-0165516.
 XX
 XX (BUCK/) BUCKLEY D I.
 XX (HABE/) HABENER J F.
 XX (MALL/) MALLORY J B.
 XX (MOJS/) MOJSOV S.

PA (MALL/) MALLORY J B.
 PA (MOJS/) MOJSOV S.
 XX
 XX Buckley DI, Habener JF, Mallory JB, Mojsov S;
 XX WPI; 1996-383697/38.
 XX
 XX New modified glucagon-like peptide I fragments - have higher
 PT activity than glucagon or have improved plasma stability, useful for
 PT treating type II diabetes
 XX
 XX Example 1; page -: 16pp; English.
 XX
 CC The present peptide is a specific example of a claimed human
 CC glucagon like peptide 1 (GLP-1) analogue, which is useful for
 CC stimulating insulin release from β -cells in the treatment of
 CC diabetes mellitus. This peptide has better resistance to
 CC degradation in plasma than GLP-1(7-37), and has a higher
 CC activity than glucagon, as exemplified by the results of an
 CC adenylylate cyclase assay where the peptide had an ED50 of 1.1 nM,
 CC compared to 0.15 nM for GLP-1(7-37) and 80 nM for glucagon.
 CC (Updated on 25-MAR-2003 to correct PF field.)
 XX
 XX Sequence 31 AA:
 SQ
 Query Match 100.0%; Score 161; DS 17; Length 31;
 Best Local Similarity 100.0%; Pred. No. 2.2e-16;
 Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 HAEQFTSDVSSYLEGQAKKEFIAMLVKGRG 31
 DQ 1 HAEQFTSDVSSYLEGQAKKEFIAMLVKGRG 31
 RESULT 13
 AA003929
 ID AA003929 standard; peptide; 31 AA.
 XX
 XX AA003929;
 AC
 AC AA003929;
 DT 25-MAR-2003 (updated)
 DT 15-APR-1997 (first entry)
 XX
 XX Glucagon like peptide 1 (7-37) analogue D-Arg36.
 XX
 KW Human; glucagon like peptide; GLP-1; analogue; stimulation;
 KW pancreas; insulin; islet cell; treatment; type II diabetes.
 XX
 OS Homo sapiens.
 XX
 XX Key Location/Qualifiers
 FT Misc-difference 30 /note= "D-form residue"
 FT Misc-difference 29 /note= "optionally absent when Arg30 and Gly31 are
 FT Misc-difference 30 absent"
 FT Misc-difference 31 /note= "optionally absent when Gly31 is absent"
 FT Misc-difference 32 /note= "optionally absent"
 XX
 XX US545618-A.
 XX
 XX 13-AUG-1996.
 XX
 XX 10-DEC-1993; 9305-0165516.
 XX
 XX 20-SEP-1991; 9105-0762768.
 XX
 XX 24-JAN-1990; 9005-0468736.
 XX
 XX 10-DEC-1993; 9305-0165516.
 XX
 XX (BUCK/) BUCKLEY D I.
 XX (HABE/) HABENER J F.
 XX (MALL/) MALLORY J B.
 XX (MOJS/) MOJSOV S.

PI Buckley DI, Habener JF, Mallory JB, Mojssov S;
 XX WPI: 1996-383697/38.
 DR
 XX New modified glucagon-like peptide I fragments - have higher
 PT activity than glucagon or have improved plasma stability, useful for
 PT treating type II diabetes
 PT
 XX Example 1; page -: 16pp; English.
 XX
 XX The present peptide is a specific example of a claimed human
 CC glucagon like peptide 1 (GLP-1) analogue, which is useful for
 CC stimulating insulin release from pancreatic islet cells, especially
 CC in the treatment of type II diabetes at doses of 1 pg/kg to
 CC 1 mg/kg.
 CC (Updated on 25-MAR-2003 to correct PF field.)
 XX Sequence 31 AA;
 SQ
 Query Match 100.0%; Score 161; DB 17; Length 31;
 Best Local Similarity 100.0%; Pred. No. 2.2e-16;
 Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 HAEGETFSDVSYLLEGOAKKEFIAMLVKGRG 31
 Db 1 HAEGETFSDVSYLLEGOAKKEFIAMLVKGRG 31
 RESULT 14
 AAW03899
 ID AAW03899 standard; peptide; 31 AA.
 XX
 AC AAW03899;
 XX
 DT 25-MAR-2003 (updated)
 DT 15-APR-1997 (first entry)
 XX
 DE Glucagon like peptide 1 (7-37) analogue D-Lys26.
 XX Human; glucagon like peptide; GLP-1; analogue; stimulation;
 KW pancreas; insulin; islet cell; treatment; type II diabetes.
 XX Homo sapiens.
 XX
 FH Key Location/Qualifiers
 FT Modified-site 1 /note= "D-form residue"
 FT Misc-difference 20 /note= "D-form residue"
 FT Misc-difference 29 /note= "optionally absent when Arg30 and Gly31 are
 FT Misc-difference 30 /note= "optionally absent when Gly31 is absent"
 FT Misc-difference 31 /note= "optionally absent"
 FT Misc-difference 31 /note= "optionally absent"
 PN US54545618-A.
 XX
 DT 13-AUG-1996.
 XX
 PF 10-DEC-1993; 93US-0165516.
 XX
 PR 20-SEP-1991; 91US-0762768.
 PR 24-JAN-1990; 90US-0468736.
 PR 10-DEC-1993; 93US-0165516.
 XX
 PA (BUCKLEY) BUCKLEY D I.
 PA (HABENER) HABENER J F.
 PA (MALLORY) MALLORY J B.
 PA (MOJSOV) MOJSOV S.
 XX
 PI Buckley DI, Habener JF, Mallory JB, Mojssov S;
 XX WPI: 1996-383697/38.
 XX New modified glucagon-like peptide I fragments - have higher
 PT activity than glucagon or have improved plasma stability, useful for

XX New modified glucagon-like peptide I fragments - have higher
 PT activity than glucagon or have improved plasma stability, useful for
 PT treating type II diabetes
 PT
 XX Example 1; page -: 16pp; English.
 XX
 XX The present peptide is a specific example of a claimed human
 CC glucagon like peptide 1 (GLP-1) analogue, which is useful for
 CC stimulating insulin release from pancreatic islet cells, especially
 CC in the treatment of type II diabetes at doses of 1 pg/kg to
 CC 1 mg/kg.
 CC (Updated on 25-MAR-2003 to correct PF field.)
 XX Sequence 31 AA;
 SQ
 Query Match 100.0%; Score 161; DB 17; Length 31;
 Best Local Similarity 100.0%; Pred. No. 2.2e-16;
 Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 HAEGETFSDVSYLLEGOAKKEFIAMLVKGRG 31
 Db 1 HAEGETFSDVSYLLEGOAKKEFIAMLVKGRG 31
 RESULT 15
 AAW03865
 ID AAW03865 standard; peptide; 31 AA.
 XX
 AC AAW03865;
 XX
 DT 25-MAR-2003 (updated)
 DT 15-APR-1997 (first entry)
 XX
 DE Glucagon like peptide 1 (7-37) analogue N-formyl-(D-His/L-His7).
 XX Human; glucagon like peptide; GLP-1; analogue; stimulation;
 KW pancreas; insulin; islet cell; treatment; type II diabetes.
 XX Homo sapiens.
 XX
 FH Key Location/Qualifiers
 FT Modified-site 1 /note= "N-formyl-(D/L)-histidine"
 FT Misc-difference 29 /note= "optionally absent when Arg30 and Gly31 are
 FT Misc-difference 30 /note= "optionally absent when Gly31 is absent"
 FT Misc-difference 31 /note= "optionally absent"
 FT Misc-difference 31 /note= "optionally absent"
 PN US54545618-A.
 XX
 DT 13-AUG-1996.
 XX
 PF 10-DEC-1993; 93US-0165516.
 XX
 PR 20-SEP-1991; 91US-0762768.
 PR 24-JAN-1990; 90US-0468736.
 PR 10-DEC-1993; 93US-0165516.
 XX
 PA (BUCKLEY) BUCKLEY D I.
 PA (HABENER) HABENER J F.
 PA (MALLORY) MALLORY J B.
 PA (MOJSOV) MOJSOV S.
 XX
 PI Buckley DI, Habener JF, Mallory JB, Mojssov S;
 XX WPI: 1996-383697/38.
 XX New modified glucagon-like peptide I fragments - have higher
 PT activity than glucagon or have improved plasma stability, useful for


```

QY 1 HAEFTTSDVSYLGGQAKEFTAMLVKRG 31
      |||||
Db 1 HAEFTTSDVSYLGGQAKEFTAMLVKRG 31

RESULT 2
US-08-470-220A-3
; Sequence 3, Application US/08470220A
; Patent No. 5707826
; GENERAL INFORMATION:
; APPLICANT: Stout, Jay
; APPLICANT: Wagner, Fred W.
; APPLICANT: Henriksen, Dennis
; APPLICANT: Partidge, Bruce
; APPLICANT: Manning, Shane
; TITLE OF INVENTION: Enzymatic Method for Modification of
; TITLE OF INVENTION: Recombinant Polypeptides
; NUMBER OF SEQUENCES: 26
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Merchant & Gould
; STREET: 3100 No. 5707826west Center
; CITY: Minneapolis
; STATE: MN
; COUNTRY: USA
; ZIP: 55402
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/470-220A
; FILING DATE: 06-JUN-1995
; CLASSIFICATION: 433
; PRIORITY INFORMATION:
; APPLICATION NUMBER: US 08/095,162
; FILING DATE: 20-JUL-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Nelson, Albin J.
; REGISTRATION NUMBER: 28,659
; REFERENCE/POCKET NUMBER: B648.32-US01
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 612-332-5300
; TELEFAX: 612-332-9081
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 31 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: Peptide
; IMMEDIATE SOURCE:
; CLONE: GLP1 (7-36)-Gly
US-08-470-220A-3

Query Match 100.0%; Score 161; DB 1; Length 31;
Best Local Similarity 100.0%; Pred. No. 9.9e-17;
Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HAEFTTSDVSYLGGQAKEFTAMLVKRG 31
      |||||
Db 1 HAEFTTSDVSYLGGQAKEFTAMLVKRG 31

RESULT 3
US-08-967-374-3
; Sequence 3, Application US/08967374
; Patent No. 6191102
; GENERAL INFORMATION:
; APPLICANT: Stout, Jay
; APPLICANT: Wagner, Fred W.
; APPLICANT: Henriksen, Dennis
; APPLICANT: Partidge, Bruce
; APPLICANT: Manning, Shane
; TITLE OF INVENTION: Enzymatic Method for Modification of
; TITLE OF INVENTION: Recombinant Polypeptides
; NUMBER OF SEQUENCES: 26
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Merchant & Gould
; STREET: 3100 No. 5707826west Center
; CITY: Minneapolis
; STATE: MN
; COUNTRY: USA
; ZIP: 55402
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/967,374
; FILING DATE: 06-JUN-1995
; CLASSIFICATION: 433
; PRIORITY INFORMATION:
; APPLICATION NUMBER: US 08/095,162
; FILING DATE: 20-JUL-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Nelson, Albin J.
; REGISTRATION NUMBER: 28,659
; REFERENCE/POCKET NUMBER: B648.32-US01
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 612-332-5300
; TELEFAX: 612-332-9081
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 31 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: Peptide
; IMMEDIATE SOURCE:
; CLONE: GLP1 (7-36)-Gly
US-08-967-374-3

Query Match 100.0%; Score 161; DB 1; Length 31;
Best Local Similarity 100.0%; Pred. No. 9.9e-17;
Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HAEFTTSDVSYLGGQAKEFTAMLVKRG 31
      |||||
Db 1 HAEFTTSDVSYLGGQAKEFTAMLVKRG 31

RESULT 4
US-08-961-405A-1
; Sequence 1, Application US/08961405A
; Patent No. 6191102
; GENERAL INFORMATION:
; APPLICANT: Dimarchi, Richard D.
; APPLICANT: Etendic, Sued
; APPLICANT: INVENTOR: USE OF GLP-1 ANALOGS AND DERIVATIVES
; TITLE OF INVENTION: ADMINISTERED PERIPHERALLY IN REGULATION OF OBESITY
; NUMBER OF SEQUENCES: 9
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: BARNES & THORNEURG
; STREET: 200 W. Madison, Suite 2601
; CITY: Chicago
; STATE: Illinois
; COUNTRY: USA
; ZIP: 60605
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/961,405A
; FILING DATE: 30-OCT-1997

```

```

; TITLE OF INVENTION: Enzymatic Method for Modification of
; TITLE OF INVENTION: Recombinant Polypeptides
; NUMBER OF SEQUENCES: 26
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Merchant & Gould
; STREET: 3100 No. 5707826west Center
; CITY: Minneapolis
; STATE: MN
; COUNTRY: USA
; ZIP: 55402
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/967,374
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/520,485
; FILING DATE: 29-AUG-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Merchant, Charles G.
; REGISTRATION NUMBER: 3,093
; REFERENCE/POCKET NUMBER: B648.32-US01
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 612-332-5300
; TELEFAX: 612-332-9081
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 31 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: Peptide
; IMMEDIATE SOURCE:
; CLONE: GLP1 (7-36)-Gly
US-08-967-374-3

Query Match 100.0%; Score 161; DB 3; Length 31;
Best Local Similarity 100.0%; Pred. No. 9.9e-17;
Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HAEFTTSDVSYLGGQAKEFTAMLVKRG 31
      |||||
Db 1 HAEFTTSDVSYLGGQAKEFTAMLVKRG 31

RESULT 4
US-08-961-405A-1
; Sequence 1, Application US/08961405A
; Patent No. 6191102
; GENERAL INFORMATION:
; APPLICANT: Dimarchi, Richard D.
; APPLICANT: Etendic, Sued
; APPLICANT: INVENTOR: USE OF GLP-1 ANALOGS AND DERIVATIVES
; TITLE OF INVENTION: ADMINISTERED PERIPHERALLY IN REGULATION OF OBESITY
; NUMBER OF SEQUENCES: 9
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: BARNES & THORNEURG
; STREET: 200 W. Madison, Suite 2601
; CITY: Chicago
; STATE: Illinois
; COUNTRY: USA
; ZIP: 60605
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/961,405A
; FILING DATE: 30-OCT-1997

```

; PRIOR APPLICATION DATA:
 ; APPLICATION NUMBER: US 60/030,213
 ; FILING DATE: 05-NOV-1996
 ; ATTORNEY/AGENT INFORMATION:
 ; NAME: Martin, Alice O.
 ; REGISTRATION NUMBER: 5,401
 ; REFERENCE/DOCKET NUMBER: 3051/90264
 ; TELECOMMUNICATION INFORMATION:
 ; TELEPHONE: 312-357-1313
 ; TELEFAX: 312-759-5646
 ; INFORMATION FOR SEQ ID NO: 1:
 ; SEQUENCE CHARACTERISTICS:
 ; LENGTH: 31 amino acids
 ; TYPE: amino acid
 ; STRANDEDNESS:
 ; TOPOLOGY: linear
 ; MOLECULE TYPE: Peptide
 ; US-08-961-405A-1

 Query Match 100.0%; Score 161; DB 3; Length 31;
 Best Local Similarity 100.0%; Pred. No. 9.9e-17;
 Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

 QY 1 HAEGTFTSDVSYLGGQAQKEFIAMLVKGRG 31
 DB 1 HAEGTFTSDVSYLGGQAQKEFIAMLVKGRG 31

 RESULT 5
 US-08-915-918A-1
 ; Sequence 1, Application US/08915918A
 ; Patent No. 6277819
 ; GENERAL INFORMATION:
 ; APPLICANT: Eficidic, Suard
 ; TITLE OF INVENTION: USE OF GLP-1 OR ANALOGS IN TREATMENT OF
 ; TITLE OF INVENTION: MYOCARDIAL INFARCTION
 ; INVENTOR: Eficidic, Suard
 ; CORRESPONDENCE ADDRESS:
 ; ADDRESSEE: BRINKS, HOPPER, GILSON & LIGONE
 ; STREET: NBC Tower - Suite 3600, 455 N. Cityfront
 ; CITY: Chicago
 ; STATE: Illinois
 ; COUNTRY: USA
 ; ZIP: 60611-5599
 ; COMPUTER READABLE FORM: disk
 ; FILING DATE: 21-AUG-1997
 ; CURRENT APPLICATION NUMBER: US/08/915,918A
 ; FILING DATE: 21-AUG-1997
 ; CLASSIFICATION: 514
 ; ATTORNEY/AGENT INFORMATION:
 ; NAME: Martin, Alice O.
 ; REGISTRATION NUMBER: 5,401
 ; REFERENCE/DOCKET NUMBER: 8792/28
 ; TELECOMMUNICATION INFORMATION:
 ; TELEPHONE: 312-321-4200
 ; TELEFAX: 312-321-4299
 ; INFORMATION FOR SEQ ID NO: 1:
 ; SEQUENCE CHARACTERISTICS:
 ; LENGTH: 31 amino acids
 ; TYPE: amino acid
 ; STRANDEDNESS:
 ; TOPOLOGY: linear
 ; MOLECULE TYPE: peptide
 ; US-08-915-918A-1

 Query Match 100.0%; Score 161; DB 3; Length 31;
 Best Local Similarity 100.0%; Pred. No. 9.9e-17;
 Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HAEGTFTSDVSYLGGQAQKEFIAMLVKGRG 31
 DB 1 HAEGTFTSDVSYLGGQAQKEFIAMLVKGRG 31

 RESULT 6
 US-09-302-596-3
 ; Sequence 3, Application US/09302596
 ; Patent No. 6284725
 ; GENERAL INFORMATION:
 ; APPLICANT: Coolidge, Thomas R.
 ; TITLE OF INVENTION: Metabolic Intervention with GLP-1 to Improve the Function of
 ; TITLE OF INVENTION: Ischemic and Reperfused Tissue
 ; INVENTOR: Coolidge, Thomas R.
 ; CURRENT APPLICATION NUMBER: US/09/302,596
 ; CURRENT FILING DATE: 1999-04-30
 ; PRIOR APPLICATION NUMBER: 60/103,498
 ; PRIOR FILING DATE: 1998-10-08
 ; NUMBER OF SEQ ID NOS: 13
 ; SOFTWARE: Patent In Ver. 2.0
 ; SEQ ID NO 3
 ; TYPE: PRT
 ; ORGANISM: mammalian
 ; US-09-302-596-3

 Query Match 100.0%; Score 161; DB 3; Length 31;
 Best Local Similarity 100.0%; Pred. No. 9.9e-17;
 Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

 QY 1 HAEGTFTSDVSYLGGQAQKEFIAMLVKGRG 31
 DB 1 HAEGTFTSDVSYLGGQAQKEFIAMLVKGRG 31

 RESULT 7
 US-08-472-349-2
 ; Sequence 2, Application US/08472349
 ; Patent No. 6284727
 ; GENERAL INFORMATION:
 ; APPLICANT: Kim, Yesook
 ; APPLICANT: Lambert, William J.
 ; APPLICANT: Qi, Hong
 ; APPLICANT: Geifang, Robert A.
 ; APPLICANT: Geoghegan, Kathleen F.
 ; APPLICANT: D'Amico, Joseph E.
 ; TITLE OF INVENTION: Prolonged Delivery of Peptides
 ; NUMBER OF SEQUENCES: 7
 ; CORRESPONDENCE ADDRESS:
 ; ADDRESSEE: Pfizer Inc
 ; STREET: 235 East 42nd Street, 20th Floor
 ; CITY: New York
 ; STATE: New York
 ; COUNTRY: U.S.A.
 ; ZIP: 10017-5785
 ; COMPUTER READABLE FORM:
 ; MEDIA TYPE: floppy disk
 ; OPERATING SYSTEM: IBM PC compatible
 ; SOFTWARE: Patent Release #1.0, Version #1.25
 ; CURRENT APPLICATION DATA:
 ; APPLICATION NUMBER: US/08/472,349
 ; FILING DATE:
 ; CLASSIFICATION: 514
 ; PRIOR APPLICATION DATA:
 ; APPLICATION NUMBER: US/08/181,655
 ; FILING DATE:
 ; ATTORNEY/AGENT INFORMATION:
 ; NAME: Shevka, Robert F.
 ; REGISTRATION NUMBER: 31,304
 ; REFERENCE/DOCKET NUMBER: PC8391

```

; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212)573-1189
; TELEFAX: N/A
; INFORMATION FOR SEQ ID NO. 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 31 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: Peptide
; HYPOTHEetical: NO
; ANTI-SENSE: NO
; ORIGIN: N/A
; ORGANISM: N/A
; STRAIN: N/A
; INDIVIDUAL ISOLATE: N/A
; HAPLOTYPE: N/A
; CELL LINE: N/A
; IMMEDIATE SOURCE:
; LIBRARY: N/A
; CLONE: N/A
; POSITIONING: N/A
; MAPPING: N/A
; MAP POSITION: N/A
; UNITS: N/A
US-08-472-349-2

Query Match 100.0%; Score 161; DB 3; Length 31;
Best Local Similarity 100.0%; Pred. No. 9.9e-17;
Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HAEQFTSDVSSYLEGQAQKEFIAMLVKGRG 31
DB 1 HAEQFTSDVSSYLEGQAQKEFIAMLVKGRG 31

RESULT 8
US-09-623-618B-2
; Sequence 2, Application US/09623618B
; Patent No. 6329336
; GENERAL INFORMATION:
; APPLICANT: Biogen, Inc.
; APPLICANT: Ezzib, Alan M.
; APPLICANT: Holmes, Darren L.
; APPLICANT: Leblanc, Anouk
; APPLICANT: St. Pierre, Serge
; TITLE OF INVENTION: LONG LASTING INSULINOTROPIC PEPTIDES
; FILE REFERENCE: 500862001620
; CURRENT APPLICATION NUMBER: US/09/623-618B
; CURRENT FILING DATE: 2000-09-05
; PRIOR FILING DATE: 2000-05-17
; PRIOR APPLICATION NUMBER: 60/159,783
; PRIOR FILING DATE: 1999-10-15
; PRIOR APPLICATION NUMBER: 60/134,405
; PRIOR FILING DATE: 1999-05-17
; NUMBER OF SEQ ID NOS: 35
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 2
; LENGTH: 31
; TYPE: PPT
; ORGANISM: Artificial Sequence
; REMARKS:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: Peptide
US-09-623-618B-2

Query Match 100.0%; Score 161; DB 4; Length 31;
Best Local Similarity 100.0%; Pred. No. 9.9e-17;
Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

QY 1 HAEQFTSDVSSYLEGQAQKEFIAMLVKGRG 31
DB 1 HAEQFTSDVSSYLEGQAQKEFIAMLVKGRG 31

RESULT 9
US-09-333-415-3
; Sequence 3, Application US/09333415
; Patent No. 6344180
; GENERAL INFORMATION:
; APPLICANT: Holst, Jens J.
; APPLICANT: Vilsbøll, Tina
; TITLE OF INVENTION: GLP-1 as a Diagnostic Test to Determine Beta-Cell
; TITLE OF INVENTION: Function and the Presence of the Condition of IGT and
; TITLE OF INVENTION: Type II Diabetes
; FILE REFERENCE: P03987050
; CURRENT APPLICATION NUMBER: US/09/333/415
; CURRENT FILING DATE: 1999-06-15
; NUMBER OF SEQ ID NOS: 13
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 3
; LENGTH: 31
; TYPE: PPT
; ORGANISM: Homo sapiens
US-09-333-415-3

Query Match 100.0%; Score 161; DB 4; Length 31;
Best Local Similarity 100.0%; Pred. No. 9.9e-17;
Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HAEQFTSDVSSYLEGQAQKEFIAMLVKGRG 31
DB 1 HAEQFTSDVSSYLEGQAQKEFIAMLVKGRG 31

RESULT 10
US-09-209-799D-1
; Sequence 1, Application US/09209799D
; Patent No. 6380357
; GENERAL INFORMATION:
; APPLICANT: Hermeling, Ronald
; APPLICANT: Narasimhan, Chakravarthy
; TITLE OF INVENTION: CHACON-LIKE PEPTIDE-1 CRYSTALS
; FILE REFERENCE: 0242
; CURRENT APPLICATION NUMBER: US/09/209,799D
; CURRENT FILING DATE: 1998-12-11
; NUMBER OF SEQ ID NOS: 29
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1
; LENGTH: 31
; TYPE: PPT
; ORGANISM: Homo sapiens
US-09-209-799D-1

Query Match 100.0%; Score 161; DB 4; Length 31;
Best Local Similarity 100.0%; Pred. No. 9.9e-17;
Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HAEQFTSDVSSYLEGQAQKEFIAMLVKGRG 31
DB 1 HAEQFTSDVSSYLEGQAQKEFIAMLVKGRG 31

RESULT 11
US-09-505-991-3
; Sequence 3, Application US/09505991
; Patent No. 6403361
; GENERAL INFORMATION:
; APPLICANT: Wagner, Fred W.
; APPLICANT: Stout, Jay
; APPLICANT: Henriksen, Dennis

```

1 Partridge, Bruce
2 Manning, Shane
3 TITLE OF INVENTION: Enzymatic Method for Modification of
4 Recombinant Polypeptides
5
6 NUMBER OF SEQUENCES: 26
7 ADDRESSEE: Merchand & Gould
8 CORRESPONDENCE ADDRESS:
9 STREET: 3100 No. 640361west Center
10 CITY: Minneapolis
11 STATE: MN
12 COUNTRY: USA
13
14 ZIP: 55402
15
16 COMPUTER READABLE FORM:
17 MEDIUM TYPE: Floppy disk
18 COMPUTER: IBM PC compatible
19 OPERATING SYSTEM: PC-DOS/MS-DOS
20 SOFTWARE: Patent Release #1.0, Version #1.30
21
22 CURRENT APPLICATION DATA:
23 APPLICATION NUMBER: US/09/505,991
24 FILING DATE: 17-Feb-2000
25 CLASSIFICATION: <UNKNOWN>
26
27 PRIORITY DATA:
28 NUMBER: 08/520,485
29 FILING DATE: 08/08/98
30 ATTORNEY/AGENT INFORMATION:
31 NAME: Carter, Charles G.
32 REGISTRATION NUMBER: 35,093
33 REFERENCE/DOCKET NUMBER: 8648.32-US/1
34
35 TELECOMMUNICATION INFORMATION:
36 TELEPHONE: 612-332-3300
37 TELEFAX: 612-332-9081
38
39 INFORMATION FOR SEQ ID NO: 3:
40 SEQUENCE CHARACTERISTICS:
41 LENGTH: 31
42 TYPE: amino acid
43 TOPOLOGY: linear
44 MOLECULE TYPE: peptide
45 IMMEDIATE SOURCE:
46 CLONE: GLP1 (7-36)-GLY
47
48 SEQUENCE DESCRIPTION: SEQ ID NO: 3:
49
50 US-09-505-991-3
51
52 Query Match 100.0%; Score 161; DB 4; Length 31;
53 Best Local Similarity 100.0%; Pred. No. 9,9e-17;
54 Matches 31; Conservative 0; Mismatches 0; Indels 0;
55
56 QY 1 HAEGFTSDVSSYLEGQAAKEFIAWLKGRG 31
57 ||||||||||||||||||||||||||||
58 DB 1 HAEGFTSDVSSYLEGQAAKEFIAWLKGRG 31
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000

Query Match 100.0%; Score 161; DB 4; Length 31;
Best Local Similarity 100.0%; Pred. No. 9,9e-17;
Matches 31; Conservative 0; Mismatches 0; Indels 0;
Gaps 0;

QY 1 HAEGFTSDVSSYLEGQAAKEFIAWLKGRG 31
|||||
DB 1 HAEGFTSDVSSYLEGQAAKEFIAWLKGRG 31

RESULT 13
US-09-657-332A-2
; Sequence 2, Application US/09657332A
; Patent No. 6514500
; GENERAL INFORMATION:
; APPLICANT: Bridon, Dominique P.
; APPLICANT: L'Archeveque, Benoit
; APPLICANT: Ezrin, Alan M.
; APPLICANT: Holmes, Darren L.
; APPLICANT: Leblanc, Anouk
; APPLICANT: St. Pierre, Serge
; TITLE OF INVENTION: LONG LASTING SYNTHETIC GLUCAGON LIKE PEPTIDE (GLP-1)
; REFERENCE: US/08/520,485
; CURRENT FILING DATE: 2001-09-10
; CURRENT FILING DATE: 2001-09-10
; PRIOR APPLICATION NUMBER: 60/159,783
; PRIOR FILING DATE: 1999-10-15
; PRIOR APPLICATION NUMBER: 60/134,406
; PRIOR FILING DATE: 1999-05-17
; NUMBER OF SEQ ID NOS: 35
; SOFTWARE: Patentin Ver. 2.1
; SEQ ID NO 2
; LENGTH: 31
; TYPE: Peptide
; ORGANISM: Artificial Sequence
; FEATURES:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: Peptide
; US-09-657-332A-2

Query Match 100.0%; Score 161; DB 4; Length 31;
Best Local Similarity 100.0%; Pred. No. 9,9e-17;
Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HAEGFTSDVSSYLEGQAAKEFIAWLKGRG 31
|||||
DB 1 HAEGFTSDVSSYLEGQAAKEFIAWLKGRG 31

RESULT 14
US-09-614-847-124
; Sequence 124, Application US/09614847
; Patent No. 6528486
; GENERAL INFORMATION:
; APPLICANT: Jansen, Bjørn Due
; APPLICANT: Mikkelsen, Jens Møllgaard
; APPLICANT: Nissen, Niels
; TITLE OF INVENTION: NOVEL PEPTIDE AGONISTS OF GLP-1 ACTIVITY
; FILE REFERENCE: 55511(45487)
; CURRENT APPLICATION NUMBER: US/09/614,847
; CURRENT FILING DATE: 2000-07-12
; PRIOR APPLICATION NUMBER: US 60/143,591
; PRIOR FILING DATE: 1999-07-13
; NUMBER OF SEQ ID NOS: 153
; SOFTWARE: Patentin Ver. 2.1
; SEQ ID NO 124
; LENGTH: 31
; TYPE: PPT
; ORGANISM: Homo sapiens
; FEATURES:
; OTHER INFORMATION: GLP-1(7-37)
; US-09-614-847-124

Query Match 100.0%; Score 161; DB 4; Length 31;
Best Local Similarity 100.0%; Pred. No. 9.9e-17;
Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HAEGFTSDVSSYLEGQAAKEFIAWLKRG 31
|||||
Db 1 HAEGFTSDVSSYLEGQAAKEFIAWLKRG 31

RESULT 15

US-09-997-792A-1
; Sequences 1, Application US/09997792A
; Accession: X-10242A
; General Information:
; APPLICANT: ELI LILLY and COMPANY
; TITLE OF INVENTION: Glucagon-Like Peptide-1 Crystals
; FILE REFERENCE: X-10242A
; CURRENT APPLICATION NUMBER: US/09/997,792A
; CURRENT FILING DATE: 2002-09-30
; PRIOR APPLICATION NUMBER: US 60/069,728
; PRIORITY FILING DATE: 1997-12-16
; INVENTOR: GREGORY M. ROBERTS
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 1
; LENGTH: 31
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-997-792A-1

Query Match 100.0%; Score 161; DB 4; Length 31;
Best Local Similarity 100.0%; Pred. No. 9.9e-17;
Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HAEGFTSDVSSYLEGQAAKEFIAWLKRG 31
|||||
Db 1 HAEGFTSDVSSYLEGQAAKEFIAWLKRG 31

Search completed: October 15, 2003, 10:57:31
Job time : 21.3279 secs

| Result | No. | Score | Query Match | Length | DB | ID | Description |
|--------|-----|-------|-------------|--------|------------------|-------------------|-------------|
| 1 | 161 | 100.0 | 31 | 9 | US-09-876-388-2 | Sequence 2, Appli | |
| 2 | 161 | 100.0 | 31 | 9 | US-09-851-738-3 | Sequence 3, Appli | |
| 3 | 161 | 100.0 | 31 | 9 | US-09-805-507-3 | Sequence 3, Appli | |
| 4 | 161 | 100.0 | 31 | 10 | US-09-859-804-3 | Sequence 3, Appli | |
| 5 | 161 | 100.0 | 31 | 10 | US-09-982-978-3 | Sequence 3, Appli | |
| 6 | 161 | 100.0 | 31 | 10 | US-09-983-021B-3 | Sequence 3, Appli | |
| 7 | 161 | 100.0 | 31 | 11 | US-09-834-729A-1 | Sequence 1, Appli | |
| 8 | 161 | 100.0 | 31 | 11 | US-09-997-792-1 | Sequence 1, Appli | |
| 9 | 161 | 100.0 | 31 | 12 | US-10-097-230-2 | Sequence 1, Appli | |
| 10 | 161 | 100.0 | 31 | 14 | US-10-072-540A-1 | Sequence 1, Appli | |
| 11 | 161 | 100.0 | 31 | 15 | US-10-093-598-19 | Sequence 1, Appli | |
| 12 | 161 | 100.0 | 31 | 15 | US-10-091-758-3 | Sequence 1, Appli | |
| 13 | 161 | 100.0 | 31 | 15 | US-10-091-255-3 | Sequence 3, Appli | |
| 14 | 161 | 100.0 | 31 | 15 | US-10-087-682-2 | Sequence 2, Appli | |
| 15 | 161 | 100.0 | 31 | 15 | US-10-285-255-3 | Sequence 2, Appli | |

```
QY 1 HAEFTTSVSVYLEGQAQKEFIAMLVKRG 31
|||||
Db 1 HAEFTTSVSVYLEGQAQKEFIAMLVKRG 31

RESULT 2
US-09-851-738-3
; Sequence 3, Application US/09851738
; Patent No. US20020053460A1
; GENERAL INFORMATION:
; APPLICANT: Coolidge, Thomas R.
; TITLE OF INVENTION: Ischemic and Reperused Tissue
; FILE REFERENCE: P036600S1
; CURRENT APPLICATION NUMBER: US/09/851,738
; CURRENT FILING DATE: 2001-03-05
; PRIOR FILING DATE: 1995-04-30
; NUMBER OF SEQ ID NOS: 13
; SOFTWARE: Patent In Ver. 2.0
; SEQ ID NO 3
; TYPE: PRT
; ORGANISM: mammalian
US-09-851-738-3
Query Match
Best Local Similarity 100.0%; Score 161; DB 9; Length 31;
Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HAEFTTSVSVYLEGQAQKEFIAMLVKRG 31
|||||
Db 1 HAEFTTSVSVYLEGQAQKEFIAMLVKRG 31

RESULT 3
US-09-805-507-3
; Sequence 3, Application US/09805507
; Patent No. US20020098195A1
; GENERAL INFORMATION:
; APPLICANT: Coolidge, Thomas R.
; TITLE OF INVENTION: TREATMENT OF ACUTE CORONARY SYNDROME WITH GLP-1
; FILE REFERENCE: US/09/805,507
; CURRENT APPLICATION NUMBER: US/09/805,507
; CURRENT FILING DATE: 2001-03-14
; PRIOR FILING DATE: 2001-03-14
; PRIOR APPLICATION NUMBER: 09/859,804
; NUMBER OF SEQ ID NOS: 13
; SOFTWARE: Patent In Ver. 2.1
; SEQ ID NO 3
; TYPE: PRT
; ORGANISM: Unknown Organism
; FEATURE:
; OTHER INFORMATION: Description of Unknown Organism: Mammalian GLP
US-09-805-507-3
Query Match
Best Local Similarity 100.0%; Score 161; DB 9; Length 31;
Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HAEFTTSVSVYLEGQAQKEFIAMLVKRG 31
|||||
Db 1 HAEFTTSVSVYLEGQAQKEFIAMLVKRG 31

RESULT 4
US-09-859-804-3
; Sequence 3, Application US/09859804
; Patent No. US20020107206A1
```

```
; GENERAL INFORMATION:
; APPLICANT: COOLIDGE, THOMAS R.
; TITLE OF INVENTION: TREATMENT OF ACUTE CORONARY SYNDROME WITH GLP-1
; FILE REFERENCE: 089187/0395
; CURRENT APPLICATION NUMBER: US/09/859,804
; CURRENT FILING DATE: 2001-05-18
; PRIOR FILING DATE: 2000-05-19
; NUMBER OF SEQ ID NOS: 13
; SOFTWARE: Patent In Ver. 2.1
; SEQ ID NO 3
; TYPE: PRT
; ORGANISM: Unknown Organism
; FEATURE:
; OTHER INFORMATION: Description of Unknown Organism: Mammalian GLP
US-09-859-804-3
Query Match
Best Local Similarity 100.0%; Score 161; DB 10; Length 31;
Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HAEFTTSVSVYLEGQAQKEFIAMLVKRG 31
|||||
Db 1 HAEFTTSVSVYLEGQAQKEFIAMLVKRG 31

RESULT 5
US-09-982-978-3
; Sequence 3, Application US/09982978
; Patent No. US2002014605A1
; GENERAL INFORMATION:
; APPLICANT: COOLIDGE, THOMAS R.
; TITLE OF INVENTION: TREATMENT OF ACUTE CORONARY SYNDROME WITH GLP-1
; FILE REFERENCE: 089187/0395
; CURRENT APPLICATION NUMBER: US/09/982,978
; CURRENT FILING DATE: 2001-10-22
; PRIOR FILING DATE: 2001-05-18
; PRIOR APPLICATION NUMBER: 09/859,804
; PRIOR FILING DATE: 2000-05-19
; NUMBER OF SEQ ID NOS: 13
; SOFTWARE: Patent In Ver. 2.1
; SEQ ID NO 3
; TYPE: PRT
; ORGANISM: Unknown Organism
; FEATURE:
; OTHER INFORMATION: Description of Unknown Organism: Mammalian GLP
US-09-982-978-3
Query Match
Best Local Similarity 100.0%; Score 161; DB 10; Length 31;
Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HAEFTTSVSVYLEGQAQKEFIAMLVKRG 31
|||||
Db 1 HAEFTTSVSVYLEGQAQKEFIAMLVKRG 31

RESULT 6
US-09-953-021B-3
; Sequence 3, Application US/09953021B
; Patent No. US20020147131A1
; GENERAL INFORMATION:
; APPLICANT: Coolidge, Thomas L.
; TITLE OF INVENTION: Metabolic Intervention with GLP-1 to Improve the Function of
; FILE REFERENCE: 089187/0395
; CURRENT APPLICATION NUMBER: US/09/953,021B
; CURRENT FILING DATE: 2001-03-05
; PRIOR FILING DATE: 1995-04-30
; NUMBER OF SEQ ID NOS: 13
; SOFTWARE: Patent In Ver. 2.0
; SEQ ID NO 3
; TYPE: PRT
; ORGANISM: mammalian
US-09-953-021B-3
Query Match
Best Local Similarity 100.0%; Score 161; DB 9; Length 31;
Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HAEFTTSVSVYLEGQAQKEFIAMLVKRG 31
|||||
Db 1 HAEFTTSVSVYLEGQAQKEFIAMLVKRG 31

RESULT 7
US-09-859-804-3
; Sequence 3, Application US/09859804
; Patent No. US20020107206A1
```



```

; FILE REFERENCE: P036600S6
; CURRENT APPLICATION NUMBER: US/09/953,021B
; CURRENT FILING DATE: 2001-09-11
; PRIOR APPLICATION NUMBER: 09/302,596
; PRIOR FILING DATE: 1999-04-30
; NUMBER OF SEQ ID NOS: 13
; SOFTWARE: Patent Ver. 2.0
; SEQ ID NO 3
; LENGTH: 31
; ORGANISM: Homo sapiens
US-09-953-021B-3

Query Match      100.0%; Score 161; DB 10; Length 31;
Best Local Similarity 100.0%; Pred. No. 5.2e-17;
Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HAEGTFTSDVSSYLEGQAAKEFIAWLKRG 31
Db 1 HAEGTFTSDVSSYLEGQAAKEFIAWLKRG 31

RESULT 7
US-09-434-229A-1
; Sequence 1, Application US/09834229A
; Publication No. US2003022823A1
; GENERAL INFORMATION:
; APPLICANT: Eficidic, Suad
; TITLE OF INVENTION: USE OF GLP-1 OR ANALOGS IN TREATMENT OF MYOCARDIAL INFARCTION
; FILE REFERENCE: X-10822A
; CURRENT APPLICATION NUMBER: US/09/834,229A
; CURRENT FILING DATE: 2001-09-11
; PRIOR APPLICATION NUMBER: US 08/915,918
; PRIOR FILING DATE: 1997-08-21
; PRIOR APPLICATION NUMBER: US 06/024,980
; PRIOR FILING DATE: 1996-08-30
; NUMBER OF SEQ ID NOS: 6
; SOFTWARE: Patentin version 3.1
; SEQ ID NO 1
; LENGTH: 31
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-834-229A-1

Query Match      100.0%; Score 161; DB 11; Length 31;
Best Local Similarity 100.0%; Pred. No. 5.2e-17;
Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HAEGTFTSDVSSYLEGQAAKEFIAWLKRG 31
Db 1 HAEGTFTSDVSSYLEGQAAKEFIAWLKRG 31

RESULT 8
US-09-997-792-1
; Sequence 1, Application US/09997792
; Publication No. US2003004546A1
; GENERAL INFORMATION:
; APPLICANT: Hermeling, Ronald
; APPLICANT: Hoffmann, James
; APPLICANT: Narasimhan, Chakravarthy
; TITLE OF INVENTION: GLUCAGON-LIKE PEPTIDE-1 CRYSTALS
; FILE REFERENCE: X-10242
; CURRENT APPLICATION NUMBER: US/09/997,792
; CURRENT FILING DATE: 2001-11-30
; NUMBER OF SEQ ID NOS: 20
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 1
; LENGTH: 31
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-997-792-1

```

```

Query Match      100.0%; Score 161; DB 11; Length 31;
Best Local Similarity 100.0%; Pred. No. 5.2e-17;
Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HAEGTFTSDVSSYLEGQAAKEFIAWLKRG 31
Db 1 HAEGTFTSDVSSYLEGQAAKEFIAWLKRG 31

RESULT 9
US-10-097-230-2
; Sequence 1, Application US/10097230
; Publication No. US20030186436A1
; GENERAL INFORMATION:
; APPLICANT: Perfetti, Riccardo
; APPLICANT: Hui, Hongxiang
; TITLE OF INVENTION: Glucose-Dependent Insulin-Secreting Cells Transfected with a
; FILE REFERENCE: 81476-0249704
; CURRENT APPLICATION NUMBER: US/10/097,230
; CURRENT FILING DATE: 2002-03-12
; NUMBER OF SEQ ID NOS: 9
; SOFTWARE: Patentin version 3.1
; SEQ ID NO 2
; LENGTH: 31
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-097-230-2

Query Match      100.0%; Score 161; DB 12; Length 31;
Best Local Similarity 100.0%; Pred. No. 5.2e-17;
Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HAEGTFTSDVSSYLEGQAAKEFIAWLKRG 31
Db 1 HAEGTFTSDVSSYLEGQAAKEFIAWLKRG 31

RESULT 10
US-10-072-540A-1
; Sequence 1, Application US/10072540A
; Publication No. US20020123466A1
; GENERAL INFORMATION:
; APPLICANT: Hoffmann, James
; TITLE OF INVENTION: GLP-1 FORMULATIONS
; FILE REFERENCE: X-11368A
; CURRENT APPLICATION NUMBER: US/10/072,540A
; CURRENT FILING DATE: 2002-02-08
; PRIOR APPLICATION NUMBER: US 60/067,600
; PRIOR FILING DATE: 1997-12-05
; NUMBER OF SEQ ID NOS: 5
; SOFTWARE: Patentin version 3.1
; SEQ ID NO 1
; LENGTH: 31
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-072-540A-1

Query Match      100.0%; Score 161; DB 14; Length 31;
Best Local Similarity 100.0%; Pred. No. 5.2e-17;
Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HAEGTFTSDVSSYLEGQAAKEFIAWLKRG 31
Db 1 HAEGTFTSDVSSYLEGQAAKEFIAWLKRG 31

RESULT 11
US-10-093-958-19
; Sequence 19, Application US/10093958
; Publication No. US20030044423A1
; GENERAL INFORMATION:
; APPLICANT: Gillies, Stephen

```

```

: TYPE: PRT
US-10-031-256-3
: ORGANISM: mammalian

Query Match 100.0%; Score 161; DB 15; Length 31;
Best Local Similarity 100.0%; Pred. No. 5.2e-17;
Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HAGGFTTSVSSYLEGQAKEFINLKYKRG 31
DB 1 HAGGFTTSVSSYLEGQAKEFINLKYKRG 31
|||||
|||||

RESULT 14
US-10-055-259-3
: Sequence 3, Application US/10055259
: Publication No. US20030091507A1
: GENERAL INFORMATION:
: APPLICANT: Holst, Jens J.
: APPLICANT: Valsroll, Erling
: TITLE OF INVENTION: USE AS A DIAGNOSTIC TEST TO DETERMINE BETA-CELL FUNCTION AND
: FILE REFERENCE: P03987U51
: CURRENT APPLICATION NUMBER: US/10/055,259
: CURRENT FILING DATE: 2002-05-21
: NUMBER OF SEQ ID NOS: 13
: SOFTWARE: PatentIn version 3.1
: SEQ ID NO 3
: LENGTH: 31
: TYPE: PRT
: ORGANISM: Homo sapiens
US-10-055-259-3

Query Match 100.0%; Score 161; DB 15; Length 31;
Best Local Similarity 100.0%; Pred. No. 5.2e-17;
Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HAGGFTTSVSSYLEGQAKEFINLKYKRG 31
DB 1 HAGGFTTSVSSYLEGQAKEFINLKYKRG 31
|||||
|||||

RESULT 15
US-10-287-892-2
: Sequence 2, Application US/10287892
: Publication No. US20030108567A1
: GENERAL INFORMATION:
: APPLICANT: Bridon, Dominique P.
: APPLICANT: B. Archeveque, Benoit
: APPLICANT: B. Archeveque, Benoit
: APPLICANT: Holmes, Darren L.
: APPLICANT: Leblanc, Anouk
: APPLICANT: St. Pierre, Serge
: TITLE OF INVENTION: LONG LASTING SYNTHETIC GLUCAGON LIKE PEPTIDE (GLP-1)
: FILE REFERENCE: 500862001512
: CURRENT APPLICATION NUMBER: US/10/287,892
: CURRENT FILING DATE: 2002-11-04
: PRIOR APPLICATION NUMBER: 09/657,332
: PRIOR FILING DATE: 2000-09-07
: PRIOR APPLICATION NUMBER: 09/657,332
: PRIOR FILING DATE: 1999-10-15
: NUMBER OF SEQ ID NOS: 35
: SOFTWARE: PatentIn Ver. 2.1
: SEQ ID NO 2
: LENGTH: 31
: TYPE: PPT
: ORGANISM: Artificial Sequence
: FEATURE:
: OTHER INFORMATION: Description of Artificial Sequence: Synthetic
: OTHER INFORMATION: Peptide
US-10-287-892-2

Query Match 100.0%; Score 161; DB 15; Length 31;

```

Best Local Similarity 100.0%; Pred. No. 5.2e-17;
Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HAEGFTSDVSSYLEGQAKEFIAMLVKGRG 31
|||||
Db 1 HAEGFTSDVSSYLEGQAKEFIAMLVKGRG 31

Search completed: October 15, 2003, 11:09:32
Job time : 45.2131 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM protein - protein search, using sw model.

Run on: October 15, 2003, 10:53:17 ; Search time 295.262 Seconds
(without alignments)
95.534 Million cell updates/sec

Title: US-09-719-410-3

Perfect score: 161

Sequence: 1 HAEQFTSDVSSYLEGQAQKEFIATLVKGRG 31

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 5728757 seqs, 909318778 residues

Total number of hits satisfying chosen parameters: 5728757

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : Pending_Patents_AA_Main.*

- 1: /cgn2_6/prodata/1/paa/US06_COMB.pep.*
- 2: /cgn2_6/prodata/1/paa/US05_COMB.pep.*
- 3: /cgn2_6/prodata/1/paa/US04_COMB.pep.*
- 4: /cgn2_6/prodata/1/paa/US03_COMB.pep.*
- 5: /cgn2_6/prodata/1/paa/US02_COMB.pep.*
- 6: /cgn2_6/prodata/1/paa/US01_COMB.pep.*
- 7: /cgn2_6/prodata/1/paa/US00_COMB.pep.*
- 8: /cgn2_6/prodata/1/paa/US00_COMB.pep.*
- 9: /cgn2_6/prodata/1/paa/US00_COMB.pep.*
- 10: /cgn2_6/prodata/1/paa/US00_COMB.pep.*
- 11: /cgn2_6/prodata/1/paa/US00_COMB.pep.*
- 12: /cgn2_6/prodata/1/paa/US00_COMB.pep.*
- 13: /cgn2_6/prodata/1/paa/US00_COMB.pep.*
- 14: /cgn2_6/prodata/1/paa/US00_COMB.pep.*
- 15: /cgn2_6/prodata/1/paa/US00_COMB.pep.*
- 16: /cgn2_6/prodata/1/paa/US00_COMB.pep.*
- 17: /cgn2_6/prodata/1/paa/US00_COMB.pep.*
- 18: /cgn2_6/prodata/1/paa/US00_COMB.pep.*
- 19: /cgn2_6/prodata/1/paa/US00_COMB.pep.*
- 20: /cgn2_6/prodata/1/paa/US00_COMB.pep.*
- 21: /cgn2_6/prodata/1/paa/US00_COMB.pep.*
- 22: /cgn2_6/prodata/1/paa/US00_COMB.pep.*
- 23: /cgn2_6/prodata/1/paa/US00_COMB.pep.*
- 24: /cgn2_6/prodata/1/paa/US00_COMB.pep.*
- 25: /cgn2_6/prodata/1/paa/US00_COMB.pep.*
- 26: /cgn2_6/prodata/1/paa/US00_COMB.pep.*
- 27: /cgn2_6/prodata/1/paa/US00_COMB.pep.*
- 28: /cgn2_6/prodata/1/paa/US00_COMB.pep.*
- 29: /cgn2_6/prodata/1/paa/US00_COMB.pep.*
- 30: /cgn2_6/prodata/1/paa/US00_COMB.pep.*
- 31: /cgn2_6/prodata/1/paa/US00_COMB.pep.*
- 32: /cgn2_6/prodata/1/paa/US00_COMB.pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

| Result No. | Score | Match Length | DB ID | Description |
|------------|-------|--------------|-------|------------------------------------|
| 1 | 161 | 100.0 | 31 1 | PCT-US01-43165-1 Sequence 1, Appli |

| | | | | |
|----|-----|-------|-------|--------------------------------------|
| 2 | 161 | 100.0 | 31 1 | PCT-US02-07011-19 Sequence 19, Appli |
| 3 | 161 | 100.0 | 31 1 | PCT-US02-13088-3 Sequence 3, Appli |
| 4 | 161 | 100.0 | 31 1 | PCT-US02-21325-3 Sequence 3, Appli |
| 5 | 161 | 100.0 | 31 1 | PCT-US02-25227-21 Sequence 21, Appli |
| 6 | 161 | 100.0 | 31 1 | PCT-US02-31693A-3 Sequence 3, Appli |
| 7 | 161 | 100.0 | 31 1 | PCT-US03-00001-5 Sequence 5, Appli |
| 8 | 161 | 100.0 | 31 1 | PCT-US03-16643-32 Sequence 32, Appli |
| 9 | 161 | 100.0 | 31 1 | PCT-US03-16645-5 Sequence 5, Appli |
| 10 | 161 | 100.0 | 31 1 | PCT-US97-01978-3 Sequence 3, Appli |
| 11 | 161 | 100.0 | 31 1 | PCT-US98-25151-1 Sequence 1, Appli |
| 12 | 161 | 100.0 | 31 1 | PCT-US98-25151-1 Sequence 1, Appli |
| 13 | 161 | 100.0 | 31 1 | US-07-892-0732-1 Sequence 1, Appli |
| 14 | 161 | 100.0 | 31 4 | US-08-044-133-2 Sequence 2, Appli |
| 15 | 161 | 100.0 | 31 7 | US-08-350-709-12 Sequence 12, Appli |
| 16 | 161 | 100.0 | 31 7 | US-08-356-231-2 Sequence 2, Appli |
| 17 | 161 | 100.0 | 31 9 | US-08-520-485-3 Sequence 3, Appli |
| 18 | 161 | 100.0 | 31 12 | US-08-842-121A-1 Sequence 1, Appli |
| 19 | 161 | 100.0 | 31 12 | US-08-860-103A-2 Sequence 2, Appli |
| 20 | 161 | 100.0 | 31 13 | US-08-908-867-37 Sequence 37, Appli |
| 21 | 161 | 100.0 | 31 13 | US-08-908-867A-37 Sequence 37, Appli |
| 22 | 161 | 100.0 | 31 13 | US-08-908-867-37 Sequence 37, Appli |
| 23 | 161 | 100.0 | 31 14 | US-09-091-605-1 Sequence 1, Appli |
| 24 | 161 | 100.0 | 31 14 | US-09-091-605-1 Sequence 1, Appli |
| 25 | 161 | 100.0 | 31 15 | US-09-206-833-2 Sequence 2, Appli |
| 26 | 161 | 100.0 | 31 15 | US-09-206-833-2 Sequence 2, Appli |
| 27 | 161 | 100.0 | 31 18 | US-09-400-802A-1 Sequence 1, Appli |
| 28 | 161 | 100.0 | 31 18 | US-09-475-158-23 Sequence 23, Appli |
| 29 | 161 | 100.0 | 31 19 | US-09-475-158A-23 Sequence 23, Appli |
| 30 | 161 | 100.0 | 31 19 | US-09-586-186-1 Sequence 1, Appli |
| 31 | 161 | 100.0 | 31 20 | US-09-646-433-3 Sequence 3, Appli |
| 32 | 161 | 100.0 | 31 21 | US-09-719-410-3 Sequence 3, Appli |
| 33 | 161 | 100.0 | 31 22 | US-09-732-538-2 Sequence 2, Appli |
| 34 | 161 | 100.0 | 31 22 | US-09-732-538-2 Sequence 2, Appli |
| 35 | 161 | 100.0 | 31 23 | US-08-851-728-1 Sequence 1, Appli |
| 36 | 161 | 100.0 | 31 23 | US-08-858-880-4 Sequence 4, Appli |
| 37 | 161 | 100.0 | 31 23 | US-08-859-804-3 Sequence 3, Appli |
| 38 | 161 | 100.0 | 31 23 | US-08-876-388-2 Sequence 2, Appli |
| 39 | 161 | 100.0 | 31 25 | US-09-953-021B-3 Sequence 3, Appli |
| 40 | 161 | 100.0 | 31 25 | US-09-953-021B-3 Sequence 3, Appli |
| 41 | 161 | 100.0 | 31 25 | US-09-982-978-3 Sequence 3, Appli |
| 42 | 161 | 100.0 | 31 26 | US-10-055-259-3 Sequence 3, Appli |
| 43 | 161 | 100.0 | 31 26 | US-10-072-540A-1 Sequence 1, Appli |
| 44 | 161 | 100.0 | 31 26 | US-10-031-258-3 Sequence 3, Appli |
| 45 | 161 | 100.0 | 31 26 | US-10-039-958-19 Sequence 19, Appli |

ALIGNMENTS

RESULT 1

PCT-US01-43165-1
; Sequence 1, Application PC/US0143165
; GENERAL INFORMATION:
; APPLICANT: Eli Lilly and Company
; FILING DATE: 2002-10-10
; FILING OFFICE: US
; FILING REFERENCE: 1991
; CURRENT APPLICATION NUMBER: PCT/US01/43165
; CURRENT FILING DATE: 2002-10-10
; PRIOR APPLICATION NUMBER: US 60/251,954
; PRIOR FILING DATE: 2000-06-12
; NUMBER OF SEQ ID NOS: 35
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 1
; LENGTH: 31
; TYPE: PRT
; ORGANISM: Homo sapiens
; ORGANISM: PCT-US01-43165-1

Query Watch 100.0% Score 161, DB 1; Length 31;
Ref: Local Similarity 100.0%; Ref No. 0;
Matches 31; Conservative 0; Mismatches 0; Gaps 0;

QY 1 HAEQFTSDVSSYLEGQAQKEFIATLVKGRG 31


```

; TYPE: PPT
; ORGANISM: Homo sapiens
PCT-US02-31693A-3
Query Match      100.0%; Score 161; DB 1; Length 31;
Best Local Similarity 100.0%; Pred. No. 2.1e-16;
Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HAGGFTSDVSSYLEGQAKEFIANLYKRG 31
    |||||||
Db 1 HAGGFTSDVSSYLEGQAKEFIANLYKRG 31

RESULT 7
; Sequence 5, Application PCT/US0300001
; GENERAL INFORMATION:
; APPLICANT: ELI LILLY AND COMPANY
; TITLE OF INVENTION: EXTENDED GLUCAGON-LIKE PEPTIDE-1 ANALOGS
; FILE REFERENCE: X-15133
; CURRENT APPLICATION NUMBER: PCT/US03/00001
; CURRENT FILING DATE: 2003-01-03
; NUMBER OF SEQ ID NOS: 60
; SOFTWARE: Patent version 3.1
; SEQ ID NO: 5
; LENGTH: 31
; TYPE: PPT
; ORGANISM: Homo sapiens
PCT-US03-00001-5
Query Match      100.0%; Score 161; DB 1; Length 31;
Best Local Similarity 100.0%; Pred. No. 2.1e-16;
Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HAGGFTSDVSSYLEGQAKEFIANLYKRG 31
    |||||||
Db 1 HAGGFTSDVSSYLEGQAKEFIANLYKRG 31

RESULT 8
; Sequence 32, Application PCT/US0316643
; GENERAL INFORMATION:
; APPLICANT: Wagner, F.
; APPLICANT: Peng, L.
; APPLICANT: Holmquist, B.
; TITLE OF INVENTION: Methods and DNA Constructs for High Yield Production of Polypeptides
; FILE REFERENCE: 1627.010901
; CURRENT APPLICATION NUMBER: PCT/US03/16643
; CURRENT FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 60/383,370
; NUMBER OF SEQ ID NOS: 148
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO: 32
; LENGTH: 31
; TYPE: PPT
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: GLP-1(7-37).
PCT-US03-16643-32
Query Match      100.0%; Score 161; DB 1; Length 31;
Best Local Similarity 100.0%; Pred. No. 2.1e-16;
Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HAGGFTSDVSSYLEGQAKEFIANLYKRG 31
    |||||||
Db 1 HAGGFTSDVSSYLEGQAKEFIANLYKRG 31

RESULT 9
; Sequence 5, Application PCT/US0316645
; GENERAL INFORMATION:
; APPLICANT: Wagner, F.
; APPLICANT: Peng, L.
; APPLICANT: Xia, U.
; APPLICANT: Holmquist, B.
; TITLE OF INVENTION: Methods and DNA Constructs for High Yield Production of Polypeptides
; FILE REFERENCE: 1627.009001
; CURRENT APPLICATION NUMBER: PCT/US03/16645
; CURRENT FILING DATE: 2003-05-24
; PRIOR APPLICATION NUMBER: US 60/383,212
; NUMBER OF SEQ ID NOS: 93
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO: 5
; LENGTH: 31
; TYPE: PPT
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: GLP-1(7-37)
PCT-US03-16645-5
Query Match      100.0%; Score 161; DB 1; Length 31;
Best Local Similarity 100.0%; Pred. No. 2.1e-16;
Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HAGGFTSDVSSYLEGQAKEFIANLYKRG 31
    |||||||
Db 1 HAGGFTSDVSSYLEGQAKEFIANLYKRG 31

RESULT 10
; Sequence 32, Application PCT/US9701978
; GENERAL INFORMATION:
; APPLICANT: Boris, Tracy L.
; APPLICANT: Broderick, Carol L.
; APPLICANT: Dimarchi, Richard D.
; APPLICANT: Grinnell, Brian W.
; APPLICANT: Miller, Anne R.
; TITLE OF INVENTION: DIABETES THERAPY
; NUMBER OF SEQUENCES: 9
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Eli Lilly and Company
; STREET: Eli Lilly Corporate Center
; CITY: Indianapolis
; STATE: Indiana
; COUNTRY: USA
; ZIP: 46285
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; INVENTION NUMBER: PCT/US97/01978
; FILING DATE: 16 FEB 1997
; CLASSIFICATION:
; ATTORNEY/AGENT INFORMATION:
; NAME: Maciak, Ronald S.
; REGISTRATION NUMBER: 35,262
; REFERENCE/DOCKET NUMBER: X-9872
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (317)276-1664
; TELEFAX: (317)277-1917
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 31 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
PCT-US97-01978-3

```

Query Match 100.0%; Score 161; DB 1; Length 31;
 Best Local Similarity 100.0%; Pred. No. 2,le-16;
 Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 HAEGETFTSDVSSYLEGQAKEFIAMLVKRG 31
 ||||||||||||||||||||||||||||||||||||
 Db 1 HAEGETFTSDVSSYLEGQAKEFIAMLVKRG 31

RESULT 11

PCT-US98-25515-1

Sequence 1, Application PC/TUS9825515
 GENERAL INFORMATION:
 TITLE OF INVENTION: James A.
 TITLE OF INVENTION: GLP-1 FORMULATIONS
 TITLE REFERENCE: X-11368
 CURRENT APPLICATION NUMBER: PCT/US98/25515
 CURRENT FILING DATE: 1998-12-02
 EARLIER FILING DATE: 1997-12-05
 EARLIER FILING DATE: 1997-12-05
 NUMBER OF SEQ ID NOS: 5
 SOFTWARE: Patentin Ver. 2.0
 SEQ ID NO 1
 TYPE: PPT
 ORGANISM: Homo sapiens
 PCT-US98-25515-1

Query Match 100.0%; Score 161; DB 1; Length 31;
 Best Local Similarity 100.0%; Pred. No. 2,le-16;
 Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 HAEGETFTSDVSSYLEGQAKEFIAMLVKRG 31
 ||||||||||||||||||||||||||||||||||||
 Db 1 HAEGETFTSDVSSYLEGQAKEFIAMLVKRG 31

RESULT 12

PCT-US98-26480-1

Sequence 1, Application PC/TUS9826480A
 GENERAL INFORMATION:
 APPLICANT: Eli Lilly and Company
 TITLE OF INVENTION: GLUCAGON-LIKE PEPTIDE-1 CRYSTALS
 CURRENT APPLICATION NUMBER: PCT/US98/26480A
 CURRENT FILING DATE: 1998-12-14
 EARLIER FILING DATE: 1997-12-16
 EARLIER FILING DATE: 1997-12-16
 NUMBER OF SEQ ID NOS: 4
 SOFTWARE: Patentin Ver. 2.0
 SEQ ID NO 1
 LENGTH: 31
 TYPE: PPT
 ORGANISM: Homo sapiens
 PCT-US98-26480-1

Query Match 100.0%; Score 161; DB 1; Length 31;
 Best Local Similarity 100.0%; Pred. No. 2,le-16;
 Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 HAEGETFTSDVSSYLEGQAKEFIAMLVKRG 31
 ||||||||||||||||||||||||||||||||||||
 Db 1 HAEGETFTSDVSSYLEGQAKEFIAMLVKRG 31

RESULT 13

US-07-899-073-2

Sequence 2, Application US/07899073
 GENERAL INFORMATION:
 APPLICANT: Andrews, Glenn C.
 APPLICANT: Dauby, Gaston O.
 APPLICANT: Francoeur, Michael L.

APPLICANT: Larson, Eric R.
 TITLE OF INVENTION: GLUCAGON-LIKE PEPTIDE AND INSULINOTROPIN
 TITLE OF INVENTION: DERIVATIVES
 NUMBER OF SEQUENCES: 6
 CORRESPONDENCE ADDRESS:
 STREET: 235 East 42nd Street, 20th Floor
 CITY: New York
 STATE: New York
 COUNTRY: U.S.A.
 ZIP: 10017-5755

COMPUTER READABLE FORM:
 MEDIUM TYPE: Floppy disk
 COMPUTER: IBM PC compatible
 SOFTWARE: SYBASE, PC/MS-DOS
 SOFTWARE: Patentin Release #1.0, Version #1.25
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/07/899/073
 FILING DATE: 19920615
 CLASSIFICATION: 514
 ATTORNEY/AGENT INFORMATION:
 NAME: Benson, Gregg C.
 REGISTRATION NUMBER: 30,997
 REFERENCE/POCKET NUMBER: PC8156GCB
 TELEPHONE: (203) 441-4901
 TELEFAX: (203) 441-5221

INFORMATION FOR SEQ ID NO: 2:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 31 amino acids
 TYPE: AMINO ACID
 TOPOLOGY: linear
 MOLECULE TYPE: peptide
 US-07-899-073-2

Query Match 100.0%; Score 161; DB 3; Length 31;
 Best Local Similarity 100.0%; Pred. No. 2,le-16;
 Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 HAEGETFTSDVSSYLEGQAKEFIAMLVKRG 31
 ||||||||||||||||||||||||||||||||||||
 Db 1 HAEGETFTSDVSSYLEGQAKEFIAMLVKRG 31

RESULT 14

US-08-044-133-2

Sequence 2, Application US/08044133
 GENERAL INFORMATION:
 APPLICANT: Kim, Yasook
 APPLICANT: Lambert, William J.
 APPLICANT: Qi, Hong
 APPLICANT: Gelfand, Robert A.
 APPLICANT: Geoghegan, Kieran F.
 APPLICANT: Danley, Dennis E.
 TITLE OF INVENTION: Prolonged Delivery of Peptides
 CORRESPONDENCE ADDRESS:
 ADDRESS: Pfizer Inc
 STREET: 235 East 42nd Street, 20th Floor
 CITY: New York
 STATE: New York
 COUNTRY: U.S.A.
 ZIP: 10017-5755

COMPUTER READABLE FORM:
 MEDIUM TYPE: Floppy disk
 COMPUTER: IBM PC compatible
 SOFTWARE: SYBASE, PC/MS-DOS
 SOFTWARE: Patentin Release #1.0, Version #1.25
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/08/044,133
 FILING DATE: 07-APR-1993
 CLASSIFICATION: 514
 ATTORNEY/AGENT INFORMATION:

NAME: Shetty, Robert P.
REGISTRATION NUMBER: 31,304
REFERENCE/DOCKET NUMBER: 983891
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212)573-1189
TELEFAX: (212)573-1939
TELEX: N/A
INFORMATION FOR SEQ ID NO: 2:
SEQUENCE CHARACTERISTICS:
LENGTH: 31 amino acids
TYPE: amino acid
STRANDEDNESS: single
MOLECULE TYPE: peptide
HYDROPHILIC: NO
ANTI-SENSE: NO
FRAGMENT TYPE: N-terminal
ORIGINAL SOURCE: N/A
ORGANISM: N/A
STRAIN: N/A
INDIVIDUAL ISOLATE: N/A
HAPLOTYPE: N/A
CELL LINE: N/A
IMMEDIATE SOURCE: N/A
CLONE: N/A
POSITION IN GENOME:
MAP POSITION: N/A
UNITS: N/A
US-08-044-133-2

Query Match 100.0%; Score 161; DB 4; Length 31;
Best Local Similarity 100.0%; Pred.No. 2,le-16; Indels 0; Gaps 0;
Matches 31; Conservative 0; Mismatches 0

QY 1 HAEGTFTSDVSSYLEGQAAKEFIAMLVKGRG 31
|||||

DB 1 HAEGTFTSDVSSYLEGQAAKEFIAMLVKGRG 31
|||||

RESULT 15
US-08-350-709-12
Sequence 12, Application US/08350709
GENERAL INFORMATION:
APPLICANT: WISHIMURA, OSAMU
INVENTOR: WISHIMURA, OSAMU
APPLICANT: KOBAYASHI, NORIHIRO
INVENTOR: KOBAYASHI, NORIHIRO
TITLE OF INVENTION: METHOD FOR PRODUCING A PEPTIDE
NUMBER OF SEQUENCES: 36
CORRESPONDENCE ADDRESS:
ADDRESSEE: DAVID G. CONLIN; DIKE, BRONSTEIN, ROBERTS &
STREET: 130 WATER STREET
CITY: BOSTON
STATE: MASSACHUSETTS
COUNTRY: US
ZIP: 02109
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/350,709
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/938857
FILING DATE: 1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: JP 024841-1991

FILING DATE: 19-FEB-1991
PRIOR APPLICATION DATA: JP 0271438-1991
FILING DATE: 18-OCT-1991
PRIOR APPLICATION DATA:
APPLICATION NUMBER: JP 0277724-1991
FILING DATE: 24-OCT-1991
PRIOR APPLICATION DATA:
APPLICATION NUMBER: JP 0198056-1991
FILING DATE: 07-AUG-1991
ATTORNEY/AGENT INFORMATION:
NAME: WILLIAMS, GREGORY D.
FIRM: WILLIAMS, GREGORY D.
REFERENCE/DOCKET NUMBER: 41614
TELECOMMUNICATION INFORMATION:
TELEPHONE: (617) 523-3400
TELEFAX: (617) 523-3400
TELEX: 200291 STRE UR
INFORMATION FOR SEQ ID NO: 12:
SEQUENCE CHARACTERISTICS:
LENGTH: 31 amino acids
TYPE: amino acid
TOPOLOGY: linear
US-08-350-709-12

Query Watch 100.0%; Score 161; DB 7; Length 31;
Best Local Similarity 100.0%; Pred.No. 2,le-16; Indels 0; Gaps 0;
Matches 31; Conservative 0; Mismatches 0

QY 1 HAEGTFTSDVSSYLEGQAAKEFIAMLVKGRG 31
|||||

DB 1 HAEGTFTSDVSSYLEGQAAKEFIAMLVKGRG 31
|||||

Search completed: October 15, 2003, 11:07:20
Job time : 296.262 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: October 15, 2003, 10:53:47 ; Search time 15.2459 seconds
(without alignments)
62.284 Million cell updates/sec

Title: US-09-719-410-3

Sequence: 1 HAEQTTSDYSSYLEGQAKEFIAMLVKGRG 31

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 148013 seqs, 30631251 residues

Total number of hits satisfying chosen parameters: 148013

Minimum DB seq length: 0

Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : Pending Patents AA_New:
1: /cgn2.6/prodata/1/paa/PCT_NEW_COMB.pep.*
2: /cgn2.6/prodata/1/paa/US06_NEW_COMB.pep.*
3: /cgn2.6/prodata/1/paa/US06_NEW_COMB.pep.*
4: /cgn2.6/prodata/1/paa/US06_NEW_COMB.pep.*
5: /cgn2.6/prodata/1/paa/US09_NEW_COMB.pep.*
6: /cgn2.6/prodata/1/paa/US10_NEW_COMB.pep.*
7: /cgn2.6/prodata/1/paa/US10_NEW_COMB.pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

| Result No. | Query Match | Score | Length | ID | Description |
|------------|-------------|-------|--------|----|--------------------|
| 1 | 161 | 100.0 | 31 | 1 | PCT-US03-15395B-16 |
| 2 | 161 | 100.0 | 31 | 1 | PCT-US03-26818-64 |
| 3 | 161 | 100.0 | 31 | 1 | PCT-US03-28093-2 |
| 4 | 161 | 100.0 | 31 | 6 | US-10-291-226-124 |
| 5 | 161 | 100.0 | 31 | 6 | US-10-656-405-2 |
| 6 | 161 | 100.0 | 32 | 1 | PCT-US03-28093-27 |
| 7 | 161 | 100.0 | 32 | 6 | US-10-656-405-2 |
| 8 | 157 | 97.5 | 32 | 6 | PCT-US03-28093-38 |
| 9 | 157 | 97.5 | 32 | 1 | US-10-291-226-147 |
| 10 | 157 | 97.5 | 32 | 6 | US-10-656-405-28 |
| 11 | 157 | 97.5 | 32 | 6 | US-10-291-226-122 |
| 12 | 157 | 97.5 | 37 | 6 | PCT-US03-26778-14 |
| 13 | 155 | 96.3 | 30 | 1 | PCT-US03-26818-48 |
| 14 | 155 | 96.3 | 30 | 1 | PCT-US03-28093-1 |
| 15 | 155 | 96.3 | 30 | 5 | US-09-341-590A-118 |
| 16 | 155 | 96.3 | 30 | 6 | US-10-291-226-114 |
| 17 | 155 | 96.3 | 30 | 6 | US-10-656-405-1 |
| 18 | 155 | 96.3 | 30 | 6 | US-10-656-405-1 |
| 19 | 155 | 96.3 | 31 | 1 | PCT-US03-26778-34 |
| 20 | 155 | 96.3 | 31 | 1 | PCT-US03-26778-6 |
| 21 | 155 | 96.3 | 31 | 1 | PCT-US03-26818-6 |
| 22 | 155 | 96.3 | 31 | 7 | US-60-485-404-34 |
| 23 | 155 | 96.3 | 32 | 1 | PCT-US03-28093-30 |
| 24 | 155 | 96.3 | 32 | 6 | US-10-656-405-30 |
| 25 | 155 | 96.3 | 36 | 5 | US-09-341-590A-92 |
| 26 | 155 | 96.3 | 36 | 5 | US-09-341-590A-92 |

Sequence 29, Appl
Sequence 29, Appl
Sequence 115, Appl
Sequence 87, Appl
Sequence 112, Appl
Sequence 113, Appl
Sequence 111, Appl
Sequence 88, Appl
Sequence 90, Appl
Sequence 103, Appl
Sequence 116, Appl
Sequence 119, Appl
Sequence 113, Appl
Sequence 83, Appl
Sequence 120, Appl
Sequence 121, Appl
Sequence 118, Appl
Sequence 8, Appl

ALIGNMENTS

RESULT 1
PCT-US03-15395B-16
; Sequence 16, Application PC/TUS0315395B
; GENERAL INFORMATION:
; APPLICANT: Eli Lilly and Company
; TITLE OF INVENTION: MODIFIED GLUCAGON-LIKE PEPTIDE-1 ANALOGS
; CURRENT APPLICATION NUMBER: PCT/US03/15395B
; CURRENT FILING DATE: 2003-06-02
; SEQ ID NOS: 1-4
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 16
; LENGTH: 31
; TYPE: PRT
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Synthetic construct
PCT-US03-15395B-16

Query Match 100.0%; Score 161; DB 1; Length 31;
Local Similarity 100.0%; Pred. No. 3.2e-15;
Matches 31; Conservative 0; Mismatches 0; Gaps 0;

OY 1 HAEQTTSDYSSYLEGQAKEFIAMLVKGRG 31
|||||
Db 1 HAEQTTSDYSSYLEGQAKEFIAMLVKGRG 31

RESULT 2
PCT-US03-26818-64
; Sequence 14, Application PC/TUS0326818
; GENERAL INFORMATION:
; APPLICANT: PRIOR, Christopher P.
; APPLICANT: LAT, Char-Bui
; APPLICANT: SADEGH, Homayoun
; APPLICANT: TURNER, Andrew J.
; TITLE OF INVENTION: MODIFIED TRANSFERLIN FUSION PROTEINS
; FILE REFERENCE: 54710-5001-01-WO
; CURRENT APPLICATION NUMBER: PCT/US03/26818
; CURRENT FILING DATE: 2003-08-28
; PRIOR APPLICATION NUMBER: US 60/406,977
; PRIOR APPLICATION DATE: 2003-08-08
; PRIOR APPLICATION NUMBER: US 10/378,094
; PRIOR FILING DATE: 2003-03-04
; NUMBER OF SEQ ID NOS: 90
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 64
; LENGTH: 31
; TYPE: PRT

```

; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: GLP-1(7-37) amino acid sequence
PCT-US03-26818-64

Query Match      100.0%; Score 161; DB 1; Length 31;
Best Local Similarity 100.0%; Pred. No. 3.2e-15;
Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HAEGTFTSDVSSYLEGQAAKEFIAWLKVGK 31
Db      1 HAEGTFTSDVSSYLEGQAAKEFIAWLKVGK 31

RESULT 3
PCT-US03-28093-2
; Sequence 124, Application US/10291226
; GENERAL INFORMATION:
; APPLICANT: Bayer Pharmaceuticals Corporation
; APPLICANT: Pan, Clark
; APPLICANT: Whelan, James
; TITLE OF INVENTION: Modified GLP-1 Receptor Agonists and Their Pharmacological
; FILE REFERENCE: MSB-7296
; CURRENT APPLICATION NUMBER: PCT/US03/28093
; PRIOR APPLICATION NUMBER: US 60/408,696
; PRIOR FILING DATE: 2002-09-16
; PRIOR FILING DATE: 2002-09-16
; PRIOR FILING DATE: 2003-01-09
; NUMBER OF SEQ ID NOS: 34
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 2
; LENGTH: 31
; TYPE: PPT
; ORGANISM: Homo sapiens
PCT-US03-28093-2

Query Match      100.0%; Score 161; DB 1; Length 31;
Best Local Similarity 100.0%; Pred. No. 3.2e-15;
Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HAEGTFTSDVSSYLEGQAAKEFIAWLKVGK 31
Db      1 HAEGTFTSDVSSYLEGQAAKEFIAWLKVGK 31

RESULT 4
US-10-291-226-124
; Sequence 124, Application US/10291226
; GENERAL INFORMATION:
; APPLICANT: Larsen, Bjarne Due
; APPLICANT: Mikkelsen, Jens Mollgaard
; APPLICANT: Neve, Soren
; TITLE OF INVENTION: NOVEL PEPTIDE AGONISTS OF GLP-1 ACTIVITY
; FILE REFERENCE: 551(A347) US/10/291,226
; CURRENT APPLICATION NUMBER: PCT/US03/28093
; CURRENT FILING DATE: 2002-11-08
; PRIOR APPLICATION NUMBER: US/09/614,847
; PRIOR FILING DATE: 12000-07-12
; PRIOR FILING DATE: 1999-07-13
; NUMBER OF SEQ ID NOS: 153
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 124
; LENGTH: 31
; TYPE: PPT
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: GLP-1(7-37)
US-10-291-226-124

Query Match      100.0%; Score 161; DB 6; Length 31;

```

```

Best Local Similarity 100.0%; Pred. No. 3.2e-15;
Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HAEGTFTSDVSSYLEGQAAKEFIAWLKVGK 31
Db      1 HAEGTFTSDVSSYLEGQAAKEFIAWLKVGK 31

RESULT 5
US-10-656-405-2
; Sequence 2, Application US/10656405
; GENERAL INFORMATION:
; APPLICANT: Bayer Pharmaceuticals Corporation
; APPLICANT: Pan, Clark
; APPLICANT: Whelan, James
; TITLE OF INVENTION: Modified GLP-1 Receptor Agonists and Their Pharmacological
; FILE REFERENCE: MSB-7296
; CURRENT APPLICATION NUMBER: US/10/656,405
; PRIOR APPLICATION NUMBER: US 60/408,696
; PRIOR FILING DATE: 2003-09-04
; PRIOR FILING DATE: 2002-09-16
; PRIOR FILING DATE: 2003-01-09
; NUMBER OF SEQ ID NOS: 34
; SOFTWARE: PatentIn version 3.2
; LENGTH: 31
; TYPE: PPT
; ORGANISM: Homo sapiens
US-10-656-405-2

Query Match      100.0%; Score 161; DB 6; Length 31;
Best Local Similarity 100.0%; Pred. No. 3.2e-15;
Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HAEGTFTSDVSSYLEGQAAKEFIAWLKVGK 31
Db      1 HAEGTFTSDVSSYLEGQAAKEFIAWLKVGK 31

RESULT 6
PCT-US03-28093-27
; Sequence 27, Application PC/US0328093
; GENERAL INFORMATION:
; APPLICANT: Bayer Pharmaceuticals Corporation
; APPLICANT: Pan, Clark
; APPLICANT: Whelan, James
; TITLE OF INVENTION: Modified GLP-1 Receptor Agonists and Their Pharmacological
; FILE REFERENCE: MSB-7296
; CURRENT APPLICATION NUMBER: PCT/US03/28093
; CURRENT FILING DATE: 2003-09-04
; PRIOR APPLICATION NUMBER: US 60/408,696
; PRIOR FILING DATE: 2002-09-16
; PRIOR FILING DATE: 2003-01-09
; NUMBER OF SEQ ID NOS: 34
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 27
; LENGTH: 32
; TYPE: PPT
; ORGANISM: Homo sapiens
PCT-US03-28093-27

Query Match      100.0%; Score 161; DB 1; Length 32;
Best Local Similarity 100.0%; Pred. No. 3.2e-15;
Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HAEGTFTSDVSSYLEGQAAKEFIAWLKVGK 31
Db      1 HAEGTFTSDVSSYLEGQAAKEFIAWLKVGK 31

```

RESULT 7
 US-10-656-405-27
 ; Sequence 27, Application US/10656405
 ; GENERAL INFORMATION:
 ; APPLICANT: Bayer Pharmaceuticals Corporation
 ; APPLICANT: Whelan, James
 ; TITLE OF INVENTION: Modified GLP-1 Receptor Agonists and Their Pharmacological
 ; FILE OF INVENTION: Methods of Use
 ; FILE REFERENCE: MSB-7296
 ; CURRENT APPLICATION NUMBER: PCT/US03/28093
 ; PRIOR APPLICATION NUMBER: US 60/408,696
 ; PRIOR FILING DATE: 2003-09-04
 ; PRIOR APPLICATION NUMBER: US 60/439,369
 ; PRIOR FILING DATE: 2003-01-09
 ; SOFTWARE: PatentIn version 3.2
 ; SEQ ID NO 27
 ; LENGTH: 32
 ; TYPE: PRT
 ; ORGANISM: Homo sapiens
 ; US-10-656-405-27
 Query Match 100.0%; Score 161; DB 6; Length 32;
 Best Local Similarity 100.0%; Pred. No. 3,2e-15;
 Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 HAEGTFTSDVSSYLEGQAAKEFTAMLYKRG 31
 DB 1 HAEGTFTSDVSSYLEGQAAKEFTAMLYKRG 31
 RESULT 8
 US-10-291-226-123
 ; Sequence 123, Application US/10291226
 ; GENERAL INFORMATION:
 ; APPLICANT: Larsen, Bjarne Due
 ; APPLICANT: Mikkelson, Jens Mollgaard
 ; TITLE OF INVENTION: NOVEL PEPTIDE AGONISTS OF GLP-1 ACTIVITY
 ; FILE OF INVENTION: NOVEL PEPTIDE AGONISTS OF GLP-1 ACTIVITY
 ; FILE REFERENCE: 55511(45487)
 ; CURRENT APPLICATION NUMBER: US/10/291,226
 ; PRIOR FILING DATE: 2002-11-08
 ; PRIOR APPLICATION NUMBER: US/09/614,847
 ; PRIOR FILING DATE: 12000-07-12
 ; PRIOR APPLICATION NUMBER: US 60/143,591
 ; NUMBER OF SEQ ID NOS: 153
 ; SOFTWARE: PatentIn Ver. 2.1
 ; SEQ ID NO 123
 ; LENGTH: 32
 ; TYPE: PRT
 ; ORGANISM: Artificial Sequence
 ; NAME/KEY: MOD_RES
 ; LOCATION: (32)
 ; OTHER INFORMATION: Description of Artificial Sequence:
 ; FEATURE:
 ; OTHER INFORMATION: Gly8-GLP-1(7-36)-Lys37(palmitoyl)(Human)
 ; US-10-291-226-123
 Query Match 97.5%; Score 157; DB 6; Length 31;
 Best Local Similarity 96.8%; Pred. No. 1.1e-14;
 Matches 30; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1 HAEGTFTSDVSSYLEGQAAKEFTAMLYKRG 31
 DB 1 HAEGTFTSDVSSYLEGQAAKEFTAMLYKRG 31
 RESULT 9
 US-10-656-405-28
 ; Sequence 28, Application US/10656405
 ; GENERAL INFORMATION:
 ; APPLICANT: Bayer Pharmaceuticals Corporation
 ; APPLICANT: Pan, Clark
 ; TITLE OF INVENTION: Modified GLP-1 Receptor Agonists and Their Pharmacological
 ; FILE OF INVENTION: Methods of Use
 ; FILE REFERENCE: MSB-7296
 ; CURRENT APPLICATION NUMBER: PCT/US03/28093
 ; PRIOR APPLICATION NUMBER: US 60/408,696
 ; PRIOR FILING DATE: 2003-09-04
 ; PRIOR APPLICATION NUMBER: US 60/439,369
 ; PRIOR FILING DATE: 2003-01-09
 ; SOFTWARE: PatentIn version 3.2
 ; SEQ ID NO 28
 ; LENGTH: 32
 ; TYPE: PRT
 ; ORGANISM: Homo sapiens
 ; US-10-656-405-28
 Query Match 97.5%; Score 157; DB 6; Length 32;
 Best Local Similarity 96.8%; Pred. No. 1.1e-14;
 Matches 30; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1 HAEGTFTSDVSSYLEGQAAKEFTAMLYKRG 31
 DB 1 HAEGTFTSDVSSYLEGQAAKEFTAMLYKRG 31
 RESULT 11
 US-10-656-405-28
 ; Sequence 28, Application US/10656405
 ; GENERAL INFORMATION:
 ; APPLICANT: Bayer Pharmaceuticals Corporation
 ; APPLICANT: Pan, Clark
 ; TITLE OF INVENTION: Modified GLP-1 Receptor Agonists and Their Pharmacological
 ; FILE OF INVENTION: Methods of Use
 ; FILE REFERENCE: MSB-7296
 ; CURRENT APPLICATION NUMBER: PCT/US03/28093
 ; PRIOR APPLICATION NUMBER: US 60/408,696
 ; PRIOR FILING DATE: 2003-09-04
 ; PRIOR APPLICATION NUMBER: US 60/439,369
 ; PRIOR FILING DATE: 2003-01-09
 ; SOFTWARE: PatentIn version 3.2
 ; SEQ ID NO 28
 ; LENGTH: 32
 ; TYPE: PRT
 ; ORGANISM: Homo sapiens
 ; US-10-656-405-28
 Query Match 97.5%; Score 157; DB 6; Length 32;
 Best Local Similarity 96.8%; Pred. No. 1.1e-14;
 Matches 30; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1 HAEGTFTSDVSSYLEGQAAKEFTAMLYKRG 31
 DB 1 HAEGTFTSDVSSYLEGQAAKEFTAMLYKRG 31

```
; APPLICANT: Whelan, James
; TITLE OF INVENTION: Modified GLP-1 Receptor Agonists and Their Pharmacological
; FILE REFERENCE: MSB-7296
; CURRENT APPLICATION NUMBER: US/10/556,405
; PRIOR FILING DATE: 2003-03-04
; PRIOR FILING DATE: 2002-09-16
; PRIOR FILING DATE: 2002-09-16
; PRIOR FILING DATE: 2003-01-09
; PRIOR FILING DATE: 2003-01-09
; NUMBER OF SEQ ID NOS: 34
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 28
; LENGTH: 32
; TYPE: PPT
; ORGANISM: Homo sapiens
US-10-556-405-28
Query Match          97.5%; Score 157; DB 6; Length 32;
Best Local Similarity 96.8%; Pred. No. 1.1e-14;
Matches 30; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1 HAEGETFTSDVSSYLEGQAQKEFTAMLVKGRG 31
DB 1 HAEGETFTSDVSSYLEGQAQKEFTAMLVKGRG 31
RESULT 12
US-10-291-226-122
; Sequence 122, Application US/A0291226
; GENERAL INFORMATION:
; APPLICANT: Larsen, Bjarne Due
; APPLICANT: Mikkelsen, Jens Mollgaard
; APPLICANT: Neve, Soren
; TITLE OF INVENTION: NOVEL PEPTIDE AGONISTS OF GLP-1 ACTIVITY
; FILE REFERENCE: MSB-7296
; CURRENT APPLICATION NUMBER: US/10/291,226
; PRIOR FILING DATE: 2002-11-08
; PRIOR FILING DATE: 2002-11-08
; PRIOR FILING DATE: 2000-07-12
; PRIOR FILING DATE: 1999-07-13
; NUMBER OF SEQ ID NOS: 153
; SOFTWARE: PatentIn ver. 2.1
; SEQ ID NO 32
; LENGTH: 37
; TYPE: PPT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:
US-10-291-226-122
Query Match          97.5%; Score 157; DB 6; Length 37;
Best Local Similarity 96.8%; Pred. No. 1.2e-14;
Matches 30; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1 HAEGETFTSDVSSYLEGQAQKEFTAMLVKGRG 31
DB 1 HAEGETFTSDVSSYLEGQAQKEFTAMLVKGRG 31
RESULT 13
PCT-US03-26778-14
; Sequence 14, Application PC/TUS0326778
; GENERAL INFORMATION:
; APPLICANT: PRIOR, Christopher P.
; APPLICANT: SADEGHI, Homayoun
; APPLICANT: TURNER, Andrew J.
; TITLE OF INVENTION: ORAL DELIVERY OF MODIFIED TRANSFERRIN FUSION PROTEINS
; FILE REFERENCE: 54710-5006-WO
; CURRENT APPLICATION NUMBER: PCT/US03/26778
; CURRENT FILING DATE: 2003-08-28
```

```
; PRIOR APPLICATION NUMBER: US 60/406,977
; PRIOR FILING DATE: 2002-08-30
; PRIOR APPLICATION NUMBER: US 10/378,094
; PRIOR FILING DATE: 2003-03-04
; PRIOR APPLICATION NUMBER: US 60/460,829
; PRIOR FILING DATE: 2003-04-08
; NUMBER OF SEQ ID NOS: 54
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 14
; LENGTH: 30
; TYPE: PPT
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: glucagon-like peptide-1
PCT-US03-26778-14
Query Match          96.3%; Score 155; DB 1; Length 30;
Best Local Similarity 100.0%; Pred. No. 1.9e-14;
Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 HAEGETFTSDVSSYLEGQAQKEFTAMLVKGR 30
DB 1 HAEGETFTSDVSSYLEGQAQKEFTAMLVKGR 30
RESULT 14
PCT-US03-26818-48
; Sequence 48, Application PC/TUS0326818
; GENERAL INFORMATION:
; APPLICANT: PRIOR, Christopher P.
; APPLICANT: LAI, Char-Huei
; APPLICANT: SADEGHI, Homayoun
; APPLICANT: TURNER, Andrew J.
; TITLE OF INVENTION: MODIFIED TRANSFERRIN FUSION PROTEINS
; FILE REFERENCE: 54710-5001-WO
; CURRENT APPLICATION NUMBER: US/10/26818
; CURRENT FILING DATE: 2003-08-26
; PRIOR APPLICATION NUMBER: US 60/406,977
; PRIOR FILING DATE: 2002-08-30
; PRIOR APPLICATION NUMBER: US 10/378,094
; PRIOR FILING DATE: 2003-03-04
; NUMBER OF SEQ ID NOS: 90
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 148
; LENGTH: 30
; TYPE: PPT
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: glucagon-like peptide-1
PCT-US03-26818-48
Query Match          96.3%; Score 155; DB 1; Length 30;
Best Local Similarity 100.0%; Pred. No. 1.9e-14;
Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 HAEGETFTSDVSSYLEGQAQKEFTAMLVKGR 30
DB 1 HAEGETFTSDVSSYLEGQAQKEFTAMLVKGR 30
RESULT 15
PCT-US03-28093-1
; Sequence 1, Application PC/TUS0328093
; GENERAL INFORMATION:
; APPLICANT: Bayer Pharmaceuticals Corporation
; APPLICANT: Pan, Clark
; APPLICANT: Whelan, James
; TITLE OF INVENTION: Modified GLP-1 Receptor Agonists and Their Pharmacological
; FILE REFERENCE: MSB-7296
; CURRENT APPLICATION NUMBER: PCT/US03/28093
; CURRENT FILING DATE: 2003-09-04
; PRIOR APPLICATION NUMBER: US 60/408,696
```

```
; PRIOR FILING DATE: 2002-09-16
; PRIOR APPLICATION NUMBER: US 60/439,369
; PRIOR FILING DATE: 2003-01-09
; NUMBER OF SEQ ID NOS: 34
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1
; LENGTH: 30
; TYPE: PRT
; ORGANISM: Homo sapiens
FCT-US03-28093-1

Query Match      96.33; Score 155; Dg 1; Length 30;
Best Local Similarity 100.0%; Pred No 1.9e-14;
Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 HAEGTFTSDYSSYLEGQAAKEFTIAWLVKGR 30
        |||||||
Db      1 HAEGTFTSDYSSYLEGQAAKEFTIAWLVKGR 30
```

Search completed: October 15, 2003, 11:07:58
Job time : 15.2459 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: October 15, 2003, 10:49:12 : Search time 25.4098 seconds
(without alignments)
117.326 Million cell updates/sec

Title: US-09-719-410-3
Perfect score: 161
Sequence: 1 HAEFTTSDVSYLEGQAKFEINLVKGRG 31

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 283308 seqs, 9616862 residues
Total number of hits satisfying chosen parameters: 283308

Minimum DB seq length: 0
Maximum DB seq length: 2000000000
Post-processing: Minimum Watch 0s
Maximum Watch 100s
Listing first 45 summaries

Database : PIR_76:.*
1: pir1:.*
2: pir2:.*
3: pir3:.*
4: pir4:.*

Prod. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

| Result No. | Score | Match | Length | ID | Description |
|------------|-------|-------|--------|----------|---------------------|
| 1 | 161 | 100.0 | 138 | 1 GCRG | glucagon precursor |
| 2 | 161 | 100.0 | 180 | 1 GCRH | glucagon precursor |
| 3 | 161 | 100.0 | 180 | 1 GCRJ | glucagon precursor |
| 4 | 161 | 100.0 | 180 | 1 GCRTOJ | glucagon precursor |
| 5 | 161 | 100.0 | 180 | 1 GCRV | glucagon precursor |
| 6 | 161 | 100.0 | 180 | 1 GCHY | glucagon precursor |
| 7 | 161 | 100.0 | 180 | 1 GCBQ | glucagon precursor |
| 8 | 161 | 100.0 | 180 | 2 A57294 | glucagon precursor |
| 9 | 149 | 92.5 | 151 | 1 GCGA | glucagon precursor |
| 10 | 149 | 92.5 | 206 | 2 I51301 | proglucagon - chic |
| 11 | 129 | 90.1 | 101 | 1 GCRFB | glucagon precursor |
| 12 | 126 | 78.3 | 30 | 2 B61125 | glucagon-like pept |
| 13 | 126 | 78.3 | 30 | 2 B61125 | glucagon-like pept |
| 14 | 126 | 78.3 | 122 | 1 GCA32 | glucagon 2 precus |
| 15 | 118 | 73.3 | 66 | 2 I51093 | glucagon - chinook |
| 16 | 118 | 73.3 | 178 | 2 I51058 | glucagon I precus |
| 17 | 117 | 72.7 | 63 | 1 GCIQC | glucagon precursor |
| 18 | 113 | 70.2 | 72 | 1 GCGKA | glucagon precursor |
| 19 | 113 | 70.2 | 60 | 1 GCOMC | glucagon precursor |
| 20 | 113 | 70.2 | 178 | 2 I51057 | glucagon II precu |
| 21 | 111 | 68.9 | 30 | 2 A44473 | glucagon-like pept |
| 22 | 103 | 64.0 | 87 | 1 GCRFS | glucagon precursor |
| 23 | 97 | 60.2 | 49 | 2 S07211 | glucagon G marbled |
| 24 | 96 | 59.6 | 124 | 1 GCA32 | glucagon 2 precus |
| 25 | 95 | 59.0 | 29 | 1 GCRF | glucagon - smaller |
| 26 | 95 | 59.0 | 29 | 1 GCRF | glucagon - smaller |
| 27 | 94 | 58.4 | 31 | 2 A44471 | glucagon G1 - Nort |
| 28 | 93 | 57.8 | 29 | 1 GCEN | glucagon - elephant |
| 29 | 90 | 55.9 | 29 | 1 GCPV | glucagon - North A |

ALIGNMENTS

RESULTS 1

GCRG
glucagon precursor - pig (fragment)
glucagon precursor - pig (fragment)
N:Contig: glucagon-related peptide; glucagon-37 (oxyntomodulin); glucos
C:Species: Sus scrofa domestica (domestic pig)
C>Date: 17-Dec-1982 #sequence-revision 31-Mar-1993 #text_change 20-Mar-1998
C/Accession: A01540; A60312; A91781; B32614; A28064
R:Thim, L.; Moody, A.J.
Regul. Pept. 2, 139-150, 1981
A>Title: The primary structure of porcine glicentin (proglucagon).
A:Reference number: A94233; X01D:81248172; PMID:6894800
A:Accession: A01540
A:Molecule type: protein
A:Residues: 1-69
R:Thim, L.; Moody, A.J.
Regul. Pept. Suppl. 2, S33, 1983
A>Title: Primary structure of a possible porcine proglucagon fragment.
A:Reference number: A60312
A:Accession: A60312
A:Molecule type: protein
A:Residues: 1-30 <TH2>
A:Note: this peptide is co-secreted with glucagon from the pancreas
A:From: W.M.; Slim, L.G.; Behrens, O.K.
J. Biol. Chem. 264, 12826-12829, 1989
A:Reference number: A92732; X01D:89327238; PMID:2753890
A:Accession: A91781
A:Molecule type: protein
A:Residues: 33-61

R:Orskov, C.; Bersani, M.; Johnsen, A.H.; Hojrup, P.; Holst, J.J.
J. Biol. Chem. 264, 12826-12829, 1989
A>Title: Complete sequences of glucagon-like peptide-1 from human and pig small int
A:Reference number: A92732; X01D:89327238; PMID:2753890
A:Accession: B32614
A:Molecule type: protein
A:Residues: 78-107 <CR>
R:Thim, L.; Kofod, H.; Orskov, C.; Harling, H.; Holst, J.J.
J. Biol. Chem. 263, 8621-8624, 1988
A>Title: Naturally occurring products of proglucagon 111-160 in the porcine and hum
A:Reference number: A28064; X01D:88243712; PMID:3379036
A:Accession: A28064
A:Molecule type: protein
A:Residues: 111-158

C:Comment: X's represent missing amino acids, mostly basic, that are predicted to e
C:Superfamily: glucagon
F:169/Product: glucagon-69 #status experimental <G69>
F:1-30/Region: glicentin-related peptide #status experimental
F:33-69/Product: glucagon-37 #status predicted <G37>
F:33-61/Product: glucagon #status experimental <GCM>
F:78-107/Product: glucagon-like peptide 1 #status experimental <GL1>

glucagon - turkey
glucagon - rabbit
glucagon - Arabian
glucagon - common
glucagon-69 - dog
glucagon - duck
glucagon - ostrich
glucagon - slider
glucagon I - Europ
glucagon - Chuchi
extendin-4 - Gila m
glucagon - Europea
glucagon - bigeye
extendin-3 - Helica
glucagon - bowfin
glucagon-36 - spot

C:superfamily: glucagon
C:residues: amidated carboxyl end; carbohydrate metabolism; duplication; hormone; in
F.1-20/Domain: signal sequence status predicted <SIG>
F.21-180/Product: proglucagon #status experimental <PCG>
F.21-89/Product: glicentin status experimental <GLN>
F.21-50/Product: glicentin-related polypeptide #status predicted <GRP>
F.53-89/Product: oxyntomodulin status experimental <ONX>
F.53-81/Product: glucagon #status experimental <GCG>
F.93-178/Product: major proglucagon fragment #status experimental <MPGF>
F.93-127/Product: glucagon-like peptide 1 #status experimental <GLP>
F.98-127/Product: truncated glucagon-like peptide 1 #status experimental <GL>
F.116-179/Product: glucagon-like peptide 2 #status predicted <GL2>
F.117/Modified site: amidated carboxyl end (Arg) (amide in mature form from followin

Query Match 100.04; Score 161; DB 1: Length 180;
Best Local Similarity 100.04; Pred. No. 1.5e-15;
Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HAEFTTSDVSSYLSGQAKFEFLMWYKRG 31
|||||
DB 98 HAEFTTSDVSSYLSGQAKFEFLMWYKRG 128
|||||

RESULT 3
GCGP
N'Alternate names: guinea pig
N'Alternate names: oxyntomodulin
C:Species: Cavia porcellus (guinea pig)
C:Date: 30-Sep-1987 #sequence_revision 31-Dec-1992 #test_change 16-Jun-2000
C:Accession: Z24856; Z23849; A60323
R:Seibin, S.; Weisib, M.; Bell, G.J.; Chan, S.J.; Steiner, D.F.
R:ESL Lett. 207; 25-30/1986
A:Title: Adipogenic rat 9 beta pig proglucagon gene are restricted to a specific
A:Accession: Z24856; Z24857; M32461; M32462; M32463; M32464; M32465; M32466; M32467; M32468; M32469; M32470; M32471; M32472; M32473; M32474; M32475; M32476; M32477; M32478; M32479; M32480; M32481; M32482; M32483; M32484; M32485; M32486; M32487; M32488; M32489; M32490; M32491; M32492; M32493; M32494; M32495; M32496; M32497; M32498; M32499; M32500; M32501; M32502; M32503; M32504; M32505; M32506; M32507; M32508; M32509; M32510; M32511; M32512; M32513; M32514; M32515; M32516; M32517; M32518; M32519; M32520; M32521; M32522; M32523; M32524; M32525; M32526; M32527; M32528; M32529; M32530; M32531; M32532; M32533; M32534; M32535; M32536; M32537; M32538; M32539; M32540; M32541; M32542; M32543; M32544; M32545; M32546; M32547; M32548; M32549; M32550; M32551; M32552; M32553; M32554; M32555; M32556; M32557; M32558; M32559; M32560; M32561; M32562; M32563; M32564; M32565; M32566; M32567; M32568; M32569; M32570; M32571; M32572; M32573; M32574; M32575; M32576; M32577; M32578; M32579; M32580; M32581; M32582; M32583; M32584; M32585; M32586; M32587; M32588; M32589; M32590; M32591; M32592; M32593; M32594; M32595; M32596; M32597; M32598; M32599; M32600; M32601; M32602; M32603; M32604; M32605; M32606; M32607; M32608; M32609; M32610; M32611; M32612; M32613; M32614; M32615; M32616; M32617; M32618; M32619; M32620; M32621; M32622; M32623; M32624; M32625; M32626; M32627; M32628; M32629; M32630; M32631; M32632; M32633; M32634; M32635; M32636; M32637; M32638; M32639; M32640; M32641; M32642; M32643; M32644; M32645; M32646; M32647; M32648; M32649; M32650; M32651; M32652; M32653; M32654; M32655; M32656; M32657; M32658; M32659; M32660; M32661; M32662; M32663; M32664; M32665; M32666; M32667; M32668; M32669; M32670; M32671; M32672; M32673; M32674; M32675; M32676; M32677; M32678; M32679; M32680; M32681; M32682; M32683; M32684; M32685; M32686; M32687; M32688; M32689; M32690; M32691; M32692; M32693; M32694; M32695; M32696; M32697; M32698; M32699; M32700; M32701; M32702; M32703; M32704; M32705; M32706; M32707; M32708; M32709; M32710; M32711; M32712; M32713; M32714; M32715; M32716; M32717; M32718; M32719; M32720; M32721; M32722; M32723; M32724; M32725; M32726; M32727; M32728; M32729; M32730; M32731; M32732; M32733; M32734; M32735; M32736; M32737; M32738; M32739; M32740; M32741; M32742; M32743; M32744; M32745; M32746; M32747; M32748; M32749; M32750; M32751; M32752; M32753; M32754; M32755; M32756; M32757; M32758; M32759; M32760; M32761; M32762; M32763; M32764; M32765; M32766; M32767; M32768; M32769; M32770; M32771; M32772; M32773; M32774; M32775; M32776; M32777; M32778; M32779; M32780; M32781; M32782; M32783; M32784; M32785; M32786; M32787; M32788; M32789; M32790; M32791; M32792; M32793; M32794; M32795; M32796; M32797; M32798; M32799; M32800; M32801; M32802; M32803; M32804; M32805; M32806; M32807; M32808; M32809; M32810; M32811; M32812; M32813; M32814; M32815; M32816; M32817; M32818; M32819; M32820; M32821; M32822; M32823; M32824; M32825; M32826; M32827; M32828; M32829; M32830; M32831; M32832; M32833; M32834; M32835; M32836; M32837; M32838; M32839; M32840; M32841; M32842; M32843; M32844; M32845; M32846; M32847; M32848; M32849; M32850; M32851; M32852; M32853; M32854; M32855; M32856; M32857; M32858; M32859; M32860; M32861; M32862; M32863; M32864; M32865; M32866; M32867; M32868; M32869; M32870; M32871; M32872; M32873; M32874; M32875; M32876; M32877; M32878; M32879; M32880; M32881; M32882; M32883; M32884; M32885; M32886; M32887; M32888; M32889; M32890; M32891; M32892; M32893; M32894; M32895; M32896; M32897; M32898; M32899; M32900; M32901; M32902; M32903; M32904; M32905; M32906; M32907; M32908; M32909; M32910; M32911; M32912; M32913; M32914; M32915; M32916; M32917; M32918; M32919; M32920; M32921; M32922; M32923; M32924; M32925; M32926; M32927; M32928; M32929; M32930; M32931; M32932; M32933; M32934; M32935; M32936; M32937; M32938; M32939; M32940; M32941; M32942; M32943; M32944; M32945; M32946; M32947; M

C:Genetics:
A:Gene: GDB:GCG
A:Cross-references: GDB:119265; OMIM:138030
A:Map position: 2q36-2q37
A:Introns: 31/2; 85/2; 131/2; 179/2

F:21-180/Product: glucagon status predicted <PG>
 F:21-50/Region: glucagon-related peptide status predicted
 F:53-81/Product: glucagon status predicted <GNC>
 F:98-127/Product: glucagon-like peptide 1 status predicted <GL1>
 F:146-180/Product: glucagon-like peptide 2 status predicted <GL2>
 F:127/Modified site: amidated carboxyl end (Arg) (amide in mature form from followin

Query Match 100.04; Score 161; DB 1; Length 180;
 Best Local Similarity 100.04; Pred. No. 1.5e-15;
 Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HAEGTFTSDVSYLGGQAAKEFIAMLVKGRG 31
 DB 98 HAEGTFTSDVSYLGGQAAKEFIAMLVKGRG 128

RESULT 6
 GCB0
 Glucagon precursor - golden hamster
 N:Contains: glucagon-related peptide; glucagon; glucagon-like peptide 1; glucagon-
 C:Species: Mesocricetus auratus (golden hamster)
 C:Date: 13-Jun-1983 sequence_revision 13-Jun-1983 #text_change 20-Mar-1998
 C:Accession: A01539
 R:Bell, G.I.; Santerre, R.F.; Mullenbach, G.T.
 A:Title: Hamster proglucagon contains the sequence of glucagon and two related pe
 A:Reference number: A01539; PMID:83167563; PMID:6835407
 A:Accession: A01539
 A:Molecule type: mRNA
 A:Residues: 1-180 <HE>
 C:Superfamily: glucagon
 C:Keywords: amidated carboxyl end; carbohydrate metabolism; duplication; hormone; pr
 F:1-30/Domain: signal sequence status predicted <SIG>
 F:21-180/Product: proglucagon status predicted <PG>
 F:53-81/Product: glucagon-related peptide status predicted
 F:98-127/Product: glucagon-like peptide 1 status predicted <GL1>
 F:146-180/Product: glucagon-like peptide 2 status predicted <GL2>
 F:127/Modified site: amidated carboxyl end (Arg) (amide in mature form from followin

Query Match 100.04; Score 161; DB 1; Length 180;
 Best Local Similarity 100.04; Pred. No. 1.5e-15;
 Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HAEGTFTSDVSYLGGQAAKEFIAMLVKGRG 31
 DB 98 HAEGTFTSDVSYLGGQAAKEFIAMLVKGRG 128

RESULT 7
 GCB0
 glucagon precursor - bovine
 N:Contains: glucagon-related peptide; glucagon; glucagon-like peptide 1; glucagon-
 C:Species: Bos primigenius taurus (cattle)
 C:Date: 14-Nov-1983 sequence_revision 14-Nov-1983 #text_change 20-Mar-1998
 C:Accession: A93970; A92081; A01538
 R:Lopez, L.-C.; Frazer, M.L.; SC, J.; Kumar, A.; Saunders, G.F.
 A:Title: Mammalian pancreatic preproglucagon contains three glucagon-related peptid
 A:Reference number: A93970; PMID:8329996; PMID:6577439
 A:Accession: A93970
 A:Molecule type: mRNA
 A:Residues: 1-180 <LO>
 A:Cross-references: EMBL:K00107
 F:Brumer, W.W.; Boucher, M.E.; Roffenberger Jr., J.E.
 J. Biol. Chem. 245, 2822-2827, 1971
 A:Title: Amino acid sequence of bovine glucagon.
 A:Reference number: A92081; PMID:71166445; PMID:5102927
 A:Molecule type: Protein
 A:Residues: 43-81

 C:Superfamily: glucagon

F:21-180/Product: glucagon status predicted <PG>
 F:21-50/Region: glucagon-related peptide status predicted
 F:53-81/Product: glucagon status predicted <GNC>
 F:98-127/Product: glucagon-like peptide 1 status predicted <GL1>
 F:146-180/Product: glucagon-like peptide 2 status predicted <GL2>
 F:127/Modified site: amidated carboxyl end (Arg) (amide in mature form from followin

Query Match 100.04; Score 161; DB 1; Length 180;
 Best Local Similarity 100.04; Pred. No. 1.5e-15;
 Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HAEGTFTSDVSYLGGQAAKEFIAMLVKGRG 31
 DB 98 HAEGTFTSDVSYLGGQAAKEFIAMLVKGRG 128

RESULT 8
 GCB0
 glucagon precursor - rat
 N:Contains: glucagon-related peptide; glucagon; glucagon-like peptide 1; glucagon-
 C:Species: Rattus norvegicus (Norway rat)
 C:Date: 30-Sep-1987 sequence_revision 30-Sep-1987 #text_change 26-Feb-1999
 C:Accession: A22655; A22656; A22657; A22658; A22659; A22660; A22661; A22662; A22663; A22664; A22665; A22666; A22667; A22668; A22669; A22670; A22671; A22672; A22673; A22674; A22675; A22676; A22677; A22678; A22679; A22680; A22681; A22682; A22683; A22684; A22685; A22686; A22687; A22688; A22689; A22690; A22691; A22692; A22693; A22694; A22695; A22696; A22697; A22698; A22699; A22700; A22701; A22702; A22703; A22704; A22705; A22706; A22707; A22708; A22709; A22710; A22711; A22712; A22713; A22714; A22715; A22716; A22717; A22718; A22719; A22720; A22721; A22722; A22723; A22724; A22725; A22726; A22727; A22728; A22729; A22730; A22731; A22732; A22733; A22734; A22735; A22736; A22737; A22738; A22739; A22740; A22741; A22742; A22743; A22744; A22745; A22746; A22747; A22748; A22749; A22750; A22751; A22752; A22753; A22754; A22755; A22756; A22757; A22758; A22759; A22760; A22761; A22762; A22763; A22764; A22765; A22766; A22767; A22768; A22769; A22770; A22771; A22772; A22773; A22774; A22775; A22776; A22777; A22778; A22779; A22780; A22781; A22782; A22783; A22784; A22785; A22786; A22787; A22788; A22789; A22790; A22791; A22792; A22793; A22794; A22795; A22796; A22797; A22798; A22799; A22800; A22801; A22802; A22803; A22804; A22805; A22806; A22807; A22808; A22809; A22810; A22811; A22812; A22813; A22814; A22815; A22816; A22817; A22818; A22819; A22820; A22821; A22822; A22823; A22824; A22825; A22826; A22827; A22828; A22829; A22830; A22831; A22832; A22833; A22834; A22835; A22836; A22837; A22838; A22839; A22840; A22841; A22842; A22843; A22844; A22845; A22846; A22847; A22848; A22849; A22850; A22851; A22852; A22853; A22854; A22855; A22856; A22857; A22858; A22859; A22860; A22861; A22862; A22863; A22864; A22865; A22866; A22867; A22868; A22869; A22870; A22871; A22872; A22873; A22874; A22875; A22876; A22877; A22878; A22879; A22880; A22881; A22882; A22883; A22884; A22885; A22886; A22887; A22888; A22889; A22890; A22891; A22892; A22893; A22894; A22895; A22896; A22897; A22898; A22899; A22900; A22901; A22902; A22903; A22904; A22905; A22906; A22907; A22908; A22909; A22910; A22911; A22912; A22913; A22914; A22915; A22916; A22917; A22918; A22919; A22920; A22921; A22922; A22923; A22924; A22925; A22926; A22927; A22928; A22929; A22930; A22931; A22932; A22933; A22934; A22935; A22936; A22937; A22938; A22939; A22940; A22941; A22942; A22943; A22944; A22945; A22946; A22947; A22948; A22949; A22950; A22951; A22952; A22953; A22954; A22955; A22956; A22957; A22958; A22959; A22960; A22961; A22962; A22963; A22964; A22965; A22966; A22967; A22968; A22969; A22970; A22971; A22972; A22973; A22974; A22975; A22976; A22977; A

F:21-180/Product: glucagon status predicted <PG>
 F:21-50/Region: glucagon-related peptide status predicted
 F:53-81/Product: glucagon status predicted <GNC>
 F:98-127/Product: glucagon-like peptide 1 status predicted <GL1>
 F:146-180/Product: glucagon-like peptide 2 status predicted <GL2>
 F:127/Modified site: amidated carboxyl end (Arg) (amide in mature form from followin

Query Match 100.04; Score 161; DB 1; Length 180;
 Best Local Similarity 100.04; Pred. No. 1.5e-15;
 Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HAEGTFTSDVSYLGGQAAKEFIAMLVKGRG 31
 DB 98 HAEGTFTSDVSYLGGQAAKEFIAMLVKGRG 128

RESULT 6
 GCB0
 Glucagon precursor - golden hamster
 N:Contains: glucagon-related peptide; glucagon; glucagon-like peptide 1; glucagon-
 C:Species: Mesocricetus auratus (golden hamster)
 C:Date: 13-Jun-1983 sequence_revision 13-Jun-1983 #text_change 20-Mar-1998
 C:Accession: A01539
 R:Bell, G.I.; Santerre, R.F.; Mullenbach, G.T.
 A:Title: Hamster proglucagon contains the sequence of glucagon and two related pe
 A:Reference number: A01539; PMID:83167563; PMID:6835407
 A:Accession: A01539
 A:Molecule type: mRNA
 A:Residues: 1-180 <HE>
 C:Superfamily: glucagon

QY 1 HAEGTFTSDVSYLGGQAAKEFIAMLVKGRG 31
 DB 98 HAEGTFTSDVSYLGGQAAKEFIAMLVKGRG 128

RESULT 5
 GCB0
 Glucagon precursor - rat
 N:Contains: glucagon-related peptide; glucagon; glucagon-like peptide 1; glucagon-
 C:Species: Rattus norvegicus (Norway rat)
 C:Date: 30-Sep-1987 sequence_revision 30-Sep-1987 #text_change 26-Feb-1999
 C:Accession: A22655; PMID:293190; PMID:414198
 R:Heinrich, G.; Gros, P.; Habener, J.F.
 A:Title: Glucagon gene sequence: four of six exons encode separate functional domains of
 A:Reference number: A22655; PMID:85054853; PMID:6094539
 A:Accession: A22655
 A:Molecule type: DNA
 A:Residues: 1-180 <HE>
 A:Cross-references: EMBL:K02809
 C:Keywords: amidated carboxyl end; carbohydrate metabolism; duplication; hormone; pancre

Query Match 100.04; Score 161; DB 1; Length 180;
 Best Local Similarity 100.04; Pred. No. 1.5e-15;
 Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HAEGTFTSDVSYLGGQAAKEFIAMLVKGRG 31
 DB 98 HAEGTFTSDVSYLGGQAAKEFIAMLVKGRG 128

RESULT 4
 GCB0
 Glucagon precursor - degu
 N:Contains: glucagon-related peptide; glucagon; glucagon-like peptide 1; glucagon-
 C:Species: Octodon degus (degu)
 C:Date: 31-Mar-1993 sequence_revision 31-Mar-1993 #text_change 18-Jun-1999
 C:Accession: C36118
 R:R.Nishi, M.; Steiner, D.F.
 A:Title: Cloning of complementary cDNA encoding islet amyloid polypeptide, insulin, and
 A:Reference number: A36118; PMID:9155952; PMID:2233024
 A:Accession: C36118
 A:Molecule type: mRNA
 A:Residues: 1-180 <MS>
 A:Cross-references: EMBL:K02809
 C:Superfamily: glucagon

QY 1 HAEGTFTSDVSYLGGQAAKEFIAMLVKGRG 31
 DB 98 HAEGTFTSDVSYLGGQAAKEFIAMLVKGRG 128

RESULT 3
 GCB0
 Glucagon precursor - bovine
 N:Contains: glucagon-related peptide; glucagon; glucagon-like peptide 1; glucagon-
 C:Species: Bos primigenius taurus (cattle)
 C:Date: 14-Nov-1983 sequence_revision 14-Nov-1983 #text_change 20-Mar-1998
 C:Accession: A93970; A92081; A01538
 R:Lopez, L.-C.; Frazer, M.L.; SC, J.; Kumar, A.; Saunders, G.F.
 A:Title: Mammalian pancreatic preproglucagon contains three glucagon-related peptid
 A:Reference number: A93970; PMID:8329996; PMID:6577439
 A:Accession: A93970
 A:Molecule type: mRNA
 A:Residues: 1-180 <LOP>
 A:Cross-references: EMBL:K00107
 R:Brumer, W.W.; Boucher, N.E.; Roffenberger Jr., J.E.
 J. Biol. Chem. 245, 2822-2827, 1971
 A:Title: Amino acid sequence of bovine glucagon.
 A:Reference number: A92081; PMID:71166445; PMID:5102927
 A:Molecule type: Protein
 A:Residues: 43-81 <BRO>
 C:Superfamily: glucagon

Query Match 100.04; Score 161; DB 1; Length 180;
 Best Local Similarity 100.04; Pred. No. 1.5e-15;
 Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HAEGTFTSDVSYLGGQAAKEFIAMLVKGRG 31
 DB 98 HAEGTFTSDVSYLGGQAAKEFIAMLVKGRG 128

RESULT 7
 GCB0
 Glucagon precursor - bovine
 N:Contains: glucagon-related peptide; glucagon; glucagon-like peptide 1; glucagon-
 C:Species: Bos primigenius taurus (cattle)
 C:Date: 14-Nov-1983 sequence_revision 14-Nov-1983 #text_change 20-Mar-1998
 C:Accession: A93970; A92081; A01538
 R:Lopez, L.-C.; Frazer, M.L.; SC, J.; Kumar, A.; Saunders, G.F.
 A:Title: Mammalian pancreatic preproglucagon contains three glucagon-related peptid
 A:Reference number: A93970; PMID:8329996; PMID:6577439
 A:Accession: A93970
 A:Molecule type: mRNA
 A:Residues: 1-180 <LOP>
 A:Cross-references: EMBL:K00107
 R:Brumer, W.W.; Boucher, N.E.; Roffenberger Jr., J.E.
 J. Biol. Chem. 245, 2822-2827, 1971
 A:Title: Amino acid sequence of bovine glucagon.
 A:Reference number: A92081; PMID:71166445; PMID:5102927
 A:Molecule type: Protein
 A:Residues: 43-81 <BRO>
 C:Superfamily: glucagon

Query Match 100.04; Score 161; DB 1; Length 180;
 Best Local Similarity 100.04; Pred. No. 1.5e-15;
 Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HAEGTFTSDVSYLGGQAAKEFIAMLVKGRG 31
 DB 98 HAEGTFTSDVSYLGGQAAKEFIAMLVKGRG 128

RESULT 6
 GCB0
 Glucagon precursor - golden hamster
 N:Contains: glucagon-related peptide; glucagon; glucagon-like peptide 1; glucagon-
 C:Species: Mesocricetus auratus (golden hamster)
 C:Date: 13-Jun-1983 sequence_revision 13-Jun-1983 #text_change 20-Mar-1998
 C:Accession: A01539
 R:Bell, G.I.; Santerre, R.F.; Mullenbach, G.T.
 A:Title: Hamster proglucagon contains the sequence of glucagon and two related pe
 A:Reference number: A01539; PMID:83167563; PMID:6835407
 A:Accession: A01539
 A:Molecule type: mRNA
 A:Residues: 1-180 <HE>
 C:Superfamily: glucagon

QY 1 HAEGTFTSDVSYLGGQAAKEFIAMLVKGRG 31
 DB 98 HAEGTFTSDVSYLGGQAAKEFIAMLVKGRG 128

RESULT 5
 GCB0
 Glucagon precursor - rat
 N:Contains: glucagon-related peptide; glucagon; glucagon-like peptide 1; glucagon-
 C:Species: Rattus norvegicus (Norway rat)
 C:Date: 30-Sep-1987 sequence_revision 30-Sep-1987 #text_change 26-Feb-1999
 C:Accession: A22655; PMID:293190; PMID:414198
 R:Heinrich, G.; Gros, P.; Habener, J.F.
 A:Title: Glucagon gene sequence: four of six exons encode separate functional domains of
 A:Reference number: A22655; PMID:85054853; PMID:6094539
 A:Accession: A22655
 A:Molecule type: DNA
 A:Residues: 1-180 <HE>
 A:Cross-references: EMBL:K02809
 C:Keywords: amidated carboxyl end; carbohydrate metabolism; duplication; hormone; pancre

Query Match 100.04; Score 161; DB 1; Length 180;
 Best Local Similarity 100.04; Pred. No. 1.5e-15;
 Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HAEGTFTSDVSYLGGQAAKEFIAMLVKGRG 31
 DB 98 HAEGTFTSDVSYLGGQAAKEFIAMLVKGRG 128

RESULT 4
 GCB0
 Glucagon precursor - degu
 N:Contains: glucagon-related peptide; glucagon; glucagon-like peptide 1; glucagon-
 C:Species: Octodon degus (degu)
 C:Date: 31-Mar-1993 sequence_revision 31-Mar-1993 #text_change 18-Jun-1999
 C:Accession: C36118
 R:R.Nishi, M.; Steiner, D.F.
 A:Title: Cloning of complementary cDNA encoding islet amyloid polypeptide, insulin, and
 A:Reference number: A36118; PMID:9155952; PMID:2233024
 A:Accession: C36118
 A:Molecule type: mRNA
 A:Residues: 1-180 <MS>
 A:Cross-references: EMBL:K02809
 C:Superfamily: glucagon

QY 1 HAEGTFTSDVSYLGGQAAKEFIAMLVKGRG 31
 DB 98 HAEGTFTSDVSYLGGQAAKEFIAMLVKGRG 128

RESULT 3
 GCB0
 Glucagon precursor - bovine
 N:Contains: glucagon-related peptide; glucagon; glucagon-like peptide 1; glucagon-
 C:Species: Bos primigenius taurus (cattle)
 C:Date: 14-Nov-1983 sequence_revision 14-Nov-1983 #text_change 20-Mar-1998
 C:Accession: A93970; A92081; A01538
 R:Lopez, L.-C.; Frazer, M.L.; SC, J.; Kumar, A.; Saunders, G.F.
 A:Title: Mammalian pancreatic preproglucagon contains three glucagon-related


```

A:Residues: 55-93 <GND>
C:Superfamily: glucagon
C:Keywords: amidated carboxyl end; carbohydrate metabolism; duplication; hormone; pa
F:1-22/Domain: signal sequence status predicted <SIG>
F:23-151/Product: proglucagon #status predicted <RCG>
F:55-83/Product: glucagon #status experimental <RCG>
F:118-147/Product: glucagon-like peptide 1 #status predicted <GL1>
F:147/Modified site: amidated carboxyl end #arg (amide in mature form from followin
Best Match 92.5%; Score 149; DB 1; Length 151;
Best Local Similarity 87.1%; Pred No. 6.3e-14;
Matches 27; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

OY 1 HAEGTFTSDVSYLGGQAKAEFAMLVKGRG 31
|||||:||||:||||:||||:||||:||||:
DB 118 HAEGTFTSDTSTYLGQAKAEFAMLVNCRG 148

RESULT 10
proglucagon - chicken
C:Species: Gallus gallus (chicken)
C:Date: 13-Sep-1986 #sequence_revision 13-Sep-1986 #text_change 16-Jul-1999
C:Accession: I51301
R:Irwin, D.M.; Wong, J.
A:Title: Endocrine and chicken proglucagon: alternative splicing generates mRNA transcri
A:Reference number: A58495; MWID:95295739; PMID:7776976
A:Accession: I51301
A:Status: preliminary; translated from GE/EMBL/DBJ
A:Molecule type: mRNA
A:Residues: 1-206 <IRW>
A:Cross-residues: GE:S78477; NTD:999386; PID:AR34506.1; PID:9999387
C:Superfamily: glucagon
C:Keywords: duplication

Best Match 92.5%; Score 149; DB 2; Length 206;
Best Local Similarity 87.1%; Pred. No. 8.8e-14;
Matches 27; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

OY 1 HAEGTFTSDVSYLGGQAKAEFAMLVKGRG 31
|||||:||||:||||:||||:||||:||||:
DB 118 HAEGTFTSDTSTYLGQAKAEFAMLVNCRG 148

RESULT 11
glucagon precursor - bullfrog (fragments)
N:Alternate names: oxyntomodulin
N:Contains: glucagon; glucagon-36 (oxyntomodulin); glucagon-like peptide 1; glucagon
C:Date: 31-Mar-1993 #sequence_revision 31-Mar-1993 #text_change 20-Mar-1998
C:Accession: B28091; C28091; D28091
R:Pollock, H.G.; Hamilton, J.W.; Rouse, J.B.; Elner, K.E.; Rawitch, A.B.
J. Biol. Chem. 263, 9746-9751, 1988
A:Title: Isolation of peptide hormones from the pancreas of the bullfrog (Rana catesbe
A:Reference number: A92730; MWID:88257102; PMID:3260236
A:Accession: B28091
A:Molecule type: protein
A:Residues: 1-206 <POL>
A:Accession: C28091
A:Residues: 1-206 <POL>
A:Molecule type: protein
A:Residues: 37-68 <POL>
A:Accession: D28091
A:Molecule type: protein
A:Residues: 69-101 <POL>
C:Superfamily: glucagon
C:Keywords: carbohydrate metabolism; duplication; hormone; Pancreas
F:1-29/Product: glucagon #status experimental <G36>
F:30-68/Product: glucagon-like peptide 1 #status predicted <RCG>
F:69-101/Product: glucagon-like peptide 1 #status experimental <GL1>

```

```

Query Match
Best Local Similarity 80.1%; Score 129; DB 1; Length 101;
Matches 23; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 1 HAEGETFTSDVSVSLGQAAKEFIAMLVKGR 30
DB 37 HADGFTTSDVSVSLGQAAKEFIAMLVKGR 66

RESULT 12
glucagon-like peptide - American eel
C:Species: Anguilla rostrata (American eel)
C:Date: 10-Mar-1994 #sequence_revision 10-Mar-1994 #text_change 21-Nov-1997
C:Accession: B61125
R:Conlon, J.M.; Andrews, P.C.; Timm, L.; Moon, T.W.
Gen. Comp. Endocrinol. 82, 23-32, 1991
A:Title: The primary structure of glucagon-like peptide but not insulin has been conserv
A:Reference number: A61125; NID:91340068; PMID:1874385
A:Accession: B61125
A:Molecule type: protein
A:Residues: 1-30 <CON>
C:Superfamily: glucagon
C:Keywords: amidated carboxyl end; duplication
F:1-30/Product: glucagon-like peptide; status experimental <GLP>
F:30/Modified site: amidated carboxyl end (Arg) #status predicted

Query Match
Best Local Similarity 78.3%; Score 126; DB 2; Length 30;
Matches 23; Conservative 4; Mismatches 3; Indels 0; Gaps 0;

QY 1 HAEGETFTSDVSVSLGQAAKEFIAMLVKGR 30
DB 1 HAEGETFTSDVSVSLGQAAKEFIAMLVKGR 30

RESULT 13
glucagon-like peptide - European eel
C:Species: Anguilla anguilla (European eel)
C:Date: 10-Mar-1994 #sequence_revision 10-Mar-1994 #text_change 21-Nov-1997
C:Accession: C61125
R:Conlon, J.M.; Andrews, P.C.; Timm, L.; Moon, T.W.
Gen. Comp. Endocrinol. 82, 23-32, 1991
A:Title: The primary structure of glucagon-like peptide but not insulin has been conserv
A:Reference number: A61125; NID:91340068; PMID:1874385
A:Accession: C61125
A:Molecule type: protein
A:Residues: 1-30 <CON>
C:Superfamily: glucagon
C:Keywords: amidated carboxyl end; duplication
F:1-30/Product: glucagon-like peptide; status experimental <GLP>
F:30/Modified site: amidated carboxyl end (Arg) #status experimental

Query Match
Best Local Similarity 78.3%; Score 126; DB 2; Length 30;
Matches 23; Conservative 4; Mismatches 3; Indels 0; Gaps 0;

QY 1 HAEGETFTSDVSVSLGQAAKEFIAMLVKGR 30
DB 1 HAEGETFTSDVSVSLGQAAKEFIAMLVKGR 30

RESULT 14
glucagon 2 precursor - American goosefish
N:Contains: glucagon; glucagon-like peptide 1
C:Species: Lophius americanus (American goosefish)
C:Date: 31-Mar-1993 #sequence_revision 31-Mar-1993 #text_change 21-Jul-2000
C:Accession: A03150
R:Lund, P.K.; Goodman, R.H.; Montminy, M.R.; Dee, P.C.; Habener, J.F.
J. Biol. Chem. 268, 3280-3284, 1993
A:Title: Anglerfish islet pre-proglucagon II. Nucleotide and corresponding amino acid se

```

```

A:Reference number: A03150; NID:9135795; PMID:6338015
A:Accession: A03150
A:Relationship: precursor
A:Title: Anglerfish islet pre-proglucagon II
A:Keywords: glucagon
C:Cross-references: GB:J00933; NID:964021; PID:CRAG3905.1; PID:964022
C:Superfamily: glucagon
C:Keywords: carbohydrate metabolism; duplication; hormone; pancreas
F:1-11/Domain: signal sequence #status predicted <SIG>
F:22-122/Product: proglucagon 2 #status predicted <PGC2>
F:52-80/Product: glucagon #status predicted <GCN>
F:89-119/Product: glucagon-like peptide 1 #status predicted <GLP>

Query Match
Best Local Similarity 78.3%; Score 136; DB 1; Length 122;
Matches 22; Conservative 6; Mismatches 3; Indels 0; Gaps 0;

QY 1 HAEGETFTSDVSVSLGQAAKEFIAMLVKGR 31
DB 89 HADGFTTSDVSVSLGQAAKEFIAMLVKGR 119

RESULT 15
glucagon - chinook salmon (fragment)
C:Species: Oncorhynchus tshawytscha (chinook salmon)
C:Date: 13-Sep-1996 #sequence_revision 13-Sep-1996 #text_change 16-Jul-1999
C:Accession: I51093
R:Irvine, D.W.; Wong, J.
Mol. Endocrinol. 9, 267-277, 1995
A:Title: Trout and chicken proglucagon: alternative splicing generates mRNA transcr:
A:Reference number: A55895; NID:95295739; PMID:7776976
A:Accession: I51093
A:Status: preliminary; translated from GB/EHEL/PDBJ
A:Molecule type: mRNA
A:Keywords: glucagon
C:Cross-references: EMBL:U19920; NID:9736366; PID:AMC59670.1; PID:9736367
C:Superfamily: glucagon
C:Keywords: duplication

Query Match
Best Local Similarity 73.3%; Score 118; DB 2; Length 66;
Matches 20; Conservative 7; Mismatches 3; Indels 0; Gaps 0;

QY 1 HAEGETFTSDVSVSLGQAAKEFIAMLVKGR 30
DB 33 HADGFTTSDVSVSLGQAAKEFIAMLVKGR 62

Search completed: October 15, 2003, 10:56:43
Job time : 25.4098 secs

```

GenCore version 5.1.6
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: October 15, 2003, 10:35:56 ; Search time 13.7213 Seconds
(without alignments)
106.246 Million cell updates/sec

Title: US-09-719-410-3

Perfect score: 161

Sequence: 1 HAEQFTFSVSVLSGAKKFNMLYKGG 31

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 127863 seqs, 47026705 residues

Total number of hits satisfying chosen parameters: 127863

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Maximum Match 0%

Listing first 45 summaries

Database : SwissProt_41.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

| Result No. | Score | Query Match | Length | DB ID | Description |
|------------|-------|-------------|--------|-------|-------------------------|
| 1 | 161 | 100.0 | 158 | 1 | GLUC_PIG |
| 2 | 161 | 100.0 | 180 | 1 | P01274 sus scrofa |
| 3 | 161 | 100.0 | 180 | 1 | P01272 bos taurus |
| 4 | 161 | 100.0 | 180 | 1 | P05116 canis familiaris |
| 5 | 161 | 100.0 | 180 | 1 | P01273 canis familiaris |
| 6 | 161 | 100.0 | 180 | 1 | P01273 mesocricetus |
| 7 | 161 | 100.0 | 180 | 1 | P55095 mus musculus |
| 8 | 161 | 100.0 | 180 | 1 | P22890 octodon deg |
| 9 | 149 | 92.5 | 206 | 1 | P06883 rattus norv |
| 10 | 143 | 88.8 | 204 | 1 | P01277 gallus gall |
| 11 | 129 | 80.1 | 103 | 1 | O12956 heloderma s |
| 12 | 126 | 78.3 | 30 | 1 | P15438 rana catesb |
| 13 | 126 | 78.3 | 122 | 1 | P41521 anguilla an |
| 14 | 125 | 77.9 | 209 | 1 | P04092 leopilius ame |
| 15 | 125 | 77.9 | 209 | 1 | P04144 xenopus lae |
| 16 | 115 | 72.4 | 33 | 1 | P04037 xeroderma |
| 17 | 115 | 72.0 | 71 | 1 | P04037 icterurus p |
| 18 | 116 | 72.0 | 78 | 1 | P03566 lepisosteus |
| 19 | 114 | 70.8 | 71 | 1 | P81880 pliaractus m |
| 20 | 113 | 70.2 | 68 | 1 | P07449 oncorhynch |
| 21 | 110 | 68.3 | 121 | 1 | P79695 carassius a |
| 22 | 103 | 64.0 | 96 | 1 | P03686 myoxocephal |
| 23 | 102 | 63.4 | 160 | 1 | G98911 petromyzon |
| 24 | 97 | 60.2 | 29 | 1 | P09567 torpedo mar |
| 25 | 96 | 59.6 | 124 | 1 | P03687 leopilius ame |
| 26 | 95 | 59.6 | 124 | 1 | P03687 leopilius ame |
| 27 | 93 | 57.8 | 26 | 1 | P13188 callolepis m |
| 28 | 90 | 55.9 | 24 | 1 | GLUC_DIMA |
| 29 | 90 | 55.9 | 29 | 1 | GLUC_LAMFL |
| 30 | 90 | 55.9 | 29 | 1 | GLUC_PABIT |
| 31 | 90 | 55.9 | 36 | 1 | GLUC_ORENI |
| 32 | 90 | 55.9 | 69 | 1 | GLUC_CANFA |
| 33 | 88 | 54.7 | 29 | 1 | P01276 anas platyr |

34 54.0 29 1 GLUC_CHIR
35 54.0 29 1 GLUC_HELSU
36 54.0 29 1 GLUC_HELSU
37 53.4 120 1 GLUC_PETNA
38 52.8 39 1 EXE3_HELHU
39 51.6 75 1 GLUC_AMICA
40 49.1 36 1 GLUC_HVICO
41 41.6 144 1 GLUC_MOUSE
42 39.8 42 1 GIP_BOVIN
43 39.8 42 1 GIP_PIG
44 39.8 144 1 GIP_RAT
45 39.1 153 1 GIP_HUMAN

ALIGNMENTS

RESULT 1
ID GLUC_PIG STANDARD: PRT: 158 AA.
AC P01274; (Rel. 01, Created)
DT 21-JUL-1986 (Rel. 16, Last sequence update)
DI 01-NOV-1989 (Rel. 47, Last modified)
DE Glucagon precursor [Contains glucagon; Glucagon-related polypeptide
DE (GRP); Glucagon; Glucagon-like peptide 1 (GLP1); Glucagon-like
DE peptide 2 (GLP2)] (Fragment).
GN GCG.
OS Sus scrofa (Pig).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Cetartiodactyla; Suidae; Sus.
OX NCBI_TaxID=9823;
RN [1] JENSEN OF 1-69.
RX MEDLINE=81248172; PubMed=6894800;
RA Thim L., Moody A.J.;
RT "The primary structure of porcine glucicentin (proglucagon).";
RL Regul. Rept. 2:1139-150(1981).
RN [2]
RP SEQUENCE OF 1-69.
RX MEDLINE=8221776; PubMed=7045833;
RA Thim L., Moody A.J.;
RT "The amino acid sequences of porcine glucicentin.";
RL Peptides 2 Suppl. 2:37-39(1981).
RN [3]
RP SEQUENCE OF 33-61.
RA Broer W.N., Sinn L.G., Behrens O.K.;
RT "The amino acid sequence of glucagon. V. Location of amide groups,
RT acid degradation studies and summary of sequential evidence.";
RL J. Am. Chem. Soc. 79:2807-2810(1957).
RN [4]
RP SEQUENCE OF 78-107.
RX MEDLINE=8327238; PubMed=2753890;
RA Thim L., Moody A.J., Johnson H., Koeberl P., Holst J.J.;
RT "Complete sequence of glucagon-like peptide-1 from human and pig
RT small intestine.";
RL J. Biol. Chem. 264:12826-12829(1989).
RN [5]
RP SEQUENCE OF 111-158.
RX MEDLINE=88243712; PubMed=3379036;
RA Buhl T., Thim L., Orskov C., Harling H., Holst J.J.;
RT "Naturally occurring products of proglucagon 111-160 in the porcine
RT and human small intestine.";
RL J. Biol. Chem. 263:8621-8624(1988).
RN [6]
RX X-RAY CRYSTALLOGRAPHY (3.0 ANGSTROMS).
RA Sasaki K., Dockrill S., Mamak D.A., Tickle I.J., Blundell T.L.;
RT "X-ray analysis of glucagon and its relationship to receptor
RT binding.";
RL Nature 257:751-757(1975).
CC -1- FUNCTION: GLUCAGON PROMOTES HYDROLYSIS OF GLYCOGEN AND LIPIDS, AND
CC -1- RAISES THE BLOOD SUGAR LEVEL.

CC -1- FUNCTION: GLP2 STIMULATES INTESTINAL GROWTH AND UPREGULATES VILLOS
CC HEIGHT IN THE SMALL INTESTINE, CONCOMITANT WITH INCREASED CRYPT
CC CELL PROLIFERATION AND DECREASED ENTEROCYTE APOPTOSIS.
CC -1- INDUCTION: PRODUCED IN THE A CELLS OF THE ISLETS OF LANGERHANS
CC IN RESPONSE TO A DROP IN BLOOD SUGAR CONCENTRATION.
CC MISCELLANEOUS: X'S IN THE SEQUENCE WERE INCLUDED BY HOMOLOGY WITH
CC -1- SIMILARITY: BELONGS TO THE GLUCAGON FAMILY.
CC DB: JGNC; 30-SEP-83.
CC InterPro: IPR000532; Glucagon.
CC Pfam: PF00123; hormone2; 3.
CC SMART: SM00070; GLUCA; 3.
CC PROSITE: PS00260; GLUCAGON; 3.
CC Glucagon family; Hormone; Cleavage on pair of basic residues;
CC 3D-structure: 1 1
CC PEPTIDE 1 69 GLICENTIN.
CC PEPTIDE 2 30 GLICENTIN-RELATED POLYPEPTIDE.
CC PEPTIDE 33 61 GLUCAGON.
CC PEPTIDE 78 107 GLUCAGON-LIKE PEPTIDE 1.
CC PEPTIDE 126 158 GLUCAGON-LIKE PEPTIDE 2.
CC TURN 39 42
CC HELIX 43 45
CC TURN 46 55
CC HELIX 46 55
CC TURN 56 57
CC SEQUENCE 158 AA; 18212 MW; 2866FCF257F33B2 CRC64;
CC
CC Query Match 100.0%; Score 161; DB 1; Length 158;
CC Best Local Similarity 100.0%; Pred. No. 1.1e-15;
CC Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
CC
CC QY 1 HAEFTFTSDVSYLGOAKKEFTAMLVKRG 31
CC |||||||||||||||||||||||||||||||||
CC DB 78 HAEFTFTSDVSYLGOAKKEFTAMLVKRG 108
CC (GLP2)).
CC
CC RESULT 2
CC GLUC_BOVIN STANDARD; PRT; 180 AA.
CC AC F01272;
CC DT 21-JUL-1986 (Rel. 01, Created)
CC DT 13-AUG-1987 (Rel. 05, Last sequence update)
CC DT 28-FEB-2003 (Rel. 41, Last annotation update)
CC DE Glucagon precursor [Contains: Glucocent-in-related polypeptide (GRPP);
CC DE Glucagon; Glucagon-like peptide 1 (GLP1); Glucagon-like peptide 2
CC (GLP2)].
CC OS Bos taurus (Bovine).
CC OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
CC OC Mammalia; Eutheria; Cetartiodactyla; Ruminantia; Pecora; Bovidae;
CC OC Bovidae; Bovinae; Bos.
CC NCBI_TaxID=9913;
CC [1]
CC RP SEQUENCE FROM N.A.
CC RA MEDLINE=83299996; PubMed=6577439;
CC RA Lopez L.C., Frazier M.L., Su C.-J., Kumar A., Saunders G.F.;
CC "Mammalian pancreatic preproglucagon contains three glucagon-related
CC peptides"; *Proc. Natl. Acad. Sci. U.S.A.* 80:5485-5489(1983).
CC [2]
CC RP SEQUENCE OF 53-81.
CC RA MEDLINE=71166445; PubMed=5102927;
CC RA Bromer W.W., Boucher M.E., Koffenberger J.E. Jr.;
CC "Amino acid sequence of bovine glucagon";
CC *J. Biol. Chem.* 246:2822-2827(1971).
CC [3]
CC RP STRUCTURE BY NMR OF 53-81.
CC RA MEDLINE=71166445; PubMed=6631957;
CC RA Braum W., Eider G., Lee X.H., Wuthrich K.;
CC "Conformation of glucagon in a lipid-water interface by 1H nuclear
CC magnetic resonance";
CC *J. Mol. Biol.* 169:921-948(1983).
CC -1- FUNCTION: GLUCAGON PROMOTES HYDROLYSIS OF GLYCOGEN AND LIPIDS, AND

CC RAISES THE BLOOD SUGAR LEVEL.
CC -1- FUNCTION: GLP2 STIMULATES INTESTINAL GROWTH AND UPREGULATES VILLOS
CC HEIGHT IN THE SMALL INTESTINE, CONCOMITANT WITH INCREASED CRYPT
CC CELL PROLIFERATION AND DECREASED ENTEROCYTE APOPTOSIS.
CC -1- INDUCTION: PRODUCED IN THE A CELLS OF THE ISLETS OF LANGERHANS
CC IN RESPONSE TO A DROP IN BLOOD SUGAR CONCENTRATION.
CC -1- SIMILARITY: BELONGS TO THE GLUCAGON FAMILY.
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by not-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
CC or send an email to license@sib-sib.ch).
CC DB: EMBL; X00107; AAA30538.1;
CC DB: JGNC; 13-FEB-02.
CC InterPro: IPR000532; Glucagon.
CC Pfam: PF00123; hormone2; 3.
CC PRINTS: PR00275; GLUCAGON.
CC SMART: SM00070; GLUCA; 3.
CC PROSITE: PS00260; GLUCAGON; 4.
CC Glucagon family; Hormone; Cleavage on pair of basic residues; Signal;
CC 3D-structure: 1 20
CC PEPTIDE 1 50 GLICENTIN-RELATED POLYPEPTIDE.
CC PEPTIDE 53 81 GLUCAGON.
CC PROPEP 84 89
CC PEPTIDE 92 128 GLUCAGON-LIKE PEPTIDE 1.
CC PROPEP 131 142
CC PEPTIDE 146 178 GLUCAGON-LIKE PEPTIDE 2.
CC TURN 60 64
CC TURN 74 74
CC HELIX 75 78
CC SEQUENCE 180 AA; 20944 MW; 809B4F05B9F15FF CRC64;
CC
CC Query Match 100.0%; Score 161; DB 1; Length 180;
CC Best Local Similarity 100.0%; Pred. No. 1.3e-15;
CC Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
CC
CC QY 1 HAEFTFTSDVSYLGOAKKEFTAMLVKRG 31
CC |||||||||||||||||||||||||||||||||
CC DB 98 HAEFTFTSDVSYLGOAKKEFTAMLVKRG 128
CC (GLP2)).
CC
CC RESULT 3
CC GLUC_CANVO STANDARD; PRT; 180 AA.
CC AC P05110;
CC DT 13-AUG-1987 (Rel. 05, Created)
CC DT 13-AUG-1987 (Rel. 05, Last sequence update)
CC DT 28-FEB-2003 (Rel. 41, Last annotation update)
CC DE Glucagon precursor [Contains: Glucocent-in-related polypeptide (GRPP);
CC DE Glucagon; Glucagon-37 (Oxyntomodulin); Glucagon-like peptide 1 (GLP1);
CC DE Glucagon-like peptide 2 (GLP2)].
CC OS Guinea porcellus (Guinea pig).
CC OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
CC OC Mammalia; Eutheria; Rodentia; Myricomphali; Caviidae; Cavia.
CC NCBI_TaxID=10341;
CC [1]
CC RP SEQUENCE FROM N.A.
CC RA MEDLINE=86248118; PubMed=3755107;
CC RA Saino S., Walsh M., Bell G.I., Chan S.J., Steiner D.F.;
CC "Mutations in the guinea pig preproglucagon gene are restricted to a
CC specific position in the pro-hormone sequence";
CC *FEBS Lett.* 203:25-30(1986).
CC [2]
CC RP SEQUENCE OF 53-81.
CC RA MEDLINE=86165412; PubMed=3956884;
CC RA Huang C.G., Eng J., Pan Y.-C.E., Hulmes J.D., Yalow R.S.;
CC "Guinea pig glucagon differs from other mammalian glucagons";

Diabetes 35:508-512(1985).

[3]

RP PARTIAL SEQUENCE OF 53-89.

RA MEDLINE-86017849; PubMed-4048553;

RA Colton J.N., Hansen F.F., Schwartz T.M.,

RA "Primary structure of glucagon and a partial sequence of

RA Cynomys baileyi (Glucagon-37) from the guinea pig.";

RL Regul. pept. 11:309-320(1985).

CC -1- FUNCTION: GLUCAGON PROMOTES HYDROLYSIS OF GLYCOGEN AND LIPIDS, AND

CC RAISES THE BLOOD SUGAR LEVEL.

CC -1- FUNCTION: GLP2 STIMULATES INTESTINAL GROWTH AND UPREGULATES VILLUS

CC HEIGHT IN THE SMALL INTESTINE, CONCOMITANT WITH INCREASED CRYPT

CC CELL PROLIFERATION AND DECREASED ENTEROCYTE APOPTOSIS.

CC -1- INDUCTION: PRODUCED IN THE A CELLS OF THE ISLETS OF LANGERHANS

CC IN RESPONSE TO A DROP IN BLOOD SUGAR CONCENTRATION.

CC -1- SIMILARITY: BELONGS TO THE GLUCAGON FAMILY.

CC THIS SWISS-PROT entry is copyright. It is produced through a collaboration

CC between the Swiss Institute of Bioinformatics and the EMBL outstation -

CC the European Bioinformatics Institute. There are no restrictions on its

CC use by non-profit institutions as long as its content is in no way

CC modified and this statement is not removed. Usage by and for commercial

CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>)

CC or send an email to license@sib-sib.ch.

CC -----

DR EMBL; D00014; BAB0010.1; -

DR EMBL; A00001; -

DR HSP; P01274; IGCN

DR InterPro: IPR000532; Glucagon.

DR Pfam: PF00123; hormone2; 3.

DR PRINTS; PR00275; GLUCAGON.

DR SMART; SM0070; GLUCA; 3.

DR PROSITE; PS00760; GLUCAGON; 4.

DR Glucagon family; Hormone; Cleavage on pair of basic residues; Signal.

FT SIGNAL 21 20

FT PEPTIDE 23 80

FT PEPTIDE 53 99

FT PEPTIDE 92 128

FT PROPEP 131 143

FT PEPTIDE 146 178

FT SEQUENCE 180 AA; 20972 MW; 702FBI81161D276 CRC64;

Query Match 100.00; Score 161; DB 1; Length 180;

Best Local Similarity 100.00; Pred. No. 136-15;

Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HAEQTFPSDVSVSYLSQAKKEFIANLVKRG 31

DB 98 HAEQTFPSDVSVSYLSQAKKEFIANLVKRG 128

RESULT 4

GLUC_HUMAN STANDARD; PRT; 180 AA.

CC 21-JUL-1986 (Rel. 01, Created)

CC 13-AUG-1987 (Rel. 05, Last sequence update)

CC 13-SEP-2003 (Rel. 42, Last annotation update)

CC Glucagon precursor [Contains: Glucenin-related polypeptide (GRP);

CC Glucagon; Glucagon-like peptide 1 (GLP1); Glucagon-like peptide 2

CC (GLP2)].

CC GCG.

CC Homo sapiens (Human).

CC Zukaryota; Metazoa; Chordata; Craniata; Vertebrata; Putelesontomi;

CC Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

CC NCBI_Taxid=9606;

CC

CC SEQUENCE FROM N.A.

CC MEDLINE-88330860; PubMed-2801414;

CC Drucker D.J., Asa S.;

CC "Glucagon gene expression in vertebrate brain.";

RL J. Biol. Chem. 263:13475-13478(1988).

[2]

RP SEQUENCE FROM N.A.

RA MEDLINE-86239053; PubMed-3725587;

RA "Structure of the human glucagon gene.";

RL Nucleic Acids Res. 14:4719-4730(1986).

CC

CC SEQUENCE FROM N.A.

CC TISSUE=Liver;

CC MEDLINE-84271477; PubMed-6877358;

CC Bell G.I., Sanchez-Pescador R., Laybourn P.J., Najjarian R.C.;

CC "Xon duplication and divergence in the human preproglucagon gene.";

CC Nature 304:368-371(1983).

CC (4) JENCE FROM N.A.

CC SEQUENCE FROM N.A.

CC TISSUE=Pancreas;

CC MEDLINE-23388257; PubMed-12477932;

CC Strausberg R.L., Peingold E.A., Grouse L.R., Derge J.G.,

CC Schausberger R.D., Collins F.S., Wagner L., Shennan C.M., Schuler G.D.,

CC Altshul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,

CC Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Bish F.,

CC Diachenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,

CC Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,

CC Brownstein M.J., Udén T.B., Toshiyuki S., Carninci P., Prange C.,

CC Saha S., Iqbalanov K.A., Peters K.J., Peterson R., Peterson R.H.,

CC Richards S., Worley K.C., Bale S., Garcia A.M., Gay L.J., Hulyk S.W.,

CC Villalón D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,

CC Fahey J., Helton E., Kettman M., Madau A., Rodriguez S., Sanchez A.,

CC Blakesley R.W., Touchman J.W., Green E.D., Dickinson M.C.,

CC Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,

CC Butcherfield T.S.N., Krzywinski M.I., Skalska O., Smalls D.E.,

CC Scherich A., Schein J.E., Jones S.J.M., Marra M.A.;

CC "Generation and annotation analysis of more than 15,000 full-length

CC human cDNA sequences.";

CC Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).

CC

CC SEQUENCE OF 53-81.

CC Thomsen J., Kristiansen K., Brunfeldt K., Sundby F.;

CC "The amino acid sequence of human glucagon.";

CC FEBS Lett. 21:315-319(1972).

CC

CC SEQUENCE OF 58-127

CC MEDLINE-8927288; PubMed-2753890;

CC Olesch C., Baudouin M., Johansen A.H., Højrup P., Holst J.J.;

CC "Complete sequences of glucagon-like peptide-1 from human and pig

CC small intestine.";

CC J. Biol. Chem. 264:12826-12829(1989).

CC

CC X-RAY CRYSTALLOGRAPHY (3.0 ANGSTROMS) OF 53-81.

CC MEDLINE-98334683; PubMed-9667960;

CC Sturm N.S., Lin Y., Burley S.K., Krstenansky J.L., Ahn J.M.,

CC Aizen B.F., Trivedi D., Hruby V.J.;

CC "Structure-function studies on positions 17, 18, and 21 replacement

CC bridges in glucagon biological activity.";

CC J. Med. Chem. 41:2693-2700(1998).

CC -1- FUNCTION: GLUCAGON PROMOTES HYDROLYSIS OF GLYCOGEN AND LIPIDS, AND

CC RAISES THE BLOOD SUGAR LEVEL.

CC -1- FUNCTION: GLP2 STIMULATES INTESTINAL GROWTH AND UPREGULATES VILLUS

CC HEIGHT IN THE SMALL INTESTINE, CONCOMITANT WITH INCREASED CRYPT

CC CELL PROLIFERATION AND DECREASED ENTEROCYTE APOPTOSIS.

CC -1- INDUCTION: PRODUCED IN THE A CELLS OF THE ISLETS OF LANGERHANS

CC IN RESPONSE TO A DROP IN BLOOD SUGAR CONCENTRATION. (El Lilly) and

CC PHARMACEUTIC: Available under the name Glucagon (El Lilly) and

CC severe hypoglycemia in insulin-dependent diabetes. Used to treat

CC -1- SIMILARITY: BELONGS TO THE GLUCAGON FAMILY.

CC -1- DATABASE: NAME-Glucagon at El Lilly;

CC NOTES-Clinical information on El Lilly glucagon products;

CC WWW="http://www.lillydiabetes.com/Products/PatientInfo.cfm"

CC -----


```

RN SEQUENCE FROM N.A.
RA Shamsadin P., Knoppel W.;
RL submitted (JUN-2000) to the EMBL/GenBank/DBJ databases.
CC -1- FUNCTION: GLUCAGON PROMOTES HYDROLYSIS OF GLYCOPEN AND LIPIDS, AND
CC RAISES THE BLOOD SUGAR LEVEL.
CC -1- FUNCTION: GLP2 STIMULATES INTESTINAL GROWTH AND UPREGULATES VILLOS
CC CELL PROLIFERATION AND DECREASED ENTEROCYTE APOPTOSIS.
CC -1- INDUCTION: PRODUCED IN THE A CELLS OF THE ISLETS OF LANGERHANS
CC -1- INDUCTION: PRODUCED IN THE A CELLS OF THE ISLETS OF LANGERHANS
CC -1- INDUCTION: PRODUCED IN THE A CELLS OF THE ISLETS OF LANGERHANS
CC -1- SIMILARITY: BELONGS TO THE GLUCAGON FAMILY.
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL Outstation
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC -----
DR EMBL: 246945; Chromosome 17.
DR PIR: A57294; A57294.
DR HSP: P01274; IGCN.
DR MD: MG1:95674; GCY.
DR InterPro: IPR000532; Glucagon.
DR Pfam: PF00123; hormone2.3.
DR PRINTS: PR00275; GLUCAGON.
DR SMART: SM0070; GLUCA.3.
DR PROSITE: PS00260; GLUCAGON; 4.
KW Glucagon family; Hormone; Cleavage on pair of basic residues; Signal.
FT SIGNAL 21 50 GLUCAGON-LIKE PEPTIDE.
FT PEPTIDE 53 81 GLUCAGON.
FT PROPEP 84 89
FT PEPTIDE 92 128 GLUCAGON-LIKE PEPTIDE 1.
FT PROPEP 131 143
FT PEPTIDE 146 178 GLUCAGON-LIKE PEPTIDE 2.
FT PROPEP 178 178
FT MOD_RES 127 127 AMIDATION (G-128 PROVIDE AMIDE GROUP).
FT SEQUENCE 180 AA; 20906 MW; 595AA6D9A58950 CRC64;
SQ
Query Match 100.0%; Score 161; DB 1; Length 180;
Best Local Similarity 100.0%; Pred. No. 1.3e-15;
Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1 HAEGTFTSDVSSYLEGQAAKEFIAWLKGRG 31
DB 98 HAEGTFTSDVSSYLEGQAAKEFIAWLKGRG 128
RESULT 7
ID GLUC_OCTDE STANDARD; PRT: 180 AA.
AC P22890.1991 (Rel. 19, Created)
DT 01-AUG-1991 (Rel. 19, Last sequence update)
DT 28-FEB-2003 (Rel. 41, Last annotation update)
DE Glucagon precursor [Contains: Glucagon-related polypeptide (GRPP);
DE Glucagon; Glucagon-like peptide 1 (GLP1); Glucagon-like peptide 2
DE (GLP2)].
GN Octodon degus (Degu).
OS Octodon degus (Degu).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Hystricognathi; Octodontidae; Octodon.
OX NCBI_TaxID=10160;
[1] SEQUENCE FROM N.A.
RA Shamsadin P., Knoppel W.;
RL submitted (JUN-2000) to the EMBL/GenBank/DBJ databases.
CC -1- FUNCTION: GLUCAGON PROMOTES HYDROLYSIS OF GLYCOPEN AND LIPIDS, AND
CC RAISES THE BLOOD SUGAR LEVEL.
CC -1- FUNCTION: GLP2 STIMULATES INTESTINAL GROWTH AND UPREGULATES VILLOS
CC CELL PROLIFERATION AND DECREASED ENTEROCYTE APOPTOSIS.
CC -1- INDUCTION: PRODUCED IN THE A CELLS OF THE ISLETS OF LANGERHANS
CC -1- INDUCTION: PRODUCED IN THE A CELLS OF THE ISLETS OF LANGERHANS
CC -1- INDUCTION: PRODUCED IN THE A CELLS OF THE ISLETS OF LANGERHANS
CC -1- SIMILARITY: BELONGS TO THE GLUCAGON FAMILY.
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL Outstation
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC -----
DR EMBL: 246945; Chromosome 17.
DR PIR: A57294; A57294.
DR HSP: P01274; IGCN.
DR MD: MG1:95674; GCY.
DR InterPro: IPR000532; Glucagon.
DR Pfam: PF00123; hormone2.3.
DR PRINTS: PR00275; GLUCAGON.
DR SMART: SM0070; GLUCA.3.
DR PROSITE: PS00260; GLUCAGON; 4.
KW Glucagon family; Hormone; Cleavage on pair of basic residues; Signal.
FT SIGNAL 21 50 GLUCAGON-LIKE PEPTIDE.
FT PEPTIDE 53 81 GLUCAGON.
FT PROPEP 84 89
FT PEPTIDE 92 128 GLUCAGON-LIKE PEPTIDE 1.
FT PROPEP 131 143
FT PEPTIDE 146 178 GLUCAGON-LIKE PEPTIDE 2.
FT PROPEP 178 178
FT MOD_RES 127 127 AMIDATION (G-128 PROVIDE AMIDE GROUP).
FT SEQUENCE 180 AA; 20906 MW; 595AA6D9A58950 CRC64;
SQ
Query Match 100.0%; Score 161; DB 1; Length 180;
Best Local Similarity 100.0%; Pred. No. 1.3e-15;
Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1 HAEGTFTSDVSSYLEGQAAKEFIAWLKGRG 31
DB 98 HAEGTFTSDVSSYLEGQAAKEFIAWLKGRG 128
RESULT 8
ID GLUC_RAT STANDARD; PRT: 180 AA.
AC P06883;
DT 01-JAN-1988 (Rel. 06, Created)
DT 01-JAN-1988 (Rel. 06, Last sequence update)
DT 28-FEB-2003 (Rel. 41, Last annotation update)
DE Glucagon precursor [Contains: Glucagon-related polypeptide (GRPP);
DE Glucagon; Glucagon-like peptide 1 (GLP1); Glucagon-like peptide 2
DE (GLP2)].
GN Rattus norvegicus (Rat).
OS Rattus norvegicus (Rat).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Rattus.
OX NCBI_TaxID=10116;
[1] SEQUENCE FROM N.A.
RA Shamsadin P., Knoppel W.;
RL submitted (JUN-2000) to the EMBL/GenBank/DBJ databases.
CC -1- FUNCTION: GLUCAGON PROMOTES HYDROLYSIS OF GLYCOPEN AND LIPIDS, AND
CC RAISES THE BLOOD SUGAR LEVEL.
CC -1- FUNCTION: GLP2 STIMULATES INTESTINAL GROWTH AND UPREGULATES VILLOS
CC CELL PROLIFERATION AND DECREASED ENTEROCYTE APOPTOSIS.
CC -1- INDUCTION: PRODUCED IN THE A CELLS OF THE ISLETS OF LANGERHANS
CC -1- INDUCTION: PRODUCED IN THE A CELLS OF THE ISLETS OF LANGERHANS
CC -1- INDUCTION: PRODUCED IN THE A CELLS OF THE ISLETS OF LANGERHANS
CC -1- SIMILARITY: BELONGS TO THE GLUCAGON FAMILY.
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL Outstation
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC -----
DR EMBL: 246945; Chromosome 17.
DR PIR: A57294; A57294.
DR HSP: P01274; IGCN.
DR MD: MG1:95674; GCY.
DR InterPro: IPR000532; Glucagon.
DR Pfam: PF00123; hormone2.3.
DR PRINTS: PR00275; GLUCAGON.
DR SMART: SM0070; GLUCA.3.
DR PROSITE: PS00260; GLUCAGON; 4.
KW Glucagon family; Hormone; Cleavage on pair of basic residues; Signal.
FT SIGNAL 21 50 GLUCAGON-LIKE PEPTIDE.
FT PEPTIDE 53 81 GLUCAGON.
FT PROPEP 84 89
FT PEPTIDE 92 128 GLUCAGON-LIKE PEPTIDE 1.
FT PROPEP 131 143
FT PEPTIDE 146 178 GLUCAGON-LIKE PEPTIDE 2.
FT PROPEP 178 178
FT MOD_RES 127 127 AMIDATION (G-128 PROVIDE AMIDE GROUP).
FT SEQUENCE 180 AA; 21165 MW; 6E8836160A9A3051 CRC64;
SQ
Query Match 100.0%; Score 161; DB 1; Length 180;
Best Local Similarity 100.0%; Pred. No. 1.3e-15;
Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1 HAEGTFTSDVSSYLEGQAAKEFIAWLKGRG 31
DB 98 HAEGTFTSDVSSYLEGQAAKEFIAWLKGRG 128

```

```

RL Mol. Endocrinol. 4:1192-1198(1990).
CC -1- FUNCTION: GLUCAGON PROMOTES HYDROLYSIS OF GLYCOPEN AND LIPIDS, AND
CC RAISES THE BLOOD SUGAR LEVEL.
CC -1- FUNCTION: GLP2 STIMULATES INTESTINAL GROWTH AND UPREGULATES VILLOS
CC HEIGHT IN THE SMALL INTESTINE, CONCOMITANT WITH INCREASED CRYPT
CC CELL PROLIFERATION AND DECREASED ENTEROCYTE APOPTOSIS.
CC -1- INDUCTION: PRODUCED IN THE A CELLS OF THE ISLETS OF LANGERHANS
CC -1- INDUCTION: PRODUCED IN THE A CELLS OF THE ISLETS OF LANGERHANS
CC -1- INDUCTION: PRODUCED IN THE A CELLS OF THE ISLETS OF LANGERHANS
CC -1- SIMILARITY: BELONGS TO THE GLUCAGON FAMILY.
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL Outstation
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC -----
DR EMBL: M57688; AAA0588.1;
DR PIR: C36118; GCRVDP.
DR HSP: P01274; IGCN.
DR InterPro: IPR000532; Glucagon.
DR Pfam: PF00123; hormone2.3.
DR PRINTS: PR00275; GLUCAGON.
DR SMART: SM0070; GLUCA.3.
DR PROSITE: PS00260; GLUCAGON; 4.
KW Glucagon family; Hormone; Cleavage on pair of basic residues; Signal;
KW Amidation.
FT SIGNAL 1 20
FT PEPTIDE 21 50 GLUCENTIN-RELATED POLYPEPTIDE.
FT PROPEP 84 89
FT PEPTIDE 92 127 GLUCAGON-LIKE PEPTIDE 1.
FT PROPEP 127 127
FT PEPTIDE 146 178 GLUCAGON-LIKE PEPTIDE 2.
FT MOD_RES 127 127 AMIDATION (G-128 PROVIDE AMIDE GROUP).
FT SEQUENCE 180 AA; 21165 MW; 6E8836160A9A3051 CRC64;
SQ
Query Match 100.0%; Score 161; DB 1; Length 180;
Best Local Similarity 100.0%; Pred. No. 1.3e-15;
Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1 HAEGTFTSDVSSYLEGQAAKEFIAWLKGRG 31
DB 98 HAEGTFTSDVSSYLEGQAAKEFIAWLKGRG 128
RESULT 8
ID GLUC_RAT STANDARD; PRT: 180 AA.
AC P06883;
DT 01-JAN-1988 (Rel. 06, Created)
DT 01-JAN-1988 (Rel. 06, Last sequence update)
DT 28-FEB-2003 (Rel. 41, Last annotation update)
DE Glucagon precursor [Contains: Glucagon-related polypeptide (GRPP);
DE Glucagon; Glucagon-like peptide 1 (GLP1); Glucagon-like peptide 2
DE (GLP2)].
GN Rattus norvegicus (Rat).
OS Rattus norvegicus (Rat).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Rattus.
OX NCBI_TaxID=10116;
[1] SEQUENCE FROM N.A.
RA Shamsadin P., Knoppel W.;
RL submitted (JUN-2000) to the EMBL/GenBank/DBJ databases.
CC -1- FUNCTION: GLUCAGON PROMOTES HYDROLYSIS OF GLYCOPEN AND LIPIDS, AND
CC RAISES THE BLOOD SUGAR LEVEL.
CC -1- FUNCTION: GLP2 STIMULATES INTESTINAL GROWTH AND UPREGULATES VILLOS
CC CELL PROLIFERATION AND DECREASED ENTEROCYTE APOPTOSIS.
CC -1- INDUCTION: PRODUCED IN THE A CELLS OF THE ISLETS OF LANGERHANS
CC -1- INDUCTION: PRODUCED IN THE A CELLS OF THE ISLETS OF LANGERHANS
CC -1- INDUCTION: PRODUCED IN THE A CELLS OF THE ISLETS OF LANGERHANS
CC -1- SIMILARITY: BELONGS TO THE GLUCAGON FAMILY.
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL Outstation
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC -----
DR EMBL: 246945; Chromosome 17.
DR PIR: A57294; A57294.
DR HSP: P01274; IGCN.
DR MD: MG1:95674; GCY.
DR InterPro: IPR000532; Glucagon.
DR Pfam: PF00123; hormone2.3.
DR PRINTS: PR00275; GLUCAGON.
DR SMART: SM0070; GLUCA.3.
DR PROSITE: PS00260; GLUCAGON; 4.
KW Glucagon family; Hormone; Cleavage on pair of basic residues; Signal;
KW Amidation.
FT SIGNAL 1 20
FT PEPTIDE 21 50 GLUCENTIN-RELATED POLYPEPTIDE.
FT PROPEP 84 89
FT PEPTIDE 92 127 GLUCAGON-LIKE PEPTIDE 1.
FT PROPEP 127 127
FT PEPTIDE 146 178 GLUCAGON-LIKE PEPTIDE 2.
FT MOD_RES 127 127 AMIDATION (G-128 PROVIDE AMIDE GROUP).
FT SEQUENCE 180 AA; 21165 MW; 6E8836160A9A3051 CRC64;
SQ
Query Match 100.0%; Score 161; DB 1; Length 180;
Best Local Similarity 100.0%; Pred. No. 1.3e-15;
Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1 HAEGTFTSDVSSYLEGQAAKEFIAWLKGRG 31
DB 98 HAEGTFTSDVSSYLEGQAAKEFIAWLKGRG 128

```



```

FT PEPTIDE 55 83 GLUCAGON.
FT PROPEP 86 116
FT PEPTIDE 118 147 GLUCAGON-LIKE PEPTIDE 1.
FT PROPEP 151 163
FT PEPTIDE 156 198 GLUCAGON-LIKE PEPTIDE 2.
FT PROPEP 199 206
FT MOD.RES 147 147 AMIDATION (G-148 PROVIDE AMIDE GROUP).
FT VARSPLIC 151 151 D->E (in isoform LPII).
FT VARSPLIC 152 206 /FTID=VSP_001756.
FT SEQUENCE 206 AA: 23875 MW: 48299 ELB02FC6A4 CRC64;
Query Match 92.5%; Score 149; DB 1; Length 206;
Best Local Similarity 87.1%; Pred. No. 7, 2e-14;
Matches 27; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 1 HAEGETTSVSYLGGQAKKEFIAMLVNGR 31
DB 118 HAEGETTSVSYLGGQAKKEFIAMLVNGR 148

RESULT 10
GLUC BELSU
ID GLUC BELSU STANDARD; PRT: 204 AA.
AC O12956; O12956;
DT 28-FEB-2003 (Rel. 41, Created)
DT 28-FEB-2003 (Rel. 41, Last sequence update)
DE Glucagon precursor [Contains: Glucagon-related polypeptide (GRPP);
DE Glucagon; glucagon-like peptide 1 (GLP-1); Glucagon-like peptide 2
DE (GLP-2)]; euspectrum (Gila monster).
CC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
CC Lepidosauria; Squamata; Scleroglossa; Anguilliformes; Helodermatidae;
CC Heloderma.
CC NCBI_TaxID=8554;
RN [1]
RP SEQUENCE FROM N.A. (ISOFORMS LPI AND LPII), AND TISSUE SPECIFICITY.
RC TISSUE=Intestine, and Pancreas;
RX MEDLINE=97172477; PubMed=9020121;
RA Chen Y.E., Drucker D.J.;
RT Tissue-specific expression of unique mRNAs that encode proglucagon-
RT derived peptides in the lizard, Xenopus laevis.
RL J. Biol. Chem. 272:4108-4115 (1997).
CC -1- FUNCTION: Promotes hydrolysis of glycogen and lipids, and raises
CC the blood sugar level.
CC -1- ALTERNATIVE PRODUCTS.
CC Event-Alternative splicing; Named isoforms-2;
CC Name=LPII;
CC IsoId=O12956-1; Sequence=Displayed;
CC Name=LPI;
CC IsoId=O12956-2; Sequence=VSP_001756, VSP_001757;
CC -1- TISSUE SPECIFICITY: Isoform LPII is expressed in both pancreas and
CC intestine. Expression of isoform LPI is restricted to the
CC pancreas.
CC -1- INDUCTION: Produced in the cells of the islets of Langerhans in
CC response to a drop in blood sugar concentration.
CC -1- SIMILARITY: BELONGS TO THE GLUCAGON FAMILY.
CC
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@sib-sib.ch).
CC
CC EMBL: U77612; AAB51129.1; -
CC BSRP: O1274; IGCN.
CC InterPro: IP0000532; Glucagon.
CC Pfam: PF00123; hormone2; 3.

```

```

DR PRINTS: PR00275; GLUCAGON.
DR SMART: SM00070; GLUCA: 3
DR PROSITE: PS00260; GLUCAGON; 2
KW Glucagon family; Hormone; Cleavage on pair of basic residues; Signal;
KW Amidation; Alternative splicing.
FT SIGNAL 1 20 BY SIMILARITY.
FT PEPTIDE 21 50 GLUCENTIN-RELATED POLYPEPTIDE.
FT PROPEP 84 114
FT PEPTIDE 116 145 GLUCAGON-LIKE PEPTIDE 1.
FT PROPEP 151 166
FT PEPTIDE 167 197 GLUCAGON-LIKE PEPTIDE 2.
FT PROPEP 197 204
FT MOD.RES 145 145 AMIDATION (G-145 PROVIDE AMIDE GROUP).
FT VARSPLIC 149 149 D->E (in isoform LPI).
FT VARSPLIC 150 204 /FTID=VSP_001756.
FT SEQUENCE 204 AA: 23553 MW: 41329 ELB02FC6A4 CRC64;
Query Match 88.8%; Score 143; DB 1; Length 204;
Best Local Similarity 83.9%; Pred. No. 5e-13;
Matches 26; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 1 HAEGETTSVSYLGGQAKKEFIAMLVNGR 31
DB 116 HAEGETTSVSYLGGQAKKEFIAMLVNGR 146

RESULT 11
GLUC RANCA
ID GLUC RANCA STANDARD; PRT: 103 AA.
AC P15438; P15439, P15440;
DT 01-JUL-1993 (Rel. 1, Created)
DT 01-JUL-1993 (Rel. 2, Last sequence update)
DE Glucagon precursor (Fragments).
DE Glucagon precursor (Fragments).
CC Rana catesbeiana (Bull frog).
CC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
CC Amphibia; Batrachia; Anura; Neobatrachia; Ranoidae; Ranidae; Rana.
CC NCBI_TaxID=8400;
RN [1]
RP TISSUE=Pancreas;
RC MEDLINE=88257102; PubMed=3260236;
RA Follock H.C., Hamilton J.W., Rouse J.B., Ebner K.E., Rawitch A.B.;
RT "Rana catesbeiana" peptide hormones from the pancreas of the bullfrog
RT (Rana catesbeiana) and two glucagon-like peptides of pancreatic polypeptide,
RT oxyntomodulin, and two glucagon-like peptides."
RL J. Biol. Chem. 263:9746-9751 (1988).
CC -1- FUNCTION: PROMOTES HYDROLYSIS OF GLYCOGEN AND LIPIDS, AND RAISES
CC THE BLOOD SUGAR LEVEL.
CC -1- INDUCTION: PRODUCED IN THE A CELLS OF THE ISLETS OF Langerhans
CC IN RESPONSE TO A DROP IN BLOOD SUGAR CONCENTRATION.
CC -1- MISCELLANEOUS: X'S IN THE SEQUENCE WERE INCLUDED BY HOMOLGY WITH
CC OTHER SPECIES SEQUENCES.
CC -1- SIMILARITY: BELONGS TO THE GLUCAGON FAMILY.
CC
CC InterPro: IP0000532; Glucagon.
DR PRINTS: PR00275; GLUCAGON.
DR SMART: SM00070; GLUCA: 3
DR PROSITE: PS00260; GLUCAGON; 3
KW Glucagon family; Hormone.
FT PEPTIDE 1 29 GLUCAGON.
FT PEPTIDE 1 36 GLUCAGON-36 (OXYNTOMODULIN).
FT PEPTIDE 39 70 GLUCAGON-LIKE PEPTIDE 1.
FT NON-CONS 70 71
FT PEPTIDE 71 103 GLUCAGON-LIKE PEPTIDE 2.
FT SEQUENCE 103 AA: 11719 MW: 3162878 ELB02FC6A4 CRC64;
Query Match 80.1%; Score 129; DB 1; Length 103;
Best Local Similarity 76.7%; Pred. No. 2, 4e-11;
Matches 23; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

```

CC Event=Alternative splicing; Named isoforms=2;

```

CC CC Name=1;
CC CC IsoId=042143-1; Sequence=Displayed;
CC CC Name=2;
CC CC IsoId=042143-2; Sequence=VSP_001755;
CC CC -!- SIMILARITY: BELONGS TO THE GLUCAGON FAMILY.
CC CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC CC the European Bioinformatics Institute. There are no restrictions on its
CC CC use by non-profit institutions as long as its content is in no way
CC CC modified and this statement is not removed. Usage by and for commercial
CC CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC CC or send an email to license@isb-sib.ch).
CC CC -----
CC CC EMBL: AF004432; AAB55660.1; -.
CC CC DR HSP: P01274; IGCN.
CC CC DR InterPro: IPR000332; Glucagon.
CC CC DR Pfam: PF00123; hormone2; 5.
CC CC DR SMART: SM00070; GLUCAG.
CC CC DR SMART: SM00070; GLUCAG.
CC CC DR PROSITE: PS00260; GLUCAGON; 5.
CC CC KW Multigene family; Hormone; signal; Cleavage on pair of basic residues;
CC CC KW Multigene family; Alternative splicing.
CC CC FT SIGNAL 1 20 POTENTIAL.
CC CC FT PROPEP 21 50
CC CC FT PEPTIDE 53 81 GLUCAGON.
CC CC FT PROPEP 84 95 GLUCAGON-LIKE PEPTIDE 1A.
CC CC FT PEPTIDE 97 133 GLUCAGON-LIKE PEPTIDE 1B.
CC CC FT PEPTIDE 136 140 GLUCAGON-LIKE PEPTIDE 1C.
CC CC FT PEPTIDE 142 172 GLUCAGON-LIKE PEPTIDE 2.
CC CC FT PEPTIDE 180 210 GLUCAGON-LIKE PEPTIDE 2.
CC CC FT PEPTIDE 227 259 GLUCAGON-LIKE PEPTIDE 2.
CC CC FT PROPEP 261 266
CC CC FT VAPSLIC 214 261
CC CC SEQUENCE 266 AA: 30951 MW: 54478BC20AF872C CRC64;
Query Match 77.69; Score 125; DB 1; Length 266;
Best local similarity 70.04; Pred. No. 2,3e-10; Mismatches 2; Indels 0; Gaps 0;
Matches 21; Conservative 7; Mismatches 2; Indels 0; Gaps 0;
OY 1 HAEQTFSDVSYLLEQAAKEFTAMLVKGR 30
DB 180 HAEQTFNDMTNLYLEKAAKEFTVGLNGR 209

```

```

RESULT 15
GLU2_XENLA
ID GLU2_XENLA STANDARD; PRT; 219 AA.
AC 042144;
DT 28-FEB-2003 (rel. 41, Created)
DT 28-FEB-2003 (rel. 41, Last sequence update)
DT 28-FEB-2003 (rel. 41, Last annotation update)
DE Glucagon-like peptide 1B (GLP-1B), glucagon-like peptide 1B (GLP-1B),
DE (GLP-1A), Glucagon-like peptide 1B (GLP-1B); Glucagon-like peptide 1C
DE (GLP-1C).
OS Xenopus laevis (African clawed frog).
CC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
CC Amphibia; Batrachia; Anura; Mesobatrachia; Pipidae; Pipidae;
CC Xenopodinae; Xenopus.
CC NCHI_TaxID=8355;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Pancreas;
RA MEDLINE=9736292; PubMed=9223287;
RA Wain D.W., Satkunarajah M., Wen Y., Brubaker P.L., Pederson R.A.,
RA "The Xenopus proglucagon gene encodes novel GLP-1-like peptides with
RA insulinotropic properties."
RL Proc. Natl. Acad. Sci. U.S.A. 94:7915-7920(1997).
CC -!- FUNCTION: Promotes hydrolysis of glycogen and lipids, and raises

```

```

CC CC the blood sugar level.
CC CC -!- SIMILARITY: BELONGS TO THE GLUCAGON FAMILY.
CC CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC CC the European Bioinformatics Institute. There are no restrictions on its
CC CC use by non-profit institutions as long as its content is in no way
CC CC modified and this statement is not removed. Usage by and for commercial
CC CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC CC or send an email to license@isb-sib.ch).
CC CC -----
CC CC EMBL: AF004433; AAB55661.1; -.
CC CC DR HSP: P01274; IGCN.
CC CC DR InterPro: IPR000332; Glucagon.
CC CC DR Pfam: PF00123; hormone2; 4.
CC CC DR SMART: SM00070; GLUCAG; 4.
CC CC DR PROSITE: PS00260; GLUCAGON; 3.
CC CC KW Multigene family; Hormone; signal; Cleavage on pair of basic residues;
CC CC KW Multigene family.
CC CC FT SIGNAL 1 20 POTENTIAL.
CC CC FT PROPEP 21 50
CC CC FT PEPTIDE 53 81 GLUCAGON.
CC CC FT PROPEP 84 95 GLUCAGON-LIKE PEPTIDE 1A.
CC CC FT PEPTIDE 97 133 GLUCAGON-LIKE PEPTIDE 1B.
CC CC FT PEPTIDE 136 140 GLUCAGON-LIKE PEPTIDE 1C.
CC CC FT PEPTIDE 142 172 GLUCAGON-LIKE PEPTIDE 1C.
CC CC FT PROPEP 175 178 GLUCAGON-LIKE PEPTIDE 1C.
CC CC FT PROPEP 213 219
CC CC SEQUENCE 219 AA: 25271 MW: ACC59933C362CE0 CRC64;
Query Match 74.58; Score 120; DB 1; Length 219;
Best local similarity 66.78; Pred. No. 9,6e-10;
Matches 20; Conservative 7; Mismatches 3; Indels 0; Gaps 0;
OY 1 HAEQTFSDVSYLLEQAAKEFTAMLVKGR 30
DB 180 HAEQTFNDMTNLYLEKAAKEFTVGLNGR 209

```

Search completed: October 15, 2003, 10:53:38
Job time : 13.7213 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM protein - protein search, using sv model

Run on: October 15, 2003, 10:48:32 ; Search time 60.9836 Seconds
(without alignments)
131,177 Million cell updates/sec

Title: US-09-719-410-3

Sequence: 1 HAEFTFSDVSYLEQAAKEFIAMLVKGRG 31

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 830525 seqs, 258052604 residues

Total number of hits satisfying chosen parameters: 830525

Minimum DB seq length: 0

Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

SPREMBL_23:*

1: sp-archaea:*

2: sp-bacteria:*

3: sp-fungi:*

4: sp-invertebrate:*

5: sp-mammal:*

6: sp-invertebrate:*

7: sp-invertebrate:*

8: sp-organelle:*

9: sp-phage:*

10: sp-plant:*

11: sp-rodent:*

12: sp-virus:*

13: sp-vertebrate:*

14: sp-unclassified:*

15: sp-bacteria:*

16: sp-archaea:*

17: sp-invertebrate:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

| Result No. | Score | Query Match | Length | DB ID | Description |
|------------|-------|-------------|--------|-------|------------------------|
| 1 | 161 | 100.0 | 186 | Q8M25 | Q8M25 ovis aries |
| 2 | 159 | 80.1 | 220 | Q8M25 | Q8M25 canis familiaris |
| 3 | 158 | 73.3 | 172 | Q8M25 | Q8M25 canis familiaris |
| 4 | 118 | 73.3 | 172 | Q8M25 | Q8M25 canis familiaris |
| 5 | 118 | 73.3 | 178 | Q8M25 | Q8M25 canis familiaris |
| 6 | 113 | 70.2 | 178 | Q8M25 | Q8M25 canis familiaris |
| 7 | 103 | 64.0 | 121 | Q8M25 | Q8M25 canis familiaris |
| 8 | 90 | 55.9 | 96 | Q8M25 | Q8M25 canis familiaris |
| 9 | 67 | 41.6 | 130 | Q8M25 | Q8M25 canis familiaris |
| 10 | 67 | 41.6 | 144 | Q8M25 | Q8M25 canis familiaris |
| 11 | 60 | 37.3 | 170 | Q8M25 | Q8M25 canis familiaris |
| 12 | 59 | 36.6 | 173 | Q8M25 | Q8M25 canis familiaris |
| 13 | 59 | 36.6 | 173 | Q8M25 | Q8M25 canis familiaris |
| 14 | 53 | 33.5 | 172 | Q8M25 | Q8M25 canis familiaris |
| 15 | 53 | 33.2 | 175 | Q8M25 | Q8M25 canis familiaris |
| 16 | 53 | 32.9 | 170 | Q8M25 | Q8M25 canis familiaris |

17 52.5 32.6 224 16 Q8M25
18 52.5 32.6 427 17 Q8M25
19 52 32.3 38 5 Q8M25
20 52 32.3 38 5 Q8M25
21 52 32.3 38 5 Q8M25
22 52 32.3 38 5 Q8M25
23 52 32.3 38 13 Q8M25
24 52 32.3 38 13 Q8M25
25 52 32.3 38 13 Q8M25
26 52 32.3 38 13 Q8M25
27 52 32.3 38 13 Q8M25
28 51.5 32.0 263 13 Q8M25
29 51.5 32.0 263 13 Q8M25
30 51 31.7 352 5 Q8M25
31 51 31.7 810 4 Q8M25
32 51 31.7 867 4 Q8M25
33 50.5 31.4 175 13 Q8M25
34 50.5 31.4 210 5 Q8M25
35 50.5 31.4 372 10 Q8M25
36 50 31.1 171 10 Q8M25
37 50 31.1 185 11 Q8M25
38 50 31.1 204 16 Q8M25
39 50 31.1 204 16 Q8M25
40 50 31.1 332 5 Q8M25
41 50 31.1 366 11 Q8M25
42 50 31.1 401 11 Q8M25
43 50 31.1 1003 5 Q8M25
44 49.5 30.7 285 17 Q8M25
45 49.5 30.7 378 5 Q8M25

ALIGNMENTS

RESULT 1
Q8M25
ID Q8M25 PRELIMINARY; PRT; 176 AA.
AC Q8M25;
DT 01-OCT-2002 (TREMELrel. 22, Created)
DT 01-OCT-2002 (TREMELrel. 22, Last sequence update)
DT 01-MAR-2003 (TREMELrel. 23, Last annotation update)
DE Preproglucagon (fragment).
OS Ovis aries (Sheep).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Cetartiodactyla; Ruminantia; Pecora; Bovidae;
OC Bovidae; Caprinae; Ovis.
RN [1]_txid=9940;
RP SEQUENCE FROM N.A.
RC TISSUE=Pancreas;
RA Limesand S.W., Hay W.W. Jr.;
RT "Characterization of the endocrine pancreas in an ovine placental
insufficiency IUGR fetus";
RL Submitted (JUL-2002) to the EMBL/GenBank/DBJ databases.
DR EMBL; AF529185; AM94409.1; -
DR InterPro; IPR000532; Glucagon.
DR Pfam; PF00123; hormone2; 3.
DR PRINTS; PR00275; GLUCAGON.
DR SMART; SM0070; GLUCA; 3.
DR NCBI; PS0060; GLUCAGON; 2.
DR NCBI; PS0060; GLUCAGON; 2.
SQ SEQUENCE 176 AA; 20335 WA; 13174039D6CE2B3 CRC64;

Query Watch 100.0%; Score 161; DB 6; Length 176;
Best Local Similarity 100.0%; Pred. No. 3.1e-16;
Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HAEFTFSDVSYLEQAAKEFIAMLVKGRG 31
DB 98 HAEFTFSDVSYLEQAAKEFIAMLVKGRG 128

RESULT 2

```

AC Q91409; Q91232;
AD 01-NOV-1996 (TEMBLrel. 01, Created)
DT 01-NOV-1996 (TEMBLrel. 01, Last sequence update)
DT 01-MAR-2003 (TEMBLrel. 01, Last annotation update)
DE PROGLUCAGON (fragment)
OS Oncorhynchus tshawytscha (Chinook salmon)
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Actinopterygii; Neopterygii; Teleostei; Euteleostei;
OC Protacanthopterygii; Salmoniformes; Salmonidae; Oncorhynchus.
OC NCBI_TaxID=7540;
LN SOURCE FROM N.A.;
LN SEQUENCE 72 AA; 8293 MW; 8584352B3C60A31 CRC64;
LN KEYWORDS: 95-295739; PubMed=7776976;
RT Irwin D.M., Wong J.;
RA "Trypt and chicken proglucagon; alternative splicing generates mRNA
RA transcripts encoding glucagon-like peptide 2.";
RL Mol. Endocrinol. 9:267-277(1995).
DR EMBL; U89474; X014283.1;
DR EMBL; U19920; AAC59670.1;
DR EMBL; P01274; JGCM.
DR InterPro: IPRO00532; Glucagon.
DR Pfam: PF00123; hormone; 2.
DR SMART: SM00460; Glucagon.
DR PROSITE: PS00260; GLUCAGON; 1.
DR NON_TER 1
DR FT
SQ SEQUENCE 72 AA; 8293 MW; 8584352B3C60A31 CRC64;

Query Match 73.3%; Score 118; DB 13; Length 72;
Best Local Similarity 66.7%; Pred. No. 3,5e-10;
Matches 20; Conservative 7; Mismatches 3; Indels 0; Gaps

QY 1 HAEQGTTSVSSVLEQANEFANVYGR 30
DB |||:|||||:|||||:|||||:|||||
39 HADGTVTSVYLLQDQAKDFVSLKSR 68

RESULT 5
Q91971 PRELIMINARY; PRT; 178 AA.
ID Q91971; Q91409; Q92169; Q92170; Q92171; Q92172; Q92173; Q92174; Q92175; Q92176; Q92177; Q92178; Q92179; Q92180; Q92181; Q92182; Q92183; Q92184; Q92185; Q92186; Q92187; Q92188; Q92189; Q92190; Q92191; Q92192; Q92193; Q92194; Q92195; Q92196; Q92197; Q92198; Q92199; Q92200; Q92201; Q92202; Q92203; Q92204; Q92205; Q92206; Q92207; Q92208; Q92209; Q92210; Q92211; Q92212; Q92213; Q92214; Q92215; Q92216; Q92217; Q92218; Q92219; Q92220; Q92221; Q92222; Q92223; Q92224; Q92225; Q92226; Q92227; Q92228; Q92229; Q92230; Q92231; Q92232; Q92233; Q92234; Q92235; Q92236; Q92237; Q92238; Q92239; Q92240; Q92241; Q92242; Q92243; Q92244; Q92245; Q92246; Q92247; Q92248; Q92249; Q92250; Q92251; Q92252; Q92253; Q92254; Q92255; Q92256; Q92257; Q92258; Q92259; Q92260; Q92261; Q92262; Q92263; Q92264; Q92265; Q92266; Q92267; Q92268; Q92269; Q92270; Q92271; Q92272; Q92273; Q92274; Q92275; Q92276; Q92277; Q92278; Q92279; Q92280; Q92281; Q92282; Q92283; Q92284; Q92285; Q92286; Q92287; Q92288; Q92289; Q92290; Q92291; Q92292; Q92293; Q92294; Q92295; Q92296; Q92297; Q92298; Q92299; Q92300; Q92301; Q92302; Q92303; Q92304; Q92305; Q92306; Q92307; Q92308; Q92309; Q92310; Q92311; Q92312; Q92313; Q92314; Q92315; Q92316; Q92317; Q92318; Q92319; Q92320; Q92321; Q92322; Q92323; Q92324; Q92325; Q92326; Q92327; Q92328; Q92329; Q92330; Q92331; Q92332; Q92333; Q92334; Q92335; Q92336; Q92337; Q92338; Q92339; Q92340; Q92341; Q92342; Q92343; Q92344; Q92345; Q92346; Q92347; Q92348; Q92349; Q92350; Q92351; Q92352; Q92353; Q92354; Q92355; Q92356; Q92357; Q92358; Q92359; Q92360; Q92361; Q92362; Q92363; Q92364; Q92365; Q92366; Q92367; Q92368; Q92369; Q92370; Q92371; Q92372; Q92373; Q92374; Q92375; Q92376; Q92377; Q92378; Q92379; Q92380; Q92381; Q92382; Q92383; Q92384; Q92385; Q92386; Q92387; Q92388; Q92389; Q92390; Q92391; Q92392; Q92393; Q92394; Q92395; Q92396; Q92397; Q92398; Q92399; Q92400; Q92401; Q92402; Q92403; Q92404; Q92405; Q92406; Q92407; Q92408; Q92409; Q92410; Q92411; Q92412; Q92413; Q92414; Q92415; Q92416; Q92417; Q92418; Q92419; Q92420; Q92421; Q92422; Q92423; Q92424; Q92425; Q92426; Q92427; Q92428; Q92429; Q92430; Q92431; Q92432; Q92433; Q92434; Q92435; Q92436; Q92437; Q92438; Q92439; Q92440; Q92441; Q92442; Q92443; Q92444; Q92445; Q92446; Q92447; Q92448; Q92449; Q92450; Q92451; Q92452; Q92453; Q92454; Q92455; Q92456; Q92457; Q92458; Q92459; Q92460; Q92461; Q92462; Q92463; Q92464; Q92465; Q92466; Q92467; Q92468; Q92469; Q92470; Q92471; Q92472; Q92473; Q92474; Q92475; Q92476; Q92477; Q92478; Q92479; Q92480; Q92481; Q92482; Q92483; Q92484; Q92485; Q92486; Q92487; Q92488; Q92489; Q92490; Q92491; Q92492; Q92493; Q92494; Q92495; Q92496; Q92497; Q92498; Q92499; Q92500; Q92501; Q92502; Q92503; Q92504; Q92505; Q92506; Q92507; Q92508; Q92509; Q92510; Q92511; Q92512; Q92513; Q92514; Q92515; Q92516; Q92517; Q92518; Q92519; Q92520; Q92521; Q92522; Q92523; Q92524; Q92525; Q92526; Q92527; Q92528; Q92529; Q92530; Q92531; Q92532; Q92533; Q92534; Q92535; Q92536; Q92537; Q92538; Q92539; Q92540; Q92541; Q92542; Q92543; Q92544; Q92545; Q92546; Q92547; Q92548; Q92549; Q92550; Q92551; Q92552; Q92553; Q92554; Q92555; Q92556; Q92557; Q92558; Q92559; Q92560; Q92561; Q92562; Q92563; Q92564; Q92565; Q92566; Q92567; Q92568; Q92569; Q92570; Q92571; Q92572; Q92573; Q92574; Q92575; Q92576; Q92577; Q92578; Q92579; Q92580; Q92581; Q92582; Q92583; Q92584; Q92585; Q92586; Q92587; Q92588; Q92589; Q92590; Q92591; Q92592; Q92593; Q92594; Q92595; Q92596; Q92597; Q92598; Q92599; Q92600; Q92601; Q92602; Q92603; Q92604; Q92605; Q92606; Q92607; Q92608; Q92609; Q92610; Q92611; Q92612; Q92613; Q92614; Q92615; Q92616; Q92617; Q92618; Q92619; Q92620; Q92621; Q92622; Q92623; Q92624; Q92625; Q92626; Q92627; Q92628; Q92629; Q92630; Q92631; Q92632; Q92633; Q92634; Q92635; Q92636; Q92637; Q92638; Q92639; Q92640; Q92641; Q92642; Q92643; Q92644; Q92645; Q92646; Q92647; Q92648; Q92649; Q92650; Q92651; Q92652; Q92653; Q92654
```

[illegible]

```

RESULT 10
Q9D867 ID Q9D867 PRELIMINARY; PRT: 144 AA.
AC Q9D867;
DT 01-JUN-2001 (TRENDSrel. 17, Created)
DT 01-JUN-2001 (TRENDSrel. 17, Last sequence update)
DT 01-DEC-2001 (TRENDSrel. 18, Last annotation update)
DR Gaps: no inhibitory polypeptides.
GN GIP
GN MUS musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
NCBI_TaxID=10090;
RX [1]
RX SOURCE FROM X A.
RX STRAIN=C57BL/6J; TISSUE=Small intestine;
RX MEDLINE=11085660; PubMed=11217851;
RA Kawai J., Hara S., Hasegawa A., Shibata K., Yoshino M., Itoh M., Ishii Y.,
RA Arakawa T., Sato A., Fukunishi Y., Konno H., Adachi J., Fukuda S.,
RA Akizawa K., Izawa M., Nishi K., Kiyosawa H., Kondo S., Yamataka I.,
RA Saito T., Okazaki Y., Gojobori T., Bono H., Kasukawa T., Saito R.,
RA Kadota K., Matsuda H.A., Ashburner M., Batalov S., Casavant T.,
RA Fleischmann W., Gasterland T., Gissi C., King B., Kotchika K., Kush J.,
RA Schriml L., Staahl U., Suzuki K., Tomita M., Wagner L., Washio T.,
RA Sakai K., Okido T., Furuno M., Aono H., Baldarelli R., Barsh G.,
RA Blake J., Bellodi D., Bojunga N., Carinici P., De Bonaldo M.F.,
RA Brownstein M.J., Bult C., Fletcher C., Fujita M., Gariboldi M.,
RA Gustincich S., Hill D., Hoffman M., Hume D.A., Kamiya M., Lee N.H.,
RA Lyons P., Marchionni L., Mashima J., Mazzarelli J., Membaerts P.,
RA Nordone P., Ring B., Ringwald K., Rodriguez Sakamoto N., Koch K.-P.,
RA Suzuki H., Toyokuni S., Wang K.H., Weitz C., Whitaker C., Wilming L.,
RA Wrayhaw-Boris A., Toshida K., Hasegawa Y., Kawaji H., Kohtsuki S.,
RA Hayashizaki Y.;
RT *Functional annotation of a full-length mouse cDNA collection.*;
RL Nature 409:685-690(2001).
DR EMBL; AK008308; BR22552.1; *.
DR HSPR; F01274.1GDN.
DR TCG; RefSeq:NM_001053249; Glucagon.
DR Pfam; PF00123; hormone; 1..
DR SMART; SM00070; GLUCI; 1..
DR PROSITE; PS00260; GLUCAGON; 1.
SQ SEQUENCE 144 AA; 16389 MW; 35B61865E5D4DA8C3 CRC64;

Query Match 41.6%; Score 67; DB 11; Length 144;
Best Local Similarity 41.9%; Pred. No. 0.043;
Matches 13; Conservative 47; Mismatches 11; Indels 0; Gaps 0;

QY 1 HAEGTFTSDYSVLESGQAKEFIAMLVKGG 31
||||| | | | | : | | | : | | |
DB 4A YEAGTFTSDYSTAMDRIQQDFVNKLAAQG 74

RESULT 11
Q9H417 ID Q9H417 PRELIMINARY; PRT: 170 AA.
AC Q9H417;
DT 01-OCT-2002 (TRENDSrel. 22, Created)
DT 01-OCT-2002 (TRENDSrel. 22, Last sequence update)
DT 01-MAR-2003 (TRENDSrel. 23, Last annotation update)
DE Vasoactive intestinal polypeptide precursor.
OS Bos taurus (Bovine).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Cetartiodactyla; Ruminantia; Pecora; Bovidae;
OC Caprinae; Bovidae; Bos.
NCBI_TaxID=9915;
RX [1]
RX SOURCE FROM N A.
RX STRAIN=MD-22092342; PubMed=12097482;
RX MEDLINE=22092342; PubMed=12097482;

```

RT "Coincident elevation of cAMP and calcium influx by PACAP-27
 RT functionally regulates secretory intrastimulatory peptide gene
 RT transcription through a novel PKA-independent signaling pathway";
 RL J. Neurosci. 22:5310-5320(2002).
 DR ENBL; AF503910; AAG28152.1; -
 DR InterPro: IPR000532; Glucagon.
 DR Pfam: PF00123; hormone2; 2.
 DR PRINTS; PR00275; hormone2; 2.
 DR SMART; SM00070; GLUCA; 2.
 DR PROSITE; PS00250; GLUCAGON; 2.
 KW SIGNAL.
 FT SIGNAL.
 FT SIGNAL.
 FT SIGNAL.
 FT CHAIN 1 23 POTENTIAL.
 FT CHAIN 81 107 PRT.
 FT CHAIN 125 152 VTP.
 SQ SEQUENCE 170 AA; 19164 MW; 9C6A6049A7BFF81 CRC64;
 Query Match 37.3%; Score 60; DB 6; Length 170;
 Best Local Similarity 43.3%; Pred. No. 0.61;
 Matches 13; Conservative 6; Mismatches 11; Indels 0; Gaps 0;
 QY 1 HAEFTFTSDVSYLGGQAKKEFIAMVKGK 30
 DB 81 HAEFTFTSDVSYLGGQAKKEFIAMVKGK 110
 RESULT 12
 ID Q9D227 PRELIMINARY; PRT; 171 AA.
 AC Q9D227; (TrEMBLrel. 17, Created)
 DT 01-JUN-2001 (TrEMBLrel. 17, Last sequence update)
 DT 01-OCT-2002 (TrEMBLrel. 22, Last annotation update)
 DE vasoactive intestinal polypeptide.
 OR NP.
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Eumalia; Eutheria; Rodentia; Sciurognathi; Muridae; Mus.
 OX NCBI_TaxID=10090;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC STRAIN=C57BL/6J; TISSUE=Cecum;
 RX MEDLINE=21085560; PubMed=11217851;
 RA Kawai J., Shinagawa A., Shibata K., Yoshino M., Itoh M., Ishii Y.,
 RA Arakawa T., Hara A., Fukunishi T., Konno H., Akachi J., Fukuda S.,
 RA Saitawa K., Kikuchi K., Nishikawa T., Kondo T., Kondo T.,
 RA Saito T., Ozaki Y., Ochi T., Saito H., Kikuchi T., Saito I.,
 RA Kadota K., Matsuda H.A., Ashburner M., Batalov S., Casavant T.,
 RA Fleischer W., Gaasterland T., Gissi C., King B., Kochiwa H.,
 RA Kuehl P., Lewis S., Matsuo Y., Nikaido I., Pesole G., Quackenbush J.,
 RA Schriml L., Staahl F., Suzuki R., Tomita M., Wagner L., Washio T.,
 RA Sakai K., Okido T., Furuno M., Aono H., Baldarelli R., Barsh G.,
 RA Blake J., Boffelli D., Bojunga N., Carninci P., de Bonaldo M.F.,
 RA Brownstein M.J., Bult C., Fletcher C., Fujita M., Gariboldi M.,
 RA Gustincich S., Hill D., Hofmann M., Hume D.A., Kameya M., Lee N.H.,
 RA Lyons P., Marchionni L., Mashima J., Mazzarelli J., Mombaerts P.,
 RA Nordone P., Ring B., Ringwald M., Rodriguez I., Sakamoto N.,
 RA Sasaki H., Sato K., Schenbach M., Sejeri I., Shibata I., Storch K.-F.,
 RA Suzuki H., Tachibana M., Wang K., Wang C., Whitaker C., Wang L.,
 RA Watanabe-Takahara Y., Yoshida K., Hasegawa Y., Kawaji H., Kotsuki S.,
 RA Hayashizaki Y.;
 FT "Functional annotation of a full-length mouse cDNA collection.";
 RL Nature 409:685-690(2001).
 DR ENBL; AK018599; BAB31301.1; -
 DR MGD; MGI:98933; Vip.
 DR InterPro: IPR000532; Glucagon.
 DR Pfam: PF00123; hormone2; 2.
 DR PRINTS; PR00275; GLUCAGON.
 DR SMART; SM00070; GLUCA; 2 ON; 2.
 DR PROSITE; PS00250; GLUCAGON; 2.
 SQ SEQUENCE 171 AA; 19135 MW; 134A4340B6DF1254 CRC64;
 Query Match 36.6%; Score 59; DB 11; Length 171;
 Best Local Similarity 43.3%; Pred. No. 0.87;

Matches 13; Conservative 6; Mismatches 11; Indels 0; Gaps 0;
 QY 1 HAEFTFTSDVSYLGGQAKKEFIAMVKGK 30
 DB 82 RADGVFTSDYSRLGGQISAKYLSLIGKR 111
 RESULT 13
 ID Q93IH2 PRELIMINARY; PRT; 389 AA.
 AC Q93IH2; (TrEMBLrel. 19, Created)
 DT 01-DEC-2001 (TrEMBLrel. 19, Last sequence update)
 DT 01-MAR-2003 (TrEMBLrel. 23, Last annotation update)
 DE Sulfur transferase precursor.
 OR STRA.
 OS Wolinella succinogenes.
 OC Bacteria; Proteobacteria; Epsilonproteobacteria; Campylobacteriales;
 OC Helicobacteraceae; Wolinella.
 OX NCBI_TaxID=844;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC Strain=ATCC 35061;
 RX PubMed=11217851;
 RA Kawai J., Simon J., Kikuchi O.,
 RA Kikuchi O., Kikuchi O., Kikuchi O., Kikuchi O.,
 RL Submitted (AUG-2001) to the EMBL/GenBank/DBJ databases.
 DR ENBL; AJ318789; CAC50085.1; -
 DR InterPro: IPR001763; Rhodanese-like.
 DR Pfam: PF00581; Rhodanese; 2.
 DR SMART; SM00450; RHOD; 3.
 DR SIGNAL; Transferase.
 FT SIGNAL.
 FT CHAIN 1 21 POTENTIAL.
 FT CHAIN 22 389 SULFUR TRANSFERASE.
 SQ SEQUENCE 389 AA; 41949 MW; 6C60850C4D9C4B9C CRC64;
 Query Match 36.6%; Score 59; DB 2; Length 389;
 Best Local Similarity 39.3%; Pred. No. 2.3;
 Matches 11; Conservative 8; Mismatches 9; Indels 0; Gaps 0;
 QY 1 HAEFTFTSDVSYLGGQAKKEFIAMVKGK 28
 DB 314 HAKGKFAAGSINIKKAGSAQBEVALLPK 341
 RESULT 14
 ID Q9DE29 PRELIMINARY; PRT; 172 AA.
 AC Q9DE29; (TrEMBLrel. 16, Created)
 DT 01-MAR-2001 (TrEMBLrel. 16, Last sequence update)
 DT 01-MAR-2003 (TrEMBLrel. 23, Last annotation update)
 DE Growth hormone-releasing hormone/pituitary adenylyate cyclase-
 DE activating polypeptide.
 OR NP.
 OS Brachydanio rerio (zebrafish) (Danio rerio).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Actinopterygii; Neopterygii; Teleostei; Ostariophysi; Cypriniformes;
 OC Cyprinidae; Danio.
 OX NCBI_TaxID=7955;
 RN [1]
 RP SEQUENCE FROM N.A.
 RA Fradinger E.A., Sherwood N.M.;
 RT "Characterization of the gene encoding both growth hormone-releasing
 RT hormone (GRF) and pituitary adenylyate cyclase-activating polypeptide
 RT (PACAP) in the zebrafish.";
 RL Submitted (DEC-1999) to the EMBL/GenBank/DBJ databases.
 DR ENBL; AF217251; AAG36782.1; -
 DR ZFIN; ZDB-GENE-020809-4; adcyap1.
 DR InterPro: IPR000532; Glucagon.
 DR PRINTS; PR00275; GLUCAGON.
 DR SMART; SM00070; GLUCA; 2.
 DR PROSITE; PS00260; GLUCAGON; 2.
 DR PROSITE; PS00260; GLUCAGON; 2.
 FT CHAIN 81 125 GROWTH HORMONE-RELEASING HORMONE.

QY 1 HAEFTSDVSSYLEGQAKEFIWLKGR 30
|::|| |::| |::| |::|
Db 128 HSDGVFTDSYRFRKOMAVKKYLWVLKGR 157

RESULT 15

[illegible]

```
Query Match      33.2%; Score 53.5;
Best Local Similarity 40.0%; Pred No. 6.1;
Matches 12; Conservative 6; Mismatches 6
```

Search completed: October 15, 2003, 10:55:48
Job time : 63.9836 secs

XX Claim 3; Page 20; 32pp; English.

XX The sequence is that of a derivative of insulinotropin which

CC has insulinotropic activity and is useful for enhancing insulin

CC action in a mammal, partic. for treating type II diabetes

CC (claimed). It is partic. suited for delivery to a mammal by

CC ionophoresis.

CC (Updated on 25-MAR-2003 to correct PN field.)

XX SQ Sequence 30 AA;

Query Match 100.0%; Score 155; DB 15; Length 30;

Best Local Similarity 100.0%; Pred. No. 1.3e-15;

Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HAEGETFTSDVSSYLEGQAAKEFIAMLVKGR 30

DB 1 HAEGETFTSDVSSYLEGQAAKEFIAMLVKGR 30

RESULT 2

AA663247

ID AAR63247 standard; peptide; 30 AA.

AC AAR63247;

XX 25-MAR-2003 (updated)

DT 02-MAY-1995 (first entry)

XX Insulinotropin (GLP-1(7-36)) for use in treating NIDDM.

DE insulinotropic activity; GLP-1; glucagon-like protein 1; NIDDM;

XX not insulin dependent diabetes mellitus; insulinotropin; truncated.

OS Synthetic.

XX EP619322-A2.

PN 12-OCT-1994.

XX 10-FEB-1994; 94EP-0300981.

XX 07-APR-1993; 93US-0041133.

XX (PTIZ) PTIZER INC.

XX (SCIO-) SCIOS INC.

XX Danley DE, Gelfand RA, Geodhegan KP, Kim Y, Lambert WJ;

PI Qi H, Gih, Hong Q, Yesock K;

XX WPI; 1994-311774/39.

XX Treatment of non-insulin dependent diabetes mellitus - using a

PT glucagon-like peptide 1 or deriv. with prolonged action for

XX sustained glycemic control

XX Claim 2; Page 46; 70pp; English.

XX This peptide is GLP-1(7-36) [GLP = glucagon-like peptide], a truncated

CC deriv. of GLP-1. GLP-1 and its deriv.s are useful in the treatment of

CC Non-Insulin Dependent Diabetes Mellitus (NIDDM). During processing in

CC the pancreas and intestine, GLP-1 (AAR63245) is converted to a 31 amino

CC acid peptide having amino acids 7-37 of GLP-1, alternatively referred

CC to as insulinotropin. GLP-1(7-37) has insulinotropic activity, i.e. it

CC is able to stimulate, or cause to be stimulated, the synthesis of the

CC hormone insulin. Other deriv.s of GLP-1 are shown in AAR63246-51. It

CC is a derivative of that previously described in EP-14 and

CC related polypeptides which produce a prolonged elevation of GLP-1 and

CC achieve sustained glycemic control in patients with NIDDM. The invention

CC provides a compsn. that has prolonged action after each administration.

CC (Updated on 25-MAR-2003 to correct PN field.)

CC (Updated on 25-MAR-2003 to correct PA field.)

XX SQ Sequence 30 AA;

Query Match 100.0%; Score 155; DB 15; Length 30;

Best Local Similarity 100.0%; Pred. No. 1.3e-15;

Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HAEGETFTSDVSSYLEGQAAKEFIAMLVKGR 30

DB 1 HAEGETFTSDVSSYLEGQAAKEFIAMLVKGR 30

RESULT 3

AA690653

ID AAR69063 standard; peptide; 30 AA.

AC AAR69063;

XX 25-MAR-2003 (updated)

DT 23-AUG-1995 (first entry)

XX Amidated Glucagon like peptide 1 (GLP1) (7-36)-NH2.

DE Glucagon Like Peptide; GLP; transpeptidation; endopeptidase;

XX trypsin, thrombin; cleavage.

OS Synthetic.

XX Key Location/Qualifiers

FT Modified-site 30

FT /label= Arg-NH2

XX WP9503405-A2.

XX 02-FEB-1995.

XX 19-JUL-1994; 94WO-US08125.

XX 20-JUL-1993; 93US-0095162.

XX (BION-) BIOMERASKA INC.

XX Henriksen D, Manning S, Partridge B, Stout J, Wagner FW;

XX WPI; 1995-075233/10.

XX Transpeptidation of recombinant polypeptides - using

PT endopeptidase such as trypsin or thrombin to modify C-terminal

PT residue.

XX Claim 33; Page 50; 69pp; English.

XX The naturally occurring sequence of Glucagon Like Peptide 1 (GLP1)

CC is AAR69072. It is a 36 AA peptide that has been recombinantly

CC produced but without a mechanism for providing for the amidation of

CC the C-terminal Arg residue. Amidated recombinant GLP1 (7-36)NH2

CC (AAR69063) was prepared from a multiplicity fusion protein contg. four

CC peptides having residues 7-34, 7-35, 7-36, and 7-37 of

CC of the native polypeptide and the terminal Arg residues. The at

CC residues 35-37 (GLP1 (7-34)-A-P-A) (AAR69064). The recombinant GLP1 (7-

CC 34)-A-P-A can be transpeptidated to yield the modified recombinant

CC native GLP1 (7-36)-NH2 (AAR69063) as follows. Trypsin was used to

CC cleave the peptide at the Lys-Ala bond in the presence of either

CC Gly-Arg-NH2 or Gly-Arg-Gly addition units so that the cleavage of

CC the Ala-Phe-Arg leaving unit is followed by the addition of

CC Gly-Arg-NH2 or Gly-Arg-Gly to the core GLP1 (7-34) to yield either

CC amidated 7-36 GLP1-NH2 or GLP1 7-36 with a terminal Gly (AAR69065).

XX (Updated on 25-MAR-2003 to correct PN field.)

XX SQ Sequence 30 AA;

Query Match 100.0%; Score 155; DB 16; Length 30;

Best Local Similarity 100.0%; Pred. No. 1.3e-15;

```

Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1 HAEGTFTDVSYLEGOAKKEFTIAWLKGR 30
DB 1 HAEGTFTDVSYLEGOAKKEFTIAWLKGR 30

RESULT 4
AAR79809
ID AAR79809 standard; peptide; 30 AA.
AC AAR79809;
XX 01-FEB-1996 (first entry)
XX Glucagon like peptide GLP-1 (7-36)amide.
XX Glucagon like peptide; GLP-1 (7-36)amide; type II diabetes;
XX non-insulin dependent; divalent metal cation; zinc.
XX Synthetic.
XX Key Location/Qualifiers
XX Modified-site 30
XX /note= "amidated"
XX EF658568-AL.
XX 21-JUN-1995.
XX 02-DEC-1994; 94EP-0308950.
XX 09-DEC-1993; 93US-0164277.
XX (ELIL) LILLY & CO ELI.
XX Galloway JA, Hoffmann JA;
XX WPI; 1995-217011/29.
XX New divalent metal complexes of glucagon-like peptide 1 - useful for
XX treating type II diabetes
XX Claim 4; Page 4; 10pp; English.
XX AAR79809 is the glucagon like peptide GLP-1 (7-36)amide. When
XX complexed to a divalent metal cation (pref. zinc) it can be
XX used to treat type II (non-insulin dependent) diabetes.
XX Sequence 30 AA;
Query Match 100.0%; Score 155; DB 16; Length 30;
Best Local Similarity 100.0%; Pred. No. 1.3e-15;
Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1 HAEGTFTDVSYLEGOAKKEFTIAWLKGR 30
DB 1 HAEGTFTDVSYLEGOAKKEFTIAWLKGR 30

RESULT 5
AAR80548
ID AAR80548 standard; peptide; 30 AA.
AC AAR80548;
XX 28-FEB-1995 (first entry)
XX Human glucagon like peptide (GLP-1).
XX Exendin-4; diabetes mellitus; hyperglycaemia;
XX insulinotropic peptide; glucagon like peptide; GLP-1.
XX

Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1 HAEGTFTDVSYLEGOAKKEFTIAWLKGR 30
DB 1 HAEGTFTDVSYLEGOAKKEFTIAWLKGR 30

RESULT 6
AAR98956
ID AAR98956 standard; peptide; 30 AA.
AC AAR98956;
XX 15-JAN-1997 (first entry)
XX Target peptide (GLP1(7-36)) used in fusion protein construct.
XX Fusion protein construct; isolation; purification;
XX growth hormone releasing factor; glucagon-like peptide 1;
XX parathyroid hormone; inclusion body; carbonic anhydrase.
XX Synthetic.
XX W09617942-AL.
XX 13-JUN-1996.
XX 07-DEC-1995; 95WO-US15800.
XX 07-DEC-1994; 94US-0350530.
XX (BION-) BIONEERASKA INC.
XX De LA MOTTE RS, Henriksen DB, Holmquist B, Manning SD;
XX Partridge BE, Stout JS, Wagner FW;
XX WPI; 1996-287186/29.
XX Isolation and purification of peptide(s) from fusion protein constructs
XX - which include a carbonic anhydrase and a variable fused
XX polypeptide

```

PS Claim 58; Page 50; 67pp; English.

CC A new method for the isolation and/or purification of a recombinant
CC peptide employs a fusion protein construct (FPC) comprising a
CC carbonic anhydrase and a variable fused polypeptide containing a
CC target peptide. The method comprises precipitating either the FPC or
CC a fragment of the FPC including the carbonic anhydrase. An
CC alternative method of producing the peptide comprises expressing the
CC FPC as part of an inclusion body. The target peptides of the FPC are
CC derived from growth hormone releasing factor (GRF), glucagon-like
CC peptide I (GLPI) or parathyroid hormone (PTH). This sequence
CC corresponds to amino acids 7-36 of GLPI.

SQ Sequence 30 AA;
Query Match 100.0%; Score 155; DB 17; Length 30;
Best Local Similarity 100.0%; Pred. No. 1.3e-15;
Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 HAEGETFTSDVSSYLEGQAAKEFIAMLVKGR 30
|||||
DB 1 HAEGETFTSDVSSYLEGQAAKEFIAMLVKGR 30

RESULT 7
AAR98975
ID AAR98975 standard; Peptide: 30 AA.
AC AAR98975;
XX
XX
XX 03-DEC-1996 (first entry)
XX
XX GLPI(7-35)-NH2.
XX GLPI: C-amide; C-amidated peptide; alpha-carboxamide;
XX recombinant protein; fusion protein; transpeptidation.
XX Synthetic.
XX
XX Key Location/Qualifiers
XX Modified-site 30
XX /note= "c-terminal amide"
XX W09617941-A2.
XX
XX 13-JUN-1996.
XX
XX 07-DEC-1995; 95MC-US15799.
XX 07-DEC-1994; 94US-0350528.
XX
XX (BION-) BIONEERASKA INC.
XX
XX Herksen DB, Holmquist B, Patridge BE, Stout JS;
XX Wagner FW;
XX WPI, 1996-287185/29.
XX
XX Production of C-terminal alpha-carboxamidated peptide(s) - by
XX cleavage and transpeptidation of recombinant multicopy peptide(s) or
XX fusion constructs
XX
XX Example 16; Page 69; 93pp; English.

CC Aminated recombinant GLPI(7-36)-NH2 (AAR98975) may be prep'd from
CC a recombinant multicopy fusion peptide by cleavage, transamidation
CC and irradiation to yield GLPI(7-36)-NH2. The aminated peptide may also
CC be produced via GLPI(7-35)-Met (AAR98978) using a transpeptidation

CC reaction.
XX
SQ Sequence 30 AA;
Query Match 100.0%; Score 155; DB 17; Length 30;
Best Local Similarity 100.0%; Pred. No. 1.3e-15;
Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 HAEGETFTSDVSSYLEGQAAKEFIAMLVKGR 30
|||||
DB 1 HAEGETFTSDVSSYLEGQAAKEFIAMLVKGR 30

RESULT 8
AAW16383
ID AAW16383 standard; Peptide: 30 AA.
AC AAW16383;
XX
XX 25-MAR-2003 (updated)
XX 01-OCT-1997 (first entry)
XX
XX Glucagon-like peptide-1(7-36).
XX
XX Glucagon-like peptide-1(7-36); GLP-1 (7-36); insulin secretagogue;
XX insulinotropic hormone; type II diabetes mellitus; therapy.
XX Rattus sp.
XX
XX US5614492-A.
XX
XX 25-MAR-1997.
XX
XX 23-NOV-1993; 93US-0156800.
XX
XX 05-SEP-1993; 93US-0756215.
XX 05-MAY-1986; 86US-0859928.
XX 26-JAN-1988; 88US-0148517.
XX 01-JUN-1990; 90US-0532111.
XX 23-NOV-1993; 93US-0156800.
XX
XX (GEO) GEN HOSPITAL CORP.
XX
XX Habener JF;
XX
XX WPI; 1997-201513/18.
XX
XX Glucagon-like peptide-1 fragment comprising amino acids 7-36 -
XX useful for enhancing insulin production in pancreatic islet cells,
XX especially for treating type II diabetes mellitus
XX
XX Claim 1; Column 34; 37pp; English.

CC Glucagon-like peptide-1 (7-36) (AAW16383) comprises amino acid
CC residues 7-36 of rat glucagon-like peptide-1 (GLP-1) (see also
CC AAW16384). It is naturally produced from GLP-1 in the intestine
CC of the pancreas. GLP-1 has been shown to stimulate the synthesis
CC of insulin in the pancreas, stimulate the release of insulin
CC and secretion of insulin from the pancreas. It can be produced
CC by chemical synthesis or by proteolytic digestion of GLP-1 for use
CC as an insulin secretagogue or for the treatment of type II diabetes
CC mellitus.
XX
XX (Updated on 25-MAR-2003 to correct PF field.)

CC
XX
SQ Sequence 30 AA;
Query Match 100.0%; Score 155; DB 18; Length 30;
Best Local Similarity 100.0%; Pred. No. 1.2e-15;
Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 HAEGETFTSDVSSYLEGQAAKEFIAMLVKGR 30
|||||
DB 1 HAEGETFTSDVSSYLEGQAAKEFIAMLVKGR 30

RESULT 9
 AAW63288
 ID AAW63288 standard; peptide: 30 AA.
 AC AAW63288;
 XX
 DT 29-SEP-1998 (first entry)
 XX
 DE Glucagon-like peptide-1 (7-36) amide.
 XX
 KA GLP-1; glucagon-like peptide; obesity.
 XX
 OS Homo sapiens.
 XX
 PH Key Location/Qualifiers
 FT Modified-site 30
 FT /note= "C-terminal amide"
 XX
 PN W0819698-A1.
 XX
 PD 14-MAY-1998.
 XX
 PR 04-NOV-1997; 97WO-US20114.
 XX
 PR 30-OCT-1997; 97US-0961405.
 XX
 PR 05-NOV-1996; 96US-0030213.
 XX
 PA (ELIL) LILLY & CO BLL.
 XX
 PI DiMarchi RD, Efendic S;
 XX
 WPI; 1998-286595/25.
 XX
 PT Use of glucagon-like peptide-1 and analogues and derivatives - to
 PT reduce body weight, e.g., in treatment of obesity
 XX
 PS Claim 12; Page 18; 42pp; English.
 XX
 CC The patent describes a new method of reducing body weight which
 CC comprises administration of a composition comprising: (i) glucagon-
 CC like peptide-1 (GLP-1); (ii) a GLP-1 analogue; (iii) a GLP-1 derivative;
 CC (iv) an agonist of the GLP-1 receptor; (v) an agonist of the GLP-1
 CC signal transduction cascade; (vi) a compound which stimulates synthesis
 CC of endogenous GLP-1; or (viii) a salt of a material described in (i)-(vii).
 CC The method may be used for treatment of obesity. The present sequence,
 CC GLP-1 (7-36) amide, represents a preferred GLP-1 compound which can be
 CC used in the method.
 XX
 SQ Sequence 30 AA;
 Query Match 100.0%; Score 155; DB 19; Length 30;
 Best Local Similarity 100.0%; Pred. No. 1.3e-15;
 Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 HAEGFTSDVSSYLEGQAAKEFIAVLVNGR 30
 DB 1 HAEGFTSDVSSYLEGQAAKEFIAVLVNGR 30
 RESULT 10
 AAW63182
 ID AAW63182 standard; peptide: 30 AA.
 AC AAW63182;
 XX
 DT 16-SEP-1998 (first entry)
 XX
 DE GLP-1(7-36).
 XX
 KA Glucagon-like peptide-1; GLP-1; diabetes; lipophilic; tetradeceanoyl;
 KW

KW carboxynonadecanoyl; deoxycholoyl; choloyl; lithocholoyl.
 XX Homo sapiens.
 OS
 PH Key Location/Qualifiers
 FT Modified-site 30
 FT /note= "optionally the C-terminal is in amide form"
 XX
 PN W0908871-A1.
 XX
 PD 05-MAR-1998.
 XX
 PR 22-AUG-1997; 97WO-DK00340.
 XX
 PR 20-DEC-1996; 96DK-0001470.
 XX
 PR 30-AUG-1995; 96DK-0000931.
 XX
 PR 08-NOV-1996; 96DK-0001259.
 XX
 PA (NOVO) NOVO-NORDISK AS.
 XX
 PI Knudsen IB, Nielsen FF, Sorensen PO;
 XX
 WPI; 1998-239721/21.
 XX
 PT Glucagon-like peptide-1 derivatives which have lipophilic
 PT substituent - exhibit protracted profiles of action relative to
 PT known glucagon-like peptide-1 compounds and are useful in
 PT treatment of diabetes
 XX
 PS Claim 36; Page -; 76pp; English.
 XX
 CC New derivatives of glucagon-like peptide-1 (GLP-1) and its fragments
 CC and their analogues are disclosed in which at least one amino acid
 CC residue of the parent peptide has a lipophilic substituent attached
 CC to the amino group. The lipophilic substituent is typically tetradecanoyl
 CC C is 35-45. The lipophilic substituent is typically tetradecanoyl
 CC carboxynonadecanoyl, deoxycholoyl, choloyl or lithocholoyl, and it
 CC is attached e.g. to the epsilon-amino group of a Lys residue in the
 CC peptide. The present sequence represents a preferred parent GLP-1
 CC fragment to which the lipophilic substituent is to be attached.
 CC GLP-1 and its analogues and fragments may be used in treatment of
 CC type 1 and type 2 diabetes. Prior art analogues exhibit a high
 CC clearance rate from the body, which limits their usefulness. The
 CC new lipophilically substituted compounds have a protracted profile
 CC (in action compared with known analogues, e.g. GLP-1 (7-37) itself
 CC (in action compared with known analogues, e.g. GLP-1 (7-37) itself
 CC specification but is not explicitly shown. It is deduced from the
 CC protein sequence shown in Swiss-Prot entry P01275 using information
 CC given in the patent.)
 XX
 SQ Sequence 30 AA;
 Query Match 100.0%; Score 155; DB 19; Length 30;
 Best Local Similarity 100.0%; Pred. No. 1.3e-15;
 Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 HAEGFTSDVSSYLEGQAAKEFIAVLVNGR 30
 DB 1 HAEGFTSDVSSYLEGQAAKEFIAVLVNGR 30
 RESULT 11
 AAW50906
 ID AAW50906 standard; peptide: 30 AA.
 AC AAW50906;
 XX
 DT 17-AUG-1998 (first entry)
 XX
 DE Glucagon-like peptide-1 analogue SEQ ID NO:5.
 XX
 KA Glucagon-like peptide-1; GLP-1 (7-37); GLP-1 analogue; surgical trauma;
 KW stress; hormonal response; insulin resistance; catabolic reaction;

KW human; incretin hormone.
 XX Synthetic.
 OS Homo sapiens.
 XX Key
 XX Location/Qualifiers
 XX Modified-site 30
 FT /note= "amidated"
 TT
 XX
 XX W09808873-A1.
 XX
 XX 05-MAR-1998.
 XX
 XX 26-AUG-1997; 97WO-US15042.
 XX
 XX 21-AUG-1997; 97US-0024982.
 XX
 XX 30-AUG-1995; 96US-0024982.
 XX
 XX (BLIL) LILLY & CO EMI.
 XX
 XX Efednic S;
 XX
 XX WPI; 1998-239722/21.
 XX
 XX Use of glucagon-like peptide-1 and analogues and their derivatives
 XX - to attenuate post-surgical catabolic changes, insulin resistance
 XX and hormonal responses to stress
 XX
 XX Claim 1; Page 13; 42pp; English.
 XX
 XX The present sequence represents a glucagon-like peptide-1 (GLP-1)
 XX analogue, which is used in the methods of the invention. The methods
 XX are: (1) for attenuating post-surgical catabolic changes and insulin
 XX resistance, comprising administering glucagon-like peptide-1 (GLP-1), a
 XX analogues thereof, or a combination thereof, to a patient, (2) for
 XX attenuating post-surgical catabolic changes and hormonal responses to
 XX stress, comprising administering a compound which exerts insulinotropic
 XX activity by interacting with the same receptor (or receptors) with which
 XX GLP-1, GLP-1 analogues and GLP-1 derivatives interact in exerting their
 XX insulinotropic activity, and (3) for attenuating post-surgical catabolic
 XX changes and hormonal responses to stress, comprising administering a
 XX compound which enhances insulin sensitivity by interacting with the same
 XX receptor (or receptors) with which GLP-1, GLP-1 analogues and GLP-1
 XX derivatives interact to enhance insulin sensitivity. The processes are
 XX used for attenuating post-surgical catabolic changes and insulin
 XX resistance and insulin resistance caused by surgical trauma and
 XX exacerbated by pre-operative fasting. GLP-1's short half-life, and hence
 XX the need for continuous administration, are not disadvantages, as the
 XX patient is usually hospitalised before surgery, and fluids are
 XX continuously administered parenterally, before, during and after surgery.
 XX
 XX Sequence 30 AA;
 XX
 XX Query Match 100.0%; Score 155; DB 19; Length 30;
 XX Best Local Similarity 100.0%; Freq. No. 1.3e-15;
 XX Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 XX
 XX QY 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR 30
 XX ||||||||||||||||||||||||||||
 XX Db 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR 30
 XX
 XX RESULT 12
 XX AAY42935
 XX ID AAY42935 standard; peptide; 30 AA.
 XX AC AAY42935;
 XX
 XX DT 20-DEC-1999 (first entry)
 XX
 XX DE Glucagon-like peptide GLP-1 (7-36).
 XX
 XX KW Glucagon-like peptide: GLP-1; antidiabetic; anti-obesity;

KW insulinotropic; appetite suppressant.
 XX
 XX Homo sapiens.
 XX
 XX X09943707-A1.
 XX
 XX 02-SEP-1999.
 XX
 XX 25-FEB-1999; 99WO-DX00085.
 XX
 XX 27-FEB-1998; 98DK-0000263.
 XX
 XX 27-FEB-1998; 98DK-0000268.
 XX
 XX 08-APR-1998; 98DK-0000508.
 XX
 XX (NOVO) NOVO-NORDISK AS.
 XX
 XX Knudsen LA, Rausfeldt PO, Nielsen PE, Madsen K;
 XX
 XX WPI; 1999-540561/45.
 XX
 XX New N-modified peptide derivatives, useful for treating diabetes,
 XX insulin resistance and obesity -
 XX
 XX Disclosure; Page 1; 62pp; English.
 XX
 XX New glucagon-like peptide-1 (GLP-1) derivatives are disclosed which
 XX comprise residues 7-45 of GLP-1 or a fragment thereof, preferably
 XX residues 7-36, 7-37 or 7-38 or their analogues, in which (a) a
 XX lipophilic substituent is attached to at least one amino acid and (b)
 XX the N-terminal is substituted with a group containing an optionally
 XX substituted 5- or 6-membered N-heterocycle, e.g. imidazole. The
 XX compounds stimulate secretion of insulin, suppress secretion of
 XX glucagon, suppress gastric motility and/or restore glucose compliance
 XX to beta-cells. They are used to treat insulin-dependent or non-insulin-
 XX dependent diabetes mellitus, insulin resistance and obesity. They have
 XX a longer half-life than GLP-1 derivatives and lack the lipophilic
 XX substituent. Some of them also exist as partially structured micelle-
 XX like aggregates, so have improved solubility and stability. The present
 XX sequence is a specifically preferred example of a GLP-1 analogue on
 XX which the derivatives are based.
 XX
 XX Sequence 30 AA;
 XX
 XX Query Match 100.0%; Score 155; DB 20; Length 30;
 XX Best Local Similarity 100.0%; Freq. No. 1.3e-15;
 XX Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 XX
 XX QY 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR 30
 XX ||||||||||||||||||||||||||||
 XX Db 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR 30
 XX
 XX RESULT 13
 XX AAY27374
 XX ID AAY27374 standard; peptide; 30 AA.
 XX AC AAY27374;
 XX
 XX DT 26-NOV-1999 (first entry)
 XX
 XX DE Glucagon-like peptide 1 (GLP-1) fragment (residues 7-36).
 XX
 XX KW Glucagon; glucagon-like peptide 1; GLP-1; detergent; glycogenolytic;
 XX gluconeogenesis; insulin secretion; diabetes mellitus; obesity;
 XX spasmodytic; hypoglycemia.
 XX
 XX OS Synthetic.
 XX
 XX Key
 XX Location/Qualifiers
 XX Modified-site 30
 XX /note= "C-terminal amide"
 XX
 XX W09947160-A1.

XX PD 23-SEP-1999.
 XX XX 08-MAR-1999; 99WO-DK00115.
 XX PF 13-MAR-1998; 98EP-0610006.
 XX PR 18-MAR-1998; 98US-0078422.
 XX XX (NOVO) NOVO-NORDISK AS.
 XX KA Kaarsholm NC;
 XX PF WPI; 1999-561858/47.
 XX DR Aqueous solution of glucagon or glucagon-like peptide-1 stabilized with
 XX PT charged detergent, for treating diabetes or obesity -
 XX PT Examples; Page 5; 27pp; English.
 XX PS The invention provides an aqueous solution that comprises: (i) at least
 XX CC one glucagon or glucagon-like peptide-1 (GLP-1), or their analogs or
 XX CC derivatives; (ii) at least one detergent; and (iii) at least one
 XX CC phosphocholine. The peptide (i) has at least two positive or negative
 XX CC charges or at least one charge of each sign. Glucagon is involved in
 XX CC glycogenolytic and gluconeogenesis processes (it also has a spasmodic
 XX CC effect on smooth muscle) while GLP-1 promotes secretion of insulin and
 XX CC suppresses that of glucagon. The polar head of detergent interacts with the
 XX CC charged side chains in (i) while the hydrophobic tail interacts with the
 XX CC hydrophobic patch in (i). The solution is used to treat (non-)insulin-
 XX CC dependent diabetes mellitus and obesity. Glucagon is also used in
 XX CC radiology as a spasmodic and for treating hypoglycemia. The detergent
 XX CC stabilizes the solutions, which are suitable for immediate use and can
 XX CC be utilized for the treatment of the diseases mentioned above. The detergents
 XX CC between 4 and 9, allowing selection of conditions that suppress chemical
 XX CC degradation. The detergents are made from natural materials so have
 XX CC better biological compatibility than known detergents. The present
 XX CC sequence represents a GLP-1 peptide fragment.
 XX SQ Sequence 30 AA;
 Query Match 100.0%; Score 155; DB 20; Length 30;
 Best Local Similarity 100.0%; Pred. No. 1.3e-15;
 Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 HAEGETFTSDVSSYLEGQAAKEFIAWLKGR 30
 DB 1 HAEGETFTSDVSSYLEGQAAKEFIAWLKGR 30
 RESULT 15
 AAY39773
 ID AAY39773 standard; peptide; 30 AA.
 XX XX AAY39773;
 XX XC 26-NOV-1999 (first entry)
 XX DT Glucagon like peptide-1 (7-36).
 XX DE Glucagon-like peptide-1; GLP-1; appetite suppression; human; diabetes;
 XX KW spontaneous food intake; therapy.
 XX OS Homo sapiens.
 XX PA (NOVO) NOVO-NORDISK AS.
 XX KN Knudsen LB, Husefeldt PO, Nielsen PF, Kaarsholm NC, Olsen HB;
 XX PI Bjorn SE;
 XX DR WPI; 1999-540500/45.
 XX XX Composition containing stabilized derivatives of glucagon-like
 XX PT peptides with high alpha-helix content, for treating diabetes and
 XX PS obesity
 XX PS Claim 30; Page -; 63pp; English.

XX PR 19-MAR-1998; 98US-0078544.
 XX PA (BION-) BIONERASKA INC.
 XX PI Goke B, Beglinger C, Coolidge TR;
 XX XX WPI; 1999-561859/47.
 XX DR New composition for controlling food intake especially in diabetes
 XX PT sufferers -
 XX PF Claim 5; Page 22; 35pp; English.
 XX PS This sequence represents a glucagon-like peptide-1 sequence used in the
 XX CC composition of the invention. The composition is for appetite
 XX CC suppression, and comprises a compound binding to a GLP-1 receptor and a
 XX CC pharmaceutical carrier. The composition can be administered to control
 XX CC appetite and/or reduce spontaneous food intake in humans, especially in
 XX CC humans with diabetes.
 XX SQ Sequence 30 AA;
 Query Match 100.0%; Score 155; DB 20; Length 30;
 Best Local Similarity 100.0%; Pred. No. 1.3e-15;
 Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 HAEGETFTSDVSSYLEGQAAKEFIAWLKGR 30
 DB 1 HAEGETFTSDVSSYLEGQAAKEFIAWLKGR 30
 RESULT 15
 AAY34198
 ID AAY34198 standard; peptide; 30 AA.
 XX XX AAY34198;
 XX DT 16-NOV-1999 (first entry)
 XX DE GLP-1 mutant peptide, GLP-1(7-36).
 XX KW GLP-1; Glucagon-like peptide-1; human; type I diabetes; type II diabetes;
 XX OS obesity; therapy; mutain.
 XX OS Homo sapiens.
 XX OS Synthetic.
 XX FH Key Location/Qualifiers
 XX FT Misc-difference 30 /note- "optionally amidated"
 XX FT
 XX PN W09943341-A1.
 XX XD 02-SEP-1999.
 XX XX 25-FEB-1999; 99WO-DK00084.
 XX PR 27-FEB-1998; 98DK-0000268.
 XX PR 27-FEB-1998; 98DK-0000272.
 XX XX (NOVO) NOVO-NORDISK AS.
 XX KN Knudsen LB, Husefeldt PO, Nielsen PF, Kaarsholm NC, Olsen HB;
 XX PI Bjorn SE;
 XX DR WPI; 1999-540500/45.
 XX XX Composition containing stabilized derivatives of glucagon-like
 XX PT peptides with high alpha-helix content, for treating diabetes and
 XX PS obesity
 XX PS Claim 30; Page -; 63pp; English.

XX This sequence represents a mutant of the human glucagon-like peptide-1
 CC (GLP-1), and has a helix content (determined by circular dichroism at
 CC 222 nm in water at 20-24 degrees C) over 25, preferably 25-50, % at
 CC peptide concentration about 0.1 microm. The GLP-1 mutant can be used in a
 CC pharmaceutical composition for the treatment of obesity, particularly to
 CC pharmaceuticals (both type I and particularly type II) and/or obesity.
 CC They have better solubility and/or stability (against endogenous
 CC diaminopeptidyl peptidase) than parent peptides, with long persistence in
 CC the plasma and retention of biological activity. They form partially
 CC structured micelle-like aggregates in solution, with the helix content
 CC practically independent of concentration.
 CC NOTE: This sequence was created from the human GLP-1 sequence using
 CC information given in the specification.

XX
 XX SQ Sequence 30 AA;

Query Match 100.0%; Score 155; DB 20; Length 30;
 Best Local Similarity 100.0%; Pred. No. 1.3e-15;
 Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HADGTFSDVSSYLEGQAKAFINLVKGR 30

DB 1 HADGTFSDVSSYLEGQAKAFINLVKGR 30

Search completed: October 15, 2003, 10:53:05
 Job time : 60.5082 secs


```

QY 1 HAEFTFTSDVSSYLEGQAKKEFIAMLYKGR 30
DB 1 HAEFTFTSDVSSYLEGQAKKEFIAMLYKGR 30

RESULT 2
US-08-095-162-1
; Sequence 1, Application US/08095162
; Patent No. 5512459
; GENERAL INFORMATION:
; APPLICANT: Wagner, Fred W.
; APPLICANT: Stout, Jay
; APPLICANT: Hentiksen, Bruce
; APPLICANT: Manning, Shane
; APPLICANT: Partidge, Bruce
; TITLE OF INVENTION: Enzymatic Method for Modification of
; RECOMBINANT POLYPEPTIDES
; NUMBER OF SEQUENCES: 26
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Merchant & Gould
; STREET: 3100 No. 5512459west Center
; CITY: Minneapolis
; STATE: MN
; COUNTRY: USA
; TELEPHONE: 612-332-5300
; TELEFAX: 612-332-5300
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/095,162
; FILING DATE: 20-JUL-1993
; CLASSIFICATION: 514
; ATTORNEY/AGENT INFORMATION:
; NAME: Nelson, Albin J.
; REGISTRATION NUMBER: 28,659
; REFERENCE/DOCKET NUMBER: 8648.32-US01
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 612-332-5300
; TELEFAX: 612-332-5300
; INFORMATION FOR SEQ ID NO: 1:
; LENGTH: 30 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: Peptide
; IMMEDIATE SOURCE:
; CLONE: GLP1 7-36-NH2 (Glucagon-like Peptide)
US-08-095-162-1
Query Match 100.0%; Score 155; DB 1; Length 30;
Best Local Similarity 100.0%; Pred. No. 5.6e-16;
Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HAEFTFTSDVSSYLEGQAKKEFIAMLYKGR 30
DB 1 HAEFTFTSDVSSYLEGQAKKEFIAMLYKGR 30

RESULT 3
US-08-470-220A-1
; Sequence 1, Application US/08470220A
; Patent No. 5707826
; GENERAL INFORMATION:
; APPLICANT: Wagner, Fred W.
; APPLICANT: Stout, Jay
; APPLICANT: Hentiksen, Bruce
; APPLICANT: Manning, Shane
; APPLICANT: Partidge, Bruce
; TITLE OF INVENTION: Enzymatic Method for Modification of
; RECOMBINANT POLYPEPTIDES
; NUMBER OF SEQUENCES: 26

```

```

; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Merchant & Gould
; STREET: 3100 No. 5707826west Center
; CITY: Minneapolis
; STATE: MN
; COUNTRY: USA
; ZIP: 55402
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/470,220A
; FILING DATE: 20-JUL-1993
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/095,162
; FILING DATE: 20-JUL-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Nelson, Albin J.
; REGISTRATION NUMBER: 28,659
; REFERENCE/DOCKET NUMBER: 8648.32-US01
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 612-332-5300
; TELEFAX: 612-332-5300
; INFORMATION FOR SEQ ID NO: 1:
; LENGTH: 30 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: Peptide
; IMMEDIATE SOURCE:
; CLONE: GLP1 7-36-NH2 (Glucagon-like Peptide)
US-08-470-220A-1
Query Match 100.0%; Score 155; DB 1; Length 30;
Best Local Similarity 100.0%; Pred. No. 5.6e-16;
Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HAEFTFTSDVSSYLEGQAKKEFIAMLYKGR 30
DB 1 HAEFTFTSDVSSYLEGQAKKEFIAMLYKGR 30

RESULT 4
US-08-927-227-1
; Sequence 1, Application US/08927227A
; Patent No. 5977071
; GENERAL INFORMATION:
; APPLICANT: Galloway, James A.
; APPLICANT: Hoffmann, James A.
; TITLE OF INVENTION: GLUCAGON-LIKE INSULINOTROPIC PEPTIDE ANALOGS,
; COMPOSITIONS AND METHODS
; FILE REFERENCE: X-9326
; CURRENT APPLICATION NUMBER: US/08/927,227A
; CURRENT FILING DATE: 1997-09-10
; NUMBER OF SEQ ID NOS: 1
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 1
; LENGTH: 30
; TYPE: PPT
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: The arginine residue at position 30 is modified so
; AS TO REPLACE THE TERMINAL CARBOXYL GROUP WITH AN
; AMINE.
US-08-927-227-1
Query Match 100.0%; Score 155; DB 2; Length 30;
Best Local Similarity 100.0%; Pred. No. 5.6e-16;
Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

QY 1 HAEGETFTSDVSSYLEGQAQKEFIAMLVKGR 30
|||||
Db 1 HAEGETFTSDVSSYLEGQAQKEFIAMLVKGR 30

RESULT 5

US-08-967-374-1
; Sequence 1, Application US/08967374
; Patent No. 6037143
; GENERAL INFORMATION:
; APPLICANT: Carter, Fred W.
; APPLICANT: Stout, Jay
; APPLICANT: Stent, Dennis
; APPLICANT: Partidge, Bruce
; APPLICANT: Manning, Shane
; TITLE OF INVENTION: Enzymatic Method for Modification of
; TITLE OF INVENTION: Recombinant Polypeptides
; NUMBER OF SEQUENCES: 26
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Merchant & Gould
; STREET: 3100 N. 6037143 West Center
; CITY: Minneapolis
; STATE: MN
; COUNTRY: USA
; ZIP: 55402
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/967,374
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/420,485
; FILING DATE: 29-AUG-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Carter, Charles G.
; REGISTRATION NUMBER: 35,093
; REFERENCE/DOCKET NUMBER: 8648.32-USDI
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 612-332-5300
; TELEFAX: 612-332-5081
; INFORMATION FOR SEQ ID NO: 1:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 30 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; IMMEDIATE SOURCE:
; CLONE: GLP1 7-36-NH2 (Glucagon-like Peptide)
US-08-967-374-1

Query Match 100.0%; Score 155; DB 3; Length 30;
Best Local Similarity 100.0%; Pred. No. 5,6e-16;
Matches 30; Conservative 0; Mismatches 0; Indels 0;

QY 1 HAEGETFTSDVSSYLEGQAQKEFIAMLVKGR 30
|||||
Db 1 HAEGETFTSDVSSYLEGQAQKEFIAMLVKGR 30

RESULT 6

US-09-348-136-1
; Sequence 1, Application US/09348136
; Patent No. 613225
; GENERAL INFORMATION:
; APPLICANT: Galloway, James A.
; TITLE OF INVENTION: GLUCAGON-LIKE INSULINOTROPIC PEPTIDE ANALOGS,
; TITLE OF INVENTION: COMPOSITIONS AND METHODS
; FILE REFERENCE: X-9332B

; CURRENT APPLICATION NUMBER: US/09/348,136
; CURRENT FILING DATE: 1999-07-06
; PRIOR APPLICATION NUMBER: US 08/927,227
; PRIOR FILING DATE: 1997-09-10
; NUMBER OF SEQ ID NOS: 1
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 1
; LENGTH: 30
; TYPE: PPT
; ORGANISM: Homo sapiens
; OTHER INFORMATION: The arginine residue at position 30 is modified so
; OTHER INFORMATION: as to replace the terminal carboxyl group with an
; OTHER INFORMATION: amide.
US-09-348-136-1

Query Match 100.0%; Score 155; DB 3; Length 30;
Best Local Similarity 100.0%; Pred. No. 5,6e-16;
Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HAEGETFTSDVSSYLEGQAQKEFIAMLVKGR 30
|||||
Db 1 HAEGETFTSDVSSYLEGQAQKEFIAMLVKGR 30

RESULT 7

US-08-961-405A-5
; Sequence 5, Application US/08961405A
; Patent No. 6191102
; GENERAL INFORMATION:
; APPLICANT: DiMarchi, Richard D.
; APPLICANT: Erendic, Sued
; TITLE OF INVENTION: USE OF GLP-1 ANALOGS AND DERIVATIVES
; TITLE OF INVENTION: ADMINISTERED PERIPHERALLY IN REGULATION OF OBESITY
; NUMBER OF SEQUENCES: 9
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: BARNES & THORNBURG
; STREET: 200 W. Madison, Suite 2601
; CITY: Chicago
; STATE: Illinois
; COUNTRY: USA
; ZIP: 60606
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/961,405A
; FILING DATE: 30-OCT-1997
; PRIOR APPLICATION NUMBER: US 60/030,213
; FILING DATE: 05-NOV-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Martini, Alice O.
; REGISTRATION NUMBER: 35,601
; REFERENCE/DOCKET NUMBER: 9051/90264
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 312-357-1313
; TELEFAX: 312-759-5646
; INFORMATION FOR SEQ ID NO: 5:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 30 amino acids
; TYPE: amino acid
; STRANDEDNESS:
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
US-08-961-405A-5

Query Match 100.0%; Score 155; DB 3; Length 30;
Best Local Similarity 100.0%; Pred. No. 5,6e-16;
Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

QY 1 HAEFTSDVSSYLEGQAAKEFIAWLKGR 30
    ||||||||||||||||||||||||||||
DB 1 HAEFTSDVSSYLEGQAAKEFIAWLKGR 30

RESULT 8
US-08-915-918A-5
; Sequence 5, Application US/08915918A
; Patent No. 6277819
; GENERAL INFORMATION:
; APPLICANT: Efendic, Sued
; TITLE OF INVENTION: USE OF GLP-1 OR ANALOGS IN TREATMENT OF
; TITLE OF INVENTION: MYOCARDIAL INFARCTION
; NUMBER OF SEQUENCES: 6
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: BRINKS, HOFER, GILSON & LIONE
; STREET: Plaza Drive
; CITY: Chicago
; STATE: Illinois
; COUNTRY: USA
; ZIP: 60611-5599
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; FILING DATE: 21-AUG-1997
; APPLICATION NUMBER: US/08/915-918A
; CLASSIFICATION: 514
; ATTORNEY/AGENT INFORMATION:
; NAME: Martin, Alice O.
; ADDRESS: 155 N. Dearborn St.
; REFERENCE/DOCKET NUMBER: 6792/28
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 312-321-4200
; TELEFAX: 312-321-4299
; INFORMATION FOR SEQ ID NO: 5:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 30 amino acids
; TYPE: amino acid
; STRANDEDNESS: linear
; MOLECULAR TYPE: Peptide
US-08-915-918A-5

Query Watch 100.0%; Score 155; DB 3; Length 30;
Best Local Similarity 100.0%; Pred. No. 5.6e-16;
Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HAEFTSDVSSYLEGQAAKEFIAWLKGR 30
    ||||||||||||||||||||||||||||
DB 1 HAEFTSDVSSYLEGQAAKEFIAWLKGR 30

RESULT 9
US-09-302-596-4
; Sequence 4, Application US/09302596
; Patent No. 6284725
; GENERAL INFORMATION:
; APPLICANT: Ehlers, Mario R.W.
; TITLE OF INVENTION: Metabolic Intervention with GLP-1 to Improve the Function of
; TITLE OF INVENTION: Pancreatic and Adipose Tissue
; FILE REFERENCE: P03660051
; CURRENT APPLICATION NUMBER: US/09/302,596
; CURRENT FILING DATE: 1999-04-30
; PRIOR APPLICATION NUMBER: 60/103,498
; PRIOR FILING DATE: 1998-10-08
; NUMBER OF SEQ ID NOS: 13
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 4

```

```

; LENGTH: 30
; TYPE: PRT
; ORGANISM: mammalian
US-09-302-596-4

Query Watch 100.0%; Score 155; DB 3; Length 30;
Best Local Similarity 100.0%; Pred. No. 5.6e-16;
Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HAEFTSDVSSYLEGQAAKEFIAWLKGR 30
    ||||||||||||||||||||||||||||
DB 1 HAEFTSDVSSYLEGQAAKEFIAWLKGR 30

RESULT 10
US-08-472-349-3
; Sequence 3, Application US/08472349
; Patent No. 6284727
; GENERAL INFORMATION:
; APPLICANT: Kim, Yesook
; APPLICANT: Lambert, William J.
; APPLICANT: Qi, Hong
; APPLICANT: Gelfand, Robert A.
; APPLICANT: Georgiev, Stefan F.
; APPLICANT: D'Amico, Robert E.
; TITLE OF INVENTION: Prolonged Delivery of Peptides
; NUMBER OF SEQUENCES: 7
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Pfizer Inc
; STREET: 235 East 42nd Street, 20th Floor
; CITY: New York
; STATE: New York
; COUNTRY: U.S.A.
; ZIP: 10017
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; FILING DATE:
; CLASSIFICATION: 514
; ATTORNEY/AGENT INFORMATION:
; NAME: Sheyda, Robert F.
; REGISTRATION NUMBER: 31,304
; REFERENCE/DOCKET NUMBER: PC8391
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212)573-1189
; TELEFAX: N/A
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 30 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; FRAGMENT TYPE: N-terminal
; ORIGIN: SOCR
; ORGANISM: N/A
; STRAIN: N/A
; INDIVIDUAL ISOLATE: N/A
; HAPLOTYPE: N/A
; CELL LINE: N/A
; IMMEDIATE SOURCE:
; LIBRARY: N/A
; CLONE: N/A

```

```

; POSITION IN GENOME:
; CHROMOSOME/SEGMENT: N/A
; MAP POSITION: N/A
; UNITS: N/A
US-08-472-349-3

Query Match
; Sequence 4, Application US/09333415
; Best Local Similarity 100.0%; Score 155; DB 3; Length 30;
; Matches 30; Conservative 0; Mismatches 0; Indels 0;
;
Oy 1 HAEFTTSDVSSYLEGQAQKEFIAMLVKGR 30
Db 1 HAEFTTSDVSSYLEGQAQKEFIAMLVKGR 30

RESULT 11
US-09-333-415-4
; Sequence 4, Application US/09333415
; Patent No. 6344180
; GENERAL INFORMATION:
; APPLICANT: Hoffmann, James J.
; TITLE OF INVENTION: GP-1 as a Diagnostic Test to Determine Beta-Cell
; TITLE OF INVENTION: Function and the Presence of the Condition of IGT and
; TITLE OF INVENTION: Type-II Diabetes
; FILE REFERENCE: P03987USO
; CURRENT APPLICATION NUMBER: US/09/333.415
; CURRENT FILING DATE: 1999-06-15
; NUMBER OF SEQ ID NOS: 13
; SOFTWARE: Patent In Ver. 2.0
; SEQ ID NO 1
; SEQ ID NO 2
; SEQ ID NO 3
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-333-415-4

Query Match
; Sequence 4, Application US/09333415
; Best Local Similarity 100.0%; Score 155; DB 4; Length 30;
; Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
;
Oy 1 HAEFTTSDVSSYLEGQAQKEFIAMLVKGR 30
Db 1 HAEFTTSDVSSYLEGQAQKEFIAMLVKGR 30

RESULT 12
US-09-585-181A-4
; Sequence 4, Application US/09585181A
; Patent No. 6358924
; GENERAL INFORMATION:
; APPLICANT: Hoffmann, James
; TITLE OF INVENTION: GP-1 FORMULATIONS
; FILE REFERENCE: X-11368
; CURRENT APPLICATION NUMBER: US/09/585.181A
; CURRENT FILING DATE: 2001-08-22
; PRIORITY DATE: 1999-06-15
; PRIORITY DATE: 1999-12-05
; NUMBER OF SEQ ID NOS: 5
; SOFTWARE: Patent In version 3.1
; SEQ ID NO 4
; SEQ ID NO 5
; TYPE: PRT
; ORGANISM: Homo sapiens
; NAME/KEY: MOD.RES
; LOCATION: (30)
; OTHER INFORMATION: AMIDATION
US-09-585-181A-4

Query Match
; Sequence 4, Application US/09585181A
; Best Local Similarity 100.0%; Score 155; DB 4; Length 30;
; Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Oy 1 HAEFTTSDVSSYLEGQAQKEFIAMLVKGR 30
Db 1 HAEFTTSDVSSYLEGQAQKEFIAMLVKGR 30

RESULT 13
US-09-209-799D-10
; Sequence 10, Application US/09209799D
; Patent No. 6388053
; GENERAL INFORMATION:
; APPLICANT: Hoffmann, Ronald
; APPLICANT: Hoffmann, James
; APPLICANT: Narasimhan, Chakravarthy
; TITLE OF INVENTION: GLUCAGON-LIKE PEPTIDE-1 CRYSTALS
; FILE REFERENCE: X-10242
; CURRENT APPLICATION NUMBER: US/09/209.799D
; CURRENT FILING DATE: 1998-12-11
; NUMBER OF SEQ ID NOS: 29
; SOFTWARE: Patent In version 3.0
; SEQ ID NO 10
; SEQ ID NO 11
; SEQ ID NO 12
; TYPE: PRT
; ORGANISM: Artificial
; OTHER INFORMATION: synthetic construct
US-09-209-799D-10

Query Match
; Sequence 10, Application US/09209799D
; Best Local Similarity 100.0%; Score 155; DB 4; Length 30;
; Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
;
Oy 1 HAEFTTSDVSSYLEGQAQKEFIAMLVKGR 30
Db 1 HAEFTTSDVSSYLEGQAQKEFIAMLVKGR 30

RESULT 14
US-09-975-905-1
; Sequence 1, Application US/09975905
; Patent No. 6388053
; GENERAL INFORMATION:
; APPLICANT: Galloway, John A
; APPLICANT: Hoffmann, James A
; TITLE OF INVENTION: Glucagon-Like Insulinotropic Peptides, Compositions and Meth
; FILE REFERENCE: X-9391
; CURRENT APPLICATION NUMBER: US/09/975.905
; CURRENT FILING DATE: 2001-10-12
; PRIORITY DATE: 2001-10-12
; PRIORITY DATE: 2000-05-18
; NUMBER OF SEQ ID NOS: 1
; SOFTWARE: Patent In version 3.1
; SEQ ID NO 1
; LENGTH: 30
; TYPE: PRT
; ORGANISM: Homo sapiens
; NAME/KEY: MOD.RES
; LOCATION: (30)
; OTHER INFORMATION: The arginine residue at position 30 is modified so as to rep
; OTHER INFORMATION: the terminal carboxyl group with an amine.
US-09-975-905-1

Query Match
; Sequence 1, Application US/09975905
; Best Local Similarity 100.0%; Score 155; DB 4; Length 30;
; Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
;
Oy 1 HAEFTTSDVSSYLEGQAQKEFIAMLVKGR 30
Db 1 HAEFTTSDVSSYLEGQAQKEFIAMLVKGR 30

RESULT 15
US-09-505-991-1

```

```
Sequence 1, Application US/09505991
Patent No. 6403361
GENERAL INFORMATION:
APPLICANT: Wagner, Fred W.
            Scott, Jay
            Henrikson, Dennis
            Phillips, Bruce
            Manning, Sharon
TITLE OF INVENTION: Enzymatic Method for Modification of
NUMBER OF SEQUENCES: 26
CORRESPONDENCE ADDRESS:
ADDRESSEE: Marchant & Gould
STREET: 3100 No. 6403361 West Center
CITY: Minneapolis
STATE: MN
COUNTRY: USA
FILL NO: 54102
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/505,991
FILING DATE: 17-Feb-2000
CLASSIFICATION: <unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/520,485
PUBLICATION NUMBER: 6,800,000
FILING DATE: 17-Feb-2000
ATTORNEY/AGENT INFORMATION:
NAME: Carter, Charles G.
REGISTRATION NUMBER: 35,093
REFERENCE/DOCKET NUMBER: 8648.32-USDI
TELECOMMUNICATION INFORMATION:
TELEPHONE: 612-332-5300
TELEFAX: 612-332-9081
INFORMATION FOR SEQ ID NO: 1:
SEQUENCE CHARACTERISTICS:
LENGTH: 30 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: peptide
IMMEDIATE SOURCE:
CLONE: GLP1 7-36-NH2 (Glucagon-like peptide)
SEQUENCE DESCRIPTION: SEQ ID NO: 1:
US-09-505-991-1

Query Match      100.0%; Score 155; DB 4; Length 30;
Best Local Similarity 100.0%; Pred. No. 5.6e-16;
Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HAEGFTSDVSSYLEGQAAKEFTANLVKGR 30
   |||||
DB 1 HAEGFTSDVSSYLEGQAAKEFTANLVKGR 30

Search completed: October 15, 2003, 10:57:32
Job time : 20.6721 secs
```



```
; TITLE OF INVENTION: TREATMENT OF ACUTE CORONARY SYNDROME WITH GLP-1
; FILE REFERENCE: 089187/0395
; CURRENT APPLICATION NUMBER: US/09/805,507
; CURRENT FILING DATE: 2001-03-14
; PRIOR APPLICATION NUMBER: 09/859,804
; PRIOR FILING DATE: 2001-05-18
; NUMBER OF SEQ ID NOS: 13
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 1
; LENGTH: 30
; TYPE: PRT
; ORGANISM: Unknown Organism
; FEATURE:
; OTHER INFORMATION: Description of Unknown Organism: Mammalian GLP
; OTHER INFORMATION: peptide
US-09-805-507-4

Query Match      100.0%; Score 155; DB 9; Length 30;
Best Local Similarity 100.0%; Pred. No. 3,2e-16;
Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HAEGTFTSDVSSYLEGQAAKEFTIAWVGR 30
Db 1 HAEGTFTSDVSSYLEGQAAKEFTIAWVGR 30

RESULT 3
US-09-859-804-4
; Sequence 4, Application US/09859804
; Patent No. 0824020107206A1
; APPLICANT: COOLIDGE, THOMAS R.
; APPLICANT: COOLIDGE, THOMAS R.
; TITLE OF INVENTION: TREATMENT OF ACUTE CORONARY SYNDROME WITH GLP-1
; FILE REFERENCE: 089187/0395
; CURRENT APPLICATION NUMBER: US/09/859,804
; CURRENT FILING DATE: 2001-05-18
; PRIOR APPLICATION NUMBER: 60/205,239
; PRIOR FILING DATE: 2000-05-19
; NUMBER OF SEQ ID NOS: 13
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 4
; LENGTH: 30
; TYPE: PRT
; ORGANISM: Unknown Organism
; FEATURE:
; OTHER INFORMATION: Description of Unknown Organism: Mammalian GLP
; OTHER INFORMATION: peptide
US-09-859-804-4

Query Match      100.0%; Score 155; DB 10; Length 30;
Best Local Similarity 100.0%; Pred. No. 3,2e-16;
Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HAEGTFTSDVSSYLEGQAAKEFTIAWVGR 30
Db 1 HAEGTFTSDVSSYLEGQAAKEFTIAWVGR 30

RESULT 4
US-09-982-978-4
; Sequence 4, Application US/0982978
; Patent No. 0824020146405A1
; APPLICANT: COOLIDGE, THOMAS R.
; APPLICANT: COOLIDGE, THOMAS R.
; TITLE OF INVENTION: TREATMENT OF ACUTE CORONARY SYNDROME WITH GLP-1
; FILE REFERENCE: 089187/0395
; CURRENT APPLICATION NUMBER: US/09/982,978
; CURRENT FILING DATE: 2001-10-22
; PRIOR APPLICATION NUMBER: 09/859,804
; PRIOR FILING DATE: 2001-05-18
; PRIOR APPLICATION NUMBER: 60/205,239
```

```
; PRIOR FILING DATE: 2000-05-19
; NUMBER OF SEQ ID NOS: 13
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 4
; LENGTH: 30
; TYPE: PRT
; ORGANISM: Unknown Organism
; FEATURE:
; OTHER INFORMATION: Description of Unknown Organism: Mammalian GLP
; OTHER INFORMATION: peptide
US-09-982-978-4

Query Match      100.0%; Score 155; DB 10; Length 30;
Best Local Similarity 100.0%; Pred. No. 3,2e-16;
Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HAEGTFTSDVSSYLEGQAAKEFTIAWVGR 30
Db 1 HAEGTFTSDVSSYLEGQAAKEFTIAWVGR 30

RESULT 5
US-09-953-021B-4
; Sequence 4, Application US/0953021B
; Patent No. US20020147131A1
; GENERAL INFORMATION:
; APPLICANT: Coolidge, Thomas L.
; APPLICANT: Ehlers, Mario R.W.
; TITLE OF INVENTION: Metabolic Intervention with GLP-1 to Improve the Function of
; FILE REFERENCE: P0360086
; CURRENT APPLICATION NUMBER: US/09/953,021B
; CURRENT FILING DATE: 2001-05-18
; PRIOR APPLICATION NUMBER: 09/302,596
; PRIOR FILING DATE: 1999-04-30
; NUMBER OF SEQ ID NOS: 13
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 4
; LENGTH: 30
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: peptide
US-09-953-021B-4

Query Match      100.0%; Score 155; DB 10; Length 30;
Best Local Similarity 100.0%; Pred. No. 3,2e-16;
Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HAEGTFTSDVSSYLEGQAAKEFTIAWVGR 30
Db 1 HAEGTFTSDVSSYLEGQAAKEFTIAWVGR 30

RESULT 6
US-09-834-229A-5
; Sequence 5, Application US/09834229A
; Patent No. US20030028253A1
; GENERAL INFORMATION:
; APPLICANT: Esendic, Suad
; TITLE OF INVENTION: USE OF GLP-1 OR ANALOGS IN TREATMENT OF MYOCARDIAL INFARCTION
; FILE REFERENCE: X-10822A
; CURRENT APPLICATION NUMBER: US/09/834,229A
; CURRENT FILING DATE: 2001-04-12
; PRIOR APPLICATION NUMBER: US 08/915,918
; PRIOR FILING DATE: 1997-08-21
; PRIOR APPLICATION NUMBER: US 06/024,980
; PRIOR FILING DATE: 1996-08-30
; NUMBER OF SEQ ID NOS: 5
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 5
; LENGTH: 30
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
```

```
; OTHER INFORMATION: synthetic construct
US-09-834-229A-5
Query Match      100.0%; Score 155; DB 11; Length 30;
Best Local Similarity 100.0%; Pred. No. 3.2e-16;
Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 HAEGFTSDVSSYLEGQAAKEFTAMLYKGR 30
DB 1 HAEGFTSDVSSYLEGQAAKEFTAMLYKGR 30
|||||
RESULT 7
US-09-997-792-10
; Sequence 10, Application US/09997792
; Publication No. US2003004546A1
; GENERAL INFORMATION:
; APPLICANT: Hoffmann, James
; APPLICANT: Hoffmann, Ronald
; APPLICANT: Hoffmann, James
; APPLICANT: Hoffmann, Ronald
; APPLICANT: Hoffmann, Ronald
; APPLICANT: Hoffmann, Ronald
; TITLE OF INVENTION: GLUCAGON-LIKE PEPTIDE-1 CRYSTALS
; FILE REFERENCE: X-10242
; CURRENT APPLICATION NUMBER: US/09/997,792
; CURRENT FILING DATE: 2001-11-30
; NUMBER OF SEQ ID NOS: 29
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 10
; LENGTH: 30
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURES:
; OTHER INFORMATION: synthetic construct
US-09-997-792-10
Query Match      100.0%; Score 155; DB 11; Length 30;
Best Local Similarity 100.0%; Pred. No. 3.2e-16;
Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 HAEGFTSDVSSYLEGQAAKEFTAMLYKGR 30
DB 1 HAEGFTSDVSSYLEGQAAKEFTAMLYKGR 30
|||||
RESULT 8
US-10-097-230-3
; Sequence 3, Application US/10097230
; Publication No. US20030186436A1
; GENERAL INFORMATION:
; APPLICANT: Perfetti, Riccardo
; APPLICANT: Rui, Hongxiang
; TITLE OF INVENTION: Glucose-Dependent Insulin-Secreting Cells Transfected with a Nucleotide Sequence Encoding GLP-1
; FILE REFERENCE: 81476-0249/04
; CURRENT APPLICATION NUMBER: US/10/097,230
; CURRENT FILING DATE: 2002-05-12
; NUMBER OF SEQ ID NOS: 9
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 3
; LENGTH: 30
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-097-230-3
Query Match      100.0%; Score 155; DB 12; Length 30;
Best Local Similarity 100.0%; Pred. No. 3.2e-16;
Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 HAEGFTSDVSSYLEGQAAKEFTAMLYKGR 30
DB 1 HAEGFTSDVSSYLEGQAAKEFTAMLYKGR 30
|||||
RESULT 9
US-10-072-540A-4
; Sequence 4, Application US/10072540A
; Publication No. US20020123466A1
; GENERAL INFORMATION:
; APPLICANT: Hoffmann, James
; APPLICANT: Hoffmann, James
; TITLE OF INVENTION: GLP-1 FORMULATIONS
; FILE REFERENCE: X-11368A
; CURRENT APPLICATION NUMBER: US/10/072,540A
; CURRENT FILING DATE: 2002-02-08
; PRIORITY FILING DATE: 2000-02-08
; PRIOR FILING DATE: 1997-12-05
; NUMBER OF SEQ ID NOS: 5
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 4
; LENGTH: 30
; TYPE: PRT
; ORGANISM: Homo sapiens
; NAME/KEY: MOD.RES
; LOCATION: (30)..(30)
; OTHER INFORMATION: AMIDATION
US-10-072-540A-4
Query Match      100.0%; Score 155; DB 14; Length 30;
Best Local Similarity 100.0%; Pred. No. 3.2e-16;
Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 HAEGFTSDVSSYLEGQAAKEFTAMLYKGR 30
DB 1 HAEGFTSDVSSYLEGQAAKEFTAMLYKGR 30
|||||
RESULT 10
US-10-125-255-1
; Sequence 1, Application US/10125255
; Publication No. US20020165342A1
; GENERAL INFORMATION:
; APPLICANT: Galloway, John A
; APPLICANT: Hoffmann, James A
; TITLE OF INVENTION: Glucagon-Like Insulinotropic Peptides, Compositions and Methods
; FILE REFERENCE: X-9332E
; CURRENT APPLICATION NUMBER: US/10/125,255
; CURRENT FILING DATE: 2002-04-17
; PRIORITY FILING DATE: 2000-05-18
; NUMBER OF SEQ ID NOS: 1
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 1
; LENGTH: 30
; TYPE: PRT
; ORGANISM: Homo sapiens
; NAME/KEY: MOD.RES
; LOCATION: (30)..(30)
; OTHER INFORMATION: The arginine residue at position 30 is modified so as to replace the terminal carboxyl group with an amine.
US-10-125-255-1
Query Match      100.0%; Score 155; DB 14; Length 30;
Best Local Similarity 100.0%; Pred. No. 3.2e-16;
Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 HAEGFTSDVSSYLEGQAAKEFTAMLYKGR 30
DB 1 HAEGFTSDVSSYLEGQAAKEFTAMLYKGR 30
|||||
RESULT 11
US-10-091-256-4
; Sequence 4, Application US/10091256
; Publication No. US2003007362A1
; GENERAL INFORMATION:
; APPLICANT: Hathaway, David R
```

```

; APPLICANT: Celligide, Thomas R
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR TREATING PERIPHERAL VASCULAR DISEASE
; FILE REFERENCE: NY 2
; CURRENT APPLICATION NUMBER: US/10/091,258
; CURRENT FILING DATE: 2002-03-05
; NUMBER OF SEQ ID NOS: 13
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 4
; LENGTH: 30
; TYPE: PRT
; ORGANISM: mammalian
US-10-091-258-4

```

```

Query Match      100.0%; Score 155; DB 15; Length 30;
Best Local Similarity 100.0%; Pred. No. 3.2e-16;
Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

QY      1 HAEGTFTSDVSSYLEGQAQKEFIAMLVKGR 30
      |||
DB      1 HAEGTFTSDVSSYLEGQAQKEFIAMLVKGR 30

```

RESULT 12

```

US-10-055-259-4
; Sequence 1, Application US/10055259
; Publication No. US20030091507A1
; GENERAL INFORMATION:
; APPLICANT: Holst, Jens J.
; TITLE OF INVENTION: GLP-1 AS A DIAGNOSTIC TEST TO DETERMINE BETA-CELL FUNCTION AND TH
; FILE REFERENCE: P03987US1
; CURRENT APPLICATION NUMBER: US/10/055,259
; CURRENT FILING DATE: 2002-06-21
; NUMBER OF SEQ ID NOS: 13
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 4
; LENGTH: 30
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-055-259-4

```

```

Query Match      100.0%; Score 155; DB 15; Length 30;
Best Local Similarity 100.0%; Pred. No. 3.2e-16;
Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

QY      1 HAEGTFTSDVSSYLEGQAQKEFIAMLVKGR 30
      |||
DB      1 HAEGTFTSDVSSYLEGQAQKEFIAMLVKGR 30

```

RESULT 13

```

US-10-265-345A-2
; Sequence 2, Application US/10265345A
; Publication No. US2003012469A1
; GENERAL INFORMATION:
; APPLICANT: Whelan, Kevin
; APPLICANT: Whelan, James
; TITLE OF INVENTION: Peptides Acting as Both GLP-1 Receptor Agonists and Glucagon
; FILE REFERENCE: NSB-7288
; CURRENT APPLICATION NUMBER: US/10/265,345A
; CURRENT FILING DATE: 2003-01-31
; PRIOR APPLICATION NUMBER: US 60/327,730
; INVENTION DATE: 2000-10-05
; NUMBER OF SEQ ID NOS: 3
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 2
; LENGTH: 30
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-265-345A-2

```

```

Query Match      100.0%; Score 155; DB 15; Length 30;
Best Local Similarity 100.0%; Pred. No. 3.2e-16;
Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

QY      1 HAEGTFTSDVSSYLEGQAQKEFIAMLVKGR 30
      |||
DB      1 HAEGTFTSDVSSYLEGQAQKEFIAMLVKGR 30

```

RESULT 14

```

US-09-754-723-1
; Sequence 1, Application US/09754723
; Publication No. US2003002394A1
; GENERAL INFORMATION:
; APPLICANT: SEEMIC, Suad
; APPLICANT: GUTNIAK, Mark
; APPLICANT: KIRK, Ole
; TITLE OF INVENTION: Use Of A Peptide
; FILE REFERENCE: 3745,234-US
; CURRENT APPLICATION NUMBER: US/09/754,723
; CURRENT FILING DATE: 2001-06-21
; PRIOR APPLICATION NUMBER: US 08/842,121
; INVENTION DATE: 1994-10-13
; PRIOR APPLICATION NUMBER: US 08/295,913
; PRIOR FILING DATE: 1994-10-13
; PRIOR APPLICATION NUMBER: PCT/DK93/00099
; PRIOR FILING DATE: 1993-03-19
; PRIOR APPLICATION NUMBER: DK 0363/92
; PRIOR FILING DATE: 1992-03-19
; NUMBER OF SEQ ID NOS: 1
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 1
; LENGTH: 31
; TYPE: PRT
; ORGANISM: Homo Sapien
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (1)...(31)
; OTHER INFORMATION: Xaa = Any Amino Acid
US-09-754-723-1

```

```

Query Match      100.0%; Score 155; DB 9; Length 31;
Best Local Similarity 100.0%; Pred. No. 3.2e-16;
Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

QY      1 HAEGTFTSDVSSYLEGQAQKEFIAMLVKGR 30
      |||
DB      1 HAEGTFTSDVSSYLEGQAQKEFIAMLVKGR 30

```

RESULT 15

```

US-09-420-785A-3
; Sequence 3, Application US/09420785A
; Patent No. US20010010923A1
; GENERAL INFORMATION:
; APPLICANT: MORTENSEN, UFFE
; APPLICANT: MORTENSEN, URBEN
; APPLICANT: STENICEK, HENNING
; APPLICANT: STENICEK, STEEN B.
; APPLICANT: BREDDAM, KLAUS
; TITLE OF INVENTION: MODIFIED CARBOXYPEPTIDASE
; FILE REFERENCE: 089487/0109
; CURRENT APPLICATION NUMBER: US/09/420,785A
; CURRENT FILING DATE: 1999-10-19
; NUMBER OF SEQ ID NOS: 4
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 3
; LENGTH: 31
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: VARIANT

```

```
; LOCATION: (31)
; OTHER INFORMATION: C-terminal amino acid which serves as a leaving
; OTHER INFORMATION: group, typically, an uncharged amino acid side
; OTHER INFORMATION: chain, preferably alanine
US-09-420-785A-3

Query Match      100.0%; Score 155; DE 2; Length 31;
Best Local Similarity 100.0%; Pred. No. 3.3e-16;
Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 HAECTFTSDYSSYLEQAAKEFLAWLYKGR 30
   |||||
DB 1 HAECTFTSDYSSYLEQAAKEFLAWLYKGR 30

Search completed: October 15, 2003, 11:09:32
Job time : 42.7869 secs
```

GenCore version 5.1.6
Copyright (c) 1993 - 2003 Compugen Ltd.

OM protein - protein search, using sw model

Run on: October 15, 2003, 10:53:17 ; Search time 285.738 Seconds
(without alignments)
95.534 Million cell updates/sec

Title: US-09-719-410-4

Sequence: 1 HAEFTFSDVSYLEQAAKEFLAWKGR 30

Scoring table: BLOSUM62
Gap 10.0 , Gapext 0.5

Searched: 5728757 seqs, 909918778 residues
Total number of hits satisfying chosen parameters: 5728757

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : Pending patents: M. Main.*

- 1: /cgn2_6/ptodata/1/paa/US06_COMB.pep.*
- 2: /cgn2_6/ptodata/1/paa/US06_COMB.pep.*
- 3: /cgn2_6/ptodata/1/paa/US07_COMB.pep.*
- 4: /cgn2_6/ptodata/1/paa/US08_COMB.pep.*
- 5: /cgn2_6/ptodata/1/paa/US081_COMB.pep.*
- 6: /cgn2_6/ptodata/1/paa/US082_COMB.pep.*
- 7: /cgn2_6/ptodata/1/paa/US083_COMB.pep.*
- 8: /cgn2_6/ptodata/1/paa/US084_COMB.pep.*
- 9: /cgn2_6/ptodata/1/paa/US085_COMB.pep.*
- 10: /cgn2_6/ptodata/1/paa/US086_COMB.pep.*
- 11: /cgn2_6/ptodata/1/paa/US087_COMB.pep.*
- 12: /cgn2_6/ptodata/1/paa/US088_COMB.pep.*
- 13: /cgn2_6/ptodata/1/paa/US089_COMB.pep.*
- 14: /cgn2_6/ptodata/1/paa/US090_COMB.pep.*
- 15: /cgn2_6/ptodata/1/paa/US091_COMB.pep.*
- 16: /cgn2_6/ptodata/1/paa/US092_COMB.pep.*
- 17: /cgn2_6/ptodata/1/paa/US093_COMB.pep.*
- 18: /cgn2_6/ptodata/1/paa/US094_COMB.pep.*
- 19: /cgn2_6/ptodata/1/paa/US095_COMB.pep.*
- 20: /cgn2_6/ptodata/1/paa/US096_COMB.pep.*
- 21: /cgn2_6/ptodata/1/paa/US097A_COMB.pep.*
- 22: /cgn2_6/ptodata/1/paa/US097B_COMB.pep.*
- 23: /cgn2_6/ptodata/1/paa/US098_COMB.pep.*
- 24: /cgn2_6/ptodata/1/paa/US099_COMB.pep.*
- 25: /cgn2_6/ptodata/1/paa/US099B_COMB.pep.*
- 26: /cgn2_6/ptodata/1/paa/US100_COMB.pep.*
- 27: /cgn2_6/ptodata/1/paa/US101_COMB.pep.*
- 28: /cgn2_6/ptodata/1/paa/US102_COMB.pep.*
- 29: /cgn2_6/ptodata/1/paa/US103_COMB.pep.*
- 30: /cgn2_6/ptodata/1/paa/US104_COMB.pep.*
- 31: /cgn2_6/ptodata/1/paa/US106_COMB.pep.*
- 32: /cgn2_6/ptodata/1/paa/US60_COMB.pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

| Result No. | Score | Match | Length | DB ID | Description |
|------------|-------|-------|--------|-------|------------------------------------|
| 1 | 155 | 100.0 | 30 | 1 | PCT-US02-13088-4 Sequence 4, Appli |

Sequence 1, Appli
Sequence 4, Appli
Sequence 25, Appli
Sequence 2, Appli
Sequence 31, Appli
Sequence 4, Appli
Sequence 4, Appli
Sequence 3, Appli
Sequence 1, Appli
Sequence 53, Appli
Sequence 27, Appli
Sequence 3, Appli
Sequence 1, Appli
Sequence 3, Appli
Sequence 3, Appli
Sequence 3, Appli
Sequence 53, Appli
Sequence 18, Appli
Sequence 21, Appli
Sequence 2, Appli
Sequence 3, Appli
Sequence 118, App
Sequence 4, Appli
Sequence 3, Appli
Sequence 3, Appli
Sequence 5, Appli
Sequence 3, Appli
Sequence 344, App
Sequence 355, App
Sequence 4, Appli
Sequence 11, Appli
Sequence 344, App
Sequence 355, App
Sequence 3, Appli
Sequence 4, Appli
Sequence 1, Appli
Sequence 5, Appli
Sequence 1, Appli
Sequence 4, Appli
Sequence 2, Appli

ALIGNMENTS

RESULT 1
PCT-US02-13088-4
; Sequence 4, Application PC/TUS0213088
; GENERAL INFORMATION:
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH
; FILE REFERENCE: RGN-3
; CURRENT APPLICATION NUMBER: PCT/US02/13088
; CURRENT FILING DATE: 2002-04-24
; NUMBER OF SEQ ID NOS: 13
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 4
; LENGTH: 30
; TYPE: PPT
; ORGANISM: mammalian
PCT-US02-13088-4

Query Match 100.0%; Score 155; DB 1; Length 30;
Best Local Similarity 100.0%; Pred No. 1.3e-15;
Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 1 HAEFTFSDVSYLEQAAKEFLAWKGR 30
|||||

```
Db      1 HAEGETFTSDVSSYLEGQAQAEFIAMLYKGR 30
PCT-US02-24141-1
RESULT 2
PCT-US02-24141-1
; Sequence 1, Application PC/TUS0224141
; GENERAL INFORMATION:
; APPLICANT: The Government of the United States of America, as represented by the
; APPLICANT: Secretary, Department of Health and Human Services
; APPLICANT: Greig, Nigel H.
; APPLICANT: Greig, Nigel H.
; APPLICANT: Doyle, Maite
; APPLICANT: Doyle, Maite
; APPLICANT: Hollova, Harold
; TITLE OF INVENTION: GLP-1, EXENDIN-4, AND PEPTIDE ANALOGS AND USES THEREOF
; FILE REFERENCE: 14014.035621
; CURRENT APPLICATION NUMBER: PCT/US02/24141
; CURRENT FILING DATE: 2002-07-30
; PRIOR APPLICATION NUMBER: 60/309,076
; PRIOR FILING DATE: 2001-07-31
; NUMBER OF SEQ ID NOS: 52
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 1
; LENGTH: 30
; TYPE: PPT
; ORGANISM: Human
PCT-US02-24141-1
Query Match      100.0%; Score 155; DB 1; Length 30;
Best Local Similarity 100.0%; Pred. No. 1.3e-15;
Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY      1 HAEGETFTSDVSSYLEGQAQAEFIAMLYKGR 30
Db      1 HAEGETFTSDVSSYLEGQAQAEFIAMLYKGR 30
PCT-US02-24141-1
RESULT 3
PCT-US02-24141-4
; Sequence 4, Application PC/TUS0224141
; GENERAL INFORMATION:
; APPLICANT: The Government of the United States of America, as represented by the
; APPLICANT: Secretary, Department of Health and Human Services
; APPLICANT: Greig, Nigel H.
; APPLICANT: Greig, Nigel H.
; APPLICANT: Doyle, Maite
; APPLICANT: Doyle, Maite
; APPLICANT: Hollova, Harold
; TITLE OF INVENTION: GLP-1, EXENDIN-4, AND PEPTIDE ANALOGS AND USES THEREOF
; FILE REFERENCE: 14014.035621
; CURRENT APPLICATION NUMBER: PCT/US02/24141
; CURRENT FILING DATE: 2002-07-30
; PRIOR APPLICATION NUMBER: 60/309,076
; PRIOR FILING DATE: 2001-07-31
; NUMBER OF SEQ ID NOS: 52
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 4
; LENGTH: 30
; TYPE: PPT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence/Note =
; OTHER INFORMATION: Synthetic Construct
PCT-US02-24141-4
Query Match      100.0%; Score 155; DB 1; Length 30;
Best Local Similarity 100.0%; Pred. No. 1.3e-15;
Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY      1 HAEGETFTSDVSSYLEGQAQAEFIAMLYKGR 30
Db      1 HAEGETFTSDVSSYLEGQAQAEFIAMLYKGR 30
PCT-US02-24141-4
RESULT 4
```

```
PCT-US02-25227-25
; Sequence 25, Application PC/TUS0225227
; GENERAL INFORMATION:
; APPLICANT: Genzyme Corporation
; APPLICANT: Wadsworth, Samuel C.
; APPLICANT: Amantano, Donna
; APPLICANT: Gregory, Richard J.
; APPLICANT: Parsons, Geoffrey
; TITLE OF INVENTION: Methods of Treating Diabetes and Other
; TITLE OF INVENTION: Blood Sugar Disorders
; FILE REFERENCE: 14014.035621
; CURRENT APPLICATION NUMBER: PCT/US02/25227
; CURRENT FILING DATE: 2002-08-07
; PRIOR APPLICATION NUMBER: US 60/310,982
; PRIOR FILING DATE: 2001-08-08
; NUMBER OF SEQ ID NOS: 54
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 25
; LENGTH: 30
; TYPE: PPT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Modified GLP-1 molecule; GLP-1 (7-36)
PCT-US02-25227-25
Query Match      100.0%; Score 155; DB 1; Length 30;
Best Local Similarity 100.0%; Pred. No. 1.3e-15;
Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY      1 HAEGETFTSDVSSYLEGQAQAEFIAMLYKGR 30
Db      1 HAEGETFTSDVSSYLEGQAQAEFIAMLYKGR 30
PCT-US02-31693A-2
RESULT 5
PCT-US02-31693A-2
; Sequence 2, Application PC/TUS0231693A
; GENERAL INFORMATION:
; APPLICANT: Bayer Corporation
; APPLICANT: Pan, Clark
; APPLICANT: Whelan, James
; APPLICANT: Clairmont, Kevin B.
; TITLE OF INVENTION: Peptides Acting as Both GLP-1 Receptor Agonists and Glucagon
; TITLE OF INVENTION: Receptor Antagonists and Their Pharmacological Methods of Use
; FILE REFERENCE: 7388 PCT/US02/31693A
; CURRENT APPLICATION NUMBER: PCT/US02/31693A
; CURRENT FILING DATE: 2002-12-19
; PRIOR APPLICATION NUMBER: US 60/327,730
; PRIOR FILING DATE: 2001-10-05
; NUMBER OF SEQ ID NOS: 34
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 2
; LENGTH: 30
; TYPE: PPT
; ORGANISM: Homo sapiens
PCT-US02-31693A-2
Query Match      100.0%; Score 155; DB 1; Length 30;
Best Local Similarity 100.0%; Pred. No. 1.3e-15;
Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY      1 HAEGETFTSDVSSYLEGQAQAEFIAMLYKGR 30
Db      1 HAEGETFTSDVSSYLEGQAQAEFIAMLYKGR 30
PCT-US03-16643-31
RESULT 6
PCT-US03-16643-31
; Sequence 31, Application PC/TUS0316643
; GENERAL INFORMATION:
; APPLICANT: Wagner, F.
; APPLICANT: Peng, L.
; APPLICANT: Xia, U.
```

```

; LENGTH: 30
; TYPE: PWT
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: Arg at position 30 is C-terminally amidated.
PCT-US98-25515-4

Query Match          100.0%; Score 155; DB 1; Length 30;
Best Local Similarity 100.0%; Pred. No. 1.3e-15;
Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 HAEGTFTSVSSYLEGQAEEFIAMLVKGR 30
DB      1 HAEGTFTSVSSYLEGQAEEFIAMLVKGR 30

RESULT 9
US-07-899-073-3
; Sequence 3, Application US/07899073
; GENERAL INFORMATION:
; APPLICANT: Andrews, Glenn C.
; APPLICANT: Burt, George O.
; APPLICANT: Franconeri, Michael L.
; APPLICANT: Larson, Eric R.
; TITLE OF INVENTION: GLUCAGON-LIKE PEPTIDE AND INSULINOTROPIN
; TITLE OF INVENTION: DERIVATIVES
; NUMBER OF SEQUENCES: 6
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Gregg C. Benson, Pfizer Inc
; STREET: Eastern Point Road
; CITY: Galston
; STATE: CT
; COUNTRY: USA
; ZIP: 06340
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/899_073
; FILING DATE: 19920615
; CLASSIFICATION: 514
; ATTORNEY/AGENT INFORMATION:
; NAME: Benson, Gregg C.
; REGISTRATION NUMBER: 30,997
; REFERENCE/DOCKET NUMBER: PC8156CGB
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (203) 441-4901
; FAX: (203) 441-5241
; INFORMATION FOR SEQ ID NO 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 30 amino acids
; TYPE: AMINO ACID
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
US-07-899-073-3

Query Match          100.0%; Score 155; DB 3; Length 30;
Best Local Similarity 100.0%; Pred. No. 1.3e-15;
Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 HAEGTFTSVSSYLEGQAEEFIAMLVKGR 30
DB      1 HAEGTFTSVSSYLEGQAEEFIAMLVKGR 30

RESULT 10
US-08-044-133-3
; Sequence 1, Application US/08044133
; GENERAL INFORMATION:
; APPLICANT: Kim, Yesook
; APPLICANT: Lambert, William J.

```

APPLICANT: Qi, Hong
APPLICANT: Gelfand, Robert A.
APPLICANT: Geopjean, Kieran P.
APPLICANT: Danley, Dennis E.
TITLE OF INVENTION: Prolonged Delivery of Peptides
NUMBER OF SEQUENCES: 7
CORRESPONDENCE ADDRESS:
ADDRESSEE: Pfizer Inc
STREET: 215 East 42nd Street, 20th Floor
CITY: New York
STATE: New York
COUNTRY: U.S.A.
ZIP: 10017-5755
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/044,133
FILING DATE: 07-SEP-1993
CLASSIFICATION: 31.304
ATTORNEY/AGENT INFORMATION:
NAME: Shevka, Robert F.
REGISTRATION NUMBER: 31,304
REFERENCE/DOCKET NUMBER: PC8391
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212)573-1189
TELEFAX: (212)573-1939
TELEX: N/A
INFORMATION FOR SEQ ID NO: 3:
SEQUENCE CHARACTERISTICS:
LENGTH: 30 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: peptide
HYPOTHETICAL: NO
ANTI-SENSE: NO
FRAGMENT TYPE: N-terminal
ORIGINAL SOURCE:
ORGANISM: N/A
STRAIN: N/A
INDIVIDUAL ISOLATE: N/A
CELL LINE: N/A
BAPLOTYPE: N/A
IMMEDIATE SOURCE:
LIBRARY: N/A
CLONE: N/A
POSITION IN GENOME:
CHROMOSOME/SEGMENT: N/A
MAP POSITION: N/A
ONLIS: N/A
US-08-044-133-3
Query Match 100.0%; Score 155; DB 4; Length 30;
Best Local Similarity 100.0%; Pred. No. 1.3e-15;
Matches 30; Conservative 0; Mismatches 0; Indels 0;
Gaps 0;
QY 1 HAEFTFTDVSYLEGQAQKEFIANLVKGR 30
DB 1 HAEFTFTDVSYLEGQAQKEFIANLVKGR 30
RESULT 11
US-08-302-855-1
Sequence 1, Application US/08302855
GENERAL INFORMATION:
APPLICANT: Kief, Ole
APPLICANT: Pridal, Lone
TITLE OF INVENTION: NOVEL MEDICAMENT
NUMBER OF SEQUENCES: 1
CORRESPONDENCE ADDRESS:

ADDRESSEE: Novo Nordisk of North America, Inc.
STREET: 405 Lexington Avenue, 94th Floor
CITY: New York
STATE: New York
COUNTRY: United States of America
ZIP: 10174-6401
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/302,855
FILING DATE: 16-SEP-1994
CLASSIFICATION: 530
PRIOR APPLICATION DATA:
APPLICATION NUMBER: DK PCT/DK93/00098
FILING DATE: 18-MAR-1993
ATTORNEY/AGENT INFORMATION:
NAME: Landiris, Elias J.
REGISTRATION NUMBER: 33,728
REFERENCE/DOCKET NUMBER: 3746,204-US
TELECOMMUNICATION INFORMATION:
TELEPHONE: 212-867-6543
TELEFAX: 212-878-9655
INFORMATION FOR SEQ ID NO: 1:
SEQUENCE CHARACTERISTICS:
LENGTH: 30 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: peptide
US-08-302-855-1
Query Match 100.0%; Score 155; DB 7; Length 30;
Best Local Similarity 100.0%; Pred. No. 1.3e-15;
Matches 30; Conservative 0; Mismatches 0; Indels 0;
Gaps 0;
QY 1 HAEFTFTDVSYLEGQAQKEFIANLVKGR 30
DB 1 HAEFTFTDVSYLEGQAQKEFIANLVKGR 30
RESULT 12
US-08-350-528-53
Sequence 53, Application US/08350528
GENERAL INFORMATION:
APPLICANT: Stout, Jay
APPLICANT: Partridge, Bruce
APPLICANT: Henriksen, Dennis
APPLICANT: Holmquist, Barton
APPLICANT: Wagner, Fred
TITLE OF INVENTION: PRODUCTION OF C-TERMINAL AMIDATED PEPTIDES FROM RECOMB
NUMBER OF SEQUENCES: 63
CORRESPONDENCE ADDRESS:
ADDRESSEE: Abbott & Gould
STREET: 3100 Northwest
CITY: Wals
STATE: MN
COUNTRY: USA
ZIP: 55402
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM compatible
OPERATING SYSTEM: DOS
SOFTWARE: Patent Release #1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/350,528
FILING DATE: 07-DEC-1994
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:


```

/ ATTORNEY/AGENT INFORMATION:
/ NAME: Carter, Charles G
/ REGISTRATION NUMBER: 35,093
/ REFERENCE/DOCKET NUMBER: 8648.45U01
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: 332-5300
/ TELEFAX:
/ TELEFAX FOR SEQ ID NO: 53:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 30 amino acids
/ TYPE: amino acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ MOLECULE TYPE: peptide
/ HYPOTHETICAL: NO
/ ANTI-SENSE: NO
/ FRAGMENT TYPE: internal
/ ORIGINAL SOURCE:
/ US-08-350-528-33

Query Match
Best Local Similarity 100.04; Score 155; DB 7; Length 30;
Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HAEGFTSDVSVYLEGQAQKEFIAMLVKGR 30
DB 1 HAEGFTSDVSVYLEGQAQKEFIAMLVKGR 30

RESULT 13
US-08-350-530A-27
/ SEQUENCE INFORMATION:
/ GENERAL INFORMATION:
/ APPLICANT: Partridge, Bruce
/ APPLICANT: Stout, Jay
/ APPLICANT: Henriksen, Dennis
/ APPLICANT: Manning, Shane
/ APPLICANT: De La Motta, Rebecca
/ APPLICANT: Holquist, Barton
/ APPLICANT: Wagner, Fred
/ TITLE OF INVENTION: PRODUCTION OF PEPTIDE USING RECOMBINANT
/ TITLE OF INVENTION: FUSION PROTEIN CONSTRUCTS
/ NUMBER OF SEQUENCES: 33
/ CORRESPONDENCE ADDRESS:
/ ADDRESS: 3100 Northwest Center, 90 S. 7th Street
/ STREET: 3100 Northwest Center, 90 S. 7th Street
/ CITY: Minneapolis
/ STATE: MN
/ COUNTRY: U.S.A.
/ ZIP: 55402
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Diskette
/ COMPUTER: IBM Compatible
/ OPERATING SYSTEM: DOS
/ SOFTWARE: FASTSQ Version 1.5
/ CURRENT/LEGACY DATA:
/ REGISTRATION NUMBER: 35,093
/ FILING DATE: 07-DEC-1994
/ CLASSIFICATION: 435
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER:
/ FILING DATE:
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Carter, Charles G
/ REGISTRATION NUMBER: 35,093
/ REFERENCE/DOCKET NUMBER: 8648.45U01
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: 612/332-5300
/ TELEFAX: 612/332-5081
/ INFORMATION FOR SEQ ID NO: 27:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 30 amino acids
/ TYPE: amino acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ MOLECULE TYPE: peptide
/ HYPOTHETICAL: NO
/ ANTI-SENSE: NO
/ FRAGMENT TYPE: internal
/ ORIGINAL SOURCE:
/ US-08-350-530A-27
```

```

/ LENGTH: 30 amino acids
/ TYPE: amino acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ MOLECULE TYPE: peptide
/ HYPOTHETICAL: NO
/ ANTI-SENSE: NO
/ FRAGMENT TYPE: internal
/ ORIGINAL SOURCE:
/ US-08-350-530A-27

Query Match
Best Local Similarity 100.04; Score 155; DB 7; Length 30;
Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HAEGFTSDVSVYLEGQAQKEFIAMLVKGR 30
DB 1 HAEGFTSDVSVYLEGQAQKEFIAMLVKGR 30

RESULT 14
US-08-356-231-3
/ SEQUENCE INFORMATION:
/ GENERAL INFORMATION:
/ APPLICANT: Andrews, Glenn C.
/ APPLICANT: Daumy, Gaston O.
/ APPLICANT: Francoeur, Michael L.
/ APPLICANT: Larson, Eric R.
/ APPLICANT: Pfizer Inc, (Non-US)
/ TITLE OF INVENTION: GLUCAGON-LIKE PEPTIDE AND INSULINOTROPIN
/ TITLE OF INVENTION: DERIVATIVES
/ NUMBER OF SEQUENCES: 6
/ CORRESPONDENCE ADDRESS:
/ ADDRESS: Gregg C. Benson, Pfizer Inc
/ STREET: Eastern Point Road
/ CITY: Groton
/ STATE: CT
/ COUNTRY: USA
/ ZIP: 06340
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Floppy disk
/ COMPUTER: IBM PC compatible
/ OPERATING SYSTEM: PC-DOS/MS-DOS
/ SOFTWARE: PatentIn Release #1.0, Version #1.25
/ CURRENT APPLICATION DATA:
/ REGISTRATION NUMBER: 30,997
/ FILING DATE: 05/08/356,231
/ CLASSIFICATION: 514
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: US 07/899,073
/ FILING DATE: 15-JUN-1992
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Benson, Gregg C.
/ REGISTRATION NUMBER: 30,997
/ REFERENCE/DOCKET NUMBER: PCB156AGCB
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (203) 441-4901
/ TELEFAX: (203) 441-5221
/ INFORMATION FOR SEQ ID NO: 3:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 30 amino acids
/ TYPE: amino acid
/ TOPOLOGY: linear
/ MOLECULE TYPE: peptide
/ US-08-356-231-3

Query Match
Best Local Similarity 100.04; Score 155; DB 7; Length 30;
Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HAEGFTSDVSVYLEGQAQKEFIAMLVKGR 30
DB 1 HAEGFTSDVSVYLEGQAQKEFIAMLVKGR 30
```

```
RESULT 15
US-08-520-485-1
: Sequence 1. Application US/08520485
: GENERAL INFORMATION:
: APPLICANT: Wagner, Fred W.
: APPLICANT: Scout, Jay
: APPLICANT: Perkins, Dennis
: APPLICANT: Perkins, Bruce
: APPLICANT: Manning, Shane
: TITLE OF INVENTION: Enzymatic Method for Modification of
: NUMBER OF SEQUENCES: 26
: CORRESPONDENCE ADDRESS:
: ADDRESSEE: Merchant & Gould
: STREET: 3100 Norwest Center
: CITY: Minneapolis
: STATE: MN
: COUNTRY: USA
: ZIP: 55408
: COMPUTER READABLE FORM:
: MEDIUM TYPE: Floppy disk
: COMPUTER: IBM PC compatible
: OPERATING SYSTEM: PC-DOS/MS-DOS
: SOFTWARE: Patent Release #1.0, Version #1.30
: CURRENT APPLICATION DATA:
: APPLICATION NUMBER: US/08/520,485
: FILING DATE: 29-AUG-1995
: CLASSIFICATION: 435
: ATTORNEY/AGENT INFORMATION:
: NAME: Carter, Charles G.
: REGISTRATION NUMBER: 37,093
: REFERENCE/DOCKET NUMBER: 8648.32-US01
: TELECOMMUNICATION INFORMATION:
: TELEPHONE: 612-332-5300
: TELEFAX: 612-332-9081
: INFORMATION FOR SEQ ID NO: 1:
: SEQUENCE CHARACTERISTICS:
: LENGTH: 30 amino acids
: TYPE: amino acid
: PRTESIS: linear
: MOLECULE TYPE: Peptide
: IMMEDIATE SOURCE:
: CLONE: GLP1 7-36-NH2 (Glucagon-like Peptide)
US-08-520-485-1
Query Match 100.0%; Score 155; DB 9; Length 30;
Best Local Similarity 100.0%; Pred. No. 1.3e-15;
Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 HABGFTSDVSSYLEGQAAKEFIAMLYKGR 30
DB 1 HABGFTSDVSSYLEGQAAKEFIAMLYKGR 30
|||||
|||||
```

Search completed: October 15, 2003, 11:07:21
Job time : 286.738 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM protein - protein search, using sv model

Run on: October 15, 2003, 10:53:47 ; Search time 14.7541 Seconds
(without alignments)
67.284 Million cell updates/sec

Title: US-09-719-410-4

Perfect score: 155
Sequence: 1 HAEQTFSDVSSYLEQAAKEFIAMLVKGR 30

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 148013 seqs, 30631251 residues

Total number of hits satisfying chosen parameters: 148013

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 04
Maximum Match 1004
Listing first 45 summaries

Database : Pending_Patents_AA_Nev: *
1: /cysn2_6/prodata/1/paa/US06_NEW_COMB.pep: *
2: /cysn2_6/prodata/1/paa/US06_NEW_COMB.pep: *
3: /cysn2_6/prodata/1/paa/US07_NEW_COMB.pep: *
4: /cysn2_6/prodata/1/paa/US08_NEW_COMB.pep: *
5: /cysn2_6/prodata/1/paa/US09_NEW_COMB.pep: *
6: /cysn2_6/prodata/1/paa/US10_NEW_COMB.pep: *
7: /cysn2_6/prodata/1/paa/US60_NEW_COMB.pep: *

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

| Result No. | Score | Query Match | Length | DB ID | Description |
|------------|-------|-------------|--------|-------|--------------------|
| 1 | 155 | 100.0 | 30 | 1 | PCT-US03-26778-14 |
| 2 | 155 | 100.0 | 30 | 1 | PCT-US03-26818-48 |
| 3 | 155 | 100.0 | 30 | 1 | PCT-US03-28093-1 |
| 4 | 155 | 100.0 | 30 | 5 | US-09-341-590A-118 |
| 5 | 155 | 100.0 | 30 | 6 | US-10-231-226-114 |
| 6 | 155 | 100.0 | 30 | 6 | US-10-656-405-1 |
| 7 | 155 | 100.0 | 30 | 6 | US-10-671-340-1 |
| 8 | 155 | 100.0 | 31 | 1 | PCT-US03-15395B-16 |
| 9 | 155 | 100.0 | 31 | 1 | PCT-US03-26778-34 |
| 10 | 155 | 100.0 | 31 | 1 | PCT-US03-26818-6 |
| 11 | 155 | 100.0 | 31 | 1 | PCT-US03-26818-6 |
| 12 | 155 | 100.0 | 31 | 1 | PCT-US03-26818-64 |
| 13 | 155 | 100.0 | 31 | 1 | PCT-US03-28093-2 |
| 14 | 155 | 100.0 | 31 | 6 | US-10-231-226-124 |
| 15 | 155 | 100.0 | 31 | 6 | US-10-656-405-2 |
| 16 | 155 | 100.0 | 31 | 7 | US-60-485-404-34 |
| 17 | 155 | 100.0 | 32 | 1 | PCT-US03-28093-27 |
| 18 | 155 | 100.0 | 32 | 1 | PCT-US03-28093-30 |
| 19 | 155 | 100.0 | 32 | 6 | US-10-656-405-27 |
| 20 | 155 | 100.0 | 32 | 6 | US-10-656-405-30 |
| 21 | 155 | 100.0 | 32 | 6 | US-10-231-226-112 |
| 22 | 155 | 100.0 | 32 | 6 | US-10-231-226-112 |
| 23 | 151 | 97.4 | 30 | 6 | US-10-231-226-815 |
| 24 | 151 | 97.4 | 30 | 6 | US-10-231-226-113 |
| 25 | 151 | 97.4 | 30 | 6 | US-10-231-226-113 |
| 26 | 151 | 97.4 | 31 | 6 | US-10-231-226-111 |

Sequence 123, App
Sequence 217, Appl
Sequence 117, Appl
Sequence 28, Appl
Sequence 88, Appl
Sequence 90, Appl
Sequence 103, Appl
Sequence 116, Appl
Sequence 119, Appl
Sequence 122, Appl
Sequence 133, Appl
Sequence 97, Appl
Sequence 121, Appl
Sequence 118, Appl
Sequence 8, Appl
Sequence 7, Appl

ALIGNMENTS

RESULT 1
PCT-US03-26778-14
; Sequence 14, Application PC/TUS0326778
; GENERAL INFORMATION:
; APPLICANT: PRIOR, Christopher P.
; APPLICANT: SADEGHI, Homayoun
; APPLICANT: TURNER, Andrew J.
; TITLE OF INVENTION: ORAL DELIVERY OF MODIFIED TRANSFERRIN FUSION PROTEINS
; CURRENT APPLICATION NUMBER: PCT/US03/26778
; CURRENT FILING DATE: 2003-08-28
; PRIOR FILING DATE: 2002-08-30
; PRIOR FILING DATE: 2002-08-30
; PRIOR FILING DATE: 2003-03-04
; PRIOR FILING DATE: 2003-04-08
; NUMBER OF SEQ ID NOS: 54
; SOFTWARE: Patent version 3.2
; SEQ ID NO 14
; LENGTH: 30
; TYPE: PPT
; COMMENT: Artificial sequence
; EXPLAN: Artificial sequence
; OTHER INFORMATION: glucagon-like peptide-1
PCT-US03-26778-14
Query Match 100.0%; Score 155; DB 1; Length 30;
Best Local Similarity 100.0%; Pred. No. 1.5e-14;
Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 HAEQTFSDVSSYLEQAAKEFIAMLVKGR 30
DB 1 HAEQTFSDVSSYLEQAAKEFIAMLVKGR 30
RESULT 2
PCT-US03-26818-48
; Sequence 48, Application PC/TUS0326818
; GENERAL INFORMATION:
; APPLICANT: PRIOR, Christopher P.
; APPLICANT: LAI, Chai-Huei
; APPLICANT: SADEGHI, Homayoun
; APPLICANT: TURNER, Andrew J.
; TITLE OF INVENTION: ORAL DELIVERY OF MODIFIED TRANSFERRIN FUSION PROTEINS
; CURRENT APPLICATION NUMBER: PCT/US03/26818
; CURRENT FILING DATE: 2003-08-28
; PRIOR APPLICATION NUMBER: US 60/406,977

```

: FEATURE:
US-09-341-590A-118
Query Match 100.0%; Score 155; DB 5; Length 30;
Best Local Similarity 100.0%; Pred. No. 1.5e-14;
Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HAEGTTSDVSSYLEGQAKEEFIAWLKGR 30
DB 1 HAEGTFSIDVSSYLEGQAKEEFIAWLKGR 30

RESULT 5
US-10-291-226-114
: Sequence 114, Application US/10291226
: GENERAL INFORMATION:
: APPLICANT: Larsen, Bjarne Due
: APPLICANT: Mikkelsson, Jens Møllegaard
: TITLE OF INVENTION: A PEPTIDE AGONISTS OF GLP-1 ACTIVITY
: FILE REFERENCE: 5551145487
: CURRENT APPLICATION NUMBER: US/10/291.226
: PRIOR FILING DATE: 2002-11-08
: PRIOR APPLICATION NUMBER: US/09/614,847
: PRIOR FILING DATE: 12000-07-12
: PRIOR APPLICATION NUMBER: US 60/243,591
: PRIOR FILING DATE: 1999-07-13
: NUMBER OF SEQ ID NOS: 153
: SOFTWARE: PatentIn Ver. 2.1
: SEQ ID NO. 114
: LENGTH: 30
: TYPE: PPT
: ORGANISM: Homo sapiens
: FEATURE:
: OTHER INFORMATION: GLP-1(7-36)
US-10-291-226-114

Query Match 100.0%; Score 155; DB 6; Length 30;
Best Local Similarity 100.0%; Pred. No. 1.5e-14;
Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HAEGTTSDVSSYLEGQAKEEFIAWLKGR 30
DB 1 HAEGTFSIDVSSYLEGQAKEEFIAWLKGR 30

RESULT 6
US-10-656-405-1
: Sequence 1, Application US/10656405
: GENERAL INFORMATION:
: APPLICANT: Bayer Pharmaceuticals Corporation
: APPLICANT: Pan, Clark
: APPLICANT: Whelan, James
: TITLE OF INVENTION: Modified GLP-1 Receptor Agonists and Their Pharmacological
: TITLE OF INVENTION: Methods of Use
: FILE REFERENCE: MSB-7296
: CURRENT APPLICATION NUMBER: US/10/656,405
: PRIOR FILING DATE: 2002-09-16
: PRIOR APPLICATION NUMBER: US 60/409,596
: PRIOR FILING DATE: 2002-09-16
: PRIOR APPLICATION NUMBER: US 60/439,369
: PRIOR FILING DATE: 2003-01-09
: NUMBER OF SEQ ID NOS: 34
: SOFTWARE: PatentIn version 3.2
: SEQ ID NO 1
: LENGTH: 30
: TYPE: PPT
: ORGANISM: Homo sapiens
US-10-656-405-1

Query Match 100.0%; Score 155; DB 6; Length 30;
Best Local Similarity 100.0%; Pred. No. 1.3e-14;

```

Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HAEQTTSDVSSYLEGQAAKEFIAMLYKGR 30
 |||||
 Db 1 HAEQTTSDVSSYLEGQAAKEFIAMLYKGR 30

RESULT 7

US-10-671-340-1
 ; Sequence 16, Application US/0671340
 ; GENERAL INFORMATION:
 ; APPLICANT: GRAVEL, DENIS
 ; APPLICANT: PERI, KRISHNA
 ; APPLICANT: ABRIAT, THIERRY
 ; APPLICANT: HABI, ABDELKRIM
 ; TITLE OF INVENTION: MODIFIED GLP-1 PEPTIDES WITH INCREASED BIOLOGICAL
 ; TITLE OF INVENTION: POTENCY
 ; FILE REFERENCE: G00D-038US
 ; CURRENT APPLICATION NUMBER: US/10/671,340
 ; CURRENT FILING DATE: 2003-09-25
 ; PRIOR APPLICATION NUMBER: US/04/415,171
 ; PRIOR FILING DATE: 2003-09-25
 ; NUMBER OF SEQ ID NOS: 1
 ; SOFTWARE: Patent Ver. 2.1
 ; SEQ ID NO 1
 ; LENGTH: 30
 ; TYPE: PPT
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
 ; OTHER INFORMATION: Peptide
 US-10-671-340-1

Query Match 100.0%; Score 155; DB 6; Length 30;
 Best Local Similarity 100.0%; Pred. No. 1.5e-14;
 Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HAEQTTSDVSSYLEGQAAKEFIAMLYKGR 30
 |||||
 Db 1 HAEQTTSDVSSYLEGQAAKEFIAMLYKGR 30

RESULT 8

PCT-US03-15395B-16
 ; Sequence 16, Application PCT/US0315395B
 ; GENERAL INFORMATION:
 ; APPLICANT: ELI LILLY AND COMPANY
 ; TITLE OF INVENTION: MODIFIED GLUCAGON-LIKE PEPTIDE-1 ANALOGS
 ; FILE REFERENCE: X-15642
 ; CURRENT APPLICATION NUMBER: PCT/US03/15395B
 ; CURRENT FILING DATE: 2003-06-02
 ; NUMBER OF SEQ ID NOS: 24
 ; SOFTWARE: Patentin version 3.2
 ; SEQ ID NO 16
 ; LENGTH: 31
 ; TYPE: PPT
 ; ORGANISM: Artificial
 ; FEATURE:
 ; OTHER INFORMATION: Synthetic construct
 PCT-US03-15395B-16

Query Match 100.0%; Score 155; DB 1; Length 31;
 Best Local Similarity 100.0%; Pred. No. 1.6e-14;
 Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HAEQTTSDVSSYLEGQAAKEFIAMLYKGR 30
 |||||
 Db 1 HAEQTTSDVSSYLEGQAAKEFIAMLYKGR 30

RESULT 9

PCT-US03-26779-34
 ; Sequence 34, Application PCT/US0326779

; GENERAL INFORMATION:
 ; APPLICANT: PRIOR, CHRISTOPHER P.
 ; APPLICANT: TURNER, ANDREW J.
 ; APPLICANT: SADEGHI, HOMAYOUN
 ; TITLE OF INVENTION: TRANSFERRIN FUSION PROTEIN LIBRARIES
 ; FILE REFERENCE: 054710-5007-WO
 ; CURRENT APPLICATION NUMBER: PCT/US03/26779
 ; CURRENT FILING DATE: 2003-08-26
 ; PRIOR APPLICATION NUMBER: US 60/406,977
 ; PRIOR FILING DATE: 2003-08-26
 ; PRIOR APPLICATION NUMBER: US 10/384,060
 ; PRIOR FILING DATE: 2003-03-10
 ; PRIOR APPLICATION NUMBER: US 60/485,404
 ; PRIOR FILING DATE: 2003-07-09
 ; NUMBER OF SEQ ID NOS: 75
 ; SOFTWARE: Patentin Ver. 2.1
 ; SEQ ID NO 34
 ; LENGTH: 31
 ; TYPE: PPT
 ; ORGANISM: Homo sapiens
 ; FEATURE:
 ; NAME/KEY: MISC FEATURE
 ; LOCATION: (31)
 ; OTHER INFORMATION: Xaa = Gly or -NH2, amino acids 7-36/37 of GLP-1
 PCT-US03-26779-34

Query Match 100.0%; Score 155; DB 1; Length 31;
 Best Local Similarity 100.0%; Pred. No. 1.6e-14;
 Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HAEQTTSDVSSYLEGQAAKEFIAMLYKGR 30
 |||||
 Db 1 HAEQTTSDVSSYLEGQAAKEFIAMLYKGR 30

RESULT 10

PCT-US03-26778-6
 ; Sequence 6, Application PCT/US0326778
 ; GENERAL INFORMATION:
 ; APPLICANT: PRIOR, CHRISTOPHER P.
 ; APPLICANT: SADEGHI, HOMAYOUN
 ; APPLICANT: TURNER, ANDREW J.
 ; TITLE OF INVENTION: ORAL DELIVERY OF MODIFIED TRANSFERRIN FUSION PROTEINS
 ; FILE REFERENCE: 54710-5006-WO
 ; CURRENT APPLICATION NUMBER: PCT/US03/26778
 ; CURRENT FILING DATE: 2003-08-26
 ; PRIOR APPLICATION NUMBER: US 60/406,977
 ; PRIOR FILING DATE: 2002-08-30
 ; PRIOR APPLICATION NUMBER: US 10/378,094
 ; PRIOR FILING DATE: 2003-03-04
 ; PRIOR APPLICATION NUMBER: US 60/460,829
 ; PRIOR FILING DATE: 2003-04-08
 ; NUMBER OF SEQ ID NOS: 54
 ; SOFTWARE: Patentin version 3.2
 ; SEQ ID NO 6
 ; LENGTH: 31
 ; TYPE: PPT
 ; ORGANISM: Homo sapiens
 ; FEATURE:
 ; NAME/KEY: MISC FEATURE
 ; OTHER INFORMATION: Glucagon-Like Peptide
 ; NAME/KEY: misc.feature
 ; LOCATION: (31)..(31)
 ; OTHER INFORMATION: Xaa can be any naturally occurring amino acid
 PCT-US03-26778-6

Query Match 100.0%; Score 155; DB 1; Length 31;
 Best Local Similarity 100.0%; Pred. No. 1.6e-14;
 Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HAEQTTSDVSSYLEGQAAKEFIAMLYKGR 30
 |||||

3

```
Db      1  HAEGFTSDVSSYLEGQAARKEFIAMLVKGR 30
RESULT 15
US-10-656-405-2
; Sequence 2, Application US/10656405
; GENERAL INFORMATION:
; APPLICANT: Bayer Pharmaceuticals Corporation
; APPLICANT: Ben, Clark
; INVENTOR: Ben, Clark
; TITLE OF INVENTION: Modified GIP-1 Receptor Agonists and Their Pharmacological
; FILE REFERENCE: MSB-7295
; CURRENT APPLICATION NUMBER: US/10/656,405
; CURRENT FILING DATE: 2003-09-04
; PRIOR APPLICATION NUMBER: US 60/408,696
; PRIOR FILING DATE: 2002-09-16
; PRIOR APPLICATION NUMBER: US 60/439,369
; PRIOR FILING DATE: 2003-01-09
; NUMBER OF SEQ ID NOS: 34
; SOFTWARE: Patent version 3.2
; SEQ ID NO: 1
; LENGTH: 31
; TYPE: PPT
; ORGANISM: Homo sapiens
US-10-656-405-2
Query Match      100.0%; Score 155; DB 6; Length 31;
Best Local Similarity 100.0%; Pred. No. 1.6e-14;
Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY      1  HAEGFTSDVSSYLEGQAARKEFIAMLVKGR 30
Db      1  HAEGFTSDVSSYLEGQAARKEFIAMLVKGR 30
Search completed: October 15, 2003, 11:07:58
Job time : 14.7541 secs
```

| Result | Score | Query | DB | ID | Description |
|--------|-------|-------|-----|----|-------------|
| 1 | 155 | 100.0 | 158 | 1 | GPC |
| 2 | 155 | 100.0 | 180 | 1 | GPC |
| 3 | 155 | 100.0 | 180 | 1 | GGH |
| 4 | 155 | 100.0 | 180 | 1 | GGH |
| 5 | 155 | 100.0 | 180 | 1 | GGH |
| 6 | 155 | 100.0 | 180 | 1 | GGH |
| 7 | 155 | 100.0 | 180 | 1 | GGH |
| 8 | 155 | 100.0 | 180 | 2 | A57294 |
| 9 | 143 | 92.3 | 151 | 1 | GGH |
| 10 | 143 | 92.3 | 205 | 2 | I1301 |
| 11 | 142 | 91.2 | 30 | 2 | GGH |
| 12 | 126 | 81.3 | 30 | 2 | GGH |
| 13 | 126 | 81.3 | 30 | 2 | GGH |
| 14 | 120 | 77.4 | 172 | 1 | GGH |
| 15 | 118 | 75.1 | 66 | 2 | I1093 |
| 16 | 118 | 75.1 | 178 | 2 | I1058 |
| 17 | 117 | 75.5 | 63 | 1 | GGH |
| 18 | 116 | 74.8 | 72 | 1 | GGH |
| 19 | 113 | 72.9 | 60 | 1 | GGH |
| 20 | 113 | 72.9 | 178 | 2 | I1057 |
| 21 | 111 | 71.6 | 30 | 2 | GGH |
| 22 | 103 | 66.5 | 87 | 1 | GGH |
| 23 | 97 | 62.6 | 29 | 2 | S0721 |
| 24 | 96 | 61.9 | 31 | 2 | S4472 |
| 25 | 95 | 61.9 | 129 | 1 | GGH |
| 26 | 94 | 61.9 | 31 | 2 | GGH |
| 27 | 94 | 60.6 | 31 | 2 | S4471 |
| 28 | 93 | 60.0 | 29 | 1 | GGH |
| 29 | 93 | 58.1 | 29 | 1 | GGH |

F:126-150/Product: glucagon-like peptide 2 #status experimental <GL2>
F:107/Modified site: amidated carboxyl end (Arg) (amide in mature form from following gl
Query Match 100.0%; Score 155; DB 1; Length 158;
Best Local Similarity 100.0%; Pred. No. 5, Se-15;
Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1 HAEGTFTSDVSSYLEGQAAKEFIAWLKGR 30
DB 78 HAEGTFTSDVSSYLEGQAAKEFIAWLKGR 107
|||||
RESULT 2
GCHU
glucagon precursor [validated] - human
N:Contains: glicentin; glicentin-related polypeptide (GRPP); glucagon; glucagon-like pep
ke peptide 1 (GLP1)
C:Species: Homo sapiens (man)
C:Date: 24-Apr-1984 #sequence_revision 31-Mar-1993 #text_change 08-Dec-2000
A:Accession: A24377; A44197; A30875; A32614; A01541; S23309
R:White, J.W.; Saunders, G.F. 4730, 1986
A:Title: Structure of the human glucagon gene.
A:Reference number: A24377; MUID:86259053; PMID:3725587
A:Accession: A24377
A:Molecule type: DNA
A:Residues: 1-180 <SE>
A:Cross-references: GB:X03991
R:Bell, G.I.; Sanchez-Pescador, R.; Laybourn, P.J.; Najarian, R.C.
Nature 304, 368-371, 1983
A:Title: Exon duplication and divergence in the human preproglucagon gene.
A:Reference number: A44197; MUID:83271477; PMID:6677536
A:Molecule type: DNA
A:Residues: 1-179 <SE>
A:Cross-references: GB:V01515; MUID:931777; PIDN:CAA24759.1; PID:g31778
R:Drucker, D.J.; Asa, S.
J. Biol. Chem. 263, 13475-13478, 1988
A:Title: Glucagon gene expression in vertebrate brain.
A:Reference number: A30875; MUID:88330860; PMID:2901414
A:Accession: A30875
A:Molecule type: mRNA
A:Cross-references: GB:T04040; MUID:g183269; PIDN:AAAS2567.1; PID:g183270
R:Orskov, C.; Bersani, M.; Johnsen, A.H.; Hojrup, P.; Holst, J.J.
J. Biol. Chem. 264, 12826-12829, 1989
A:Title: Complete sequences of glucagon-like peptide-1 from human and pig small intestine
A:Reference number: A92732; MUID:89327238; PMID:2753890
A:Accession: A32614
A:Molecule type: protein
A:Residues: 98-127 <OR>
R:Thomsen, J.; Kristiansen, K.; Brunfeldt, K.; Sundby, F.
Regul. Pept. 21, 15-319, 1972
A:Title: The amino acid sequence of human glucagon.
A:Reference number: A91373
A:Accession: A01541
A:Molecule type: protein
A:Residues: 53-81 <THO>
R:Tsuigita, A.; Takamoto, K.; Kano, M.; Iwade, H.
Eur. J. Biochem. 206, 691-696, 1992
A:Title: C-terminal sequencing of protein. A novel partial acid hydrolysis and analysis
A:Reference number: S23309
A:Accession: S23309
A:Molecule type: protein
A:Residues: 53-81 <THO>
C:Comment: In pancreatic alpha-cells, proglucagon is processed to glicentin-related polypeptide 1, glucagon-like peptide 1, glucagon-like peptide 2, and glucagon.
C:Genetics:
A:Gene: GDB:803
A:Cross-references: GDB:119265; OMIM:138030
A:Map position: 2q36-2q37
A:introns: 31/2; 85/2; 131/2; 179/2

C:Superfamily: glucagon
C:Keywords: amidated carboxyl end; carbohydrate metabolism; duplication; hormone; in
mature form from following glucagon-like peptide 1 (GLP1)
F:126-150/Product: glucagon-like peptide 2 #status experimental <GL2>
F:107/Modified site: amidated carboxyl end (Arg) (amide in mature form from following
glucagon-like peptide 1 (GLP1))
Query Match 100.0%; Score 155; DB 1; Length 180;
Best Local Similarity 100.0%; Pred. No. 6, Se-15;
Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1 HAEGTFTSDVSSYLEGQAAKEFIAWLKGR 30
DB 98 HAEGTFTSDVSSYLEGQAAKEFIAWLKGR 127
|||||
RESULT 3
GCGP
glucagon precursor - guinea pig
N:Alternate names: oxyntomodulin
N:Contains: glicentin-related peptide; glucagon; glucagon-37 (oxyntomodulin); glucag
C:Species: Cavia porcellus (guinea pig)
C:Date: 30-Sep-1987 #sequence_revision 31-Dec-1992 #text_change 16-Jun-2000
A:Accession: A24856; A23849; A60323
R:Seino, S.; Welsh, M.P.; Bell, G.I.; Chan, S.J.; Steiner, D.F.
Regul. Pept. 205, 25-30, 1986
A:Title: The amino acid sequence of the guinea pig preproglucagon gene are restricted to a specific
A:Reference number: A24856; MUID:86248115; PMID:3755107
A:Accession: A24856
A:Molecule type: mRNA
A:Residues: 1-180 <SE>
A:Cross-references: DBJ:D00014; GB:R00014; MUID:g220286; PIDN:BA00010.1; PID:g22028
R:Huang, C.G.; Eng, J.; Pan, Y.C.E.; Haines, J.D.; Yalow, R.S.
Diabetes 35, 508-512, 1986
A:Title: Guinea pig glucagon differs from other mammalian glucagons.
A:Reference number: A23849; MUID:86165412; PMID:3956884
A:Accession: A23849
A:Molecule type: protein
A:Residues: 53-81 <THO>
R:Conlon, J.M.; Hansen, H.P.; Schwartz, T.W.
Regul. Pept. 11, 309-320, 1985
A:Title: Primary structure of glucagon and a partial sequence of oxyntomodulin (gluc
A:Reference number: A60323; MUID:86017849; PMID:4048553
A:Accession: A60323
A:Molecule type: protein
A:Residues: 53-81 <CON>
A:Note: glucagon-37 was not completely sequenced
C:Keywords: amidated carboxyl end; carbohydrate metabolism; duplication; hormone; pa
in mature form from following glucagon-like peptide 1 (GLP1)
F:126-150/Product: glucagon-like peptide 2 #status predicted <PG>
F:107/Modified site: amidated carboxyl end (Arg) (amide in mature form from following
glucagon-like peptide 1 (GLP1))
Query Match 100.0%; Score 155; DB 1; Length 180;
Best Local Similarity 100.0%; Pred. No. 6, Se-15;
Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1 HAEGTFTSDVSSYLEGQAAKEFIAWLKGR 30
DB 98 HAEGTFTSDVSSYLEGQAAKEFIAWLKGR 127
|||||

```

RESULT 4
GCBO
A:Contains: glucagon precursor - degu
C:Species: Octodon degus (degu)
C:Accession: C36118
B: Nishi, M.; Stalder, D.F.
Mol. Endocrinol. 4, 1192-1198, 1990
A:Title: Cloning of complementary DNAs encoding islet amyloid polypeptide, insulin, and
A:Reference number: A36118; MUID:91155952; PMID:2283024
A:Accession: C36118
A:Molecule type: mRNA
A:Residues: 1-180 <NIS>
A:Cross-references: GB:M57688; NID:9202467; FIDN:AAA0588.1; PID:9202468
C:Keywords: amidated carboxyl end; carbohydrate metabolism; duplication; hormone; pancre
P:1-20/Domain: signal sequence #status predicted <SIG>
F:21-180/Product: proglucagon #status predicted <PGC>
F:53-81/Region: glucagon-like peptide 1 #status predicted <GL1>
F:53-81/Product: glucagon-like peptide 1 #status predicted <GL1>
F:98-127/Product: glucagon-like peptide 2 #status predicted <GL2>
F:146-178/Product: glucagon-like peptide 2 #status predicted <GL2>
F:127/Modified site: amidated carboxyl end (Arg) (amide in mature form from following gl
Query Match 100.0%; Score 155; DB 1; Length 180;
Best Local Similarity 100.0%; Pred. No. 6.3e-15; Indels 0; Gaps 0;
Matches 30; Conservative 0; Mismatches 0;
QY 1 HAEGTFTSDVSSYLEGQAAKEFIAMLYKGR 30
DB 98 HAEGTFTSDVSSYLEGQAAKEFIAMLYKGR 127

RESULT 5
GCBO
A:Contains: glucagon precursor - rat
C:Species: Rattus norvegicus (Norway rat)
C:Date: 30-Sep-1987 #sequence_revision 30-Sep-1987 #text_change 26-Feb-1999
C:Accession: A22655; A25190; A41198
R: Heinrich, G.; Gros, P.; Habener, J.F.
J. Biol. Chem. 259, 14082-14087, 1984
A:Title: Glucagon gene structure and expression of six exons encode separate functional domains of
A:Reference number: A22655; MUID:85054853; PMID:6094539
A:Accession: A22655
A:Molecule type: DNA
A:Residues: 1-180 <HEI>
A:Cross-references: EMBL:K02809
A:Note: the authors translated the codon TTG for residue 10 as Glu and ACC for residue 5
R:Mojsos, S.; Heinrich, G.; Wilson, I.B.; Ravazola, M.; Orci, L.; Habener, J.F.
J. Biol. Chem. 261, 11880-11889, 1986
A:Title: Preproglucagon gene expression in pancreas and intestine diversifies at the lev
A:Reference number: A25190; MUID:850504324; PMID:3528148
A:Accession: A25190
A:Molecule type: mRNA
A:Residues: 1-180 <MOJ>
R: Heinrich, G.; Gros, P.; Lund, P.K.; Bentley, R.C.; Habener, J.F.
Endocrinology 115, 2175-2181, 1984
A:Title: Pre-proglucagon messenger ribonucleic acid: nucleotide and encoded amino acid s
A:Reference number: A41198; MUID:85051023; PMID:6548696
A:Accession: A41198
A:Status: preliminary
A:Molecule type: mRNA
A:Residues: 1-180 <HEI>
A:Cross-references: GB:K02810; GB:K02811; GB:K02812
C:Genetics: 31/2; 85/2; 131/2; 179/2
A:Introns: 31/2; 85/2; 131/2; 179/2
C:Superfamily: glucagon
C:Keywords: amidated carboxyl end; carbohydrate metabolism; duplication; hormone; pancre
F:1-20/Domain: signal sequence #status predicted <SIG>

```

```

F:21-180/Product: proglucagon #status predicted <PGC>
F:53-81/Region: glucagon-like peptide #status predicted <GL1>
F:53-81/Product: glucagon-like peptide 1 #status predicted <GL1>
F:98-127/Product: glucagon-like peptide 2 #status predicted <GL2>
F:146-178/Product: glucagon-like peptide 2 #status predicted <GL2>
F:127/Modified site: amidated carboxyl end (Arg) (amide in mature form from followin
Query Match 100.0%; Score 155; DB 1; Length 180;
Best Local Similarity 100.0%; Pred. No. 6.3e-15; Indels 0; Gaps 0;
Matches 30; Conservative 0; Mismatches 0;
QY 1 HAEGTFTSDVSSYLEGQAAKEFIAMLYKGR 30
DB 98 HAEGTFTSDVSSYLEGQAAKEFIAMLYKGR 127

RESULT 6
GCBO
A:Contains: glucagon precursor - golden hamster
N:Contains: glucagon-like peptide; glucagon; glucagon-like peptide 1; glucagon-1
C:Species: Mesocricetus auratus (golden hamster)
C:Date: 13-Jun-1983 #sequence_revision 13-Jun-1983 #text_change 20-Mar-1998
C:Accession: A01539
R: Bell, G.I.; Santer, R.F.; Mullenbach, G.T.
Proc. Natl. Acad. Sci. U.S.A. 80, 5485-5489, 1983
A:Title: Hamster proglucagon contains the sequence of glucagon and two related pe
A:Reference number: A01539; MUID:83167563; PMID:6835407
A:Accession: A01539
A:Molecule type: mRNA
A:Residues: 1-180 <BEL>
A:Cross-references: EMBL:J00059
C:Superfamily: glucagon
C:Keywords: amidated carboxyl end; carbohydrate metabolism; duplication; hormone; pe
F:1-20/Domain: signal sequence #status predicted <SIG>
F:21-180/Product: proglucagon #status predicted <PGC>
F:53-81/Region: glucagon-like peptide 1 #status predicted <GL1>
F:53-81/Product: glucagon-like peptide 1 #status predicted <GL1>
F:98-127/Product: glucagon-like peptide 2 #status predicted <GL2>
F:146-180/Product: glucagon-like peptide 2 #status predicted <GL2>
F:127/Modified site: amidated carboxyl end (Arg) (amide in mature form from followin
Query Match 100.0%; Score 155; DB 1; Length 180;
Best Local Similarity 100.0%; Pred. No. 6.3e-15; Indels 0; Gaps 0;
Matches 30; Conservative 0; Mismatches 0;
QY 1 HAEGTFTSDVSSYLEGQAAKEFIAMLYKGR 30
DB 98 HAEGTFTSDVSSYLEGQAAKEFIAMLYKGR 127

RESULT 7
GCBO
A:Contains: glucagon precursor - bovine
N:Contains: glucagon-related peptide; glucagon; glucagon-like peptide 1; glucagon-1
C:Species: Bos taurus (cattle)
C:Accession: A93970; A92081; A01538
R: Lopez, L.C.; Frazier, M.L.; Su, C.J.; Kumar, A.; Saunders, G.F.
Proc. Natl. Acad. Sci. U.S.A. 80, 5485-5489, 1983
A:Title: Mammalian pancreatic preproglucagon contains three glucagon-related peptide
A:Reference number: A93970; MUID:83299936; PMID:6577439
A:Accession: A93970
A:Molecule type: mRNA
A:Residues: 1-180 <LOP>
A:Cross-references: EMBL:K00107
R: Tom, W.W.; Tomoda, T.; Koffenberger Jr., J.B.
J. Biol. Chem. 246, 2822-2827, 1971
A:Title: Amino acid sequence of bovine glucagon.
A:Reference number: A92081; MUID:71166445; PMID:5102927
A:Accession: A92081
A:Molecule type: protein
A:Residues: 53-81 <BO>
C:Superfamily: glucagon

```



```

Query Match      83.3%; Score 129; DB 1; Length 101;
Best Local Similarity 76.7%; Pred. No. 2e-11;
Matches 23; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 1 HAEGTFTSDVSSYLEGQAAKEFIAWLKGR 30
Db 37 HAEGTFTSDVSSYLEGQAAKEFVWLKGR 66

RESULT 12
GCAF2
glucagon-like peptide - American eel
C:Species: Anguilla rostrata (American eel)
C:Date: 10-Mar-1994 #sequence_revision 10-Mar-1994 #text_change 21-Nov-1997
C:Accession: B61125
R:Conlon, J.M.; Andrews, P.C.; Thim, L.; Moon, T.W.
Gen. Comp. Endocrinol. 82, 23-32, 1991
A:Title: The primary structure of glucagon-like peptide but not insulin has been conserved in teleost fish
A:Reference number: A61125; MUID: 91340068; PMID: 1874385
A:Accession: B61125
A:Molecule type: protein
A:Residues: 1-30 <CON>
C:Superfamily: glucagon
C:Keywords: amidated carboxyl end; duplication
F:1-30/Product: glucagon-like peptide #status experimental <GLP>
F:30/Modified site: amidated carboxyl end (Arg) #status predicted

Query Match      81.3%; Score 126; DB 2; Length 30;
Best Local Similarity 76.7%; Pred. No. 1.4e-11;
Matches 23; Conservative 4; Mismatches 3; Indels 0; Gaps 0;

QY 1 HAEGTFTSDVSSYLEGQAAKEFIAWLKGR 30
Db 1 HAEGTFTSDVSSYLEGQAAKEFVWLKGR 30

RESULT 13
C61125
glucagon-like peptide - European eel
C:Species: Anguilla anguilla (European eel)
C:Date: 10-Mar-1994 #sequence_revision 10-Mar-1994 #text_change 21-Nov-1997
C:Accession: C61125
R:Conlon, J.M.; Andrews, P.C.; Thim, L.; Moon, T.W.
Gen. Comp. Endocrinol. 82, 33-37, 1991
A:Title: The primary structure of glucagon-like peptide but not insulin has been conserved in teleost fish
A:Reference number: A61125; MUID: 91340068; PMID: 1874385
A:Accession: C61125
A:Molecule type: protein
A:Residues: 1-30 <CON>
C:Superfamily: glucagon
C:Keywords: amidated carboxyl end; duplication
F:1-30/Product: glucagon-like peptide #status experimental <GLP>
F:30/Modified site: amidated carboxyl end (Arg) #status experimental

Query Match      81.3%; Score 126; DB 2; Length 30;
Best Local Similarity 76.7%; Pred. No. 1.4e-11;
Matches 23; Conservative 4; Mismatches 3; Indels 0; Gaps 0;

QY 1 HAEGTFTSDVSSYLEGQAAKEFIAWLKGR 30
Db 1 HAEGTFTSDVSSYLEGQAAKEFVWLKGR 30

RESULT 14
GCAF2
glucagon 2 precursor - American goosfish
A:Contains: glucagon-like peptide 1
A:Title: The primary structure of glucagon-like peptide but not insulin has been conserved in teleost fish
C:Date: 31-Mar-1993 #sequence_revision 31-Mar-1993 #text_change 21-Jul-2000
C:Accession: A05150
R:Lund, P.K.; Goodman, R.H.; Montminy, M.R.; Dee, P.C.; Habener, J.F.
J. Biol. Chem. 258, 3280-3284, 1983
A:Title: Anglerfish islet pre-proglucagon II. Nucleotide and corresponding amino acid se

```

```

A:Reference number: A05150; MUID: 83135785; PMID: 6338015
A:Accession: A05150
A:Molecule type: mRNA
A:Residues: 1-122 <UN>
C:Cross-references: GB:J00933; NID:964021; PID:CAA23905.1; PID:964022
C:Superfamily: glucagon
C:Keywords: carbohydrate metabolism; duplication; hormone; pancreas
F:1-21/Domain: signal sequence #status predicted <SIG>
F:22-122/Product: proglucagon 2 #status predicted <PGC2>
F:82-80/Product: glucagon #status predicted <GCN>
F:89-119/Product: glucagon-like peptide 1 #status predicted <GL1>

Query Match      77.4%; Score 120; DB 1; Length 122;
Best Local Similarity 70.0%; Pred. No. 4.8e-10;
Matches 21; Conservative 6; Mismatches 3; Indels 0; Gaps 0;

QY 1 HAEGTFTSDVSSYLEGQAAKEFIAWLKGR 30
Db 89 HAEGTFTSDVSSYLEGQAAKEFVWLKGR 118

RESULT 15
T1002
glucagon - chinook salmon (fragment)
C:Species: Oncorhynchus tshawytscha (chinook salmon)
C:Date: 13-Sep-1996 #sequence_revision 13-Sep-1996 #text_change 16-Jul-1999
C:Accession: I51093
R:Irwin, D.M.; Wong, J.
Mol. Endocrinol. 9, 267-277, 1995
A:Title: Trout and chicken proglucagon: alternative splicing generates mRNA transcripts
A:Reference number: A55895; MUID: 95295739; PMID: 7776976
A:Accession: I51093
A:Status: preliminary; translated from GB/EMBL/DBJ
A:Molecule type: mRNA
A:Residues: 1-122 <CON>
C:Cross-references: PDB:1U19920; NID:9736366; PID:AA059670.1; PID:9736367
C:Superfamily: glucagon
C:Keywords: duplication

Query Match      76.1%; Score 118; DB 2; Length 66;
Best Local Similarity 66.7%; Pred. No. 4.9e-10;
Matches 20; Conservative 7; Mismatches 3; Indels 0; Gaps 0;

QY 1 HAEGTFTSDVSSYLEGQAAKEFIAWLKGR 30
Db 33 HAEGTFTSDVSSYLEGQAAKEFVWLKGR 62

Search completed: October 15, 2003, 10:56:43
Job time : 24.5902 secs

```


[2] SEQUENCE FROM N.A.
MEDLINE=86259053; Pubmed=3725587;
RA White J.W., Saunders G.F.;
RA "Structure of the human glucagon gene";
RE Nucleic Acids Res. 14:4719-4730(1986).
[3]
SEQUENCE FROM N.A.
TTSURU-Iwiter;
RA MEDLINE=83271477; Pubmed=6877359;
RA "Structure of the human glucagon gene";
RA "Exon-intron organization and divergence in the human preproglucagon gene.";
RE Nature 304:368-371(1983).
[4]
SEQUENCE FROM N.A.
TSSURU-Fanctres;
RA MEDLINE=22388257; Pubmed=12477932;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Huettenhofer A.P., Buell K.R., Strydom C.F., Bhat N.K.,
RA Hopkins T.J., Jordan M., Venter A., Zeng X., White O., Holt R.,
RA Diatchenko L., Narasimha K., Parmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carncini P., Prange C.,
RA Roha S.A., McQuellan P.J., McKernan K.J., Alamek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., HuLYK S.W.,
RA Villalón D.K., Morley D.K., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahey J.J., Helton E., Kettmann K., Madan A., Rodriguez S., Sanchez A.,
RA Blattberg W., Nelson C.R., Young A.C., Shurchant A., Bouffard G.E.,
RA Rodriguez A.C., Grimwood J., Schwartz J., Myers B.N., M.C.,
RA Butterfield Y.S.N., Krzyzanski J.I., Skalska U., Smalls D.E.,
RA Scherch A., Schein J.F., Jones S.J.M., Marra M.A.;
RA "Generation and initial analysis of more than 15,000 full-length
human and mouse cDNA sequences".
Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903 (2002).
[5]
SEQUENCE OF 53-81.
RA Tsuru J., Kristiansen K., Brunfeldt K., Sundby F.;
RA "The amino acid sequence of human glucagon.";
RL FEBS Lett. 21:315-315(1972).
[6]
SEQUENCE OF 98-127.
RA MEDLINE=89327238; Pubmed=2753890;
RA Crskov C., Bersani M., Johnsen A.H., Hoejrup P., Rolst J.J.;
RA "Complete sequences of glucagon-like peptide-1 from human and pig
small intestine,";
RL Biol. Chem. 264:12826-12829 (1989).
[7]
X-RAY CRYSTALLOGRAPHY (3.0 ANGSTROMS) OF 53-81.
RA MEDLINE=98134683; Pubmed=9667960;
RA Sturm N.S., Liu Y., Hurley S.K., Krstenansky J.L., Ahn J.M.,
RA Aizhen B.Y., Trivedi D., Hubay V.J.;
RA "Structure-function studies on positions 17, 18, and 21 replacement
analogues of glucagon: the importance of charged residues and salt
bridges in glucagon biological activity".
J. Med. Chem. 41:2693-2700 (1998).
[8]- FUNCTION: GLUCAGON PROMOTES HYDROLYSIS OF GLYCERIN AND LIPIDS, AND
-I- FUNCTION: GLP2 STIMULATES INTESTINAL GROWTH AND UPREGULATES VILLUS
HEIGHT IN THE SMALL INTESTINE. CONCOMITANT WITH INCREASED CRPT
CELL PROLIFERATION AND DECREASED ENTEROCYTE APOPTOSIS
-II- INDUCTION: PRODUCED IN THE CELLS OF THE ISLETS OF LANGERHANS
IN RESPONSE TO A DROP IN BLOOD SUGAR CONCENTRATION.
-III- PHARMACEUTICAL: Available under the names Glucagon (Zili Lilly) and
Glucagen or glucagon Novo Nordisk (Novo Nordisk). Used to treat
severe hypoglycemia in insulin-dependent diabetics.
-IV- SIMILARITY: BELONGS TO THE GLUCAGON FAMILY.
NOTES: NAME-Glucagon at Zili Lilly/
[www-zili-lilly-com/products/patinfo.htm](http://www.zili-lilly.com/products/patinfo.htm)


```

RN SEQUENCE FROM N.A.
RA Shamsadin R., Knebel W.;
RT "mouse glucagon full length cDNA.";
RL Submitted (JUN-2000) to the EMBL/GenBank/DBJ databases.
CC -1- FUNCTION: GLUCAGON PROMOTES HYDROLYSIS OF GLYCOCEN AND LIPIDS, AND
CC RAISES THE BLOOD SUGAR LEVEL.
CC -1- FUNCTION: GLP2 STIMULATES INTESTINAL GROWTH AND UPREGULATES VILUS
CC CELL PROLIFERATION AND DECREASED ENTEROCYTE APOPTOSIS.
CC -1- INDUCTION: PRODUCED IN THE A CELLS OF THE ISLETS OF LANGERHANS
CC IN RESPONSE TO A DROP IN BLOOD SUGAR CONCENTRATION.
CC -1- SIMILARITY: BELONGS TO THE GLUCAGON FAMILY.
CC
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@sib-sib.ch).
CC
CC EMBL; 246845; CAA86902.1; -.
CC DR EMBL; A2276754; AAK9698.1; -.
CC DR PIR; A57294; A57294.
CC DR HSSP; P01274; IGCN.
CC DR MGI; MGI:95674; Gcg.
CC DR InterPro; IPR000532; Glucagon.
CC DR PRINTS; PR00275; Glucagon.
CC DR PROSITE; PS00260; Glucagon.
CC DR SMART; SM00070; Glucagon.
CC FT SIGNAL; 21 50 GLICENTIN-RELATED POLYPEPTIDE.
CC FT PEPTIDE; 53 81 GLUCAGON.
CC FT PROPEP; 84 89
CC FT PROPEP; 131 142
CC FT PEPTIDE; 146 178 GLUCAGON-LIKE PEPTIDE 1.
CC FT PROPEP; 92 128
CC FT PROPEP; 131 143
CC FT PEPTIDE; 146 178 GLUCAGON-LIKE PEPTIDE 2.
CC FT PROPEP; 146 178
CC SQ SEQUENCE 180 AA; 20906 MW; 595A6D09A58950 CRC64;
CC
CC Query Match 100.0%; Score 155; DB 1; Length 180;
CC Best Local Similarity 100.0%; Pred. No. 6.3e-15;
CC Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
CC
CC QY 1 HASTFTSDVSYSYLEGOAAKEFIAMLYVGR 30
CC |||||||||||||||||||||||||||||||||||
CC DB 98 HASTFTSDVSYSYLEGOAAKEFIAMLYVGR 127
CC
CC RESULT 7
CC ID GLUC_OCTDE STANDARD; PRT; 180 AA.
CC AC P22890; 1991 (Rel. 19, Created)
CC DT 01-AUG-1991 (Rel. 19, Last sequence update)
CC DT 26-FEB-2003 (Rel. 41, Last annotation update)
CC DE Glucagon precursor [Contains: Glucatin-related polypeptide (GRP);
CC DE Glucagon; Glucagon-like peptide 1 (GLP1); Glucagon-like peptide 2
CC DE (GLP2)].
CC GN GCG.
CC OS Octodon degus (Degu).
CC OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
CC OC Mammalia; Eutheria; Rodentia; Hystricognathi; Octodontidae; Octodon.
CC OX NCBI_TaxID=10160;
CC RA SEQUENCE FROM N.A.
CC RX MEDLINE=91155952; PubMed=2293034;
CC RA Nishi M., Steiner D.P.;
CC RT "Cloning of complementary DNAs encoding islet amyloid polypeptide,
CC RT insulin, and glucagon precursors from a New World rodent, the degu,
CC RT Octodon degus.";
```

```

Nol. Endocrinol. 4:1192-1198(1990).
CC -1- FUNCTION: GLUCAGON PROMOTES HYDROLYSIS OF GLYCOCEN AND LIPIDS, AND
CC RAISES THE BLOOD SUGAR LEVEL.
CC -1- FUNCTION: GLP2 STIMULATES INTESTINAL GROWTH AND UPREGULATES VILUS
CC HEIGHT IN THE SMALL INTESTINE, CONCOMITANT WITH INCREASED CRYPT
CC CELL PROLIFERATION AND DECREASED ENTEROCYTE APOPTOSIS.
CC -1- INDUCTION: PRODUCED IN THE A CELLS OF THE ISLETS OF LANGERHANS
CC IN RESPONSE TO A DROP IN BLOOD SUGAR CONCENTRATION.
CC -1- SIMILARITY: BELONGS TO THE GLUCAGON FAMILY.
CC
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@sib-sib.ch).
CC
CC EMBL; M57688; AAA0588.1; -.
CC DR PIR; C36118; GCR000.
CC DR HSSP; P01274; IGCN.
CC DR EMBL; A2276754; AAK9698.1; -.
CC DR PIR; A57294; A57294.
CC DR HSSP; P01274; IGCN.
CC DR PRINTS; PR00275; Glucagon.
CC DR SMART; SM00070; Glucagon.
CC DR PROSITE; PS00260; Glucagon.
CC DR InterPro; IPR000532; Glucagon.
CC DR PRINTS; PR00275; Glucagon.
CC DR PROSITE; PS00260; Glucagon.
CC DR SMART; SM00070; Glucagon.
CC FT SIGNAL; 1 20 GLICENTIN-RELATED POLYPEPTIDE.
CC FT PEPTIDE; 21 50 GLUCAGON.
CC FT PROPEP; 53 81
CC FT PROPEP; 84 89
CC FT PROPEP; 131 142
CC FT PEPTIDE; 146 178 GLUCAGON-LIKE PEPTIDE 1.
CC FT MOD_RES; 127 127
CC FT MOD_RES; 127 127
CC SQ SEQUENCE 180 AA; 21165 MW; 658836160A9A3051 CRC64;
CC
CC Query Match 100.0%; Score 155; DB 1; Length 180;
CC Best Local Similarity 100.0%; Pred. No. 6.3e-15;
CC Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
CC
CC QY 1 HASTFTSDVSYSYLEGOAAKEFIAMLYVGR 30
CC |||||||||||||||||||||||||||||||||||
CC DB 98 HASTFTSDVSYSYLEGOAAKEFIAMLYVGR 127
CC
CC RESULT 8
CC ID GLUC_RAT STANDARD; PRT; 180 AA.
CC AC P05883;
CC DT 01-JAN-1988 (Rel. 06, Created)
CC DT 01-JAN-1988 (Rel. 06, Last sequence update)
CC DT 28-FEB-2003 (Rel. 41, Last annotation update)
CC DE Glucagon precursor [Contains: Glucatin-related polypeptide (GRP);
CC DE Glucagon; Glucagon-like peptide 1 (GLP1); Glucagon-like peptide 2
CC DE (GLP2)].
CC GN GCG.
CC OS Rattus norvegicus (Rat).
CC OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
CC OC Mammalia; Eutheria; Rodentia; Muridae; Murinae; Rattus.
CC OX NCBI_TaxID=10116;
CC RA SEQUENCE FROM N.A.
CC RX MEDLINE=85054853; PubMed=6094539;
CC RA Heinrich G., Gros P., Habener J.F.;
CC RT "Glucagon gene sequence. Four of six exons encode separate functional
CC RT domains of rat eye pigmentation."
CC RA J. Biol. Chem. 259:14082-14087(1984).
CC RN [1]
CC RP SEQUENCE FROM N.A.
CC RX MEDLINE=85051023; PubMed=6548696;
CC RA Heinrich G., Gros P., Lund P.K., Bentley R.C., Habener J.F.;
```

```

FT      "Pre-proglucagon messenger ribonucleic acid: nucleotide and encoded
RT      amino acid sequences of the rat pancreatic complementary
RL      deoxyribonucleic acid.",
RL      Endocrinology 115:2176-2181(1984).
RN      [3]
RX      MEDLINE=86304324; PubMed=3528148;
RX      MoJsov S., Heinrich G., Wilson I.B., Ravazzola M., Orci L.,
RX      Habener J.F.;
RX      Preproglucagon gene expression in pancreas and intestine diversifies
RT      at the C-terminus of the precursor during processing.;
RL      J Biol Chem 263:11860-11863(1986).
CC      -1- FUNCTION: GLUCAGON PROMOTES HYDROLYSIS OF GLYCOGEN AND LIPIDS, AND
CC      RAISES THE BLOOD SUGAR LEVEL.
CC      -1- FUNCTION: GLP2 STIMULATES INTESTINAL GROWTH AND UPREGULATES VILLUS
CC      CELL PROLIFERATION AND DECREASED ENTEROCYTE APOPTOSIS.
CC      -1- INDUCTION: PRODUCED IN THE A CELLS OF THE ISLETS OF LANGERHANS
CC      IN RESPONSE TO A DROP IN BLOOD SUGAR CONCENTRATION.
CC      -1- SIMILARITY: BELONGS TO THE GLUCAGON FAMILY.
CC      -----
CC      This SWISS-PROT entry is copyright. It is produced through a collaboration
CC      between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC      the European Bioinformatics Institute. There are no restrictions on its
CC      use by non-profit institutions as long as its content is in no way
CC      modified and this statement is not removed. Usage by and for commercial
CC      entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC      or send an email to license@isb-sib.ch).
CC      -----
CC      EMBL; K02813; AA041235.1; -.
CC      EMBL; K02809; AA041235.1; JOINED.
CC      EMBL; K02811; AA041235.1; JOINED.
CC      EMBL; K02812; AA041235.1; JOINED.
CC      PIR; A22659; GCRF.
CC      DR      HSSP; P01274; IGCN.
CC      DR      InterPro; IPR000532; Glucagon.
CC      DR      Pfam; PF00123; hormone2; 3.
CC      DR      PRINTS; PR00275; GLUCAGON.
CC      DR      SMART; SM00070; GLUCA. 3.
CC      DR      PROSITE; PS00260; Hormone; Cleavage on pair of basic residues; Signal.
KW      Glucagon family; Hormone; Cleavage on pair of basic residues; Signal.
FT      SIGNAL 1 20
FT      PROPEP 21 40 GLUCENTIN-RELATED POLYPEPTIDE.
FT      PROPEP 53 80 GLUCAGON.
FT      PROPEP 84 89
FT      PROPEP 92 128 GLUCAGON-LIKE PEPTIDE 1.
FT      PROPEP 131 143 GLUCAGON-LIKE PEPTIDE 2.
FT      PROPEP 146 178 GLUCAGON-LIKE PEPTIDE 2.
SQ      SEQUENCE 180 AA; 20846 MW; 76931409D03C7978 CRC64;
Query Match 100.0%; Score 155; DB 1; Length 180;
Best Local Similarity 100.0%; Pred. No. 6.3e-15;
Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY      1 HAEGETFDSVSVLSQAEKFTANLVKGR 30
DB      98 HAEGETFDSVSVLSQAEKFTANLVKGR 127
RESULT 9
GLUC_CHICK
AC      P01277; G91410; STANDARD; PRT; 205 AA.
DT      21-JUL-1986 (Rel. 01, Created)
DT      23-FEB-2003 (Rel. 41, Last sequence update)
DT      23-FEB-2003 (Rel. 41, Last annotation update)
DE      Glucagon Phegson. A peptide hormone secreted by the endocrine
DE      cells of the pancreas. It is a glucagon-like peptide 1 (GLP1)
DE      (GLP2).
OS      Gallus gallus (Chicken), and
OS      Meleagris gallopavo (Common turkey).
CC      Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

```

```

CC      Archosauria; Aves; Neognathae; Galliformes; Phasianidae; Phasianinae;
CC      Gallus.
RN      NCBI_TaxID=9031, 9103;
RP      SEQUENCE FROM N.A. (ISOFORM PANCREATIC).
RX      SPECIES=Chicken; TISSUE=Pancreas;
RX      MEDLINE=90249492; PubMed=2338135;
RX      Hasegawa S., Terazono K., Nata K., Takada T., Yamamoto H.,
RX      Okamoto H.;
RX      Nucleotide sequence determination of chicken glucagon precursor
RT      cDNA. Chicken proglucagon does not contain glucagon-like peptide
RT      2. FEBS Lett. 264:117-120(1990).
EL      [2]
RP      SEQUENCE FROM N.A. (ISOFORM INTESTINAL).
RX      SPECIES=Chicken; TISSUE=Intestinal mucosa;
RX      MEDLINE=95295739; PubMed=7776976;
RX      Irwin D.M., Wong J.;
RX      Trout and chicken proglucagon: alternative splicing generates mRNA
RT      transcripts encoding glucagon-like peptide 2.;
RT      J. Endocrinol. 9:267-277(1995).
RP      SEQUENCE OF 55-83.
RX      SPECIES=Chicken;
RX      MEDLINE=76069271; PubMed=1194290;
RX      Pollock H.G., Kimmel J.R.;
RX      "Chicken glucagon. Isolation and amino acid sequence studies. ";
RT      J. Biol. Chem. 250:9377-9380(1975).
RN      [4]
CC      COMPOSITION, AND SEQUENCE OF 55-83.
CC      SPECIES=M.galllopavo;
CC      MEDLINE=73074118; PubMed=4645932;
CC      "Frandsen L., Frandsen L.; Reding L.G., Suedby F.;
CC      "Frandsen L., Frandsen L.; Reding L.G., Suedby F.;
CC      immunology.";
CC      Event-Alternative splicing; Named isoforms=2;
CC      IsoId=P01277-1; Sequence-Displayed;
CC      Name=Pancreatic;
CC      IsoId=P01277-2; Sequence=VSP_001753, VSP_001754;
CC      Name=Intestinal;
CC      INDUCTION: PRODUCED IN THE A CELLS OF THE ISLETS OF LANGERHANS IN
CC      RESPONSE TO A DROP IN BLOOD SUGAR CONCENTRATION.
CC      -1- MISCELLANEOUS: THE COMPOSITION OF TURKEY GLUCAGON APPEARS TO BE
CC      IDENTICAL WITH CHICKEN.
CC      -1- SIMILARITY: BELONGS TO THE GLUCAGON FAMILY.
CC      -----
CC      This SWISS-PROT entry is copyright. It is produced through a collaboration
CC      between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC      the European Bioinformatics Institute. There are no restrictions on its
CC      use by non-profit institutions as long as its content is in no way
CC      modified and this statement is not removed. Usage by and for commercial
CC      entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC      or send an email to license@isb-sib.ch).
CC      -----
CC      EMBL; Y07539; CAA68327.1; -.
CC      DR      EMBL; S78477; BAB34506.1; -.
CC      DR      PIR; I51301; I51301.
CC      DR      HSSP; P01274; IGCN.
CC      InterPro; IPR000532; Glucagon.
CC      Pfam; PF00123; hormone2; 3.
CC      PRINTS; PR00275; GLUCAGON.
CC      SMART; SM00070; GLUCA. 3.
CC      PROSITE; PS00260; Hormone; Cleavage on pair of basic residues; Signal;
KW      Amidation; Alternative splicing.
FT      SIGNAL 1 22
FT      PEPTIDE 23 52 GLUCENTIN-RELATED POLYPEPTIDE.

```

```

FT PROPEP 55 83 GLUCAGON.
FT PROPEP 86 116
FT PEPTIDE 118 147 GLUCAGON-LIKE PEPTIDE 1.
FT PROPEP 151 163
FT PEPTIDE 166 198 GLUCAGON-LIKE PEPTIDE 2.
FT PROPEP 199 206
FT MOD_RES 147 147 AMIDATION (G-148 PROVIDE AMIDE GROUP).
FT VARSPLIC 151 151 D -> E (in isoform Pancreatic).
FT VARSPLIC 152 206 /FTID-VSP_001753.
FT SEQUENCE 206 AA; 23875 MW; A3299ELB02FCG44 CRC64;
Query Match 92.3%; Score 143; DB 1; Length 206;
Best Local Similarity 86.7%; Pred. No. 3, 7e-13;
Matches 26; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 1 HAEFTTSDVSSYLEGQAQKEFIAMVNGR 30
DB 118 HAEFTTSDVSSYLEGQAQKEFIAMVNGR 147

RESULT 10
GLUC_HLSV
ID GLUC_HLSV STANDARD; PRI: 204 AA.
AC O12956; O12955;
DT 28-FEB-2003 (Rel. 41, Created)
DT 28-FEB-2003 (Rel. 41, Last sequence update)
DE Glucagon precursor [Contains: Glucocin-related polypeptide (GRP);
DE Glucagon; Glucagon-like peptide 1 (GLP-1); Glucagon-like peptide 2
DE (GLP-2)].
OS Helodermatops, subgenus (Gila monster).
OC Lepidosauroidea, Chordata; Craniata; Vertebrata; Euteleostomi;
OC Helodermatidae; Squamata; Scleroglossa; Anguilliformes; Helodermatidae;
OC Helodermatidae.
OX NCBI_TaxID=8554;
RN [1]
RP SEQUENCE FROM N.A. (ISOFORMS LPI AND LPII), AND TISSUE SPECIFICITY.
RC TISSUE=Intestine, and Pancreas;
RA MEDLINE=97172477; PubMed=920121;
RT "When I.B., Drucker D.J.: Isolation of unique mRNAs that encode proglucagon-
RT derived peptides or GLP-1 in the lizard."
RL J. Biol. Chem. 272:4108-4115 (1997).
CC -1- FUNCTION: Promotes hydrolysis of glycogen and lipids, and raises
CC the blood sugar level.
CC -1- ALTERNATIVE PRODUCTS:
CC Event-Alternative splicing: Named isoforms=2;
CC Name=LPII;
CC ISOID=O12956-1; Sequence=Displayed;
CC Name=LPI;
CC ISOID=O12956-2; Sequence=VSP_001756, VSP_001757;
CC -1- TISSUE SPECIFICITY: Isoform LPII is expressed in both pancreas and
CC intestine. Expression of isoform LPII is restricted to the
CC pancreas. Expression of isoform LPI is restricted to the
CC pancreas, and intestine.
CC -1- INDUCTION: Produced in the cells of the islets of Langerhans in
CC response to a drop in blood sugar concentration.
CC -1- SIMILARITY: BELONGS TO THE GLUCAGON FAMILY.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL Outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC -----
CC EMBL: U77612; AAB51129.1; -.
CC EMBL: U77611; AAB51128.1; -.
CC HSP: P01274; IGCN.
CC InterPro: IPR000532; Glucagon.
CC Pfam: PF00123; hormone2; 3.

```

```

DR PRINTS; PR00275; GLUCAGON.
DR SMART; SM00070; GLUCA; 3.
DR PROSITE; PS00260; GLUCAGON; 2.
KW Glucagon family; Hormone; Cleavage on pair of basic residues; Signal;
KW Amidation; Alternative splicing.
FT SIGNAL 1 20 BY SIMILARITY.
FT PEPTIDE 21 50 GLUCININ-RELATED POLYPEPTIDE.
FT PEPTIDE 53 81 GLUCAGON.
FT PROPEP 84 114 GLUCAGON-LIKE PEPTIDE 1.
FT PEPTIDE 116 145
FT PROPEP 149 161
FT PEPTIDE 164 198
FT PROPEP 197 206
FT MOD_RES 145 145 AMIDATION (G-146 PROVIDE AMIDE GROUP).
FT VARSPLIC 149 149 D -> E (in isoform LPI).
FT VARSPLIC 150 204 /FTID-VSP_001756.
FT SEQUENCE 204 AA; 23553 MW; B132EF346873E72 CRC64;
Query Match 88.4%; Score 137; DB 1; Length 204;
Best Local Similarity 83.3%; Pred. No. 2, 6e-12;
Matches 25; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 1 HAEFTTSDVSSYLEGQAQKEFIAMVNGR 30
DB 116 HAEFTTSDVSSYLEGQAQKEFIAMVNGR 145

RESULT 11
GLUC_RANCA STANDARD; PRI: 103 AA.
ID GLUC_RANCA
AC O15356; P15439; P15440;
DT 01-JUL-1993 (Rel. 24, Created)
DT 01-JUL-1993 (Rel. 24, Last sequence update)
DT 01-JUL-1993 (Rel. 26, Last annotation update)
DE Glucagon precursor (Fragments).
OS Rana catesbeiana (Bull frog).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Amphibia; Batrachia; Anura; Neobatrachia; Ranioidea; Rana.
OX NCBI_TaxID=8400;
RN [1]
RP SEQUENCE.
RC TISSUE=Pancreas; PubMed=3260236;
RA Pollock H 1997; J. Biol. Chem. 272:10485-10490.
RT "Isolation of peptide hormones from the pancreas of the bullfrog,
RT (Rana catesbeiana). Amino acid sequences of pancreatic polypeptide,
RT oxyntomodulin, and two glucagon-like peptides."
RL J. Biol. Chem. 263:9746-9751 (1988).
CC -1- FUNCTION: PROMOTES HYDROLYSIS OF GLYCOGEN AND LIPIDS, AND RAISES
CC THE BLOOD SUGAR LEVEL.
CC -1- INDUCTION: PRODUCED IN THE A CELLS OF THE ISLETS OF LANGERHANS
CC IN RESPONSE TO A DROP IN BLOOD SUGAR CONCENTRATION.
CC -1- MISCELLANEOUS: X'S IN THE SEQUENCE WERE INCLUDED BY HOMOMOLOGY WITH
CC OTHER SPECIES SEQUENCES.
CC -1- OTHER SPECIES SEQUENCES:
CC HSP: P01274; IGCN; BELONGS TO THE GLUCAGON FAMILY.
CC InterPro: IPR000532; Glucagon.
DR PRINTS; PR00275; GLUCAGON.
DR SMART; SM00070; GLUCA; 3.
DR PROSITE; PS00260; GLUCAGON; 3.
KW Glucagon family; Hormone.
FT PEPTIDE 1 29 GLUCAGON.
FT PEPTIDE 30 70 GLUCAGON-LIKE PEPTIDE 1.
FT PEPTIDE 71 103 GLUCAGON-LIKE PEPTIDE 2.
FT SEQUENCE 103 AA; 11719 MW; 316287B7BAC1C8F7 CRC64;
Query Match 81.2%; Score 129; DB 1; Length 103;
Best Local Similarity 76.7%; Pred. No. 1, 8e-11;
Matches 23; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

```

```

QY 1 HAEGETFTSDVSSYLEGQAAKEFIAMVKGK 30
  |||:|||||:|||||:|||||:|||||:|||||
DB 39 HADSTFTSDVSSYLEGQAAKEFIAMVKGK 68

RESULT 12
GLU2_XENLA
AC GLU2_XENLA STANDARD; PRT; 30 AA.
DT 01-NOV-1995 (Rel. 32, Created)
DT 01-NOV-1995 (Rel. 32, Last sequence update)
DT 15-SEP-2003 (Rel. 42, Last annotation update)
DE Glucagon-like peptide (GLP).
OS Anguilla anguilla (European freshwater eel), and
OS Anguilla rostrata (American eel).
CC Sakaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
CC Actinopterygii; Neopterygii; Teleostei; Anguilliformes; Anguillidae;
CC NCBI_TaxID=7936, 7938;
RN [1]
RP SEQUENCE.
RC SPECIES=A. anguilla, and A. rostrata;
RC TISSUE=Pancreas;
RX MEDLINE=91340068; PubMed=1874385;
RA Conlon J.M., Andrews P.C., Thim L., Moon T.W.;
RT "The primary structure of glucagon-like peptide but not insulin has
RT been conserved between the American eel, Anguilla rostrata and the
RT European eel, Anguilla anguilla.";
RL Gen. Comp. Endocrinol. 82:23-32(1991).
DB EMBL; F000432; BELONGS TO THE GLUCAGON FAMILY.
PIR: B61125; B61125.
DR HSSP: P01275; C61125.
DR InterPro: IPR000532; Glucagon.
DR Pfam: PF00123; hormone2; 1.
DR SMART: SM00070; GLUCA; 1.
DR PROSITE: PS00260; GLUCAGON; 1.
KW Glucagon family; Amidation.
FT MOD_RES 30 30
FT SEQUENCE 30 AA; 3376 MW; 592DA5E9D6E49D0 CRC64;
SQ
Query Match 81.38; Score 126; DB 1; Length 30;
Best Local Similarity 76.78; Pred. No. 1.4e-11;
Matches 23; Conservative 4; Mismatches 3; Indels 0; Gaps 0;

QY 1 HAEGETFTSDVSSYLEGQAAKEFIAMVKGK 30
  |||:|||||:|||||:|||||:|||||:|||||
DB 1 HAEGETFTSDVSSYLEGQAAKEFIAMVKGK 30

RESULT 13
GLU2_XENLA
AC GLU2_XENLA STANDARD; PRT; 266 AA.
DT 28-FEB-2003 (Rel. 41, Created)
DT 28-FEB-2003 (Rel. 41, Last sequence update)
DT 28-FEB-2003 (Rel. 41, Last annotation update)
DE Glucagon I precursor [Contains: Glucagon; Glucagon-like peptide 1A
DE (GLP-1A); Glucagon-like peptide 1B (GLP-1B); Glucagon-like peptide 1C
DE (GLP-1C); Glucagon-like peptide 2 (GLP-2)].
OS Xenopus laevis (African clawed frog).
CC Sakaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
CC Amphibia; Batrachia; Anura; Mesobaurechia; Pipidoidea; Pipidae;
CC NCBI_TaxID=8355;
RN [1]
RP SEQUENCE FROM N.A., AND ALTERNATIVE SPLICING.
RC TISSUE=Pancreas;
RX MEDLINE=97368293; PubMed=9232387;
RA Irwin D.M., Satkunaratnam M., Wen Y., Brubaker P.L., Pederson R.A.,
RA Wheeler M.B.;
RT "The Xenopus proglucagon gene encodes novel GLP-1-like peptides with

```

```

insulinotropic properties.";
Proc. Natl. Acad. Sci. U.S.A. 94:7915-7920(1997).
-1- FUNCTION: Promotes hydrolysis of glycogen and lipids, and raises
the blood sugar level.
-1- ALTERNATIVE PRODUCTS:
Event-Alternative splicing; Named isoforms=2;
Name=1;
Name=2;
IsoId=042143-1; Sequence=Displayed;
Name=2; 042143-2; Sequence=VSP_001755;
-1- SIMILARITY: BELONGS TO THE GLUCAGON FAMILY.
This SWISS-PROT entry is copyright. It is produced through a collaboration
between the Swiss Institute of Bioinformatics and the EMBL outstation at
the European Bioinformatics Institute. There are no restrictions on its
use by non-profit institutions as long as its content is in no way
modified and this statement is not removed. Usage by and for commercial
entities requires a license agreement (See http://www.isb-sib.ch/announce/
or send an email to license@isb-sib.ch).
CC EMBL; F000432; DAB55660.1;
CC HSSP: P01274; ICGN.
CC InterPro: IPR000532; Glucagon.
CC Pfam: PF00123; hormone2; 5.
CC PRINTS: PR00275; GLUCAGON.
CC SMART: SM00070; GLUCA; 5.
CC PROSITE: PS00260; GLUCAGON; 5.
KW Glucagon family; Hormone; Signal; Cleavage on pair of basic residues;
KW Multigene family; Alternative splicing.
FT SIGNAL 1 20
FT PROPEP 21 50
FT PROPEP 51 84
FT PROPEP 85 91
FT PEPTIDE 92 133
FT PROPEP 136 140
FT PEPTIDE 142 172
FT PROPEP 175 178
FT PEPTIDE 180 210
FT PROPEP 213 224
FT PEPTIDE 227 259
FT PROPEP 261 266
FT VARSPLIC 214 261
SQ SEQUENCE 266 AA; 30951 MW; 544F78C20AF872C CRC64;
Query Match 80.68; Score 125; DB 1; Length 266;
Best Local Similarity 70.04; Pred. No. 1.7e-10;
Matches 21; Conservative 7; Mismatches 2; Indels 0; Gaps 0;

QY 1 HAEGETFTSDVSSYLEGQAAKEFIAMVKGK 30
  |||:|||||:|||||:|||||:|||||:|||||
DB 180 HAEGETFTSDVSSYLEGQAAKEFIAMVKGK 209

RESULT 14
GLU2_LOPAM
AC GLU2_LOPAM STANDARD; PRT; 122 AA.
DT 01-NOV-1986 (Rel. 03, Created)
DT 01-NOV-1986 (Rel. 03, Last sequence update)
DT 16-OCT-2001 (Rel. 40, Last annotation update)
DE Glucagon II precursor [Contains: Glucagon-related polypeptide (GREP);
DE Glucagon II; Glucagon-like peptide II].
OS Lophius americanus (American eel).
CC Sakaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
CC Actinopterygii; Neopterygii; Teleostei; Euteleostei;
CC NCBI_TaxID=8073;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=83135785; PubMed=6338015;
RA Lund P.K., Goodman R.H., Montminy M.R., Dee P.C., Habener J.F.;
RA "Anglerfish islet pre-proglucagon II. Nucleotide and corresponding

```

```

amino acid sequence of the cDNA.*;
J. Biol. Chem. 258:3280-3284(1983).
(2)
RN PROCESSION;
RA MEDLINE=66246913; PubMed=326301;
RA Med. 28-Feb-2003 (Rel. 41, Last sequence update)
RA "Reiff, Andrews P.-Clotted peptides isolated from anglerfish islets
RA and metabolic cleavage products of (pre)proglucagon-II.*;
RA Peptides 7:331-339(1986)
EL Peptides 7:331-339(1986)
CC -1- FUNCTION: PROMOTES HYDROLYSIS OF GLYCOGEN AND LIPIDS, AND RAISES
CC THE BLOOD SUGAR LEVEL.
CC -1- INDUCTION: PRODUCED IN THE A CELLS OF THE ISLETS OF LANGERHANS
CC IN RESPONSE TO A DROP IN BLOOD SUGAR CONCENTRATION.
CC -1- SIMILARITY: BELONGS TO THE GLUCAGON FAMILY.
CC
CC THIS SWISS-PROT entry is copyrighted. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL Outstation
CC at the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC
CC EMBL: V06632; CAA23905.1; -
CC FR: A05150; GCA82.
CC DR HSP: P01274; IGCN.
CC DR SMART: SM00123; GLUCAG.
CC DR PRINTS: PR00123; GLUCAG.
CC DR PRINTS: PR00275; GLUCAG.
CC DR SMART: SM00070; GLUC.
CC DR PROSITE: PS00260; GLUCAG.
CC KW Glucagon family; Hormone; Cleavage on pair of basic residues; Signal.
FT SIGNAL 1 21
FT PEPTIDE 22 49 GLUCENTIN-RELATED POLYPEPTIDE.
FT PROPEP 52 80 GLUCAGON II.
FT PROPEP 83 96
FT PEPTIDE 89 119 GLUCAGON-LIKE PEPTIDE II.
SQ SEQUENCE 122 AA; 14171 MW; 51408C47BF15519 CRC64;

Query Match 77.4%; Score 120; DB 1; Length 122;
Best Local Similarity 70.0%; Pred. No. 4e-10;
Matches 21; Conservative 6; Mismatches 3; Indels 0; Gaps 0;

QY 1 HADGTFSDVSYSYLSQAKKEFIAMLYKGR 30
DB 89 HADGTFSDVSYSYLSQAKKEFIAMLYKGR 118

RESULT 15
GLU2_XENIA
ID GLU2_XENIA STANDARD; PRT: 219 AA.
AC 042144;
DT 28-FEB-2003 (Rel. 41, Created)
DT 28-FEB-2003 (Rel. 41, Last sequence update)
DE Glucagon II precursor [Contains: Glucagon; Glucagon-like peptide 1A
DE (GLP-1A); Glucagon-like peptide 1B (GLP-1B); Glucagon-like peptide 1C
DE (GLP-1C)].
OC Xenopus laevis (African clawed frog).
OC Amphibia; Batrachia; Chorda; Clad: Vertebrata; Euteleostomi;
OC Anura; Mesobatrachia; Pipoidae; Pipidae;
OC Xenopodinae; Xenopus.
OC NCBI_TaxID=8255;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Pancreas;
RX MEDLINE=97368292; PubMed=9223287;
RA Irwin D.M., Sathunarajah W., Wen Y., Strubaker P.L., Pederson R.A.,
RA "The Xenopus proglucagon gene encodes novel GLP-1-like peptides with
RA insulinotropic properties.*;
RA Proc. Natl. Acad. Sci. U.S.A. 94:7915-7920(1997).
RL Proc. Natl. Acad. Sci. U.S.A. 94:7915-7920(1997).
CC -1- FUNCTION: Promotes hydrolysis of glycogen and lipids, and raises
the blood sugar level.
CC -1- SIMILARITY: BELONGS TO THE GLUCAGON FAMILY.
CC
CC THIS SWISS-PROT entry is copyrighted. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL Outstation
CC at the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC
CC EMBL: AF004433; AAB65561.1; -
CC DR HSP: P01274; IGCN.
CC DR InterPro: IPR000532; Glucagon.
CC DR Pfam: PF00123; Hormone2; 4.
CC DR SMART: SM00123; GLUCAG.
CC DR PRINTS: PR00123; GLUCAG.
CC DR PRINTS: PR00275; GLUCAG.
CC DR SMART: SM00070; GLUC.
CC DR PROSITE: PS00260; GLUCAG.
CC KW Glucagon family; Hormone; Signal; Cleavage on pair of basic residues;
FT SIGNAL 1 20 POTENTIAL.
FT PROPEP 21 50
FT PEPTIDE 53 81 GLUCAGON.
FT PROPEP 84 95
FT PEPTIDE 97 133 GLUCAGON-LIKE PEPTIDE 1A.
FT PROPEP 136 140
FT PEPTIDE 142 173 GLUCAGON-LIKE PEPTIDE 1B.
FT PROPEP 175 178
FT PEPTIDE 180 210 GLUCAGON-LIKE PEPTIDE 1C.
FT PROPEP 213 219
SQ SEQUENCE 219 AA; 25271 MW; ACC699233C362CE0 CRC64;

Query Match 77.4%; Score 120; DB 1; Length 219;
Best Local Similarity 56.7%; Pred. No. 7.3e-10;
Matches 20; Conservative 7; Mismatches 3; Indels 0; Gaps 0;

QY 1 HADGTFSDVSYSYLSQAKKEFIAMLYKGR 30
DB 180 HADGTFSDVSYSYLSQAKKEFIAMLYKGR 209

Search completed: October 15, 2003, 10:53:39
Job time : 14.2787 secs

```

GenCore version 5.1.6
Copyright (C) 1993 - 2003 CompuGen Ltd.

OK protein - protein search, using sw model

Run on: October 15, 2003, 10:48:32 ; Search time 59,0164 Seconds
(without alignments)
131.177 Million cell updates/sec

Title: US-09-719-410-4

Perfect score: 155
Sequence: 1 HAEQFTSDVSSYLEQQAKEFIAMLVKGR 30

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 830525 segs, 238052604 residues

Total number of hits satisfying chosen parameters: 830525

Minimum DB seq length: 0

Maximum DB seq length: 4000000000

Post-processing: Minimum Watch 0s

Maximum Watch 100s

Listing first 45 summaries

Database :

SPTREXBL_23:*

1: sp-archaea:*

2: sp-bacteria:*

3: sp-fungi:*

4: sp-invertebrate:*

5: sp-human:*

6: sp-mammal:*

7: sp-mhc:*

8: sp-organelle:*

9: sp-phage:*

10: sp-plant:*

11: sp-rodent:*

12: sp-virus:*

13: sp-vertebrate:*

14: sp-unclassified:*

15: sp-virus:*

16: sp-unknown:*

17: sp-archaea:*

18: sp-archaea:*

19: sp-archaea:*

20: sp-archaea:*

21: sp-archaea:*

22: sp-archaea:*

23: sp-archaea:*

24: sp-archaea:*

25: sp-archaea:*

26: sp-archaea:*

27: sp-archaea:*

28: sp-archaea:*

29: sp-archaea:*

30: sp-archaea:*

31: sp-archaea:*

32: sp-archaea:*

33: sp-archaea:*

34: sp-archaea:*

35: sp-archaea:*

36: sp-archaea:*

37: sp-archaea:*

38: sp-archaea:*

39: sp-archaea:*

40: sp-archaea:*

41: sp-archaea:*

42: sp-archaea:*

43: sp-archaea:*

44: sp-archaea:*

45: sp-archaea:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

| Result No. | Score | Query Match | Length | ID | Description |
|------------|-------|-------------|--------|-----------|---------------------|
| 1 | 155 | 100.0 | 176 | 6 Q8M125 | Q8M125 ovis aries |
| 2 | 155 | 100.0 | 180 | 6 Q5LIG0 | Q5LIG0 canis fam |
| 3 | 129 | 83.2 | 220 | 13 Q8M1L9 | Q8M1L9 hominid |
| 4 | 118 | 76.1 | 72 | 13 Q91409 | Q91409 oncorhynch |
| 5 | 118 | 76.1 | 178 | 13 Q91971 | Q91971 oncorhynch |
| 6 | 113 | 72.9 | 178 | 13 Q91189 | Q91189 oncorhynch |
| 7 | 103 | 66.5 | 121 | 13 Q9DD86 | Q9DD86 brachydanio |
| 8 | 20 | 58.1 | 136 | 13 Q9DG43 | Q9DG43 ambloplites |
| 9 | 61 | 59.4 | 144 | 11 Q9D877 | Q9D877 mus musculu |
| 10 | 61 | 59.4 | 144 | 11 Q9D877 | Q9D877 mus musculu |
| 11 | 60 | 58.7 | 170 | 6 Q8M277 | Q8M277 bovis taurus |
| 12 | 59 | 58.1 | 171 | 11 Q9D227 | Q9D227 mus musculu |
| 13 | 59 | 58.1 | 389 | 2 Q93LH2 | Q93LH2 wellnella s |
| 14 | 54 | 34.8 | 172 | 13 Q9DE29 | Q9DE29 brachydanio |
| 15 | 53.5 | 34.5 | 175 | 13 Q9QX24 | Q9QX24 ictalurus p |
| 16 | 52.5 | 33.9 | 427 | 17 Q8TLY0 | Q8TLY0 methanosarc |

ALIGNMENTS

RESULT 1

Q8M125 PRELIMINARY; PRF: 176 AA.
AC Q8M125; 22. Created
AT 01-OCT-2002 (TREMREL. 22. Last sequence update)
DT 01-OCT-2002 (TREMREL. 22. Last sequence update)
DT 01-MAR-2003 (TREMREL. 23. Last annotation update)
DE Preproglucagon (Fragment).
OS Ovis aries (Sheep).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Buteleostomi;
OC Mammalia; Eutheria; Cetartiodactyla; Ruminantia; Pecora; Bovidae;
OX NCIT: C0000000; Ovis.
OX NCIT: TaxID=9940;
EN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Pancreas;
RA Limesand S.W., Hay W.W. Jr.;
RT "Characterization of the endocrine pancreas in an ovine placental
RL Insufficiency IDUG fetus."
RL Submitted (JUL-2002) to the EMBL/GenBank/DBJ databases.
DR EMBL: AF593185; AM94409.1;
DR InterPro: IPR000532; Glucagon.
DR TrEMBL: P00000; Hormones 3.
DR PRINTS: P000275; GLUCAGON.
DR SMART: SM00070; GLUCAG. 3.
DR PROSITE: PS00260; GLUCAGON; 2.
FT NON_TER. 176
SQ SEQUENCE 176 AA; 20335 MW; 13174039BD6CE2B3 CRC64;

Query Match 100.0%; Score 155; DB 6; Length 176;

Best Local Similarity 100.0%; Pred. No. 1.5e-15;

Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HAEQFTSDVSSYLEQQAKEFIAMLVKGR 30

DB 98 HAEQFTSDVSSYLEQQAKEFIAMLVKGR 127

RESULT 2

```

Q95L60
AC Q95L60 PRELIMINARY; PRT; 180 AA.
DT 01-NOV-2001 (TRENDEL. 19, Last sequence update)
DT 01-DEC-2001 (TRENDEL. 19, Last sequence update)
DT 01-MAR-2003 (TRENDEL. 23, Last annotation update)
DT 01-MAR-2003 (TRENDEL. 23, Last annotation update)
OS Proglucagon.
OS Canis familiaris (Dog).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Carnivora; Fissipedia; Canidae; Canis.
OX NCBI_TaxID=9615;
RN [1]
RP SEQUENCE FROM N.A.
RX Irwin D.M., Wong J., Proglucagon: alternative splicing generates mRNA
RT transcripts encoding glucagon-like peptide 2.
RL Mol. Endocrinol. 9:267-277(1995).
DR ENBL: AF308439; AA109425.1; -.
DR InterPro: IPR000532; Glucagon.
DR PFam: PF00123; hormone2; 3.
DR PRIMS: PR00275; hormone2; 3.
DR SMART: SM00070; GLUC. 3.
DR PROSITE: PS00260; GLUCAGON; 2.
SQ SEQUENCE 180 AA; 21114 MW; 80F65941AFC324FD CRC64;

Query Match
Best Local Similarity 100.0%; Score 155; DB 6; Length 180;
Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

CY 1 HAEFTFSDVSYLEGQAKEFTAMLYKGR 30
DQ 98 HAEFTFSDVSYLEGQAKEFTAMLYKGR 127

RESULT 3
ID Q8UWL9 PRELIMINARY; PRT; 220 AA.
AC Q8UWL9;
DT 01-MAR-2002 (TRENDEL. 20, Created)
DT 01-MAR-2002 (TRENDEL. 20, Last sequence update)
DT 01-OCT-2002 (TRENDEL. 22, Last annotation update)
OS Proglucagon.
OS Hoplobatrachus rugulosus.
OC Amphibia; Batrachia; Anura; Neobatrachia; Ranoidae; Ranidae;
OC Hoplobatrachus.
OX NCBI_TaxID=110072;
RN [1]
RP SEQUENCE FROM N.A.
RX Yeung C.-M., Chow B.K.C.;
RT Identification of a proglucagon cDNA from Rana tigrina rugulosa that
RT encodes two GLP-1s.
RL Gen. Comp. Endocrinol. 124:0-0(2001).
DR IR32424; AA135748.1; -.
DR InterPro: IPR000533; Glucagon.
DR PFam: PF00123; hormone2; 4.
DR PRIMS: PR00275; hormone2; 4.
DR SMART: SM00070; GLUC. 4.
DR PROSITE: PS00260; GLUCAGON; 4.
SQ SEQUENCE 220 AA; 25615 MW; C72D926E7F89E381 CRC64;

Query Match
Best Local Similarity 83.2%; Score 129; DB 13; Length 220;
Matches 23; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

CY 1 HAEFTFSDVSYLEGQAKEFTAMLYKGR 30
DQ 135 HAEFTFSDVSYLEGQAKEFTAMLYKGR 164

RESULT 4
ID Q91409 PRELIMINARY; PRT; 72 AA.

```

```

AC Q91409; Q91232;
DT 01-NOV-1996 (TRENDEL. 01, Created)
DT 01-NOV-1996 (TRENDEL. 01, Last sequence update)
DT 01-MAR-2003 (TRENDEL. 23, Last annotation update)
OS Proglucagon.
OS Oncorhynchus tshawytscha (Chinook salmon) (King salmon).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Actinopterygii; Neopterygii; Teleostei; Euteleostei;
OC Protacanthopterygii; Salmoniformes; Salmonidae; Oncorhynchus.
OX NCBI_TaxID=7490;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=95295739; PubMed=7776976;
RX Irwin D.M., Wong J., Proglucagon: alternative splicing generates mRNA
RT transcripts encoding glucagon-like peptide 2.
RL Mol. Endocrinol. 9:267-277(1995).
DR ENBL: S78474; AA14383.1; -.
DR ENBL: U19920; AAC59670.1; -.
DR HSSP: P01274; IGCN.
DR InterPro: IPR000532; Glucagon.
DR PFam: PF00123; hormone2; 2.
DR SMART: SM00070; GLUC. 2.
DR PROSITE: PS00260; GLUCAGON; 1.
SQ SEQUENCE 72 AA; 8293 MW; 8584352B1C360A31 CRC64;

Query Match
Best Local Similarity 76.1%; Score 118; DB 13; Length 72;
Matches 20; Conservative 7; Mismatches 3; Indels 0; Gaps 0;

CY 1 HAEFTFSDVSYLEGQAKEFTAMLYKGR 30
DQ 39 HAEFTFSDVSYLEGQAKEFTAMLYKGR 68

RESULT 5
ID Q91971 PRELIMINARY; PRT; 178 AA.
AC Q91971; Q91408; Q91188; Q92169;
DT 01-NOV-1996 (TRENDEL. 01, Created)
DT 01-NOV-1996 (TRENDEL. 01, Last sequence update)
DT 01-JUN-2001 (TRENDEL. 17, Last annotation update)
OS Proglucagon.
OS Oncorhynchus tshawytscha (Rainbow trout) (Salmo gairdneri).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Actinopterygii; Neopterygii; Teleostei; Euteleostei;
OC Protacanthopterygii; Salmoniformes; Salmonidae; Oncorhynchus.
OX NCBI_TaxID=8022;
RN [1]
RP SEQUENCE FROM N.A.; AND ALTERNATIVE SPLICING.
RX TISSUE=DISTAL SMALL INTESTINE, AND PANCREAS;
RX MEDLINE=95295739; PubMed=7776976;
RX Irwin D.M., Wong J.;
RT Proglucagon: alternative splicing generates mRNA
RT transcripts encoding glucagon-like peptide 2.
RL Mol. Endocrinol. 9:267-277(1995).
CC -1- FUNCTION: PROMOTES HYDROLYSIS OF GLUCOGEN AND LIPIDS, AND RAISES
CC THE BLOOD SUGAR LEVEL (BY SIMILARITY).
CC -1- ALTERNATIVE PRODUCTS: 2 ISOPROPS; INTESTINAL (SHOWN HERE) AND
CC PANCREATIC; ARE PRODUCED BY ALTERNATIVE SPLICING.
CC -1- INDUCTION: PRODUCED IN THE A CELLS OF THE ISLETS OF LANGERHANS IN
CC RESPONSE TO A DROP IN BLOOD SUGAR CONCENTRATION.
CC -1- SIMILARITY: BELONGS TO THE GLUCAGON FAMILY.
DR ENBL: U19918; AAC50213.1; -.
DR ENBL: U19918; AAC50212.1; -.
DR ENBL: U19918; AAC50213.1; -.
DR ENBL: U19918; AAC50213.1; JOINED.
DR ENBL: S78475; AAB34505.1; -.
DR HSSP: P01274; IGCN.
DR InterPro: IPR000532; Glucagon.

```

```

QY      1 HAEGFTFSVSYLEGQAKEFTAMVKG 29
DB      30 HAEGTITSVSYLQDAQRGFVMSKSG 118

RESULT 7
QSDD6E
AC ID QSD56; PRELIMINARY; PRT; 121 AA.
AD QSD56;
DT DT 01-MAR-2001 (TRMELrel. 16, Created)
DI DI 01-MAR-2001 (TRMELrel. 16, Last sequence update)
DT DT 01-OCT-2002 (TRMELrel. 22, Last annotation update)
DE DE Glucagon polypeptide.
GN GN GCG OR GLU.
OS OS Brachydanio rerio (Zebrafish) (Danio rerio).
OC OC Sukarya; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC OC Actinopterygii; Neopterygii; Teleostei; Ostariophysi; Cypriniformes;
CX CX NCBI_TaxId=7953;
RN RN SOURCE FROM N.A.
RX RX NEELINE-94A25190; PubMed=10495291;
RA Arventon F., Zecchin E., Bortolussi M.;
RT RT "Early appearance of pancreatic hormone-expressing cells in the
RT zebrafish embryo.";
RL RL Mech. Dev. 87:217-221(1999).
DR DR SWBL; AJ133697; CMC20109.1; -.
DR DR HSSP; P01274; IGCN.
DR DR JFIN; XDB-GENE-010219-1; GCY.
DR DR InterPro; IPRO00532; Glucagon.
DR DR TrEMBL; F000037; mouseGluc2.
DR DR PRINTS; PR00275; GLUCAGON.
DR DR SMART; SM00070; GLUCA.2.
DR DR PROSITE; PS00260; GLUCAGON; 2.
DR DR Polyprotein.
FT FT CHAIN 49 79 GLUCAGON.
SQ SQ SEQUENCE 121 AA 121 GLUCAGON-LIKE PEPTIDE 1.
Query Match 66.5%; Score 103; DB 13; Length 121;
Fast Local Similarity 66.7%; Fragment=0;
Matches 20; Conservative 5; Mismatches 5; Indels 0; Gaps 0;

QY      1 HAEGFTFSVSYLEGQAKEFTAMVKG 30
DB      98 HAEGTITSVSYLQDAQRGFVMSKSG 117

RESULT 8
QSDG43
AC ID QSDG43; PRELIMINARY; PRT; 96 AA.
AD QSDG43;
DT DT 01-MAR-2001 (TRMELrel. 16, Created)
DI DI 01-MAR-2001 (TRMELrel. 16, Last sequence update)
DT DT 01-OCT-2002 (TRMELrel. 22, Last annotation update)
DE DE Proglucagon (fragment).
OS OS Ambloplites rupestris (Rock bass).
OC OC Sukarya; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC OC Actinopterygii; Neopterygii; Teleostei; Euteleostei; Neoclaeoli;
OC OC Centrarchidae; Ambloplites.
CX CX NCBI_TaxId=109273;
RN RN SOURCE FROM N.A.
RX RX AL-Mahrouki A.A., Irwin D.M., Youson J.H.;
RA RA "Rock Bass Proglucagon.";
RT RT Submitted (SEP-1999) to the EMBL/GenBank/DDBJ databases.
DR DR EMBL; AF150499; AGI61778.1; -.
DR DR TrEMBL; F000032; ROCKBASS.
DR DR InterPro; IPRO05532; Glucagon.
DR DR Pfam; PF00123; hormone2.2.
DR DR PRINTS; PR00275; GLUCAGON.

```


| RESULT 10 | | |
|-----------|--|--------------|
| ID | PRELIMINARY: | PRT: 144 AA. |
| AC | Q9D887: | |
| DT | 01-JUN-2001 (TRENDELrel. 17, Created) | |
| DT | 01-JUN-2001 (TRENDELrel. 17, Last sequence update) | |
| DT | 01-DEC-2001 (TRENDELrel. 19, Last annotation update) | |
| DE | Gastric inhibitory polypeptide. | |
| GN | GIP | |
| OR | musculus (Mouse). | |
| OC | Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus. | |
| NCBI | NCBI TaxID:10090; | |
| FN | [1] | |
| RP | SEQUENCE FROM N.A. | |
| RC | STRAIN-C57BL/6J; TISSU=Small intestine; | |
| FX | MEDLINE-21085660; PubMed-11217851; | |
| RA | Kawai J., Hasegawa A., Shibata K., Yoshino M., Itoh M., Ishii Y., | |
| RA | Arakawa K., Hara A., Kikunishi K., Kikuchi T., Tanaka T., | |
| RA | Saito T., Okazaki Y., Gotchoji T., Bono H., Kasukawa T., Saito R., | |
| RA | Kadoya K., Matsuda H.A., Ashburner M., Batalov S., Casavant T., | |
| RA | Fleischmann W., Gaasterland U., Gissi C., King B., Kochiwa H., | |
| RA | Kuehl P., Lewis S., Matsuo Y., Nikaido I., Pesole G., Quackenbush J., | |
| RA | Rachl P.L.M., Staubli F., Suzuki R., Tomita M., Wagner L., Washio T., | |
| RA | Sakai K., Okiko T., Furuno M., Aono H., Baldarelli R., Baren G., | |
| RA | Blake J., Sorfelli D., Bojunga N., Carrington W., De Souda K.F., | |
| RA | Guo Y., Gao Y., Hill C., Hofmann M., Hume D.A., Kamiya M., Lee N.H., | |
| RA | Gustinch S.P., Marchionini L., Mashima J., Mazzarelli J., Nomberts P., | |
| RA | Lyons P., Ring B., Rinevald M., Rodriguez I., Sakamoto N., | |
| RA | Sasaki H., Sato K., Schoenbach C., Seya T., Shibata Y., Storch K.-F., | |
| RA | Suzuki H., Toyooka K., Wang K.H., Weitz C., Whitaker C., Wilming L., | |
| RA | Yoshikawa-Boris A., Yoshida K., Hasegawa Y., Kawaji H., Kotsuki S., | |
| RA | Hayashizaki Y.; | |
| RA | Function: Generation of a full-length mouse cDNA collection.; | |
| RA | Accession: U00001 (2001-01-01); | |
| RA | EMBL: AK008308; BA02552.1; - | |
| DR | HSSP: P01274; IGCN | |
| DR | MGD: MGI:107504; GIP. | |
| DR | InterPro: IPR000332; Glucagon. | |
| DR | Pfam: PF00123; hormone2; 1. | |
| DR | SMART: SM00070; GLUCAG; 1. | |
| DR | PROSITE: PS00260; GLUCAG; 1. | |
| DR | PROSITE: 144 AA; 15839 MW; 365618655D04R83 CNG64; | |
| QY | Query Match 39.4%; Score 61; DB 11; Length 144; | |
| DB | Best Local Similarity 40.03; Pred. No. 29; | |
| DB | Matches 12; Conservative 7; Mismatches 11; Indels 0; Gaps 0; | |
| QY | 1 HAEGTFTSDVSSVLEGGAKETFIAMLVKGR 30 | |
| DB | : : : : : : : : : : : : | |
| DB | 44 YAEETFTSDVSSVLEGGAKETFIAMLVKGR 73 | |
| RESULT 11 | | |
| AC | Q8M177: | |
| DT | 01-OCT-2002 (TRENDELrel. 22, Created) | |
| DT | 01-OCT-2002 (TRENDELrel. 22, Last sequence update) | |
| DT | 01-MAR-2003 (TRENDELrel. 23, Last annotation update) | |
| DE | Vasocactive intestinal polypeptide precursor. | |
| DE | Bo taurus (Bovine). | |
| OC | Eukaryota; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Cetartiodactyla; Ruminantia; Pecora; Bovidea; | |
| OC | Ruminantia; Bovinae; Bos. | |
| NCBI | NCBI TaxID:9913; | |
| FN | [1] | |
| RP | SEQUENCE FROM N.A. | |
| RC | MEDLINE-22092342; PubMed-12097482; | |
| FX | Hasenllick C., Lee H.-W., Chen Y., Grimaldi M., Elden L.E.; | |

RT "Coincident elevation of cAMP and calcium influx by PACAP-27 synergistically regulates vasoactive intestinal polypeptide gene expression in the rat hypothalamus."

RL J. Neurosci. 22:5310-5320(2002).

DR EMBL; AF503910; AM28152.1; -

DR InterPro: IPR000532; Glucagon.

DR Pfam: PF00123; Hormone2; 2.

DR SMART; SM0076; GLUCAGON.

DR SMART; SM0076; GLUCAGON.

DR PROSITE; PS00269; GLUCAGON; 2.

KW SIGNAL.

FT SIGNAL 1 22 POTENTIAL.

FT CHAIN 81 107 PHI.

FT CHAIN 125 152 VIP.

SQ SEQUENCE 170 AA; 19164 MW; 9C6A049AF7BFP81 CRC64;

Query Match 38.7%; Score 60; DB 6; Length 170;

Best Local Similarity 43.3%; Pred. No. 0.5;

Matches 13; Conservative 6; Mismatches 11; Indels 0; Gaps 0;

QY 1 HAEQFTSDVSYSLGQAKREFIAWVGR 30

DB 81 HADGVFTSDYSLGQAKREFIAWVGR 110

RESULT 12

ID Q9D227 PRELIMINARY; PRT; 171 AA.

DT 01-JUN-2001 (TrEMBLrel. 17, Created)

DT 01-JUN-2001 (TrEMBLrel. 17, Last sequence update)

DT 01-OCT-2002 (TrEMBLrel. 22, Last annotation update)

DE Vasoactive intestinal polypeptide.

GN VIP

OS Mus musculus (Mouse).

CC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

CC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

ON NCBI_TaxID=10090;

RP SEQUENCE FROM N.A.

RP STRAIN=C57BL/6J; TISSUE=Cecum;

RP K01668; Mus musculus; Shihata; 851;

RA Kawai T., Shibagawa Y., Yoshino M., Itoh M., Ishii Y.,

RA Arakawa T., Hara A., Fukunishi Y., Konno H., Adachi J., Fukuda S.,

RA Aizawa K., Izawa M., Nishi K., Kiyosawa H., Kondo S., Yamazaki I.,

RA Saiko T., Okazaki Y., Gojohori T., Bono H., Kasukawa T., Saito R.,

RA Kadota K., Matsuda H.A., Ashburner M., Batalov S., Casavant T.,

RA Fleischmann W., Gaasterland T., Gissi C., King B., Kochiwa H.,

RA Kuehl P., Lewis S., Matsuo Y., Nikolaio I., Pesole G., Quackenbush J.,

RA Schmal L.M., Staibil F., Suzuki R., Tomita M., Wagner L., Washio T.,

RA Sakai K., Okido T., Furuno M., Aono H., Baldarelli R., Barsh G.,

RA Blake J., Boffelli D., Bojunga N., Carninci P., de Bonaldo M.F.,

RA Brownstein M.J., Bult C., Fletcher C., Fujita M., Gariboldi M.,

RA Gustincich S., Hill D., Hornann M., Hume D.A., Kamiya K., Lee N.H.,

RA Kyous P., Mochizumi T., Mashima J., Mazzaletti J., Mombauris P.,

RA Nakagawa M., Nakagawa T., Nakagawa T., Sakamoto K., Sato K.,

RA Suzuki H., Sato K., Schmitt C., Seitz C., Shikama T., Koch K.-P.,

RA Suzuki H., Toyooka K., Wang K.H., Weitz C., Whitaker C., Whiting L.,

RA Wyszewski A., Yoshida K., Hasegawa Y., Kawaji H., Kohsaki S.,

RA Hayashizaki Y.

RT "Functional annotation of a full-length mouse cDNA collection."

RL Nature 409:685-690(2001).

DR EMBL; AK018599; BAB31301.1; -

DR MGD; MGI:98933; Vip.

DR InterPro: IPR000532; Glucagon.

DR Pfam: PF00123; Hormone2; 2.

DR PRINTS; PR00275; GLUCAGON.

DR SMART; SM0076; GLUCAGON.

DR PROSITE; PS00269; GLUCAGON; 2.

SQ SEQUENCE 171 AA; 19135 MW; 134A434DE5DF1254 CRC64;

Query Match 38.1%; Score 59; DB 11; Length 171;

Best Local Similarity 43.3%; Pred. No. 0.71;

Matches 13; Conservative 6; Mismatches 11; Indels 0; Gaps 0;

QY 1 HAEQFTSDVSYSLGQAKREFIAWVGR 30

DB 82 HADGVFTSDYSLGQAKREFIAWVGR 111

RESULT 13

RS1SH2 PRELIMINARY; PRT; 389 AA.

AC Q931H2

DT 01-DEC-2001 (TrEMBLrel. 19, Created)

DT 01-DEC-2001 (TrEMBLrel. 19, Last sequence update)

DT 01-MAR-2003 (TrEMBLrel. 23, Last annotation update)

DE Sulfur transferase precursor.

GN STRA.

OS Wolinella succinogenes.

CC Bacteria; Proteobacteria; Epsilonproteobacteria; Campylobacteriales;

CC Helicobacteraceae; Wolinella.

ON NCBI_TaxID=844;

RP SEQUENCE FROM N.A.

RP The sulfur transferase of Wolinella succinogenes.

RL Submitted (AUG-2001) to the EMBL/GenBank/DBJ databases.

DR EMBL; AJ318789; CAC50085.1; -

DR InterPro: IPR001763; Rhodanese-like.

DR Pfam: PF00581; Rhodanese; 2.

DR SMART; SM00450; RHOD; 3.

KW Signal; Transferase.

FT SIGNAL 1 21 POTENTIAL.

FT CHAIN 22 389 SULFUR TRANSFERASE.

SQ SEQUENCE 389 AA; 41949 MW; 6C00850CD9C4B9C CRC64;

Query Match 38.1%; Score 59; DB 2; Length 389;

Best Local Similarity 39.3%; Pred. No. 1.9;

Matches 11; Conservative 8; Mismatches 9; Indels 0; Gaps 0;

QY 1 HAEQFTSDVSYSLGQAKREFIAWVGR 28

DB 314 HAKGFAGSINIEKKGKSAQEFVALLPK 341

RESULT 14

ID Q9DE29 PRELIMINARY; PRT; 172 AA.

DT 01-MAR-2001 (TrEMBLrel. 16, Created)

DT 01-MAR-2001 (TrEMBLrel. 16, Last sequence update)

DT 01-MAR-2003 (TrEMBLrel. 23, Last annotation update)

DE Growth hormone-releasing hormone/pituitary adenylate cyclase-

DE activating polypeptide.

GN ADCYAP1.

OS Brachydanio rerio (Zebrafish) (Danio rerio).

CC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

CC Actinopterygii; Neopterygii; Teleostei; Ostariophysi; Cypriniformes;

CC Cyprinidae; Danio.

ON NCBI_TaxID=7955;

RP SEQUENCE FROM N.A.

RP "Characterization of the gene encoding both growth hormone-releasing

RP hormone (GRF) and pituitary adenylate cyclase-activating polypeptide

RP (PACAP) in the zebrafish."

RL Submitted (DEC-1999) to the EMBL/GenBank/DBJ databases.

DR EMBL; AF217251; AAG36782.1; -

DR ZFIN; ZDB-GENE-020809-4; adcyap1.

DR InterPro: IPR000532; Glucagon.

DR Pfam: PF00123; Hormone2; 2.

DR PRINTS; PR00275; GLUCAGON.

DR SMART; SM0076; GLUCAG; 2.

DR PROSITE; PS00260; GLUCAGON; 2.

FT CHAIN 81 125 GROWTH HORMONE-RELEASING HORMONE.

